

HS009194873B2

(12) United States Patent

Dawson et al.

(10) Patent No.: US 9,194,873 B2 (45) Date of Patent: Nov. 24, 2015

(54) HCV ANTIGEN-ANTIBODY COMBINATION ASSAY AND METHODS AND COMPOSITIONS FOR USE THEREIN

(71) Applicant: **Abbott Laboratories**, Abbott Park, IL

(72) Inventors: George J. Dawson, Libertyville, IL

(US); Suresh M. Desai, Libertyville, IL (US); Robin A. Gutierrez, Gurnee, IL (US); A. Scott Muerhoff, Kenosha, WI (US); John Prostko, Kenosha, WI (US)

(73) Assignee: ABBOTT LABORATORIES, Abbott

Park, IL (US)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 0 days.

(21) Appl. No.: 14/139,108

(22) Filed: Dec. 23, 2013

(65) **Prior Publication Data**

US 2014/0272933 A1 Sep. 18, 2014

Related U.S. Application Data

- (60) Provisional application No. 61/785,124, filed on Mar. 14, 2013, provisional application No. 61/788,136, filed on Mar. 15, 2013.
- (51) **Int. Cl.** *G01N 33/576* (2006.01) *G01N 33/543* (2006.01)
- (52) **U.S. CI.** CPC *G01N 33/5767* (2013.01); *G01N 33/54306* (2013.01); *G01N 2469/20* (2013.01)
- (58) Field of Classification Search None

See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

5,006,309 A	4/1991	Khalil
5,063,081 A	11/1991	Cozzette
5,089,424 A	2/1992	Khalil
5,135,875 A	8/1992	Meucci
5,241,070 A	8/1993	Law
5,242,828 A	9/1993	Bergstrom
5,294,404 A	3/1994	Grandone
5,352,803 A	10/1994	Mattingly
5,359,093 A	10/1994	Adamczyk
5,468,646 A	11/1995	Mattingly
5,496,925 A	3/1996	Mattingly
5,543,524 A	8/1996	Mattingly
5,573,904 A	11/1996	Mattingly
5,593,896 A	1/1997	Adamczyk
5,783,699 A	7/1998	Mattingly

5,795,784	A	8/1998	Arnquist
5,856,194	A	1/1999	Arnquist
6,096,319	A	8/2000	Seidel
6,225,047	B1	5/2001	Hutchens
6,329,209	B1	12/2001	Wagner
6,623,921	B2 *	9/2003	Aoyagi et al 435/5
6,727,092	B2*	4/2004	Shah et al 435/320.1
2003/0170881	A1	9/2003	Davis
2004/0018577	A1	1/2004	Campbell
2005/0054078	A1	3/2005	Miller
2006/0160164	A1	7/2006	Miller
2008/0020401	A1	1/2008	Grenier
2008/0113339	A1*	5/2008	Rodgers et al 435/5
2008/0248493	A1	10/2008	Mattingly
2010/0297607	A1	11/2010	Zheng
2012/0009196	A1	1/2012	Muerhoff

FOREIGN PATENT DOCUMENTS

CA	2450710	1/2003
CA	2450710 A1	1/2003
CA	2450710 C	11/2013
EP	0471293	2/1992
EP	2099825	9/2009
WO	99/51773	10/1999
WO	00/07023	2/2000
WO	00/56943	9/2000

OTHER PUBLICATIONS

Shah et al (Transfusion 43:1067-1074, 2003).*

Beckett et al., "A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation," Protein Sci., 8 (4):921-929 (1999).

Gu et al., "Three conformational snapshots of the hepatitis C virus NS3 helicase reveal a ratchet translocation mechanism," Proc. Natl. Acad. Sci. USA, 107(2):521-528 (2010).

Huston et al., "Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in *Escherichia coli*," Proc. Natl. Acad. Sci. USA, 85(16):5879-5883 (1988).

International Search Report and Written Opinion in PCT/US2013/077504 dated Jul. 1, 2014.

Wallemacq et al., "Evaluation of the new AxSYM cyclosporine assay: comparison with TDx monoclonal whole blood and Emit cyclosporine assays," Clin. Chem., 45(3):432-435 (1999).

Yatscoff et al., "Abbott TDx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood," Clin. Chem., 36(11):1969-1973 (1990).

Patent Cooperation Treaty, Notification of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, in International application No. PCT/US13/77504, dated Jul. 1, 2014 (26 pages).

* cited by examiner


Primary Examiner — Mary E Mosher (74) Attorney, Agent, or Firm — Irene M. Reininger

(57) ABSTRACT

The present invention generally relates to combination immunoassays, reagents and kits for simultaneous detection of HCV antigens and anti-HCV antibodies in a test sample.

13 Claims, 1 Drawing Sheet

Position of HCV NS3 Recombinant Proteins



HCV ANTIGEN-ANTIBODY COMBINATION ASSAY AND METHODS AND COMPOSITIONS FOR USE THEREIN

The present application is filed as a U.S. non-provisional patent application claiming the benefit of priority of U.S. Provisional Patent Application No. 61/785,124, which was filed Mar. 14, 2013, and U.S. Provisional Patent Application No. 61/788,136, which was filed Mar. 15, 2013. The entire text of the aforementioned applications is incorporated herein by reference in its entirety.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 20, 2015, is named 11951USO1_SL.txt and is 313,761 bytes in size.

RELATED APPLICATIONS

[Not Applicable]

FIELD OF THE INVENTION

The present invention generally relates to immunoassays for detection and diagnosis of HCV infection. More particularly, the present invention relates to combination immunoassays, reagents and kits for simultaneous detection of HCV antigens and anti-HCV antibodies in a test sample.

BACKGROUND OF THE INVENTION

According to WHO statistics, as many as 170 million people worldwide are infected by hepatitis C virus (HCV), a viral infection of the liver. 75 to 85% of persons infected with HCV progress to chronic infection, approximately 20% of these cases develop complications of chronic hepatitis C, including cirrhosis of the liver or hepatocellular carcinoma after 20 years of infection. The current recommended treatment for HCV infections is a combination of interferon and ribavirin drugs, however the treatment is not effective in all cases and the liver transplantation is indicated in hepatitis C-related end-stage liver disease. At present, there is no vaccine available to prevent HCV infection, therefore all precautions to avoid infection must be taken.

Thus, patient care, as well as the prevention of transmission of Hepatitis C Virus (HCV) by blood and blood products or by close personal contact requires extreme vigilance using sensitive detection assays. This creates a need for specific methods for screening and identifying carriers of HCV and HCV-contaminated blood or blood products. Serological 55 determination of HCV exposure relies on the detection of HCV present in human blood plasma or sera. This can be accomplished by detection of distinct structural and non-structural proteins encoded by the virus or alternatively by detection of antibodies to HCV.

After exposure to the HCV pathogen, there is initially no evidence of viral presence, i.e. no detectable viral RNA or serology markers. This is referred to as the "window period" (WP). Generally, after 10 days following exposure to HCV, viral RNA can be detected while anti-HCV antibodies 65 become detectable approximately 70 days later (Busch M P and Dodd R Y, Transfusion 40(10): 1157-1160, 2000). Pre-

2

vention of HCV infection spread it is ever more important to have reliable blood-screening tests that are designed to narrow the detection window.

There are numerous methods for the detection of HCV infection based on serological screening of the blood for detecting the presence of HCV core antigen or antibodies against HCV polypeptides in patient serum or plasma. It has been noted that the assays directed at detection of HCV core antigen assay detects HCV infection between 40 to 50 days earlier than the HCV screening based on antibody screening assays. HCV core protein is a structural protein of HCV comprising the first 191 amino acids of the polyprotein and that forms the internal viral coat encapsidating the genomic RNA. Two different types of serologic assays have been developed which permit detection of HCV core antigens in serum. One assay format detects HCV core antigens in subjects prior to seroconversion and is utilized in screening blood donors, while the other assay format detects core antigens only in hepatitis C patients, regardless of their HCV antibody 20 status, and is utilized in clinical laboratories to diagnose exposure to HCV or to monitor antiviral therapy.

Typically however, the HCV core antigen blood screening assays only detect core antigen at pre-seroconversion or early post-seroconversion phase. Furthermore, HCV core antigen assays are unable to detect core antigen when the antigen forms immune-complexes with anti-core antibodies in the late seroconversion phase. This creates a need for a serological assay that can detect HCV core antigen in the pre-seroconversion phase as well as anti-HCV antibodies in the sero-

The utility of such combination HCV screening assays is significant as such assays will be a significant improvement over the current serology blood screening method with respect to narrowing the WP. However, one of the challenges to the successful antigen antibody combined assay is to select appropriate antigens and antibodies for performing such assays. The present invention addresses this need.

BRIEF SUMMARY OF THE INVENTION

The present invention generally relates to combination immunoassays, reagents and kits for simultaneous detection of HCV antigens and anti-HCV antibodies in a test sample More particularly, the present invention describes an immunoassay for the combined detection of HCV antigen and HCV antibody in a test sample comprising:

- a) simultaneously providing the following reagents:
- i. a solid phase capable of binding to biotin
- ii. biotinylated anti-HCV antibody for the capture of an HCV antigen present the test sample;
- iii. a biotinylated HCV antigen for the capture of anti-HCV antibody in the test sample; and
- iv. a detectably labeled HCV antigen for binding to anti-HCV antibody captured by the biotinylated HCV antigen of (iii); and
- b) incubating the reagents of step (a) under conditions to produce a reaction mixture that
 - (i) the biotinylated anti-HCV antibody of (a)(ii) binds to the solid phase through the biotin and specifically binds to HCV antigen present in the test sample to produce an anti-HCV antibody-HCV antigen complex captured on the solid phase;
- (ii) the biotinylated antigen of (a)(iii) binds to the solid phase through the biotin and specifically binds to anti-HCV antibodies present in the test sample to produce an HCV antigen-anti-HCV antibody complex captured on the solid phase and the detectably labeled HCV antigen

- of (a)(iv) specifically binds to the anti-HCV antibody in the an HCV antigen-anti-HCV antibody complex captured on the solid phase;
- c) isolating solid phase that comprises attached captured antibody, and captured HCV antigen from unreacted test 5 sample and reagents
- d. contacting the isolated solid phase with a detectably labeled conjugate antibody that binds to the HCV antigen captured in the an anti-HCV antibody-HCV antigen complex of (b)(ii); and
- e. detecting the signal generated from the detectable label moieties upon triggering of the signal, wherein presence of the signal indicates presence of HCV in the test sample.

In an exemplary embodiment, the immunoassay may further comprise:

- (a) providing
- (v) a second biotinylated HCV antigen for the capture of anti-HCV antibody in the test sample wherein the second HCV antigen is distinct from the HCV antigen in step (aiii); and
- (vi). a detectably labeled HCV antigen for binding to anti-HCV antibody captured by the biotinylated HCV antigen of (v); and
- (b) (iii) the biotinylated antigen of (a)(v) binds to the solid phase through the biotin and specifically binds to anti-HCV 25 antibodies present in the test sample to produce an HCV antigen-anti-HCV antibody complex captured on the solid phase and the detectably labeled HCV antigen of (a)(vi) specifically binds to the anti-HCV antibody in the an HCV antigen-anti-HCV antibody complex captured on the solid phase. 30

Such an immunoassay may also detect a third or a plurality of additional HCV antigens by:

- (a) providing
- (vii) a third (or plurality of additional) biotinylated HCV antigen for the capture of anti-HCV antibody in the test 35 sample wherein the third HCV antigen is distinct from the HCV antigen in step 1(a)(iii) or step 2(a)(v); and
- (viii) a detectably labeled HCV antigen for binding to anti-HCV antibody captured by the biotinylated HCV antigen of (vii); and
- (b) (iv) the biotinylated antigen of (a)(vii) binds to the solid phase through the biotin and specifically binds to anti-HCV antibodies present in the test sample to produce an HCV antigen-anti-HCV antibody complex captured on the solid phase and the detectably labeled HCV antigen of (a)(viii) 45 specifically binds to the anti-HCV antibody in the an HCV antigen-anti-HCV antibody complex captured on the solid phase.

Another aspect of the invention describes an immunoassay for the simultaneous detection of both HCV antigens and 50 HCV antibodies in a test sample, wherein the combination assay comprises:

- a. a first capture antigen comprising a peptide sequence of a first HCV protein;
- b. a first detection antigen comprising a peptide sequence 55 of a first HCV protein and further comprising a detectable
- c. a second capture antigen comprising an antigenic sequence from a second HCV protein
- d. a second detection antigen comprising an antigenic 60 sequence from a second HCV protein and further comprising a detectable label
- e. a third capture antigen comprising an antigenic sequence from a third HCV protein
- f. a third detection antigen comprising an antigenic 65 sequence from a third HCV protein and further comprising a detectable label

4

g. a first capture antibody

h. a conjugate antibody comprising a detectable label wherein the capture antibody and the conjugate antibody specifically bind a fourth HCV protein from the test sample, and the combination assay is performed by:

- (i) contacting the test sample with the capture antigen, the detection antigen, the capture antibody and the conjugate antibody under conditions to allow:
- a) formation of a sandwich complex between the first cap ture antigen and the detection antigen and first anti-HCV antibody present in the test sample;
- b) formation of a sandwich complex between the second capture antigen and the second detection antigen and an anti-HCV antibody against the second HCV protein present in the test sample;
 - c) formation of a sandwich complex between the third capture antigen and the third detection antigen and an anti-HCV antibody against the third HCV protein present in the test sample; and
 - d) formation of a complex between the capture antibody, the conjugate antibody and an HCV antigen present in the sample; and
 - (ii) measuring a signal generated from the detectable labels as a result of formation of the complexes, thereby simultaneously detecting HCV antigens and HCV antibodies present in the sample.

In any of the immunoassay summarized above, the first, second, third and fourth HCV proteins are independently selected from the group consisting of core antigen, E1, E2, NS2, NS3, NS4 and NS5 or distinct and independent portions of any one of core antigen, E1, E2, NS2, NS3, NS4 and NS5.

In certain embodiments, two or more of the first, second, third and fourth HCV proteins are independently selected from different portions of the same protein selected from the group consisting of core antigen, E1, E2, NS2, NS3, NS4 and NS5.

In specific preferred embodiments, in the immunoassays of the invention the first HCV protein is core antigen designed for the detection of anti-Core antibodies present in a test sample. More specifically, the capture antigen for capturing anti-Core antibodies is a core peptide that comprises a deletion of amino acids 34 and 48 and amino acids 115-121. In some embodiments, the detection antigen for detection anti-Core antibodies also is a core peptide that comprises a deletion of amino acids 34 and amino acids 115-121. In particular embodiments, the combination immunoassay is designed for the detection of both core antigens and anti-core antibodies in the test sample. Such a detection is facilitated by use of the core deletion antigens summarized above as capture and detection antigens. Hence, in the immunoassays outlines above, both the first antigen and the fourth protein each are Core related proteins, namely, the first antigen is supplied in the test assay and the fourth protein is present in the test sample as a result of presence of HCV in the sample.

In particular embodiments that employ capture of antigens from the test sample, the immunoassays may employ a plurality of antibodies wherein each of the plurality of antibodies is directed to distinct epitope of the same HCV antigen (e.g., an antibody directed to the lipid binding region of Core and an antibody directed to the DNA binding region of Core as two separate capture antibodies for capturing Core antigen).

The immunoassays of the invention further comprise providing a second pair of capture antibody and conjugate antibody, wherein the second capture/conjugate antibody pair specifically bind to the same HCV protein as the first capture/conjugate antibody pair of the immunoassay summarized above or specifically bind a different HCV protein.

In particular embodiments, the capture antigens and the capture antibody are attached to a solid support.

In other embodiments, the first capture antigen is a biotinylated core peptide, and the first detection antigen is an acridinylated core peptide wherein each the biotinylated and detection antigen is a core peptide comprising a deletion of amino acids 34 and 48 and amino acids 115-121.

Additional specific embodiment comprise the second capture antigen is a biotinylated NS3 recombinant antigen and the second detection antigen is an acridinylated NS3 recombinant antigen. In other specific embodiments the third capture antigen is biotinylated NS4 peptide and the third detection antigen is an acridinylated NS4 peptide.

In particular embodiments, the capture antibody is biotinylated C11-7 monoclonal antibody.

In other embodiments, the detection antibody conjugate comprises antibodies selected from the group consisting of C11-9 and C11-14 or combinations thereof.

multiple HCV components from a test sample comprising:

- a. providing a biotin-binding solid phase
- b. contacting the solid phase with a mixture that comprises:
- i. biotinylated first capture antigen, biotinylated second 25 capture antigen, biotinylated third capture antigen and biotinylated antibody specific for a fourth HCV antigen;
- ii detectably labeled first, second, and third detection anti-

under conditions and time sufficient for

- (1) immune complexes to form between antibodies in the test sample that are independently immunoreactive with and captured by the first, second and third biotinylated antigens, 35 respectively and HCV proteins in the sample that are immunoreactive with the biotinylated antibody, and
- (2) immune complexes to form between the capture antibodies and the respective first, second and third detectably labeled antigens;
- c. isolating solid phase that comprises attached detectably labeled captured antibodies, and captured fourth HCV antigen from unreacted test sample and reagents
- d. contacting the isolated solid phase with a detectably labeled conjugate antibody that binds to the captured fourth HCV antigen; and
- e. detecting the signal generated from the detectably labeled moieties upon triggering of the signal, wherein presence of the signal indicates presence of HCV in the test 50

Again in such an assay, the first, second, third, and fourth HCV protein is independently selected from the group consisting of group consisting of core antigen, E1, E2, NS2, NS3, NS4 and NS5. More specifically, in one particular embodi- 55 ment, the HCV core antigen comprising a deletion of amino acids 34 and 48 and amino acids 115-121; the second antigen is NS3 antigen; the third antigen is NS4 antigen; and the biotinylated antibody is directed against HCV core antigen. In specific embodiments, the anti-Core monoclonal antibody 60 is an antibody specific for the lipid binding domain of HCV core. Alternatively, or additionally, the NS3 antigen is a recombinant HCV NS3 antigen comprising a NS3 helicase sequence that comprises each of domains I, II and III of the helicase, wherein the antigen has increased immunoreactivity 65 against HCV antibodies from serum as compared to C33 antigen.

Also contemplated herein is an immunoassay for detection of multiple HCV antibodies from a test sample comprising:

- a. providing a biotin-binding solid phase
- b. contacting the solid phase with a mixture that comprises:
- i. biotinylated first capture antigen, biotinylated second capture antigen, biotinylated third capture antigen; and
- ii detectably labeled first, second, and third detection antigens under conditions and time sufficient for
- (1) immune complexes to form between antibodies in the test sample that are independently immunoreactive with and captured by the first, second and third biotinylated antigens, respectively, and
- (2) immune complexes to form between the capture antibodies and the respective first, second and third detectably labeled antigens:
- c. isolating solid phase that comprises attached detectably labeled captured antibodies, from unreacted test sample and reagents; and
- d. detecting the signal generated from the detectably Also described herein is an immunoassay for detection of 20 labeled moieties upon triggering of the signal, wherein presence of the signal indicates presence of HCV in the test sample. Again, in such an immunoassay the first, second, and third HCV protein is independently selected from the group consisting of group consisting of core antigen, E1, E2, NS2, NS3, NS4 and NS5. In one particular exemplary assay, the first antigen is HCV core antigen; the second antigen is NS3 antigen; and the third antigen is NS4 antigen. More particularly, the capture core antigen may be, but need not be an antigen comprises a deletion of amino acids 34 and 48 and amino acids 115-121. The NS3 antigen also may be any NS3 antigen derived from NS3. In certain embodiments, the NS3 antigen is a recombinant HCV NS3 antigen comprising a NS3 helicase sequence that comprises each of domains I, II and III of the helicase, wherein the antigen has increased immunoreactivity against HCV antibodies from serum as compared to C33 antigen.

The invention further comprises kits for the simultaneous detection of HCV antigens and antibodies in a sample comprising:

- a first pair of capture antigen and detection antigen for detecting a first anti-HCV antibody against a first HCV protein, wherein the detection antigen is detectably labeled a second pair of capture antigen and detection antigen for detecting a second anti-HCV antibody against a second HCV protein; wherein the detection antigen is detectably labeled
- a third pair of capture antigen and detection antigen for detecting a third anti-HCV antibody against a third HCV protein, wherein the detection antigen is detectably labeled
- a first pair of capture antibody and conjugate antibody for detecting a fourth HCV protein, wherein the conjugate antibody is detectably labeled.

In the kits, the first, second, third and fourth HCV proteins are independently selected from the group consisting of core antigen, E1, E2, NS2, NS3, NS4 and NS5 or distinct and independent portions of any one of core antigen, E1, E2, NS2, NS3, NS4 and NS5. Specifically, the kits are designed to detect two or more of the first, second, third and fourth HCV proteins which are independently selected from different portions of the same protein selected from the group consisting of core antigen, E1, E2, NS2, NS3, NS4 and NS5. In preferred kits, the first HCV protein is core antigen, preferably, it is core peptide that comprises a deletion of amino acids 34 and 48 and amino acids 115-121. The kit comprising an anti-Core antibody detection antigen wherein the core peptide in the detection antigen comprises a deletion of amino acids 34 and 48 and amino acids 115-121. The kits also may detect core antigens in the sample and hence may advantageously com-

prise an anti-Core capture and detection antibody. Such a capture antibody may comprise two or more antibodies.

The kit may also comprise a second pair of capture antibody and conjugate antibodies, wherein the second capture/ conjugate antibody pair specifically bind to the same HCV 5 protein as the first capture/conjugate antibody pair or specifically bind a different HCV protein. In particular embodiments, the capture antigens and the capture antibody are attached to a solid support.

Any of the immunoassays employing the antigens of the 10 invention may readily be adapted for use in an automated system or a semi-automated system.

BRIEF DESCRIPTION OF SEVERAL VIEWS OF THE DRAWINGS

FIG.. 1 shows the position of HCV NS3 recombinant antigens of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides HCV combination immunoassays that provide enhanced detection of exposure to HCV, by detecting both antibodies to HCV as is performed in conventional immunoassays, and by detecting HCV core 25 antigen that may be present in the blood of individuals in the early stage of infection, prior to the development of antibodies to HCV. This invention meets the need in the art for a combination immunoassay for the simultaneous detection of both HCV antigens and anti-HCV antibodies in a sample in a 30 single assay. The antigen/antibody combination assay methods rely on the identification and use of antigenic and immunogenic HCV antibodies and antigens that are present during the early stages of HCV seroconversion, thereby increasing detection accuracy and reducing the incidence of false results 35 during the window period.

Biological samples that can be tested for HCV using the combination assays of the present invention include any sample suspected to contain HCV virions, antigens or antibodies. The term "sample", as used herein, is used in its 40 broadest sense. A "biological sample", as used herein, includes, but is not limited to, any quantity of a substance from a living thing or formerly living thing. Such living things include, but are not limited to, humans, mice, rats, monkeys, are not limited to, blood, (e.g., whole blood or components thereof), plasma, serum, urine, saliva, amniotic fluid, synovial fluid, endothelial cells, leukocytes, monocytes, other cells, organs, tissues, bone marrow, lymph nodes and spleen.

In the anti-HCV antibody detection aspect of the combi- 50 nation assay at least one (i.e., one or more) capture antigen is employed to bind and therefore captures anti-HCV antibodies present in the test sample. The capture antigens are generally antigenic peptides (containing one or more epitopes) derived from an HCV protein encoded by the HCV genome. The 55 sequence of the entire HCV genome and the encoded HCV polyprotein sequence are documented in GenBank (accession #M62321 and #AAA45676, respectively) and available to those skilled in the art. Some exemplary core antigens that could be used include antigens derived from the DNA binding 60 domain (amino acids 1-125) of core protein. Still other preferred core antigens are derived from the lipid binding domain of core located at amino acid residues 134-171 of core (MGYIPLVGAPLGGAARALAHGVRVprotein LEDGVNYATGNLPG) (SEQ ID NO: 89). However, in the 65 present invention particularly preferred core antigens include antigens derived from core protein that comprise certain dele-

tions or substitution in the known epitope binding regions for specific monoclonal antibodies such that monoclonal antibodies used for HCV core antigen detection would fail to detect these modified core antigens but would nonetheless detect complete core antigen from the test sample. Thus, these novel modified core antigens can be coated onto a solid phase support and/or used in solution phase to capture antibodies present in human serum or plasma that are directed toward the Core region of HCV but at the same time evade detection by the conjugate antibody used for the detection of Core Ag in an HCV Combo assay, but at the same time, allow detection of anti-Core antibodies that would also be expected to be in the test sample and identified in the same HCV Combo assay format. Preferred core antigens for use in the assays of the present invention comprise mutant core proteins that comprise a deletion of amino acids 34 and 48 and amino acids 115 - 121

By using the novel core capture antigens described herein, the present invention overcomes a significant problem that is seen with the currently available *Ac-DBA-c11-9/c11-14 20 conjugate that is used for the detection of core antigen in an HCV combination assay because the currently available core antigens used for capture of anti-core antibodies also react with detection antibodies designed to conduct serological detection of core antigen. Previously, constructs were made to obviate this problem by deletion of 5 amino acids (amino acids 32 33 and 34 for the C11-9 binding region and amino acids and residues 47 and 48 from the c11-14 binding region of core), however, these constructs yielded poorer anti-core antibody detection as these residues are highly immunogenic in anti-Core positive patients. The use of the core antigens that are described herein as capture antigens overcomes this problems due to their design which encompasses more minimal deletions that can successfully avoid detection by the *Ac-DBA c11-9/c11-14 conjugate but preserve or enhance detection of anti-core reactive specimens. In the combination assays of the present invention core antigens for the capture and detection of anti-HCV core antibodies advantageously comprise deletions of core amino acids sufficient for elimination of the binding of the capture antibody to the detection core antigen, for example, amino acids 115-121 are deleted.

Definitions

The present invention provides reagents for the detection of HCV in a test sample. Preferably, this detection is achieved dogs, rabbits and other animals. Such substances include, but 45 by the simultaneous detection of both HCV antigens and anti-HCV antibodies in the test sample. Throughout the specification certain terms are frequently used and as such the following section provides additional definitions of those terms. The term "antibody" (Ab) and "antibodies" (Abs) refer to monoclonal antibodies (mAb (singular) or mAbs (plural)), polyclonal antibodies (pAbs (plural)), multispecific antibodies, human antibodies, humanized antibodies (fully or partially humanized; a polypeptide comprising a modified variable region of a human antibody wherein a portion of the variable region has been substituted by the corresponding sequence from a non-human sequence and wherein the modified variable region is linked to at least part of the constant region of a human antibody), animal antibodies (such as, but not limited to, a bird (for example, a duck or a goose), a shark, a whale, and a mammal, including a non-primate (for example, a cow, a pig, a camel, a llama, a horse, a goat, a rabbit, a sheep, a hamster, a guinea pig, a cat, a dog, a rat, a mouse, etc.) or a non-human primate (for example, a monkey, a chimpanzee, etc.), recombinant antibodies, chimeric antibodies (cAb; a polypeptide comprising all or a part of the heavy and light chain variable regions of an antibody from one host species linked to at least part of the antibody constant

regions from another host species), single chain antibodies, single domain antibodies, Fab fragments, F(ab') fragments, Fab'-SH fragments, F(ab')2 fragments, Fd fragments, Fv fragments, single-chain Fv fragments ("scFv"), disulfide-linked Fv fragments ("sdFv"), dAb fragments, diabodies, an isolated 5 complementarity determining region (CDR), and anti-idiotypic ("anti-Id") antibodies, bifunctional or dual-domain antibodies (e.g., dual variable domain antibodies, or DVD-IgGs), and functionally active, epitope-binding fragments (or antigenically reactive fragments) of any of the above. In particular, antibodies include immunoglobulin molecules and immunologically active (or antigenically reactive) fragments of immunoglobulin molecules, namely, molecules that contain an analyte-binding site as further described in (n) herein, and variants as further described in (ac) herein Immunoglo- 15 bulin molecules can be of any type (for example, IgG, IgE, IgM, IgD, IgA and IgY), class (for example, IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2), or subclass. An antibody, whose affinity (namely, KD, kd or ka) has been increased or improved via the screening of a combinatory antibody library 20 that has been prepared using bio-display, is referred to as an "affinity maturated antibody." For simplicity sake, an antibody against an analyte is frequently referred to herein as being either an "anti-analyte antibody" or merely an "analyte antibody" (e.g., an anti-HCV antibody or an HCV antibody). 25

In the present invention the assay "component," "components," and "at least one component," refer generally to a capture antibody, a detection or conjugate antibody, a control, a calibrator, a series of calibrators, a sensitivity panel, a container, a buffer, a diluent, a salt, an enzyme, a co-factor for an enzyme, a detection reagent, a pretreatment reagent/solution, a substrate (e.g., as a solution), a stop solution, and the like that can be included in a kit for assay of a test sample, such as a patient urine, serum or plasma sample, in accordance with the methods described herein and other methods known in the art. Thus, in the context of the present disclosure, "at least one component," "component," and "components" can include a polypeptide as described herein, which is optionally immobilized on a solid support. Some components can be in solution or lyophilized for reconstitution for use in an assay.

In conducting the assays of the present invention, it may be useful to use a control. "Control" refers to a composition known to not contain anti-HCV antibody ("negative control") or to contain anti-HCV antibody ("positive control"). A positive control can comprise a known concentration of anti-HCV antibody. "Control," "positive control," and "calibrator" may be used interchangeably herein to refer to a composition comprising a known concentration of anti-HCV antibody. A "positive control" can be used to establish assay performance characteristics and is a useful indicator of the integrity of reagents (e.g., analytes).

Inking sequences can be found in Bird et al., Science 242: 423-426 (1988); Huston et al., PNAS USA 85: 5879-5883 (1988); and McCafferty et al., Nature 348: 552-554 (1990). Linking sequences also can be modified for additional functions, such as attachment of drugs or attachment to solid supports. In the context of the present disclosure, an mAb, for example, can contain a linking sequence sation of drugs or attachment to solid supports. In the context of the present disclosure, an mAb, for example, can contain a linking sequence salo can be modified for additional functions, such as attachment of drugs or attachment to solid supports. In the context of the present disclosure, an mAb, for example, can contain a linking sequence, such as a His tag, an enterokinase cleavage site, or both.

"Patient" and "subject" may be used interchangeably herein to refer to an animal, such as a bird (e.g., a duck or a goose), a shark, a whale, and a mammal, including a non-

The NS3 antigens of the present invention are useful in serological assays for the detection of anti-HCV antibodies in a test sample because such antibodies recognize epitopes contained within the NS3 antigens of the present invention. 55 "Epitope," "epitopes" and "epitopes of interest" refer to a site(s) on any molecule (in this case the NS3 antigens described herein) that is recognized and can bind to a complementary site on a specific binding partner, such as an antibody or antigenically reactive fragment thereof. An epitope consists of the precise amino acid residues of a region of an antigen (or fragment thereof) known to bind to the complementary site on the specific binding partner. An antigenic fragment can contain more than one epitope.

In the assays that are described herein, one or other component of the assay may comprise a detectable label. The terms "label" and "detectable label" mean a moiety attached

10

to a specific binding partner, such as an antibody or an analyte, to render the reaction between members of a specific binding pair, such as an antibody and an analyte, detectable, and the specific binding partner, e.g., antibody or analyte, so labeled is referred to as "detectably labeled." A label can produce a signal that is detectable by visual or instrumental means. Various labels include signal-producing substances, such as chromogens, fluorescent compounds, chemiluminescent compounds, radioactive compounds, and the like. Representative examples of labels include moieties that produce light, e.g., acridinium compounds, and moieties that produce fluorescence, e.g., fluorescein. Other labels are described herein. In this regard, the moiety itself may not be detectably labeled but may become detectable upon reaction with yet another moiety. Use of "detectably labeled" is intended to encompass the latter type of detectable labeling.

"Linking sequence" refers to a natural or artificial polypeptide sequence that is connected to one or more polypeptide sequences of interest (e.g., full-length, fragments, etc.). The term "connected" refers to the joining of the linking sequence to the polypeptide sequence of interest. Such polypeptide sequences are preferably joined by one or more peptide bonds. Linking sequences can have a length of from about 4 to about 50 amino acids. Preferably, the length of the linking sequence is from about 6 to about 30 amino acids. Natural linking sequences can be modified by amino acid substitutions, additions, or deletions to create artificial linking sequences. Exemplary linking sequences include, but are not limited to: (i) Histidine residues (His tags), such as a 6×His tag (SEQ ID NO: 90), which contains six histidine residues, are useful as linking sequences to facilitate the isolation and purification of polypeptides and antibodies of interest. (ii) Enterokinase cleavage sites, like His tags, are used in the isolation and purification of proteins and antibodies of interest. Often, enterokinase cleavage sites are used together with His tags in the isolation and purification of proteins and antibodies of interest. Various enterokinase cleavage sites are known in the art. (iii) Miscellaneous sequences can be used to link or connect the light and/or heavy chain variable regions 40 of single chain variable region fragments. Examples of other linking sequences can be found in Bird et al., Science 242: 423-426 (1988); Huston et al., PNAS USA 85: 5879-5883 (1988); and McCafferty et al., Nature 348: 552-554 (1990). Linking sequences also can be modified for additional functions, such as attachment of drugs or attachment to solid supports. In the context of the present disclosure, an mAb, for example, can contain a linking sequence, such as a His tag, an enterokinase cleavage site, or both.

"Patient" and "subject" may be used interchangeably herein to refer to an animal, such as a bird (e.g., a duck or a goose), a shark, a whale, and a mammal, including a non-primate (for example, a cow, a pig, a camel, a llama, a horse, a goat, a rabbit, a sheep, a hamster, a guinea pig, a cat, a dog, a rat, and a mouse) and a primate (for example, a monkey, a chimpanzee, and a human). Preferably, the patient or subject is a human, such as a human at risk for HCV infection or a human infected with HCV.

In analysis of the results of the immunoassays described herein it may be useful to include certain levels of detection as cutoff levels. "Predetermined cutoff" and "predetermined level" refer generally to an assay cutoff value that is used to assess diagnostic/prognostic/therapeutic efficacy results by comparing the assay results against the predetermined cutoff/level, where the predetermined cutoff/level already has been linked or associated with various clinical parameters (e.g., severity of disease, progression/nonprogression/improvement, etc.). While the present disclosure may provide exem-

plary predetermined levels, it is well-known that cutoff values may vary depending on the nature of the immunoassay (e.g., antibodies employed, etc.). It further is well within the ordinary skill of one in the art to adapt the disclosure herein for other immunoassays to obtain immunoassay-specific cutoff 5 values for those other immunoassays based on this disclosure. Whereas the precise value of the predetermined cutoff/level may vary between assays, the correlations as described herein should be generally applicable.

As described below, it may be desirable in some embodi- 10 ments of the invention to provide a pretreatment of the test sample. "Pretreatment reagent," e.g., lysis, precipitation and/ or solubilization reagent, as used in a diagnostic assay as described herein is one that lyses any cells and/or solubilizes any analyte that is/are present in a test sample. Pretreatment is 15 not necessary for all samples, as described further herein. Among other things, solubilizing the analyte (i.e., anti-HCV antibody) entails release of the analyte from any endogenous binding proteins present in the sample. A pretreatment reagent may be homogeneous (not requiring a separation 20 step) or heterogeneous (requiring a separation step). With use of a heterogeneous pretreatment reagent there is removal of any precipitated analyte binding proteins from the test sample prior to proceeding to the next step of the assay. The pretreatment reagent optionally can comprise: (a) one or more sol- 25 vents and salt, (b) one or more solvents, salt and detergent, (c) detergent, (d) detergent and salt, or (e) any reagent or combination of reagents appropriate for cell lysis and/or solubilization of analyte.

The assays also may be subject to rigorous quality control. 30 "Quality control reagents" in the context of immunoassays and kits described herein, include, but are not limited to, calibrators, controls, and sensitivity panels. A "calibrator" or "standard" typically is used (e.g., one or more, such as a plurality) in order to establish calibration (standard) curves 35 for interpolation of the concentration of an analyte, such as an antibody or an analyte. Alternatively, a single calibrator, which is near a predetermined positive/negative cutoff, can be used. Multiple calibrators (i.e., more than one calibrator or a varying amount of calibrator(s)) can be used in conjunction so 40 as to comprise a "sensitivity panel."

The terms "sample," "test sample," and "patient sample" may be used interchangeably herein. The sample, such as a sample of urine, serum, plasma, amniotic fluid, cerebrospinal monocytes, can be used directly as obtained from a patient or can be pre-treated, such as by filtration, distillation, extraction, concentration, centrifugation, inactivation of interfering components, addition of reagents, and the like, to modify the character of the sample in some manner as discussed herein or 50 otherwise as is known in the art. Preferably, the sample is urine, serum or plasma.

In some assays, it may be desirable to provide calibration of the assay. "Series of calibrating compositions" refers to a plurality of compositions comprising a known concentration 55 of anti-HCV antibody, wherein each of the compositions differs from the other compositions in the series by the concentration of anti-HCV antibody.

Throughout the present specification, it is noted that the NS3 antigens and/or other reagents may be bound to a solid 60 support or solid phase, both of which terms are used interchangeably. The term "solid phase" refers to any material that is insoluble, or can be made insoluble by a subsequent reaction. The solid phase can be chosen for its intrinsic ability to attract and immobilize a capture agent. Alternatively, the 65 solid phase can have affixed thereto a linking agent that has the ability to attract and immobilize the capture agent. The

12

linking agent can, for example, include a charged substance that is oppositely charged with respect to the capture agent itself or to a charged substance conjugated to the capture agent. In general, the linking agent can be any binding partner (preferably specific) that is immobilized on (attached to) the solid phase and that has the ability to immobilize the capture agent through a binding reaction. The linking agent enables the indirect binding of the capture agent to a solid phase material before the performance of the assay or during the performance of the assay. The solid phase can, for example, be plastic, derivatized plastic, magnetic or non-magnetic metal, glass or silicon, including, for example, a test tube, microtiter well, sheet, bead, microparticle, chip, and other conFIG.urations known to those of ordinary skill in the art.

In certain descriptions of the assays described herein it may be useful to refer to either the NS3, NS4 or core antigen or the HCV antibody as a specific binding partner. "Specific binding partner" is a member of a specific binding pair. A specific binding pair comprises two different molecules, which specifically bind to each other through chemical or physical means. Therefore, in addition to antigen and antibody specific binding pairs of common immunoassays, other specific binding pairs can include biotin and avidin (or streptavidin), carbohydrates and lectins, complementary nucleotide sequences, effector and receptor molecules, cofactors and enzymes, enzyme inhibitors and enzymes, and the like. Furthermore, specific binding pairs can include members that are analogs of the original specific binding members, for example, an analyte-analog. Immunoreactive specific binding members include antigens, antigen fragments, and antibodies, including monoclonal and polyclonal antibodies as well as complexes, fragments, and variants (including fragments of variants) thereof, whether isolated or recombinantly produced. The term "specific" and "specificity" in the context of an interaction between members of a specific binding pair (e.g., an antigen (or fragment thereof) and an antibody (or antigenically reactive fragment thereof)) refer to the selective reactivity of the interaction. The phrase "specifically binds to" and analogous phrases refer to the ability of antibodies (or antigenically reactive fragments thereof) to bind specifically to a given antigen (or a fragment thereof) and not bind specifically to other entities.

Antigens for Use in the Present Invention

As described herein the present invention describes the fluid, placental cells or tissue, endothelial cells, leukocytes, or 45 detection of a combination of HCV antigens in one assay to advantageously provide a sensitive and selective detection of HCV in the test sample being assayed. In certain preferred embodiments, the combination assay further detects the presence of anti-HCV antibodies. More particularly, the HCV antigens may be any antigen that is typically monitored in an HCV assay. Such antigens include but are not limited to core antigen, E1, E2, NS2, NS3, NS4 and NS5 or distinct and independent portions of any one of core antigen, E1, E2, NS2, NS3, NS4 and NS5. Immunoassays for the detection of such antigens individually are commercially available to those of skill in the art and any of the antigens used in such commercially available assays may readily be used as capture or detection antigens in the immunoassays of the present invention. For example, HCV NS3 protein and mutants thereof principally have to two main protein parts, the first corresponds to amino acids 1192-1457 per the HCV polyprotein numbering of P26664 (Genbank, reproduced herein as SEQ ID NO:2; Choo et al., PNAS 1991;) also known as C33 (as described originally by Chiron) or as "9NB49H". The second portion of the NS3 protein corresponds to amino acids 1192-1657 also known as NS3 helicase or "NS3h." Antigens comprising all or portions of these two proteins can readily be

used in the detection of anti-HCV antibodies in a test sample. For example, C33 is a well-known antigen derived from the NS3 protein of HCV and may readily be used herein as either the capture or detection antigen for the detection NS3 antibodies in the combination immunoassays of the present 5 invention.

Other NS3 derived antigens include those described in concurrently filed U.S. Provisional Application No. 61/784, 822 entitled "HCV NS3 Recombinant Antigens and Mutants Thereof for Improved Antibody Detection", Attorney Docket no. 03946-26530US01. Such antigens are variant of the C33 and the NS3 helicase proteins in which the N-termini or C-termini sequences were modified. In some embodiments, antigens were created that included cysteine to serine mutations. These mutations allowed for increased resistance of the antigen to oxidation thereby preserving epitope presentation and hence immunoreactivity. The cysteine to serine mutations also allowed for site-specific modification of the protein (via chemical conjugation using maleimide reagents) by mutating only selected cysteine residues, e.g. those deemed to be unim- 20 portant for maintenance of immunoreactivity. Furthermore, at least some of the cysteine to serine substituted mutants disrupt the ability of full length helicase enzyme (HCV aa1192-1657) to bind nucleotide triphosphates (e.g. ATP). This maintains the protein in an open or extended conforma- 25 tion (see Gu & Rice, PNAS, 2010, 107:521-528 and refer14

ences therein) and is shown in the present invention to produce enhanced immunoreactivity.

Exemplary NS3 antigens that may be used in of the present invention are shown in Table 1 herein below. In general, these NS3 antigens may be described as recombinant HCV NS3 antigen comprising a NS3 helicase sequence that comprises each of domains I, II and III of said helicase, wherein said antigen has increased immunoreactivity against HCV antibodies from serum as compared to C33 antigen, wherein said recombinant HCV NS3 antigen comprises one or more of the characteristics selected from the group consisting of: diminished ATP-binding activity as compared to the ATP-binding activity of wild-type NS3 helicase; diminished ATPase activity as compared to wild-type NS3 as compared to the ATPbinding activity of wild-type NS3 helicase, and increased redox stability as compared to the redox stability of wild-type NS3 helicase. More particularly, in the context of the present invention, the wild-type HCV NS3 comprises a sequence of SEQ ID NO: 87 and wherein the recombinant antigen of the invention comprises at least one mutation as compared to the sequence of SEQ ID NO:87. Detailed description of production and testing of these antigens is provided in concurrently filed U.S. Provisional Application No. 61/784,822, entitled "HCV NS3 Recombinant Antigens and Mutants Thereof for Improved Antibody Detection", having Attorney Docket No. 03946-26530US01.

TABLE 1

		TADLE I
Antigen designation	Antiqen	Sequence
	K210N	avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptqsqNstkv
_	KZION	paayaaqqyk vlvlnpsvaa tlqfqaymsk ahqidpnirt
		gvrtittgsp itystygkfl adggesggay diiicdeshs
		tdatsilqiq tvldqaetaq arlvvlatat ppqsvtvphp
		nieevalstt geipfygkai plevikggrh lifchskkk
		delaaklval ginavayyrg ldvsviptsg dvvvvatdal
		mtgytgdfds vidcntcvtq tvdfsldptf tietitlpqd
		aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvlcec
		ydagcawyel tpaettvrlr aymntpglpv c qdhlefweg
		vftglthida hflsqtkqsg enlpylvayq atvcaraqap
		ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp
		vtkyimtcms adlevvt (SEQ ID NO: 109)
В	S211A	avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkAtkv
		paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt
		gvrtittgsp itystygkfl adgg £ sggay diii c de £ hs
		tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp
		nieevalstt geipfygkai plevikggrh lif c h <i>skkk</i> c
		delaaklval ginavayyrg ldvsviptsg dvvvvatdal
		mtgytgdfds vid <u>c</u> nt <u>c</u> vtq tvdfsldptf tietitlpqd
		avsrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvl c e c
		ydag c awyel tpaettvrlr aymntpglpv c qdhlefweg
		vftglthida hflsqtkqsg enlpylvayq atv c araqap
		ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp
		vtkyimtcms adlevvt (SEQ ID NO: 110)
С	T212E	avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgksEkv
		paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt
		gvrtittgsp itystygkfl ad <i>ggesggay</i> diii <u>c</u> de e hs
		tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp
		nieevalstt geipfygkai plevikggrh lif <u>c</u> h <i>skkk</i> c
		delaaklval ginavayyrg ldvsviptsg dvvvvatdal
		mtgytgdfds vid $\underline{\mathbf{c}}$ nt $\underline{\mathbf{c}}$ vtq tvdfsldptf tietitlpqd
		aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvl c e c
		ydag c awyel tpaettvrlr aymntpglpv c qdhlefweg
		vftglthida hflsqtkqsg enlpylvayq atv <u>e</u> araqap
		ppswdqmwk c lirlkptlhg ptpllyrlga vqneitlthp
		vtkyimtcms adlevvt (SEQ ID NO: 111)

TABLE 1-continued

D Y241S, availpren lettmrapyf tohnaspyru, gafavahlha ptogketky paavaagoyk vilviprova tlejanjamska shijohjint grittitigap tityatyukil adagasgasy ditigidadha indevalett gespfygkai plevikggrh lifejankkig delaaklval ginavayrg ldvavipreg dvvvatdal mtgytgdfa videntevqt twifeldptf tietitlpdd ayartqrrg turghplyr fragaperpag midasvilee ydagasayal treattvir aymatpglpv eqdhlefweg ydagasayal treattvir aymatpglpv eqdhlefweg yftglindan hingkytgdfa videntevqt twifeldptf tietitlpdd ayartqrrg turghplyr fragaperpag midasvilee ydagasayal treattvir aymatpglpv eqdhlefweg yftglindan hingkytgdfa ytviliprova tigfgaymak ahajdprirt grutitigap tivaysyfil adgagasyar ditigheka cheaklival ginavayrg ladvalprag dvavatdal mtgytgdfa videntevqt twifeldptf tietitlpdd ayartqrrg turghpyfr fragaperpag midasvilee ydagasayal tynettvir aymatpglpv eqdhlefweg yftglindan hingkytgdfa videntevqt twifeldptf tietitlpdd ayartqrrg turghpyfr fragaperpag midasvilee ydagasayal tynettvir aymatpglpv eqdhlefweg yftglindan hingkytgd envyragaperpag midasvilee ydagasayal tynettvir aymatpglpv eqdhlefweg yftglindan hingkytgd gdvyraya tavaraqap ppowdqmwke lirkptlap tpllyriga ympetitlip vthyimtems adlevt (SEQ 10 No: 113) F E2910 avdipven lettmrapvf tdnssppvvp qefqvahlha ptgggkstkv paavasagyk vivinpavaa tigfgaymak ahajdqnirt grutittgap tivatytgfi adgagasyad ditiedogfan tdataligig tvidqaetag arivvlatar pspovtyphp nieevalatt gespfyghai plevikgga ditiedogfan tdataligig tvidqaetag arivvlatar pspovtyphp nieevalatt gespfyghai plevikggm litelakkid atgytgdfa videntevqt vidfildptf tietitlpdd ayartqrrg turghpylyr fragaperpag midasvilee yftglinda hilaghqylyr fragaperpag midasvilee yftglinda hilaghqyla ilighayay atvaraqap ppswdqmke	Antiger designa	ı ıtion Antigen	Sequence
gvrittigpp tywsykfi adegdsgaya diiledenbe todatsligig tvidqaetag anlvulata pgaytvyhp nleevalatt gelpfygkai plevikggth lifehakki delaaklval ginawayyra ldworbtag wytgdfds videntgwtg twdfaldpif tietitlpdd aysttgrag tyghgifyr fwaperpag midawvleeg ydagcawyel tpaettvrir aymntpglpv eqdnlefweg vtglithida milagtkage enlpylaya twgaradap ppowdgmako lirikpilmp ptpllyrlga vqmeitithp vtkyintems adleevt (SEQ ID NO: 112) E D290N awdfipven lettmrapyf tinnegppup ciefgvahhla ptgegketkv paavadagyk wluhpevaa tlefgaymak amgidpnirt gwrititgpp itywtykfil adegdsgaya diilekelbe rdatsligig tvidqaetag anivulatat pgegavtyhp nleewalatt gelpfygkai plevikkggh lifehakki delaaklval ginawayyra ldworbtag dwywytadal mtgytgdfds videntevut twdfaldpif tietitlpdd aysttgrag tyghgylyr fwaperpag midawvleeg ydagcawyel tpaettvrir aymntpglpv cgdnlefweg vttglthida hilogtkage enlpylaya twgestagap ppswdgmako lirikptlmp ptpllyrlga vqmeitlthp vtkyintems adleevt (SEQ ID NO: 113) F E291Q avdfipven lettmrapyf tdnsappvvp qefqvahlha ptgegketkv paayaaqyk vluhpavaa tlefgaymak amgidpnirt gyrtitgpm ityvsykfi adeglaggay diilegdphs rdatsligig vidqaetag arlvvlatat ppgavtvphp nleevalatt gelpfygkai levikggrh lifehakki mtgytdoffds videntevut vvaffaldpif tietitlpdd aysttgrag tsympkykai plevikggrh lifehakki mtgytdoffds videntevut twaffaldpif tietitlpdd aysttgrag tsympkykai plevikggrap delighakki mtgytdoffds videntevut twaffaldpif tietitlpdd aysttgrag tsympkyky reperpeg midsevleeg ydagcawyel tpaettvrir aymntpglpv cgdnlefweg vttglithda hifletykage enlyplylaya vqmeitlthp vtkyintems adlevut (SEQ ID NO: 115) H A193A avdfipven lettmrapyf tdnsegppvp gefqvahlha ptgegketkv paayaaqsyk vluhpavaa tlefgaymak amgidpnirt gyrtitgpm itysykfi adgsgayay diilomakki delaaklval ginawayyrg ldveviptng dywvaetada mtgytgdfds videntevut vtkfeldpuf tietitlpdd aysttgrag tgrgkpiyr fvapperpag midsevleeg vydagcawyel tpaettvrir aymntplpv cgdrlefweg vydagdawyel tpaettvrir gyrtiylps a vgreitlhp vtkyintems allevut (SEQ ID NO: 115) H T419G avdfipven lettmrapyf tdnsegpspy midsevleeg vydagdawyel tpaettvrir gyrtiy	D	Y241S,	avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv
icatesligig tvidqaetag ariwvlatat ppggavtyphp nleewalatt geinydgai plevikgghl lifehakki delaaklval ginawayyrg ldvovipteg dvwvatdal mtgytgdfds viantevtq tvdfaldptf tietitlpdd aysrtgrgr tgrgkpglyr fvapgerpag mfdsovleeg ydagcawyel tpaettvrlr aymntpglyv cqdlefweg vftglthida hfleqtkygg enlpylvayq atvgaraqap ppswdqmoko lirlbprlhg ptpllyrlga vqmeilthp vtkyimteme adlevvt (SEQ ID NO: 112) E D290N avdfipven lettmropyf tdnseppvvp cisfqvahlha ptgegkstkv paayaqayk Vulnpavaa tlgfgaymok abgidpnirt gyrtittgap itystygkfl adoggeggay diigNeEns tdatsligig vidqaetag ariwvlatat ppgertvfha nawalatt geapfygkal plevikggal lifehakfla delaaklatt geapfygkal plevikggal mtgytgdfds vidqaetag rivytlatat ppgertvfha aysrtgrgr tgrgkpgtyr fvapgerpeg mfdsovleeg ydaggaayyel tpaettvrlr aymntpglyv codlefweg vftglthida hfleqtkygg enlpylvayq atvgaraqap ppswdgmoko lirlbprlhg ptpllyrlga vqmeitlthp vtkyimtems adlevvt (SEQ ID NO: 113) F E291Q avdfipven lettmropyf tdnseppvvp qefqvahlha ptgegkstkv paayaaqyk vlulnpavaa tlgfgaymok abgidpnirt gyrtittgp itystygkfl adoggasgaya diidcdqgfls tdatsligig tvdqaetag arlvukatt ppgsvtvphp nleevalstt geipfygkal plevikggh lifehakkkl delaaklval ginawayyng ldwsytpsg dvvvvatdal mtgytgdfds vidqentgvtg tvdfaldptf tietitlpdd aysrtgrgr tgrgkpglyr vapgerppg mfdsovleeg ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflegtkygg enlpylvaya tvgaraqap ppswdgmoko lirlbprlhg ptpllyrlga vqmeitlthp vtkyimtems adlevvt (SEQ ID NO: 113) G H293A avdfipven lettmropyf tdnseppvvp gefqvahlha ptgegkstkv paayaaqgyk vluhpavaa tlgfaymok abgidpnirt gyrtittgp itystygkfl adggaggay diiidedaks rdatsligig tvldqaetag arlvukatt ppgevtvphp nleevalatt geipfygkir vapgerpag mfdsovleeg ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vtrgithida hflegtkage enlpylvyaya tvgaraqap ppswdgmoko lirlbprlhg ptpllyrlya vqmeitlthp vtkjimtems adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnseppvvp gefqvahlha ptgegkstkv paayaaqgyk vluhpavaa tlgfgaymok abgidpnirt gyrtittgp itystygkfl adggaggay diitedehs rdatsligg tvldqaetag arlvvlatat ppgevtvphp nleevalatt geipfyg			
nleewalott geipfygkai plevikggih lifehakkik delaaklval ginawyyng ldwoythga dwywytadal mtgytgdfda videnteytg twifeldpif tietitlpdd aysttgrig tgyfgylfyr fwagapenga midasvleeg ydagcawyel tpaettvir aymntpglpv ogdhlefweg vftgithida hifeghkage enlpylavg atvegracap ppswdqmako lirikptlhg ptpllyriga vqneitithp vtkyimtems adleewt (SEQ ID No: 112) E D290N avdfipven lettmrspyf tdnssppvvp ciefqvahlha ptgsgkstkv paayaaqgyk vlvinpavaa tlgfgaymak ahgidpnirt gyrtittgep itystygkin jalegleggya diigighes tdatsilgig tvldqaetag arivvlatat ppgavtvphp nleevalott geipfygkai plevikggrh lifehakkik delaaklval ginavayyrg ldvsviptsg dwywvatdal mtgytgdfds videnteytg tvdfeldpf tietitlpdd aysttgrig trgfypglyr fvapgerpeg midasvleeg vdagcawyel tpaettvrir aymntpglvv cqdhlefweg vtfgithda hilegtkage enlpylvayg atvearaqap ppswdqmako lirikptlp gptpllyriga vqmeitlthp vtkyintems adleewt (SEQ ID No: 113) F E291Q avdfipven lettmrspyf tdnssppvvp gefqvahlha ptgsgkstkv paayaagyk vlvinpavaa tlefsaymak ahgidpnirt gyrtittgp itystyffi adgesgay diicideghs rdatsilgig tvldqaetag arivvlatat ppgavtvphp nleevalett geipfygkai plevikggrh lifehakkik delaaklval ginawayyrg ldvsviptag dwywatdal mtgytgdfds videnteyt tvdfalpfyf tietitlpdd aysttgrig tgrgkpfyr fvapgerpag midasvleeg vdagcawyel tpaettvrir aymntpglvv cqdhefweg vttgithida hiflsqtkgsg enlpylvayg atvearaqap ppswdqmako lirikptlhg ptpllyrlga vqmeitlthp vtkyimtems adleevt (SEQ ID No: 114) G H291A avdfipven lettmrspyf tdnssppvvp qefqvahlha ptgsgkstkv paayaagyk vlvinpsvaa tlgfgaymsk ahgidpnirt gyrtittgp itystygkfi adggsgsgy diiicdeska tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nleevalett geipfygkai plevikggrh lifehakkk delaaklval ginawyyrg ldvayetpsg dvisitedeska tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nleevalett geipfygkai plevikggrh lifehakkk delaaklval ginavyyrg ldvayetpsg vysgraraqap ppswdqmako lirikptlng ptpllyrlya vqmeitlthp vtkyimtems adlevvt (SEQ ID No: 116) H O460H avdfipven lettmrspyf tdnssppvvp qefqvahlha ptgsgkstkv paayaaqyk vlvinpsvaa tlgfgaymak ahgidpnirt gyrtittsgp trytsyffi adgesgay diicdeshs tda			
delaaklval ginawayyzg idvoviptog dvwvatdal megytodfab videntevtq twidpidpt tietitlepd ayesterrgy tgrghpjyr fvapgerpog midesvleeg ydageavyel tpaettvirl aymntpglyv eqdilefveg vftgithida hilegtkgog enlpylvayq atvearagap ppswdomoko litikpilng ptpllyrlga vapeitlthp vtkyintomes adlevut (SEQ ID NO: 112) E D290N avdfipven lettmrspyt tdnssppvvy cisfqvahlha ptgogketkv paayaaqgyk vlvinpsvaa tlgfgaymak ahgidpnirt gvrtittspy itystyskfi adoggeggay diligkegns tdatsilgig tvidqaetag arlvulatat pgogvtvshp nieevalett gelpfygkal plevikggrh lifshakkog delaaklval ginavayyzg ldvaviptog dvvvardad mygrtgrig tgrghpjyr fvapgerpog midesvolege ydagaavaye tpaettvilr aymntpjlvv eqdilefveg vftgithida hilegtkgog enlpylvayq atvearagap ppowdqmoko litihptlhp ptpllyrlga veneitlthp vtkyimtoms adlevut (SEQ ID NO: 113) F E291Q avdfipven lettmrspyf tdnseppvvp gefqvahla ptgogketky paayaaqyyk vlvinpsvaa tlgfagymok ahgidpnirt gyrtittepp itystyskfi adoggeggay dilied@ghs tdatsilgig tvidqaetag arlvulatat pgaptvysph nieevalett gelpfygkai plevikggrh lifshakkki delaaklval ginavayyrg ldvavitgag dvvvvatdal mtgytpdfds videntgvtq tvdfaldptf tietitlpqd aysttgrg tgydqasyay tydaydayay tydayayatayap ppswdomkok litikptlip ptpllyrlya vqmeitithp vtkyimtoms adlevut (SEQ ID NO: 114) G H293A avdfipven lettmrspyf tdnseppvvp gefqvahlha ptgogketky paayaaqgyk vlvinpsvaa tlgfgaymok ahgidpnirt gelithida hiflegtkage enlypivaya tvageraaqap ppswdomkok litikptlip ptpllyrlya vqmeitithp vtkyimtoms adlevut (SEQ ID NO: 114) G H293A avdfipven lettmrspyf tdnseppvvp gefqvahlha ptgogketky paayaaqgyk vlvinpsvaa tlgfgaymok ahgidpnirt gyrtittida hiflegtkage enlypivayay atvearaqap ppswdomkok litikptlip ptpllyrlya vqmeitithp vtkyimtoms adlevut (SEQ ID NO: 115) H T419G avdfipven lettmrspyf tdnseppvvp gefqvahlha ptgogketky paayaaqgyk vlvinpsvaa tlgfgaymok ahgidpnirt gyrtittiga tvidqaetag arlvvlatat ppgotvybp nieevalett gelpfygkar plevikggrh lifehakkki delaaklval ginavayyrg ldvaviptag dvvvaaraqap ppswdomoko litikptlip ptpllyrlya vqmeitithp vtkyimtoms adlevut (SEQ ID NO: 115) I Q460H avdfipven			
mgytqdfdö videntevit vafsidptf tietitlpd aysttqrg tgytgyplyr kaysperpsg mfdssvlees ydagcawyel tpaettvir aymntpglyv oqdhlefweg vftqithida hifleqtkoge enlyylavay atvegaraqsp ppowdqmwko lirikptlbg ptpllyrlay avgeitlthp vtkyimtems adlevut (SRQ ID No: 112) E D290N avdfipven lettmrspvf tdnssppvvp cisfqvahlha ptgsgkstkv paayaaqgyk vlvlnpovaa tlgfgaymok abgidpnirt gvriitsps itystygkli adgsgagsy diiigfm&bs tdatsllgig tvldqaetag arlvvlatat ppgsvtvphp nisevalut geirptyskai plevikggh lifehakk& delaaklval ginavayyrg ldvsviptog dvvvvatdal mtgytgdfds videntevtq tvdfoldptf tietitlpdd ayvstqrrgr tgrgkpglyr fvapperpsg mfdssvlees ydagcawyel tpaettvrlr aymntpglyv cqdhlefweg vtfglthdå hiflettkog enlyylvayq atvearaqsp ppswdqmwko lirikptlbg ptpllyrlga vapreitlthp vtkyintems adlevut (SRQ ID No: 113) F E291Q avdfyren lettmrspvf tdnssppvvp gefgvahlha ptgsgkstkv paayaaqgyk vlvlnpovaa tlgfgaymsk abgidpnirt gvriittsps itystygkli adgsgagsy diiigdgbs tdatslldig tvldqaetag arlvvlatat ppgsvtvphp nisevalut gefrydkai plevikggrh lifehakk& delaaklval ginavayyrg ldvsviptag dvvvvatdal mtgytgdfds videntevtq tvdfaldptf tietitlpdd aysttgrrgr tgrgkpgiyr fvapperpsg mfdssvlees ydagcawyel tpaettvrlr aymntpglvv cqhlefweg vttglthida hiflegtkgsg enlpylvayq atvearaqsp ppswdqmkok lirikptlbg ptpllyrlga vapeitlhp vtkyimtems adlevut (SRQ ID No: 114) G H293A avdfipven lettmrspvf tdnssppvvp gefgvahlha ptgsgkstkv paayaaqyyk vlvlnpsvaa tlgfgaymsk abgidpnirt gyrtittspy itystygkfl adgsgagsya diiided&As tdatsllgig vldqaetag arlvvlatat ppgsvtvphp nisevalut geipfygkai plevikggth lifehakk& delaaklval ginavayyrg ldvaytptsg dvvvvatdal mtgytgdfds videntevtq tvdfaldptf tietitlpdd aysttqrgr tgrgkpgiyr rkapperpsg mfdssvlees ydagcavyel tpaettvrir aymntpglyv cqdfalefwe vttgrdr tgrgkpgiyr properpsg mfdssvlees ydagcavyel tpaettvrir aymntpglyv cqdralha ptgsgkstkv paayaaqyk vlvlnpsvaa tlgfgaymsk abgidpnirt gyrtittsp itystygkfl adgsgagsy diiidedshs tdatsllgig vldqaetag arlvvlatat ppgsvtvphp nisevalut geipfygkai plevikggrh lifehakk& delaaklval ginavayyrg ldvayeprag mfdssvlees vtkylthi			
ayöstçirgi tgiqhgiyi fvapqerpog mfdesvleeg ydagaawyel tpaettviri aymıtpilv oqdılefweg vftgithida hfleqtkuge enlyylvayq atvaraqap ppowdqmoko lirihptilm ptpilyliqa vqmeilthp vtkyimtems adlevut (SEQ ID NO: 112) E D290N avdipven lettmrspyf tdnseppvup cisfqvahlha ptgegkstkv paayaaqyyk vlvinpevaa tigfqaymak ahgidpnirt gvriittgep ityetygkfi adggeggay diiigNeshs tdatsilgig tvidqaetag arlvvitast ppgevtvphp nieevalatt geipfygkai plevikggih lifehskkki delaaklval ginavayyrg ldvwiptng dvvvvatdal mtgytgdfds videntevtq tvdfeldptf tietitlpqd ayertqrsg tgyfkgjiyr fvapqerpeg mfdesvlee ydagcawyel tpaettvir aymutpglpv oqdilefweg vteglihdia hfleqtkuge enlyylvayq atvearaqap ppowdqmwko lirikptilm ptpllyrlga vomeilthp vtkyimtems adlevut (SEQ ID NO: 113) F E291Q avdfipven lettmrspyf tdnseppvvp qsfqvahlha ptgegkstkv paayaaqysk vlvinpovaa tlgfgaymak ahgidpnirt gyriittgep ityerygkfi adggeggay diiqdogdis tdatsilgig tvldqaetag arlvviatat ppgevtvphp nieevalatt gelpfygkai plevikggrh lifehskiki delaaklval ginavayyrg ldveviptng dvvvvatdal mtgytgdfds videntytq tvdfidpdf tietitlpqd ayostqrrgy tgrgkpjyr fvapperpeg mfdesvleeg vdageswyel tpaettvrir aymutpglvv oqdilefweg vftglthid influgtkuge enlyylvayq atvearaqap ppowdqmako lirikptlm ptpllyrlga vqueitlthp vtkyimtems adlevut (SEQ ID NO: 114) G H293A avdfipven lettmrspyf tdnseppvvp qsfqvahlha ptgegkstkv paayaaqgyk vlvlnpovaa tlgfgaymsk ahgidpnirt gyrtittgyp trystyffi adggeggay diidedsks tdataklval ginavayrg ldveviptng dvvvvatdal mtgytgdfds videntevut tvdfeldptf tietitlpqd ayostqrrgy tgrgkpjyr fvapperpeg mfdesvleeg ydageavyel tpaettvrlr aymtpglpv oqdilefweg vftglthida hfleqtkuge enlyylvayq atvearaqap ppowdqmoko lirikptlm ptpllylvayq atvearaqap ppowdqmoko lirikptlmp ptpllylvayq atvearaqap pp			
ydagcasyel tpaettvir aymntpajpv ogdniefweg vftgithida filegtkage enjpylavay atvearaqap ppswdamwke lirikptihg ptpllyrlag vagesithtp vtkyimteme adlevvt (SEQ ID No: 112) E D290M avdfipven lettmrspyf tdnssppvvp cisfqvahlha ptgsgkstkv paayaaggyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystyskfi adgsgasgag diiseMshs tdatsilgig tvldqaetag arlvvlatat ppgsvtrphp nisevalett gelpfygkai plevlkgght lifehskkk delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtsytgdfdo videntevtg tvdfolaptf tietitlpqd aysrtgrrg; tgrgkpgiyr fvapgerpsg mfdssvlcec ydagcasyel tpaettvirl aymntpajpv ogdniefweg vftglthida hflsgtkugs enlpylvayq atvearaqap ppswdqmwke lirikptlihg ptpllyrlga vqneitithp vtkyimteme adlevvt (SEQ ID No: 113) F E2910 avdfipven lettmrspyf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaggyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystyskfi adgsgsggay diiied@ghs tdatsilgig tvldqaetag arlvvlatat ppsvtyphp nisevalett gelpfygkai plevlkggth lifehskkk delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtsytgdfdo videntevtg tvdfolaptf tietitlpqd aysrtgrrg; tgrgkpgiyr fvapgerpsg mfdssvlcec ydagcasyel tpaettvirl aymntpglpv ogdhlefweg vftglthida filsgtkags enlpylvayq atvearaqap ppswdgmwke lirlkptlhg ptpllyrlga vqneitithp vtkyimtems adlevvt (SEQ ID No: 114) G H293A avdfipven lettmrspyf tdnssppvvp gsfqvahlha ptgsgkstkv paayaaggyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystyskfi algsgaggag diided&as tdatsilgig tvldqaetag arlvvlatat ppgsvtyphp nisevalett gelpfygkai plevlkggth lifehskkkg delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtsytgdfdo videntevtg tvdfolapti tettitlpqd aysrtgrrg; tgrgkpgiyr fvapgerpsg mfdssvlcec ydagcasyel tpaettvirl aymntpglpv ogdhlefweg vftglthida hflsqtkags enlpylvayq atvearaqap ppswdgmwke lirlkptlhg ptpllyrlay avqueitithp vtkyimtems adlevvt (SEQ ID No: 115) H T419G avdfipven lettmrspvf tdnssppvvp gsfqvahlha ptgsgkstkv paayaaggyk vlvlnpsvat tlgfgaymsk ahgidpnirt gvrtittgsp itystyskfi adgsgsggag diided&s tdatsilgig tvldqaetag arlvvlatat ppsvtvphp nieevalett gelfygkai plevlkgsph lifehskke delaaklval ginavayyrg ldvsvipt			
E D290N avdfipven lettmropyf tdnseppvvp cinfqvahlha ptgsgkntkv panyanagyk vlvlnpovna tlgfgaymmk ahgidpnirt gvrtirtgep itystyskih adgasgagaga diligNachs tdatoilgig tvldqaetag arlvvlatat ppgsvtrphp nieevalett gelpfygkai plevlkggyn lifeNachs delaaklval ginavayyrg ldvsvipteg dwvvvatdal mtgytgdfds videntevtg tvdfsleptif ettitlpdd aysrtgrig tgrgkpgiyr fvapgerpeg mfdssvleeg ydagcawyel tpsettvrlr aymntpglpv cgdhlefweg vftglthida hflegtkog enlpylvayq atvgaraqap ppswdqmwka lirlkptlhg ptpllyrlga vqneitlthp vtkyimtems adlevvt (SEQ ID No: 113) F E2910 avdfipven lettmrspvf tdnssppvvp gsfqvahlha ptgsgkstkv panyanagyk vlvlnpavna tlgfgaymmk ahgidpnirt gvrtittgep itystygkfl adgsgsggay dliigdgshs tdatoilgig tvldqaetag arlvvlatat ppgsvtyphp nieevalett gelpfygkai plevikggnh lifehskkk delaaklval ginavayyrg ldvsvipteg dvvvvatdal mtgytgdfds videntevtg tvdfsldptf tietitlpdd aysrtgrig tygfyglyf ryspgerpeg mfdssvleeg ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflogtkoge enlpylvayq atvgaraqap ppswdgmwka lirlkptlhg ptpllyrlga vqneitlthp vtkyimtems adlevvt (SEQ ID No: 114) G H293A avdfipven lettmrspvf tdnssppvvp gsfqvahlha ptgsgkstkv panyanaggyk vlvlnpavna tlgfgaymmk ahgidpnirt gvrtittgep itystygkfl adgsgsggay dliidedsh tdatoilgig tvldqaetag arlvvlatat ppgsvtyphp nieevalett gelpfygkai plevikggrh lifehskkkg delaaklval ginavayyrg ldvsikggsh lifehskkkg delaaklval ginavayyrg ldvsiygsh lifehskkkg delaaklval ginavayyrg ldvsvipteg dvvvvatdal mtgytgdfdo videntevt (SEQ ID No: 114) H T4190 avdfipven lettmrspvf tdnssppvvp gsfqvahlha ptgsgkstkv panyaaggyk vlvlnpavna tlgfgaymmk ahgidpnirt gvrtittgep tytgygkfl adgsgsggay dliidedsh tdatoilgig tvldqaetag arlvvlatat ppgsvtyphp nieevalett gelpfygkai plevikggrh lifehskkg delaaklval ginavayyrg ldvsvipteg dvvvvatdal mtgytgdfdo videntevtg tvdfsldptf tietitlppd aysrtgrrg tgrgkpgiyr fvapgerpeg mfdssvleeg ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkage gelpylvaya atvgaraqap ppswdgmwka lirlkpthg ptpllyrlaa vqneitlthp vtkyimtems adlevvt (SEQ ID No: 116) I Q460H avdfipven lettmrspvf t			
E D2901 avdfipven lettmrspyf tdnssppvvp cisfqvahlha ptgsgkstkv payaaggyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittspy itystysfil adgg&sggay diiieNeshs tdatcildigi tvldqaetag arivvlatat ppgsvtvphy nieevalett geipfygkai plevikgyn lifghokksk delaaklval ginavayyng ldvsviptsg dvvvvatdal mtgytgdfds vidgntevtg tvdfsldpff tietitlpdd aysrtgrg; tgrghgjiyf vapgerpsg mfdssvleeg ydagcawyel tpaettvilr aymmtpglpv eqdhlefweg vftglthida hfingtkogs enlpylvayg atvaaraqap ppswdgmwke lirlkptlhg ptpllyrlga vgneitlthp vtkyimtoms adlevvt (SEQ ID NO: 113) F E2910 avdfipven lettmrspyf tdnssppvvp gefqvahlha ptgsgkstkv paayaaggyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gyvtittsps livystysfil adgssgsgy diidcdgchs tdatcilgig tvldqaetag arivvlatat ppgsvtvphp nieevalett gelfygkai plevikgyn liefdskeked delaaklval ginavayyng ldvsviptsg dvvvvatdal mtgytgdfds videntevtg tvdfaletag tettitlpdd aysrtgrg; tgrghpgiy; fvapgerpsg mfdssvleeg yddgcasyel tpaettvilr aymmtpglpv eddhlefweg vftglthida hflegtkogs enlpylvayg atvasraqap ppswdgmwke lirlkptlhg ptpllyrlga vgneitlthp vtkyimtoms adlevvt (SEQ ID NO: 114) G H293A avdfipven lettmrspyf tdnssppvvp gefqvahlha ptgsgkstkv paayaaggyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgp itystygkfl adgsgsgys diitedschs tdatcilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalett gelfyfyskai plevikggrh lifehokksg delaaklval ginavayyrg ldvsviptg dvvvvatdal mtgytgdfds videntevet tfdfolpfr leteilipdd aysrtgrg; tgrghpgiyr fvapgerpsg mfdssvleeg ydagcawyel tpsettvrir aymmtpglpv edhlefweg vftglthida hflagtkogs enlpylvayq atvgaraqap ppswdgmwke lirlkptlhg ptpllyrlga vyneitlthp vtkyimtoms adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspyf tdnssppvvp gefqvahlha ptgsgkstkv paayaaggyk vlvlnpavaa tlgfgaymsk ahgidpnirt gvrtittsps itystygkfl adgsgsgyay diitedschs tdatcilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalett gelfyfyskai plevikgsth lifehokksg delaaklval ginavayyrg dtvsylpta avgaraqap ppswdgmwke lirlkptlhg ptpllyrlag vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 115) I Q460H avdfipven lettmrspyf tdnssppvvp gefqvahlha ptgsgkstkv paayaaggyk vlv			
B D290N avdfipven lettmrspyf tdnssppvvp cisfqvahlha ptgsgkstkv paayaasgyk vlvlnpsvas tlefdaymsk ahdidpnirt gyrtittsgs jtvstyskil adgasgasgad ilielseks tdatsilgig tvldqaetag arivvlatat ppgsvtrphp nieevalett gejfrygkai plevlkggh lifehskku delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevet tvfdeldptf tietitlpdd aysrtgrig tggdpglyr fvapgerpsg mfdsevleeg yddgcasyel tpaettvrlr aymurpglpv edhlefweg vftglthida hfleqtkgg enlpylvayg atvgaragap ppswdqmwke lirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevet (SEQ ID No: 113) F E291Q avdfipven lettmrspyf tdnssppvvp gsfqvahlha ptgsgkstkv paayaasgyk vlvlnpavaa tlgfgaymsk ahgidpnirt gyrtitsgs itystyskin adgasgsgay dliiedogshs tdatsilgig tvldqaetag arivvlatat ppgsvtvphp nieevalett gelfyfyskai plevlkggth lifehskku delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevet tvfslephfat eletitlpd aysrtgrig tgrgkpglyr fvapgerpsg mfdssvleeg ydagcasyel tpeattvrlr aymurpglpv edhlefweg vftglthida hflsgtkgg enlpylvayq atvgaraqap ppswdqmwke lirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevet (SEQ ID No: 114) G H293A avdfipven lettmrspyf tdnssppvvp gsfqvahlha ptgsgkstkv paayaaggyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gyrtittsg itystygkfi adgsgsgsgay dliiedesks tdatsilgig tvldqaetag arivvlatat ppswtyphp nieevalett geipfygkai plevlkggth lifehskku delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevet tvdfsldpt tietitlppd aysrtgrig trgkpglyr fvapgerpsg mfdssvleeg ydagcasyel tpaettvrlr aymutpglpv eqdhlefweg vftglthida hflsqtkggs enlpylvayq atvgaraqap ppswdqmke lirlkptlhg ptpllyrlga vqneitlthp vftyintoms allevet (SEQ ID No: 114) H T419G avdfipven lettmrspyf tdnssppvvp gsfqvahlha ptgsgkstkv paayaaggk vlvlnpsvaa tlgfgaymsk ahgidpnirt gyrtittsge tytgtygkfl afgdsgaggag dliiedesks tdatsilgig tvldqaetag arivvlatat ppgsvtyphp nieevalett gejfrygkai plevlkggth lifehskku delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevet tvfsfeldptf tietitlpdd aysrtgrig tgydpglyr fvapgerpsg mfdssvleeg ydagcasyel tpaettvrlr aymutpglpv eqdhlefweg vftglthida hfloqtkgsg enlpylvay			
paayaaggyk vlvInpewas tlefdgaymek abgidpnirt gyrtittsgep itystykfif adaggasgaya didiseMeshs tdateilgig tvidqaeatag arlwvlatat pegavtvphp nieewalett geipfygkai plevikggrh lifehakkis delaaklval ginavayyrg idwavipteg dwvwvatdal mtgytgdfde videntgvtg twdfeldptf tietitlpdd aysrtqrrgr tgrgkpgjyr fvapgerpsg mfdsevlgeg ydagsaavyel tpaettvrlr aymuntpgjhv eqdhlefweg vrtigithida hflsgtkgag enlpylvayq atvearagap ppswdqmwke lirlkpthg ptpllyriga vgmeitlthp vtkyimtems adlevvt (SEQ ID No: 115) F E291Q avdfipven lettmrspvf tdnssppvvp qsfqvahlaa ptgsgkstkv paayaaggyk vlvInpavaa tlgfgaymek abgidpnirt gyrtittgep itystyykfi adggssgaya diligde@is tdateilgig tvldqaeatag arlvvlatat ptgsutvphp nieevalstt geipfygkai plevikggrh lifehakkig delaaklval ginavayyrg ldvsvipteg dvvvvatdal mtgytgdfds videntevqt twdfoldptf eietitlpqd aysttgrrgr tgrgkpgjyr fvapgerpsg mfdssvleeg ydagcawyel tpaettvrir aymuntpglpv qdhlefweg vftglthida hflsgtkgag enlpylvayq atvearagap ppswdqmwke lirlkpthg ptpllyrlag vqmeitlthp vtkyimtems adlevvt (SEQ ID No: 114) G H293A avdfipven lettmrspvf tdnssppvvp qsfqvahlaa ptgsgkstkv paayaaggyk vlvInpsvaa tlgfgaymsk abgidpnirt gyrtittgsp itystysfif adggsgagay diligde@As tdateilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehakkig delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds vidgnteyt tvdfeldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleee ydageawyel tpaettvrlr aymutpglpv oqdhlefweg vftglthida hflsgtkgag enlpylvaya atvearagap ppswdqmwke lirlkpthg ptpllyrlag vqmeitlthp vtkyimtems adlevvt (SEQ ID No: 115) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaggyk vlvInpsvaa tlgfgaymsk abgidpnirt gyrtittgep itystygkfi adggsgagay diligde@hs tdateilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalst geipfygkai plevikggrh lifehakkig delaaklval ginavayyrg ldvsviptsg ddvvvvatdal mtgytgdfd viddenteyt tvdfeldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleee vftgthida hflsgtkage glaylvaya tvgaragap ppswdgmwke lirlkpthg tyflylyaga vgneitlthp vleymtems allevt (SEQ ID No: 116)			
gyriitigep itystygkfl adggægay diileimehs tadsilgig tvidqaetag arlvvlatat ppgwtvphp niewalst geipfygkai plevikggrh lifghakk@ delaaklval ginavayyrg ldweviptag dwywatdal mtgytgdfds videntevtg twdfeldptf tietitlpdd aywrtqrrg trygghgyfy fvapgerpsg mfdswleec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vttgithida hflsqtkgeg enlpylwayd atvearagap ppswdqmwke lirlkpthig ptpllyriga vqmeitlthp vtkyimtems adlevvt (SEQ ID No: 113) F E291Q avdfipven lettmrspvt tdnssppvvp qsfqvahla ptgsgkstkv paayaaggyk vlvlnpavaa tlgfgaymsk ahgidpnirt gyrittgpp itystygkfl adggægay diiledggfns tdatsilgig tvldqaetag arlvvlatat ppgotvphp nieevalstt geipfygkai plevikggrh lifghakk@ delaaklval ginavayyrg ldvsviptsg dwywatdal mtgytgdfds vidgnteytq tvdfeldptf tietitlpdd aywrtqrrg tgygkpgiyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vtfgthida hfisgtkgsg enlpylwayd atvearagap ppswdgmwke lirlkpthg ptpllyrlga vqmeitlthp vtkyimtems adlevvt (SEQ ID No: 114) G H293A avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaggyk vlvlnpavaa tlgfgaymsk ahgidpnirt gyrtittgpp itystygkfl adggægay diiledeGAs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehakk@ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds vidgntevqt tvdfeldptf tleitilpqd aysrtqrrg tgygkpgiyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftgithida hflsqtkgeg enlpylvayd atvearagap ppswdgmwke lirlkpthg ptpllyrlga vqmeitlthp vtkyimtems allevvt (SEQ ID No: 116) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaggyk vlvlnpavaa tlgfgaymsk ahgidpnirt gyrtittgpp itystygkfl adggægagay diiledeGhs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehakk@ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGdfds videntevqt tvdfeldptf tietitlpqd aysrtqrrg tgrgkpgiyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vtfgthida hflsqtkgeg enlpylvayd atvearaqap ppswdgmwke lirlkpthg ptpllyrlga vqmeitlthp vtkyimtems adlevvt (SEQ ID No: 116)	E	D290N	
tatabiligi tvladgaetag arlvvlatat ppgavtvphp nieevalstt geipftyskai plevikggrh lifehskkæ delaaklval ginavayyrg ldveviptsg dvvvatdal mtgytgdfds videntevtg tvdfeldptf tietitlpdd aymrtqrrgr tgrgkpglyr fvapgerpsg mfdsevleec ydagcawyel tpaettvrlr aymntpglyv cqdhlefweg vftglthida hflsqtkgsg enlpylvayq atvearaqap ppswdqmwke lirlkpths ptpllyrjag vqmeitlthp vtkyimtems adlevvt (SEQ ID No: 113) F E291Q avdfipven lettmrspvf tdnssppvvp qefqvahlha ptgegkstkv paayaaggyk vlvlnpavaa tlgfgaymsk abgidpnirt gvrtittgep itystygkfl adggssgaya diligdqgshs tdatsilgig tvldqaetag arlvvlatat ppgavtvphp nieevalstt geipftyskai plevikggrh lifehskkæ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevdt tvdfsldptf tietitlpdd aysttqrrgr tgrgkpglyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglyv cgdhlefweg vftglthida hflsqtkgsg enlpylvayq atvearaqap ppswdqmwke lirlkptlhg ptpllyrjag vqmeitlthp vtkyimtems adlevvt (SEQ ID No: 114) G H293A avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaggyk vlvlnpavaa tlgfgaymsk abgidpnirt gvrtittgsp itystygkfl adggssgaya diligde&as tdatsilgig tvldqaetag arlvvlatat ppgavtvphp nieevalstt geipftyskai plevikggrh lifehskkæ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevdt tvdfsldptf tietitlpqd aysttgrrgr tgrgkpglyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglyv ogdhlefweg vftglthida hflsqtkgsg enlpylvayq atvearaqap ppswdqmwke lirlkptlhg ptpllyrlga vqmeitlthp vtkyimtems adlevvt (SEQ ID No: 115) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaggyk vlvlnpsvaa tlgfgaymsk abgidpnirt gvrtittgsp itystygkfl adggssgay diligde&hs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskkæ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgygdfds videntevet vtdfeldptf tietitlpqd aysttgrrgr tgrgkpglyr fvapgerpsg mfdssvleec ydagcawyel trilkptlhg ptpllyrlag vqmeitlthp vtkyimtems adlevvt (SEQ ID No: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv papsyaaggyk vlvlnpavaa tlgfgaymsk abgidpnirt gyrtittgep itystygkfl ad			
nieewalstt geipfygkai plevikggrh lifehakke delaaktval ginavayyrg idsvejtegs dywvatdal mtgytgdfde videntevtg tvdfeldptf tietitlpdd ayertqrgr tgrgkpgiyf vapgerspa mfdesvleee ydageawyel tpaettvrlr aymntpglpv cgdhlefweg vftglthida hflsgtkgag enlpylavag atvearagap ppswdqmwke lirlkptlhg ptpllyrlga vqneitlthp vtkyimtems adlevvt (SEQ ID No: 113) F			
delaaklval ginavayyrg ldwsviptesg dvvvvatdal mtgytgdfde vidgntevtg tvdfsldytf tietitlpdd aysttgrgr tgrgkpdfyr fvapgerpsg mfdssvleeg ydagcawyel tpaettvrlr aymntpglyv cgdhlefweg vftglthida hflsgtkgsg enlpylvayg atvgaraqap ppswdgmwke lirlkptlng ptpllyrlga vgneitlthp vtkyimtems adlevvt (SEQ ID No: 113) F E291Q avdfipven lettmrspvf tdnssppvvp qsfqvahlna ptgsgkstkv paayaaggyk vlvlnpavaa tlgfgamsk ahgidpnirt gyrtittgsp itystygkfl adggssgsgy diiigdggfns tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskkg delaaklval ginavayyrg ldwsviptsg dvvvvatdal mtgytgdfds vidgntevqt tvdfsldytf tietitlpdd aysttgrgr tgrgkpgiyr fvapgerpsg mfdssvleeg ydagcawyel trapettvrlr aymntpglyv cgdhlefweg vftglthida hflsgtkgsg enlpylvayg atvgaraqap ppswdgmwke lirlkptlhg ptpllyrlga vgmeitlthp vtkyimtems adlevvt (SEQ ID NO: 114) G H293A avdfipven lettmrspvf tdnssppvvp gsfgvahlna ptgsgkstkv paayaaggyk vlvlnpavaa tlgfgamsk ahgidpnirt gyrtittgsp itystygkfl adggsgsgay diiigdegAs tdatsilgig tvldqaetag arlvvlatat ppgsrtvphp nieevalstt geipfygkai plevikggrh lifehskkg delaaklval ginavayyrg ldwsviptsg dvvvvatdal mtgytgdfds vidgntevqt twdfsldytf tietitlpqd aysttgrgr tgrgkpgiyr fvapgerpsg mfdssvleeg ydagcawyel tpaettvrlr aymntpglyv cgdhlefweg vftglthida hflsgtkgsg enlpylvayq atvgaraqap ppswdgmwke lirlkptlhg ptpllyrlga vqmeitlthp vklyimtems adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnssppvvp gsfqvahlna ptgsgkstkv paayaaggyk vlvlnpsva tlgfgamsk shgidpnirt gyrtittgsp itystygkfl adggsggay diiigdegAs tdatsilgig tvldqaetag arlvvlatat pgsgvtvphp nieevalstt geipfygkai plevikggrh lifehskkg delaaklval ginavayyrg ldwsviptsg dvvvvatdal mtgycgdfds videntevqt tvdfsldptr tietitlpqd aysttgrrgr tgrgkpgiyr fvapgerpsg mfdssvleeg ydagcawyel trilkptlhg ptpllyrlga vqmeitlthp vtkyimtems adlevvt (SEQ ID NO: 115) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlna ptgsgkstkv pagvagagyk vlunpsva tlgfgaymsk ahgidpnirt gyrtittgpp itystygkfl adggsgay diiigdeGhs tdatsilgig tvldqaetag arlvvlatat pgsgvtvph nieevalste geipfygkai plevikggrh li			
mtgytgdfeb videntevtq tvafeldptf tietitlpdd aysttqrgr tygkpdyfy tvapgerpsg mddssvleee ydageawyel tpaettvrlr aymntpglpv eqdhlefweg vftglthida hflsgtkgsg enlyplvayg atvegaragap ppswdqmwke lirlkptlng ptpllyrlga vqmeitlthp vtkyimtems adlevwt (SEQ ID No: 113) F E291Q avdfipven lettmrspvt tdnssppvvp qsfqvahlha ptgsgkstkv paayaaggyk vlvlnpavaa tlgfgaymsk ahgidpnirt gvrittgsp itystygkfl adgggsgay diligdgelss tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskkkg delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfeb vidgntevqt tvaffsldptf tietitlpdd aysttqrgr tgygkpdyf vapgerpsg mfdssvleee ydageawyel tpaettvrlr aymntpglpv eqdhlefweg vftglthida hflsgtkgsg enlpylvayq atvearagap ppswdqmwke lirlkptlng ptpllyrlga vqmeitlthp vtkyimtems adlevvt (SEQ ID No: 114) G H293A avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaggyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrittgsp itystygkfl adgggsgay diligdels tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskkg delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevqt tvaffsldptf tietitlpdd aysttqrgr tggkpdyr tvapgerpsg mfdssvleee ydageawyel tpaettvrlr aymntpglpv eqdhlefweg vttglthida hflsgtkgag enlpylvayq atvegaragap ppswdqmwke lirlkptlng ptpllyrlga vqmeitlthp vtkyimtems adlevvt (SEQ ID No: 115) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaggyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrittgsp itystygkfl adgggsgay dilidels tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskkg delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgydgdfds videntevtq tvaffsldptf tietitlpdd aysrthrgr tgrgkpgivr fvapgerpsg mfdssvleeg ydageawyel tpaettvrlr aymntpglpv eqdhlefweg vftglthida hflsgtkgag enlpylvayq atvearagap ppswdqmwke lirlkptlng ptpllyrlga vqmeitlthp vtkyimtems adlevvt (SEQ ID No: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahla ptgsgkstkv paayaaggyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrittgep itystygkfl adggsgay dilidelsh tdatsligh videntevtq tvdfsldptf tietitlpd			
ydagcawyel tpaettvīr aymntpdīpv codhlefweg vftglīhida hfisgtkgeg enlpylvayq atvearaqap ppswdqmwkc lirikptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 113) F			
ppswdqmwkc lirlkptlmg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 113) F			
ppsødgmake lirikpting ptpllyriga vgneitithp vtkyimtoms adlevvt (SEQ ID NO: 113) F E291Q avdfipven lettmrspvf tdnssppvvp gsfqvahlha ptgsgkstkv paayaaqsyk vlvlnpovaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfi adggsggay diiic@dg@hs tdatsligig tvldqaetag arlvvlatat ppgsvtrphp nieevalstt geipfygkai plevikggrh lifehskkk@ delaaklval ginavayvrg idsvsviptsg dvvvvatdal mtgytgdfds videntevtg tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvlcec ydagcawyel tirhetvir aymntpglpv cgdhlefweg vftglthida hflsgtkgsg enlpylvayq atvearaqap ppswdgmake lirlkptlng ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 114) G H293A avdfipven lettmrspvf tdnssppvvp gsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpavaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adgggsggay diiicde2As tdatsligig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskk@ delaaklval ginavayvrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtg tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvlcec ydagcawyel tpaettvrlr aymntpglpv cgdhlefweg vftglthida hflsgtkgsg enlpylvayq atvearaqap ppswdgmwke lirlkpthg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgketkv paayaaqgyk vlvlnpavaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggsggay diiicde2hs tdatsligig tvldqaetag arlvvlatat ppgstvphp nieevalstt geipfygkai plevikggrh lifehskk@ delaaklval ginavayvrg ldvsviptsg dvvvvatdal mtgyGgdfds videntevq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpjyr fvapgerpsg mfdssvlcec ydagcawyel tpaettvrlr aymntpglpv cgdhlefweg vftglthida hflsgtkgs enlpylvayq atvearaqap ppswdgmwke lirlkpthg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpavaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adgsgsggay diiicde3hs tdatsligig tvldqaetag arlvvlatat ppgsvtyphp nieevalstt geipfygkai plevikggrh lifehskk@ delaaklval ginavayvrg ldvsviptsg dvvvvatdal mtgytgdfds videntevq tvdfsldptf tietitlpqd aysrtHrrgr tgrgkpgiyr fvapgerpsg			ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg
F E291Q avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpavaa tlgfgaymsk ahgidpnitt gvrtittgap itystystfl adggsgagy dilied@ghs tdatsilgig tvldqaetag arlvvlatat ppgsvtyphp nieevalst geipfygkaf plevikggpf blfchskk% delaaklval ginavayvrg ldwsviptsg dvvvatdal mtgytgdfds videntgvtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgjvr fvapgerpsg mfdssvleeg ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsgtkags enlpylvavq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 114) G H293A avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpavaa tlgfgaymsk ahgidpnirt gvrtittgap itystygkfl adggsgagy dilied@shs tdatsilgig tvldqaetag arlvvlatat ppgsvtyphp nieevalst geipfygkai plevikggrh lifchskk% delaaklval ginavayvrg ldwsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleeg ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsgtkags enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnssppvvp gsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgap itystygkfl adggsgagy dilied@shs tdatsilgig tvldqaetag arlvvlatat ppgsvtyphp nieevalst geipfygkai plevikggrh lifchskk% delaaklval ginavayvrg ldwsviptsg dvvvvatdal mtgyGgdfds videntevtq tvdfsldptf tietitlpdd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleeg ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsgtkag enlpylvayq atvearaqap ppswdqmwkc dirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp gsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgap itystygkfl adggsgagy dilied@shs tdatsilgig tvldqaetag arlvvlatat ppgsvtyphp nieevalstt geipfygkai ptevläggrh lifchskk% delaaklval ginavayvrg ldwsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpdd aysrtHrngr tggskpgiyr fvapgerpsg mfdssvleeg ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hfisgtkage arlvvl			
E291Q avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gyrtittsps itystyskfl adgs_gagya dlijedogshs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskk@ delaaklval ginavayyrg ddvsviptg dvvvvatdal mtgytgdfds videnteytq tvdfsldptf tietitlpdd aysrtqrrgr tgrgkpglyif rtwpgerpsg mfdssvleeg ydagoawyel tpaettvrlr aymntpglpv eqdhlefweg vftgithida hflsqtkqsg enlpylvayq atvearaqap ppswdgmwko lirlkptlhg ptpllyrlga vqmeitlthp vtkyimtems adlevvt (SEQ ID NO: 114) G H293A avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaagyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gyrtittgsp itystygkfl adgcsgaya diijedesAs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskk@ delaaklval ginavayyrg ldvsviptg dvvvvatdal mtgytgdfds videnteyt tvdfsldptf tietitlpdd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleeg ydagoawyel tpaettvrl aymntpglpv eqhlefweg vftglthida hflsqtkgsg enlpylvayq atvearaqap ppswdqmwko lirlkptlhg ptpllyrlga vqmeitlthp vtkyimtems adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gyrtittgsp itystygkfl adgsgagy diijedeshs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskk@ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgdfds videntevtq tvdfsldptf tietitlpdd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleeg ydagoawyel tpaettvrlr aymntpglpv eqhlefweg vftglthida hflogtkgsg enlpylvayq atvearaqap ppswdqmwko lirlkptlhg ptpllyrlga vqmeitlthp vtkymtems adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gyrtittsgs itystygkfl adgsgagay diijedeshs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskk@ delaaklval ginavayyrg dvaviptag dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpdd aysrthrrgr tgrgkpglyfyr fvapgerpsg mfdssvleeg ydagoawyel tpaettvrlr aymntpglpv eqdhlefweg vftglthida hflogtkgs enlpylvay			
paayaaggyk vlvlnpsvaa tlgfgaymsk habidpnirt gvrtittgsp itystygkfl adggsggay diiigdQghs tdatsilgig tvldqaetag arlvvlatat ppgstvphp nieevalstt geipfygkai plevikggrh lifehskke delaaklval ginavayyrg idvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvlgec ydageawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsgtkgsg enlpylvayq atvearaqap ppswdgmwkc lirlkptlhg ptpllyrlga vqmeitlthp vtkyimtoms adlevvt (SEQ ID NO: 114) G H293A avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaggyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggsggay diiigdeAs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpdd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydageawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsgtkgsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqmeitlthp vtkyimtoms adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaagyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggsggay diiideAs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgdfds videntevtq tvdfsldptf tietitlpdd aysrtgrrgr tgrgkpgjyr fvapgerpsg mfdssvleec ydageawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsgtkgsg enlpylvayq atvearaqap ppswdgmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp gsfqvahlha ptgsgkstkv paayaaggyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggsggay diiidedshs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videnteytq tvdfsldptf tietitlpdd aysrtHrgrgr tgrgkpgiyf fvapgerpsg mfdssvleec ydageawyel tpaettvrly aymntpglpv cqdhlefweg vftglthida hflegtkgs enlpylvayq atvearaqap ppswdgmykc lirlkpthg ptpllyrlya vqmeitlthp			veryimeems datevve (SEQ ID No. 113)
gvrtittgsp itystyskfl adg@sggay diligd@shs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskk@ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videnteyt tvdfsldpft tietitlpdd aysrtgrrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv cqhlefweg vftglthida hflsgtkqsg enlpylvayq atvearaqap ppswdqmwkc lirkptlhg ptpllyrlga vqmeitlthp vtkyimtoms adlevvt (SEQ ID NO: 114) G H293A avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adg@sggay diligdeAs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt gifygkai plevikggrh lifehskk@ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videnteytg tvdfsldptf tietitlpdd aysrtgrrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsgtkqsg enlpylvayq atvearaqap ppswdgmwkc lirkptlhg ptpllyrlga vqmeitlthp vtkyimtoms adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnssppvvp gsfqvahlha ptgsgkstkv paayaaggyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adg@sggay diligdeAs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskk@ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videnteyt tvdfsldptf tietitlpdd aysrtgrrgr tgrgkpgiyr fvapgerpeg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirkpthg ptpllyrlga vqmeitlthp vtkyimtoms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adgsggagay diligdeBs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskk@ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videnteyt tvdfsldptf tietitlpdd aysrtHrrgr tgrgkpgiyf fvapgerpeg mfdssvleec ydagcawyel tpaettvrl aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdgmvkc lirlkptlyg typlygrapg mfdssvleec ydagcawyel tpaettyrl aymntpglpv cqdhlefweg vftglthida	F	E291Q	
idatsilgig tvldqaetag arlvvlatat ppgsvtyphp nieevalstt geipfygkai plevikgrh lifghskkkg delaaklval ginavayyrg idvsviptsg dvvvvatdal mtgytgdfds vidgntevtq tvdfsldptf tietitlpqd aysttqrrg tgrgkpgiyr fvapgaperpsg mfdssvleeg ydagcawyel tpaettvrlr aymntpglpv cgdhlefweg vftglthida hflsqtkgsg enlpylvayq atvearaqap ppswdqmwke lirkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 114) G H293A avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaggyk vlvlnpavaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggsggay diiicdscAs tdatsilgig tvldqaetag arlvvlatat ppgsvtyphp nieevalstt geipfygkai plevikggrh lifghskkg delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videnteyt tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleeg ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflegtkgs enlpylvayq atvearaqap ppswdqmwke lirkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaggyk vlvlnpavaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggsggay diiicdscBs tdatsilgig tvldqaetag arlvvlatat ppgsvtyphp nieevalstt geipfygkai plevikggrh lifghskkkg delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapperpsg mfdssvleeg yfdgthida hflsqtkgs enlpylvayq atvearaqap ppswdqmwke lirlkpthg ptpllyrlga vgneitlthp vtkyimtoms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaggyk vlvlnpavaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adgsggay diiicdscBs tdatsilgig tvldqaetag arlvvlatat ppgsvtyphp nieevalstt geipfygkai plevikggrh lifghskkkg delaaklval mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtHrrgr tgrgkpgiyr fvapperpsg mfdssvleeg ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkgs enlpylvayq atvearaqap ppswdgmwke lirlkptlhg ptpllyrlga vqneitlthp			
nieevalstt geipfygkai plevikggrh lifehskk% delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr trgrgkpjur fvapgerpsg mfdssvleeg ydagoawyel tpaettvrlr aymntpglpv ogdhlefweg vftglthida hflsqtkgsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 114) G H293A avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gyrtittgsp itystygkfl adggsgag diiicdeAs tdatsiligi tvldqaetag arlvvlatat ppgsvtyhph nieevalstt geipfygkai plevikggrh lifehskk%c delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgivr fvapgerpsg mfdssvleeg yfdgthida hflsgtkgsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gyrtittsgp itystysyffl adggsgay diiodechs tdatsilgig tvldqaetag arlvvlatat ppgsvtyphp nieevalstt geipfygkai plevikggrh lifehskk%c delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgivr fvapgerpsg mfdssvleeg ydagoawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkgsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahla ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gyrtittsgp itystysgfl adggsgay diiidedehs tdatsilgig tvldqaetag anlyvlatat ppgsvtyphp nieevalstt geipfygkai plevikggrh lifehskk%c delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtHrrgr tgrgkpgivr fvapgerpsg mfdssvleeg vdagoawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkgsg enlpylvayq atvgaraqap ppswdqmwke lirlkpthg ptpllyrlga vqneitlthp			
delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpjyr fvapgerpsg mfdssvleeg ydagcawyel tpaettvrlr aymntpglpv cgdhlefweg vftglthida hflsgtkgsg enlpylvayq atvearagap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtems adlevvt (SEQ ID NO: 114) G H293A avdfipven lettmrspvf tdnssppvvp gsfqvahlha ptgsgkstkv paayaaggyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gyrtittgsp itystygkfl adggsgsgay diiigdeas tdatsilgig tvldqaetag arlvvlatat ppgsvtryhp nieevalstt geipfygkai plevikggrh llfehskkke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpjyr fvapgerpsg mfdssvleeg ydagcawyel tpaettvrlr aymntpglpv cgdhlefweg vftglthida hflsgtkgsg enlpylvayq atvearaqap ppswdqmwkc vlvlnpsvat tlgfgaymsk ahgidpnirt gyrtittgsp itystygkfl adggsggay diiodeas tdatsilgig tvldqaetag arlvvlatat ppgsvtryhp nieevalstt geipfygkai plevikggrh llfehskkke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpjyr fvapgerpsg mfdssvleeg ydagcawyel tpaettvrlr aymntpglpv cgdhlefweg vftglthida hflsgtkgsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vyneitlthp vtkyimtems adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspyf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaggyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gyrtittgsp tjtgttygkfl adggesgay diiodeas tdatsilgig tvlaqtetag enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vyneitlthp vtkyimtems adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspyf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaggyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gyrtittgsp tytygkfl adggesgay diiodeas tdatsilgig tvldqaetag arlvvlatat ppgsvtyphp nieevalstt geipfygkai plevikggrh lifehskkke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtHrgr tgrgkpgkai plevikggrh lifehskke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtHrgr tgrgkpgiyf fvapgerpsg mfdssvleeg ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg yftglt			
mtgytgdfds videntevtq tvdfsleptf tietitlpqd aysrtqrrgr tgrgkpgiyr fyapgerpsg mfdssvleeg ydageawyel tpaettvrlr aymntpglpv eqdhlefweg vftglthida hflsqtkgsg enlpylvayq atvearaqap ppswdqmwke lirlkptlap ptpllyrlga vqmeitlthp vtkyimtoms adlevvt (SEQ ID NO: 114) G H293A avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpavaa tlgfgaymsk ahgidpnirt gyrtittgsp itystygfl adggaggay diided&as tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskk%r delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydageawyel tpaettvrlr aymntpglpv eqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwke lirlkptlmp tpllyrlga vqmeitlthp vtkyimtoms adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpavaa tlgfgaymsk ahgidpnirt gyrtittgsp itystygkfl adggaggay diicde&bs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifghskkkg delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydageawyel tpaettvrlr aymntpglpv eqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwke lirlkptlng ptpllyrlga vqmeitlthp vtkyimtoms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpovaa tlgfgaymsk ahgidpnirt gyrtittgsp itystygkfl adggaggay diicde&bs tdatsilgig tvldqaetag arlvvlatat ppgsvtyphp nieevalstt geipfygkai plevikgrh lifehskkke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtHrgr tgrgkpgiyr fvapgarpsg mfdssvleec ydageawyel tpaettvrlr aymntpglpv eqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwke lirlkptlng ptpllyrlga vqneitlthp			
aysttqrgr tgrgkpgiyr fvapgerpsg mfdssvleeg ydagcawyel tpaettvrlr aymntpglpv oqdhlefweg vftglthida hfleqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 114) G H293A avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggsggay diiiqdeAs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videnteytq tvdfsldptf tietitlpqd aysrtqrgr tgrgkpgiyr fvapgerpsg mfdssvleeg ydagcawyel tpaettvrlr aymntpglpv oqdhlefweg vftglthida hflsqtkgsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggsggay diiiqdeGhs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgdfds videntevtq tvdfsldptf tietitlpdd aysrttrgr; tgrgkpgiyr fvapgerpsg mfdssvleeg ydagcawyel tpaettvrlr aymntpglpv oqdhlefweg vftglthida hfleqtkgsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggsggay diiiqdeGhs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpdd aysrtHrrgr tgrgkpydai plevikggrh lifchskke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpdd aysrtHrrgr tgrgkpgiyr fvapgerpsg mfdssvleee ydagcawyel tpaettvrlr aymntpglpv oqdhlefweg vftglthida hfleqtkqs enlpylvayq atvearaqap ppswdqmwkc lirlkpthg ptpllyrlga vqneitlthp			
ydagcawyel tpaettvrlr aymntpglpv eqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 114) G H293A avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvvtittgsp itystygkfl adggsggay diiigdegAs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskke delaaklval ginavayyrs ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpdd aysrtqrgr tgrgkpgivr fvapgerpsg mfdssvleec yfdagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hfleqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggcsggay diiiqdechs tdatsilgig tvddqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgdfds videntevtq tvdfsldptf tietitlpdd aysrtqrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hfleqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggcsggay diiiqdechs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpdd aysrtftrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg tvdpsperpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg tvdplayqu atvearaqap ppswdqmwkc lipaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp			
ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkylmtoms adlevvt (SEQ ID NO: 114) G H293A avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggsggay diiicdeAs tdatsilgig tvldqaetag arlvvlatat ppgsvtyphp nieevalstt geipfygkai plevikggrh lifchskkg delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds vidqnetqut tvdfsldptf tietitlpqd aysrtqrrg tgrgkpgiyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggsggay diiicdeAs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskklg delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggsggay diiicdeChs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskklg delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds vidqnetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskklg delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds vidqnetvq tvdfsldptf tietitlpqd aysrtHrrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp			
avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gyrtittgsp itystygkfl adggsggay diiicdeAs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggth lifghskkle delaaklval ginavayyrg ldvsviptsg dvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagaawyel tpaettvrlr aymntpglpv eqdhlefweg vftglthida hflsqtkgsg enlpylvayq atvearaqap ppswdqmwke lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gyrtittgsp itystygkfl adggsggay diiicdeAs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifghskkle delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagoawyel tpaettvrlr aymntpglpv eqdhlefweg vftglthida hflsqtkgsg enlpylvayq atvearaqap ppswdqmwke lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevut (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqayk vlvlnpsvaa tlgfgaymsk ahgidpnirt gyrtittgsp itystygkfl adggsggay diiicdeAs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggth lifghskkle delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrttrrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagoawyel tpaettvrlr aymntpglpv eqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwke lirlkptlhg ptpllyrlga vqneitlthp			vftglthida hflsqtkqsg enlpylvayq atv c araqap
G H293A avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgldpnirt gvrtittgsp itystygkfl adggsggay dilicdeAs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nleevalstt geipfygkai plevikggrh lifehskkke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagoawyel tpaettvrlr aymntpglpv eqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgldpnirt gvrtittgsp itystygkfl adggssggay dilicdeChs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nleevalstt geipfygkai plevikggrh lifehskkke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrgr tgrgkpgjvr fvapgerpsg mfdssvleec ydagoawyel tpaettvrlr aymntpglpv eqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgldpnirt gvrtittgsp itystygkfl adggsggay dilicdeChs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nleevalstt geipfygkai plevikggrh lifehskkke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtHrrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagoawyel tpaettvrlr aymntpglpv eqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp			
paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggaggay diiigdæAs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskkke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleee ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggasgay diiiqdæAs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskkke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleee ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggasgay diii_ddæAs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskkke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtHrrgr tgrgkpgiyr fvapgerpsg mfdssvleee ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkpthg ptpllyrlga vqneitlthp			vtkyimt c ms adlevvt (SEQ ID NO: 114)
gvrtittgsp itystygkfl adg@sggay diliedeAs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskk@ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysttqrrgr tgrgkpgiyr fvapgerpsg mfdssvleee ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlng ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk angidpnirt gvrtittgsp itystygkfl adg@sggay diliedeAs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskk@ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleee ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlng ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk angidpnirt gvrtittgsp itystygkfl adg@sggay diliedeAs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskk@ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevqt tvdfsldptf tietitlpqd aysrtHrrgr tgrgkpgiyr fvapgerpsg mfdssvleee ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkgg enlpylvayq atvearaqap ppswdqmwkc lirlkptlng ptpllyrlyay dvvvatdal mtgytgdfds videntevqt tvdfsldptf tietitlpqd aysrtHrrgr tgrgkpgiyr fvapgerpsg mfdssvleee ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkgg enlpylvayq atvearaqap ppswdqmwkc lirlkptlng ptpllyrlya vqneitlthp	G	H293A	avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv
icdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskik@ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtgrrgr tgrgkpgjyr fvapgerpsg mfdssvleee ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adg@sggay dtiicde@s tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskk@ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgdfds videntevtq tvdfsldptf tietitlpqd aysrtgrrgr tgrgkpgiyr fvapgerpsg mfdssvleee ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkgsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adg@sggay diiicde@s tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtHrrgr tgrgkpgiyr fvapgerpsg mfdssvleee ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkgsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp			
nieevalstt geipfygkai plevikggrh lifehskkæ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleee ydagcawyel tpaettvrlr aymntpglpv eqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adgæsggay diiiedæhs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskkæ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleee ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adgæsggay diiiedæhs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskkæ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtHrrgr tgrgkpgiyr fvapgerpsg mfdssvleee ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwko lirlkptlhg ptpllyrlga vqneitlthp			
delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtems adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggesggay diiiedechs tdatsilgig nieevalstt geipfygkai plevikggrh lifehskke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgagkpgiyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtems adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adgesggay diiiedechs tdatsilgig nieevalstt delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtfrrgr geipfygkai plevikggrh lifehskke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtHrrgr geipfygkai plevikggrh lifehskke delaaklval ginavayyrg ldvsviptsg dvvvvatdal htgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtHrrgr ydagcawyel typaettvrlr aymntpglpv cqdhlefweg yftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlyaq vtpeitlthp			
mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrittgsp tystygkfl adggesggay diiiedeghs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskkke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleee ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtitgsp itystygkfl adggesggay diiiedeghs tdatsilgig nieevalstt geipfygkai plevikggrh lifehskke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtHrrgr tgrgkpgiyr fvapgerpsg mfdssvleee ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp			
aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggesggay diiicdechs tdatsilgig tvldqaetag arlvvlatat ppgsvtyphp nieevalstt geipfygkai plevikggrh lifehskkde delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggesggay diiicdechs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskkde delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtHrrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkgsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp			
ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwke lirlkptlhg ptpllyrlga vqneitlthp vtkyimtems adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggesggay diiicdens tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskke delaaklval ginavayyrg ldvsviptsg dvvvatdal mtgyGgffds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwke lirlkptlhg ptpllyrlga vqneitlthp vtkyimtems adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggesggay diiicdens tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskkee delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtHrrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwke lirlkptlhg ptpllyrlga vqneitlthp			
vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adgesggay diiiedeshs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifenskke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvlee ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adgesggay diiiedeshs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifenskke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtHrrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp			
ppswdqmwkc lirlhptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 115) H T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adg@sggay diii_de@hs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskk@ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvlcec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adg@sggay diii_de@hs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskk@ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds aysrtHrgr tgrgkpgiyr fvapgerpsg mfdssvlcec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp			
T419G avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adg@sggay diiiod@hs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskkk@delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvlcec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvcaraqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adg@sggay diiicd@hs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskkke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtHrrgr tgrgkpgiyr fvapgerpsg mfdssvlcec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvcaraqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp			
paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggsggay diiicdeshs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskks delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgdfds vidcntcvtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvlcec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvcaraqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggsggay diiicdeshs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskks delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds aysrtHrgr tgrgkpgiyr fvapgerpsg mfdssvlcec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvcaraqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp			vtkyimtcms adlevvt (SEQ ID NO: 115)
paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adgæggay diiigdæshs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskkæ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgdfds vidcntcvtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvlccc ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvcaraqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adgægggay diiicdæshs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskkæ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds aysrtHrgr tgrgkpgiyr fvapgerpsg mfdssvlccc ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvcaraqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp	Н	T419G	avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv
tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskk& delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgdfds vidcntcvtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvlcec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvcaraqap ppswdqmwko lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggsggay diidedehs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskk& delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds vidcntcvtq tvdfsldptf tietitlpqd aysrthrrgr tgrgkpgiyr fvapgerpsg mfdssvlcec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvcaraqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp			
nieevalstt geipfygkai plevikggrh lifchskk& delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgyGgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv eqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtems adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adgesgay diiiedess tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtHrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv eqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp			
delaaklval ginavayyrg İdvsviptsg dvvvvatdal mtgyGgdfds vidcntcvtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvlcec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvcaraqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adgcsggay diiicdchs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskkc delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds vidcntcvtq tvdfsldptf tietitlpqd aysrtHrrgr tgrgkpgiyr fvapgerpsg mfdssvlcec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvcaraqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp			
mtgyGgdfds videntevte tvdfsldptf tietitlped aysrtqrrgr tgrgkpgjyr fvapgerpsg mfdssvleee ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtems adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adgesggay diiiedeshs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifenskke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds aysrtHrgr tgrgkpgiyr fvapgerpsg mfdssvleee ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp			
aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvlcec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adg@sggay diiicde@hs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskkke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds vidcntevt tvdfsldptf tietitlpqd aysrthrrgr tgrgkpgivr fvapgerpsg mfdssvlcec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp			
ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvcaraqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adgcsggay diiocdchs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskkc delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds vidcntcvtq tvdfsldptf tietitlpqd aysrthrrgr tgrgkpgivr fvapgerpsg mfdssvlcec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvcaraqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp			
vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adgesggay diiiedehs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifenskke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtHrrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp			
ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggsggay diiiqdeshs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskks delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds aysrtHrgr tgrgkpgiyr fvapgerpsg mfdssvlcec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvcaraqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp			
vtkyimtoms adlevvt (SEQ ID NO: 116) I Q460H avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adg@sggay diiiod@hs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifolskkk@delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds vidontovt tvdfsldptf tietitlpqd aysrtHrrgr tgrgkpgiyr fvapgerpsg mfdssvloeo ydagoawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvoaraqap ppswdqmwko lirlkptlhg ptpllyrlga vqneitlthp			
paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggsggay diiicdess tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskks delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtHrrgr tgrgkpgiyr fvapgerpsg mfdssvlcec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp			
paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggsggay diiicdess tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskks delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds vidcntcvtq tvdfsldptf tietitlpqd aysrtHrrgr tgrgkpgiyr fvapgerpsg mfdssvlcec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvcaraqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp	I	O460H	avdfipven lettmrspyf tdnssppvvp gsfgvahlha ptgsgkstky
gvrtittgsp itystygkfl adg@sggay dilied@hs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskk@ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtHrrgr tgrgkpgiyr fvapgerpsg mfdssvleee ydagcawyel tpaettvrlr aymntpglpv eqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp	-	2.5011	
tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskkkc delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds vidcntcvt tvdfsldptf tietitlpqd aysrtHrrgr tgrgkpgiyr fvapgerpsg mfdssvlcec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvcaraqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp			
nieevalstt geipfygkai plevikggrh lifehskkke delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevte tvdfsldptf tietitlpqd aysrtHrrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp			
delaaklval ginaväyyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtHrrgr tgrgkpgiyr fvapgerpsg mfdssvleee ydagcawyel tpaettvrlr aymntpglpv eqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp			
aysrtHrrgr tgrgkpgiyr fvapgerpsg mfdssvl <u>c</u> ec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atv <u>c</u> araqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp			
ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atv <u>c</u> araqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp			
vftglthida hflsqtkqsg enlpylvayq atv <u>c</u> araqap ppswdqmwk c lirlkptlhg ptpllyrlga vqneitlthp			
ppswdqmwk $oldsymbol{c}$ lirlkptlhg ptpllyrlga vqneitlthp			
			vtkyimtcms adlevvt (SEQ ID NO: 117)

TABLE 1-continued

Antigen designation	Antigen Sequence
J	R464A avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfqaymsk ahgidpnirt gvrtittgsp itystygkfl adggsggay diiicdechs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskkkc delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds vidcntevtq tvdfsldptf tietitlpqd aysrtqrrgA tgrgkpgiyr fvapgerpsg mfdssvlcec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvcaraqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 118)
К	avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gyrtittgsp itystygkfl adgæsggay diiicdæhs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskkæ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds vidcntcvtq tvdfsldptf tietitlpqd aysrtqrrgr tgKgkpgiyr fvapgerpsg mfdssvlcec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvcaraqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 119)
L	avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggsggay diiicdens tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskkkg delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds vidontevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvloec ydageakyel tpaettvrlr aymntpglpv eqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvoaraqap ppswdqmwke lirlkptlhg ptpllyrlga vqneitlthp vtkyimtoms adlevvt (SEQ ID NO: 120)
М	Any combination of two mutations selected from the group consisting of K210N, S211A, T212E, Y241S, D290N, E291Q, H293A, T419G, Q460H, R464A, R467K and W501A
И	Any combination of three mutations selected from the group consisting of K210N, S211A, T212E, Y241S, D290N, E291Q, H293A, T419G, Q460H, R464A, R467K and W501A
0	Any combination of four mutations selected from the group consisting of K210N, S211A, T212E, Y241S, D290N, E291Q, H293A, T419G, Q460H, R464A, R467K and W501A
P	Any combination of five mutations selected from the group consisting of K210N, S211A, T212E, Y241S, D290N, E291Q, H293A, T419G, Q460H, R464A, R467K and W501A
Q	Any combination of six mutations selected from the group consisting of K210N, S211A, T212E, Y241S, D290N, E291Q, H293A, T419G, Q460H, R464A, R467K and W501A
R	Any combination of seven mutations selected from the group consisting of K210N, S211A, T212E, Y241S, D290N, E291Q, H293A, T419G, Q460H, R464A, R467K and W501A
S	Any combination of eight mutations selected from the group consisting of K210N, S211A, T212E, Y241S, D290N, E291Q, H293A, T419G, Q460H, R464A, R467K and W501A
Т	Any combination of nine mutations selected from the group consisting of K210N, S211A, T212E, Y241S, D290N, E291Q, H293A, T419G, Q460H, R464A, R467K and W501A
Ū	Any combination of ten mutations selected from the group consisting of K210N, S211A, T212E, Y241S, D290N, E291Q, H293A, T419G, Q460H, R464A, R467K and W501A

TABLE 1-continued

Antigen designa	tion Antigen Sequence
V	Any combination of eleven mutations selected from the group consisting of K210N, S211A, T212E, Y241S, D290N, E291Q, H293A, T419G, Q460H, R464A, R467K and W501A
W	Any combination of twelve mutations selected from the group consisting of K210N, S211A, T212E, Y241S, D290N, E291Q, H293A, T419G, Q460H, R464A, R467K and W501A
х	avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adg@sggay diii_cd@hs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lif_chskkk@ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds vidcntcvtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagSawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvcaraqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 121)
Y	avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adggsggay diiicdesh tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifchskk@ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds vidcntcvtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvlccc ydagcawyel tpaettvrlr aymntpglpv Sqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvcaraqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 122)
Z	avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adg@sggay diii_cde\(\) tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lif_chskk@ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds vid_cnte_vtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvl_cec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atv_caraqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 123)
A1	avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adg@sggay diiicd@hs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifghskkk@ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvcaraqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtcms adlevvt (SEQ ID NO: 124)
A2	avdfipven lettmrspvf tdnssppvvp qsfqvahlha ptgsgkstkv paayaaqgyk vlvlnpsvaa tlgfgaymsk ahgidpnirt gvrtittgsp itystygkfl adgæsggay diiicdæhs tdatsilgig tvldqaetag arlvvlatat ppgsvtvphp nieevalstt geipfygkai plevikggrh lifehskkæ delaaklval ginavayyrg ldvsviptsg dvvvvatdal mtgytgdfds videntevtq tvdfsldptf tietitlpqd aysrtqrrgr tgrgkpgiyr fvapgerpsg mfdssvleec ydagcawyel tpaettvrlr aymntpglpv cqdhlefweg vftglthida hflsqtkqsg enlpylvayq atvearaqap ppswdqmwkc lirlkptlhg ptpllyrlga vqneitlthp vtkyimtems adlevvt (SEQ ID NO: 125)
A3	Any combination of mutations of any of A-W in combination with one two or three, four or five of the mutations shown in X , Y , Z , $A1$, and $A2$.

In other embodiments, another aspect of the combination immunoassay detects the presence of antibodies to Core antigen. Some exemplary core antigens that could be used include antigens derived from the DNA binding domain (amino acids 1-125) of core protein. Still other preferred core 60 antigens are derived from the lipid binding domain of core located at amino acid residues 134-171 of core protein (MGYIPLVGAPLGGAARALAHGVRV-

LEDGVNYATGNLPG) (SEQ ID NO: 89). However, in the present invention particularly preferred core antigens include 65 antigens derived from core protein that comprise certain deletions or substitution in the known epitope binding regions for

specific monoclonal antibodies such that monoclonal antibodies used for HCV core antigen detection would fail to detect these modified core antigens but would nonetheless detect complete core antigen from the test sample. Thus, these novel modified core antgens can be coated onto a solid phase support and/or used in solution phase to capture antibodies present in human serum or plasma that are directed toward the Core region of HCV but at the same time evade detection by the conjugate antibody used for the detection of Core antigen present in a test sample in an HCV combination immunoassay. Thus a combination immunoassay can be performed that detects both Core antigen present in the test sample at the

same time as detecting anti-Core antibodies that would also be expected to be in the test sample and identified in the same HCV Combo assay format. The Core antigens that can be used for the purpose of detecting anti-Core antibodies from the test sample preferably comprise deletions of amino acids 5 34 and 48 and amino acids 115-121 of Core antigen.

As noted herein throughout the methods of the invention typically are immunoassay methods. In exemplary embodiments, such methods include methods for isolating a molecule of interest (such as for example a specific antibody that is present in a test sample, or a specific antigen that may be present in the test sample). In order to facilitate such isolation, the molecule of interest comprises or is attracted to a purification tag that contacts a tag binding partner. The association of the purification tag and the tag binding partner thus may be 15 used to separate the molecule of interest from a mixture of molecules. Purification tags can comprise moieties with the same or similar structures. In certain embodiments, the tagging moiety of an affinity tag can be associated with a funcchemical bonds, in linear, branched or cyclic arrangements, optionally including single, double, triple bond, aromatic carbon-carbon bonds, as well as carbon-nitrogen bonds, nitrogen-nitrogen bonds, carbon-oxygen bonds, carbon-sulfur bonds, phosphorus-oxygen bonds, phosphorus-nitrogen 25 bonds, and any combination thereof. In certain embodiments, the association between the tagging moiety and functional tag comprises ether, thioether, carboxamide, sulfonamide, urea or urethane moieties. In preferred embodiments, the linkage comprises a polyalkylene chain, i.e., a linear or branched 30 arrangement of carbon-carbon bonds. In other embodiments, the linkage comprises a polyalkylene oxide chain, including a polyethylene glycol moiety. Examples, of affinity tags include, but are not limited to, biotin, digoxigenin (Dig), dinitrophenol (DNP), zinc fingers, fluorinated polymers, and 35 polypeptide sequences such as polyhistidine motifs.

The affinity tags are in some embodiments advantageously used to isolate the molecule of interest by relying on the binding or attraction of the affinity tag and a functional group that is attracted to or binds the affinity tag. In some embodi- 40 ments, solid substrates having an affinity for the tag in that the solid substrate is derivatized with the tag binding partner. In some embodiments, the binding partner may be immobilized on an affinity substrate. The term "affinity substrate" can refer to an immobile matrix or support bound to a binding partner 45 that is capable of forming a strong and preferably reversible interaction with the purification tag of a molecule. An affinity substrate can include a resin, a bead, a particle, a membrane, a gel. The binding partner recognizes or binds to the purification tag specifically. Specific binding partners will depend 50 on the affinity tag, but include charged moieties and one member of a binding pair such as receptor-ligand, antibodyantigen, carbohydrate-lectin, and biotin-streptavidin (or avidin, neutravidin or an anti-biotin antibody).

In specific and preferred embodiments, either the C or the 55 N terminus of any or all of the antigens used in the combination immunoassay may be biotinylated or may comprise a biotin binding moiety (e.g., avidin or streptavidin or neutravidin or an anti-biotin) as the affinity tag. These peptides are biotinylated or avidin/streptavidin-conjugated peptides and 60 will serve as capture antigens. Likewise, the antigens may alternatively be labeled with a detection label in which case they will serve as detection antigens. The detection and capture antigens may have the same underlying amino acid sequence or alternatively, may have different sequences. In 65 exemplary embodiments, the capture antigens are biotinylated at either the C or the N terminus to facilitate binding

22

thereof to solid supports that have the biotin binding partner (i.e., avidin or streptavidin). For exemplary production purposes, the biotinylated peptides are recombinantly expressed in E. coli BL2L(DE3) cells via an IPTG induction system at 25° C. In situ biotinylation at the C-terminal or N-terminal biotinylation is accomplished by co-transformation of the BL21(DE3) cells with the HCV expression plasmid expressing the desired peptide and a second plasmid containing the BirA gene from E. coli (Weiss et al. (1994) Protein Expression & Purif, 14:751-755; Schatz et al. (1993) Biotechnology, 11:1138-1143). Purification of the recombinant proteins is performed using divalent cation chelators that are shown to prevent metal-catalyzed oxidation and aggregation of the protein. Protein stability is significantly improved when EDTA or related divalent cation chelator is added to the buffers used during purification and to the final storage buffer or buffers used in the immunoassay.

Antibodies for Use in the Combinations Assays

As discussed herein throughout the combination immutional tag directly by a single bond or via a linkage of stable 20 noassays advantageously also determine the presence of one or more HCV antigens present in the test sample. In such embodiments, it will be desirable to use monoclonal anti-HCV antibodies to capture the antigen from the test sample and then use further conjugate antibodies to detect the presence of antigen that has been captured. There are numerous commercially available antibodies that may be used in this endeavor. Specifically, such antibodies preferably determine the presence of Core antigen in the test sample. Antibodies directed to Core antigen are known to those of skill in the art include, for example, those described in US Patent Publication No. 20120009196. In addition, the present invention further contemplates that use of monoclonal antibodies described in concurrently filed U.S. Patent Application No. 61/783,529, entitled "HCV Core Lipid Binding Domain Monoclonal Antibodies" that is specifically immunoreactive with the lipid binding domain of HCV core antigen. More particularly, the HCV core antigen is amino acid residues 134-171 of HCV. In more particular embodiments, the antibody specifically binds at least one epitope formed by amino acid sequence MGYIPLVGAPLGGAARALAHGVRV-LEDGVNYATGNLPG (SEQ ID NO: 89). In more specific embodiments, the antibody is immunoreactive with an epitope formed by amino acids 141-161, 134-154 and 151 to 171 of HCV core antigen.

> In specific exemplary embodiments the antibodies used in the combination immunoassay are antibodies designed to detect HCV core protein or fragments thereof in a test sample. Such antibodies may detect the DNA binding domain, the lipid binding domain or indeed the complete Core protein. In some embodiments, the detection antibody used in the immunoassay is directed to the lipid binding domain of core peptide and exemplary such antibodies are described in concurrently filed U.S. Provisional Application No. 61/783,529 entitled "HCV Core Lipid Binding Domain Monoclonal Antibodies", Attorney Docket no. 03946-26531 US01. In still other embodiments, the anti-HCV Core antibodies used in the combination assays may be for example, C11-3, C11-7, C11-9, and C11-14 (as described in U.S. Pat. No. 6,727,092; Morota, et al, J. Virol. Meth., 2009, 157:8-14).

> In a specific assay of the present invention, the combination immunoassay at least detects core antigen as well detecting core antibodies in the test sample. In such embodiments, it becomes desirable, although not essential to ensure that the capture antigen that is designed to capture anti-Core one that preferably comprise certain deletions or substitution in the known epitope binding regions for specific monoclonal antibodies such that monoclonal antibodies used for HCV core

antigen detection would fail to detect these modified core antigens but would nonetheless detect complete core antigen from the test sample. Exemplary anti-core antibodies to be used as capture antibodies include antibodies AOT3, C11-3, C11-7, C11-9, and C11-14 as described in U.S. Pat. No. 5 6,727,092 as well as Morota, et al, J. Virol. Meth., 2009,

Immunodiagnostic Assays and Reagents

In particular embodiments, the antigens and antibodies described above are contemplated for use as immunodiagnostic reagents in combination immunoassays designed for the detection of multiple HCV components found in a test sample suspected of having been infected with HCV. Immunodiagnostic reagents (be they antibodies or antigens) will be comprised of the above-described antigen polypeptides and antibodies (typically in combination) such that they can be used in a combination immunoassay designed for the detection of HCV antigens including but not limited to the NS3 region of HCV, the core antigen of HCV, the NS4 region of HCV or combinations thereof as well as anti-HCV antibodies directed 20 against one or more of these regions. For purposes of capture, the antigens and/or antibodies of which the immunodiagnostic reagent is comprised can be coated on a solid support such as for example, a microparticle, (e.g., magnetic particle), bead, test tube, microtiter plate, cuvette, membrane, scaffold- 25 ing molecule, film, filter paper, disc or chip. In this regard, where the immunodiagnostic reagent comprises a combination of antigens (e.g., directed at different HCV proteins or different fragments of the same HCV protein), the antigens can be co-coated on the same solid support or can be on 30 separate solid supports. Likewise, where the immunodiagnostic reagent comprises one or more antibodies that will be used to capture one or more antigens from the test sample, such antibodies can be co-coated on the same solid support or can be on separate solid supports.

Notably, the immunodiagnostic reagent will include the antigens and antibodies may be labeled with a detectable label or labeled with a specific partner that allows capture or detection. For example, the labels may be a detectable label, such as a fluorophore, radioactive moiety, enzyme, biotin/ 40 avidin label, chromophore, chemiluminescent label, or the like. Such labels are described in further detail infra.

Still further the invention contemplates the preparation of HCV diagnostic kits comprising the immunodiagnostic reagents described herein and instructions for the use of the 45 immunodiagnostic reagents in combination immunoassays for determining the presence of HCV in a test sample by detecting the presence of two or more HCV proteins and/or anti-HCV antibodies in such a sample. For example, the kit can comprise instructions for assaying the test sample for 50 anti-HCV antibody (e.g., an anti-Core antibody in the test sample) by immunoassay. While preferred embodiments employ chemiluminescent microparticle immunoassay for assaying the test sample, it should be understood that the antigens and antibodies used in the combination immunoas- 55 to conduct a diagnostic assay or facilitate quality control says of the present invention may be used in any other immunoassay formats known to those of skill in the art for determining the presence of HCV in a test sample. The instructions can be in paper form or computer-readable form, such as a disk, CD, DVD, or the like. Alternatively or additionally, the 60 kit can comprise a calibrator or control, e.g., purified, and optionally lyophilized, anti-HCV antibody or antigen, and/or at least one container (e.g., tube, microtiter plates or strips, which can be already coated with one or more of the capture components (antigens and/or antibodies) of the combination 65 immunoassay) for conducting the assay, and/or a buffer, such as an assay buffer or a wash buffer, either one of which can be

provided as a concentrated solution, a substrate solution for the detectable label (e.g., an enzymatic label), or a stop solution. Preferably, the kit comprises all components, i.e., reagents, standards, buffers, diluents, etc., which are necessary to perform the assay. In specific embodiments, it is preferred that all the components are individually presented in the kit such that the immunoassay may be performed as a capture-on-the-fly type combination immunoassay in which the solid support is coated with an agent that allows binding of the capturing moiety (e.g., a biotinylated antigen or a biotinylated antibody) and the kit further comprises each of the individual capture and detection antigen pairs and the biotinylated capture antibodies in one container and a second container provides the detection antibody conjugate. The instructions for conducting the assay also can include instructions for generating a standard curve or a reference standard for purposes of quantifying anti-HCV antibody.

24

Any antibodies, which are provided in the kit, such as anti-IgG antibodies and anti-IgM antibodies, can also incorporate a detectable label, such as a fluorophore, radioactive moiety, enzyme, biotin/avidin label, chromophore, chemiluminescent label, or the like, or the kit can include reagents for labeling the antibodies or reagents for detecting the antibodies (e.g., detection antibodies) and/or for labeling the analytes or reagents for detecting the analyte. The antibodies, calibrators and/or controls can be provided in separate containers or pre-dispensed into an appropriate assay format, for example, into microtiter plates. In a preferred combination immunoassay there are two containers provided. In the first container is provided at least a first, second and third pair of antigens, wherein the first antigen in each pair is a capture antigen from a given HCV protein that is biotinylated and the second antigen in each pair is a detection antigen from the same protein as the first antigen but is labeled with a detectable label (e.g., it is acridinylated) as well as one or more biotinylated antibodies designed for detecting one or more HCV antigens from a test sample; and in the second container is provided the antibody that forms the conjugation partner for detection of the antigen that is captured by the biotinylated antibodies from the first container. It is contemplated that where there are multiple biotinylated antibodies in the first container, the multiple antibodies that form the conjugation partners may be present in a single container or individual containers for each different antigen detecting conjugate antibody.

Optionally, the kit includes quality control components (for example, sensitivity panels, calibrators, and positive controls). Preparation of quality control reagents is well-known in the art and is described on insert sheets for a variety of immunodiagnostic products. Sensitivity panel members optionally are used to establish assay performance characteristics, and further optionally are useful indicators of the integrity of the immunoassay kit reagents, and the standardization

The kit can also optionally include other reagents required evaluations, such as buffers, salts, enzymes, enzyme co-factors, substrates, detection reagents, and the like. Other components, such as buffers and solutions for the isolation and/or treatment of a test sample (e.g., pretreatment reagents), also can be included in the kit. The kit can additionally include one or more other controls. One or more of the components of the kit can be lyophilized, in which case the kit can further comprise reagents suitable for the reconstitution of the lyophilized components.

The various components of the kit optionally are provided in suitable containers as necessary, e.g., a microtiter plate. The kit can further include containers for holding or storing a

sample (e.g., a container or cartridge for a sample). Where appropriate, the kit optionally also can contain reaction vessels, mixing vessels, and other components that facilitate the preparation of reagents or the test sample. The kit can also include one or more instrument for assisting with obtaining a test sample, such as a syringe, pipette, forceps, measured spoon, or the like.

In preferred embodiments, the detectable label is at least one acridinium compound. In such embodiments, the kit can comprise at least one acridinium-9-carboxamide, at least one 10 acridinium-9-carboxylate aryl ester, or any combination thereof. If the detectable label is at least one acridinium compound, the kit also can comprise a source of hydrogen peroxide, such as a buffer, solution, and/or at least one basic solution. It should be understood that in the immunodiagnostic reagent the antigens for antibody detection may be detectably labeled, and any antibodies provided in kit for use along with such reagents also may be detectably labeled.

If desired, the kit can contain a solid support phase, such as a magnetic particle, bead, test tube, microtiter plate, cuvette, 20 membrane, scaffolding molecule, film, filter paper, disc or chip.

Method of Determining the Presence, Amount or Concentration of HCV in a Test Sample

The present disclosure provides a combination immunoas- 25 say method for determining the presence, amount or concentration of anti-HCV antibodies and HCV antigens in a test sample. Any suitable assay known in the art can be used in such a method as long as such an assay uses one or more of antigens for detecting HCV antibodies and/or one or more 30 anti-HCV antibodies for detecting one or more HCV antigens in the test sample. Examples of such assays include, but are not limited to, immunoassay, such as sandwich immunoassay (e.g., monoclonal-polyclonal sandwich immunoassays, including radioisotope detection (radioimmunoassay (RIA)) 35 and enzyme detection (enzyme immunoassay (EIA) or enzyme-linked immunosorbent assay (ELISA) (e.g., Quantikine ELISA assays, R&D Systems, Minneapolis, Minn.)), competitive inhibition immunoassay (e.g., forward and reverse), fluorescence polarization immunoassay (FPIA), 40 enzyme multiplied immunoassay technique (EMIT), bioluminescence resonance energy transfer (BRET), and homogeneous chemiluminescent assay, etc.

In specific embodiments of the combination immunoassays, the recombinant antigens (e.g., core, NS3 and NS4 antigens) may be used as capture reagents (e.g., by using such antigens in which the amino- or carboxy-terminal of the antigen comprises a biotin tag) or as a detection (conjugate) reagents in which the antigens are either directly or indirectly labeled with acridinium. Indirect labeling requires the use of 50 acridinylated BSA covalently coupled to the free thiol of unpaired cysteine residues within a protein via SMCC-type linker. To facilitate such indirect labeling certain of the antigens used in the combination immunoassays of the present invention may readily be further modified to include additional cysteine residues at the C-terminus.

Typically, immunoassays are performed in 1-step or 2-step format. Solid phase reagents for capture of immune complexes formed in solution in the 1-step assay include antibiotin monoclonal antibody, streptavidin or neutravidin to 60 capture the biotinylated moiety (be it a biotinylated antigen for capture of an HCV antibody or a biotinylated antibody for the capture of an HCV protein/antigen in the test sample).

In a SELDI-based immunoassay, a capture reagent that specifically binds anti-HCV-antibody or an HCV antigen is attached to the surface of a mass spectrometry probe, such as a pre-activated protein chip array. The anti-HCV antibody or

26

the antigen is then specifically captured on the biochip, and the captured moiety is detected by mass spectrometry. Alternatively, the anti-HCV antibody can be eluted from the capture reagent and detected by traditional MALDI (matrixassisted laser desorption/ionization) or by SELDI. A chemiluminescent microparticle immunoassay, in particular one employing the ARCHITECT® automated analyzer (Abbott Laboratories, Abbott Park, III.), is an example of a preferred immunoassay in which a combination of multiple antigens (preferably antigens from two or more HCV proteins) as well as multiple anti-HCV antibodies may readily be employed. An agglutination assay, such as a passive hemagglutination assay, also can be used. In an agglutination assay an antigen-antibody reaction is detected by agglutination or clumping. In a passive hemagglutination assay, erythrocytes are coated with the antigen and the coated erythrocytes are used in the agglutination assay.

Methods well-known in the art for collecting, handling and processing urine, blood, serum and plasma, and other body fluids, are used in the practice of the present disclosure, for instance, when the immunodiagnostic reagents comprise multiple antigens and/or in an anti-HCV antibody immunoassay kit. The test sample can comprise further moieties in addition to the polypeptide of interest, such as antibodies, antigens, haptens, hormones, drugs, enzymes, receptors, proteins, peptides, polypeptides, oligonucleotides or polynucleotides. For example, the sample can be a whole blood sample obtained from a subject. It can be necessary or desired that a test sample, particularly whole blood, be treated prior to immunoassay as described herein, e.g., with a pretreatment reagent. Even in cases where pretreatment is not necessary (e.g., most urine samples), pretreatment optionally can be done for mere convenience (e.g., as part of a regimen on a commercial platform).

The pretreatment reagent can be any reagent appropriate for use with the combination immunoassay and kits of the invention. The pretreatment optionally comprises: (a) one or more solvents (e.g., methanol and ethylene glycol) and salt, (b) one or more solvents, salt and detergent, (c) detergent, or (d) detergent and salt. Pretreatment reagents are known in the art, and such pretreatment can be employed, e.g., as used for assays on Abbott TDx, AxSYM®, and ARCHITECT® analyzers (Abbott Laboratories, Abbott Park, Ill.), as described in the literature (see, e.g., Yatscoff et al., Abbott TDx Monoclonal Antibody Assay Evaluated for Measuring Cyclosporine in Whole Blood, Clin. Chem. 36: 1969-1973 (1990), and Wallemacq et al., Evaluation of the New AxSYM Cyclosporine Assay: Comparison with TDx Monoclonal Whole Blood and EMIT Cyclosporine Assays, Clin. Chem. 45: 432-435 (1999)), and/or as commercially available. Additionally, pretreatment can be done as described in Abbott's U.S. Pat. No. 5,135,875, European Pat. Pub. No. 0 471 293, U.S. Provisional Pat. App. 60/878,017, filed Dec. 29, 2006, and U.S. Pat. App. Pub. No. 2008/0020401 (incorporated by reference in its entirety for its teachings regarding pretreatment). The pretreatment reagent can be a heterogeneous agent or a homogeneous agent.

With use of a heterogeneous pretreatment reagent, the pretreatment reagent precipitates analyte binding protein (e.g., protein that can bind to anti-HCV antibody or an antigen that can bind to an anti-HCV antibody form the present in the sample. Such a pretreatment step comprises removing any analyte binding protein by separating from the precipitated analyte binding protein the supernatant of the mixture formed by addition of the pretreatment agent to sample. In such an

assay, the supernatant of the mixture absent any binding protein is used in the assay, proceeding directly to the antibody capture step.

With use of a homogeneous pretreatment reagent there is no such separation step. The entire mixture of test sample and 5 pretreatment reagent are contacted with a labeled specific binding partner for anti-HCV antibody (i.e., an antigen) or the labeled specific binding partner for the HCV antigen (i.e., an antibody). The pretreatment reagent employed for such an assay typically is diluted in the pretreated test sample mixture, either before or during capture by the first specific binding partner. Despite such dilution, a certain amount of the pretreatment reagent (for example, 5 M methanol and/or 0.6 methylene glycol) is still present (or remains) in the test sample mixture during capture.

In a heterogeneous format, after the test sample is obtained from a subject, a first mixture is prepared. The mixture contains the test sample being assessed for anti-HCV antibodies and a first specific capture binding partner, wherein the first specific capture binding partner and any anti-HCV antibodies 20 contained in the test sample form a first specific capture binding partner-anti-HCV antibody complex. The first specific capture binding partner may be any of a core antigen, an NS3 antigen or an NS3. Exemplary NS3 antigens used in the invention may be any one or more of the antigens shown in 25 Table 1 herein above. Likewise, in the combination assays of the invention the mixture also contains a second and third specific capture binding partner and these second and third specific capture binding partners form second and third specific capture binding partner-anti-HCV antibody complexes 30 with anti-HCV antibodies that are present in the test sample. Such second, third and fourth antigens may be one or more of at least one HCV antigen selected from the group consisting of core antigen, NS3, NS4, NS5, and portions thereof.

In addition the combination immunoassay may, and preferably does, include at least one anti-HCV capture antibody that will form a specific complex with a fourth specific binding partner that is found in the test sample (i.e., an antigen or HCV protein that is found in the test sample) so as to form an anti-HCV antibody-fourth specific binding partner complex with the fourth antigen that is present in the test sample. Preferably, the fourth specific binding pair is one that detects Core antigen in a test sample, and hence the binding pair is an anti-Core antibody for detection of the fourth antigen (Core) in the test sample.

The order in which the test sample and the various specific binding partners are added to form the mixture is not critical. In some embodiments, the first, second, and third specific capture binding partners (i.e., antigens) and the anti-HCV capture antibody are immobilized on a solid phase. In still 50 other embodiments, none of these four components are immobilized but are instead all added at the same time to the test sample to effect capture onto the solid phase. The solid phase used in the combination immunoassay can be any solid phase known in the art, such as, but not limited to, a magnetic 55 particle, a bead, a test tube, a microtiter plate, a cuvette, a membrane, a scaffolding molecule, a film, a filter paper, a disc and a chip.

After the immunocomplexes are formed between the first, second and third specific capture binding partners and their 60 respective anti-HCV antibodies found in the test sample, and the first anti-HCV capture antibodies (e.g., anti-Core) and their respective HCV antigens or HCV proteins found in the test sample, any unbound anti-HCV antibody or HCV antigen/protein is removed from the complex using any technique 65 known in the art. For example, the unbound anti-HCV antibody or antigen can be removed by washing. Desirably, how-

28

ever, the first, second and third specific binding partners and the anti-HCV antibodies are present in excess of any anti-HCV antibody and antigens, respectively present in the test sample, such that all anti-HCV antibody and antigens that are present in the test sample become bound by the first, second, and third specific binding partner and anti-HCV capture anti-bodies respectively.

After any unbound anti-HCV antibody and antigen is removed, detection is achieved by addition of a first specific detection binding partner to the mixture to form a first specific capture binding partner-anti-HCV antibody-first specific detection binding partner complex. The first specific detection binding partner is preferably a combination of an anti-IgG antibody and an anti-IgM antibody. Moreover, also preferably, the first specific detection binding partner is labeled with or contains a detectable label as described above. In specific embodiments, the first specific detection partner may instead or in addition be an antigen that binds the captured antibody. Likewise, in the combination assays of the invention the mixture also contains a second and third specific detection binding partner and these second and third specific detection binding partners form second or third specific capture binding partner-anti-HCV antibody-second or third specific detection binding partner complexes with the captured anti-HCV antibodies that are present in the test sample. Again, the second and third specific detection binding partners may be a combination of an anti-IgG antibody and an anti-IgM antibody. In specific embodiments, the second and third specific detection partners may instead or in addition be an antigen that binds the captured antibody. Moreover, also preferably, the second and third specific detection binding partners, be they anti-IgM or IgG antibodies or antigens, are labeled with or contains a detectable label as described above. In addition the combination immunoassay may, and preferably does, include at least one anti-HCV conjugate antibody that will form a specific complex with the captured antigen or HCV protein that is found in the test sample so as to form a anti-HCV antibody-fourth specific binding partner-anti-HCV conjugate antibody complex with the fourth antigen that captured from the test sample.

Any suitable detectable label as is known in the art can be used as any one or more of the detectable labels. For example, the detectable label can be a radioactive label (such as ³H, ¹²⁵I, ³⁵S, ¹⁴C, ³²P, and ³³P), an enzymatic label (such as 45 horseradish peroxidase, alkaline peroxidase, glucose 6-phosphate dehydrogenase, and the like), a chemiluminescent label (such as acridinium esters, thioesters, or sulfonamides; luminol, isoluminol, phenanthridinium esters, and the like), a fluorescent label (such as fluorescein (e.g., 5-fluorescein, 6-carboxyfluorescein, 3'6-carboxyfluorescein, 5(6)-carboxyfluorescein, 6-hexachloro-fluorescein, 6-tetrachlorofluorescein, fluorescein isothiocyanate, and the like)), rhodamine, phycobiliproteins, R-phycoerythrin, quantum dots (e.g., zinc sulfide-capped cadmium selenide), a thermometric label, or an immuno-polymerase chain reaction label. An introduction to labels, labeling procedures and detection of labels is found in Polak and Van Noorden, Introduction to Immunocytochemistry, 2nd ed., Springer Verlag, N.Y. (1997), and in Haugland, Handbook of Fluorescent Probes and Research Chemicals (1996), which is a combined handbook and catalogue published by Molecular Probes, Inc., Eugene, Oreg. A fluorescent label can be used in FPIA (see, e.g., U.S. Pat. Nos. 5,593,896, 5,573,904, 5,496,925, 5,359,093, and 5,352,803, which are hereby incorporated by reference in their entireties). An acridinium compound can be used as a detectable label in a homogeneous chemiluminescent assay (see, e.g., Adamczyk et al., Bioorg. Med. Chem. Lett. 16: 1324-1328

(2006); Adamczyk et al., Bioorg. Med. Chem. Lett. 4: 2313-2317 (2004); Adamczyk et al., Biorg. Med. Chem. Lett. 14: 3917-3921 (2004); and Adamczyk et al., Org. Lett. 5: 3779-3782 (2003)).

A preferred acridinium compound is an acridinium-9-carboxamide. Methods for preparing acridinium 9-carboxamides are described in Mattingly, J. Biolumin. Chemilumin. 6: 107-114 (1991); Adamczyk et al., J. Org. Chem. 63: 5636-5639 (1998); Adamczyk et al., Tetrahedron 55: 10899-10914 (1999); Adamczyk et al., Org. Lett. 1: 779-781 (1999); Adamczyk et al., Bioconjugate Chem. 11: 714-724 (2000); Mattingly et al., In Luminescence Biotechnology: Instruments and Applications; Dyke, K. V. Ed.; CRC Press: Boca Raton, pp. 77-105 (2002); Adamczyk et al., Org. Lett. 5: 3779-3782 (2003); and U.S. Pat. Nos. 5,468,646, 5,543,524 and 5,783, 15 699 (each of which is incorporated herein by reference in its entirety for its teachings regarding same).

Another preferred acridinium compound is an acridinium-9-carboxylate aryl ester. An example of an acridinium-9carboxylate aryl ester of formula II is 10-methyl-9-(phenoxy-20 carbonyl)acridinium fluorosulfonate (available from Cayman Chemical, Ann Arbor, Mich.). Methods for preparing acridinium 9-carboxylate aryl esters are described in McCapra et al., Photochem. Photobiol. 4: 1111-21 (1965); Razavi et al., Luminescence 15: 245-249 (2000); Razavi et al., Lumines- 25 cence 15: 239-244 (2000); and U.S. Pat. No. 5,241,070 (each of which is incorporated herein by reference in its entirety for its teachings regarding same). Such acridinium-9-carboxylate aryl esters are efficient chemiluminescent indicators for hydrogen peroxide produced in the oxidation of an analyte by 30 at least one oxidase in terms of the intensity of the signal and/or the rapidity of the signal. The course of the chemiluminescent emission for the acridinium-9-carboxylate aryl ester is completed rapidly, i.e., in under 1 second, while the acridinium-9-carboxamide chemiluminescent emission 35 extends over 2 seconds. Acridinium-9-carboxylate aryl ester, however, loses its chemiluminescent properties in the presence of protein. Therefore, its use requires the absence of protein during signal generation and detection. Methods for separating or removing proteins in the sample are well-known 40 to those skilled in the art and include, but are not limited to, ultrafiltration, extraction, precipitation, dialysis, chromatography, and/or digestion (see, e.g., Wells, High Throughput Bioanalytical Sample Preparation. Methods and Automation Strategies, Elsevier (2003)). The amount of protein removed 45 or separated from the test sample can be about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95%. Further details regarding acridinium-9-carboxylate aryl ester and its use are set forth in U.S. patent application Ser. 50 No. 11/697,835, filed Apr. 9, 2007, and published on Oct. 9, 2008, as U.S. Pat. App. Pub. No. 2008/0248493. Acridinium-9-carboxylate aryl esters can be dissolved in any suitable solvent, such as degassed anhydrous N,N-dimethylformamide (DMF) or aqueous sodium cholate.

Chemiluminescent assays can be performed in accordance with the methods described in Adamczyk et al., Anal. Chim. Acta 579(1): 61-67 (2006). While any suitable assay format can be used, a microplate chemiluminometer (Mithras LB-940, Berthold Technologies U.S.A., LLC, Oak Ridge, 60 Tenn.) enables the assay of multiple samples of small volumes rapidly. The chemiluminometer can be equipped with multiple reagent injectors using 96-well black polystyrene microplates (Costar #3792). Each sample can be added into a separate well, followed by the simultaneous/sequential addition of other reagents as determined by the type of assay employed. Desirably, the formation of pseudobases in neutral

or basic solutions employing an acridinium aryl ester is avoided, such as by acidification. The chemiluminescent response is then recorded well-by-well. In this regard, the time for recording the chemiluminescent response will depend, in part, on the delay between the addition of the reagents and the particular acridinium employed.

30

The order in which the test sample and the specific binding partner(s) are added to form the mixture for chemiluminescent assay is not critical. If the first specific capture binding partner is detectably labeled with an acridinium compound, detectably labeled first specific capture binding partner-anti-HCV antibody complexes form. Alternatively, if a first specific detection binding partner is used and the first specific detection binding partner is detectably labeled with an acridinium compound, detectably labeled first specific capture binding partner-anti-HCV antibody-first specific detection binding partner complexes form (similarly, for second and third complexes in the combination assays described above). Any unbound specific binding partner, whether labeled or unlabeled, can be removed from the mixture using any technique known in the art, such as washing.

Hydrogen peroxide can be generated in situ in the mixture or provided or supplied to the mixture before, simultaneously with, or after the addition of an above-described acridinium compound. Hydrogen peroxide can be generated in situ in a number of ways such as would be apparent to one skilled in the art.

Alternatively, a source of hydrogen peroxide can be simply added to the mixture. For example, the source of the hydrogen peroxide can be one or more buffers or other solutions that are known to contain hydrogen peroxide. In this regard, a solution of hydrogen peroxide can simply be added.

Upon the simultaneous or subsequent addition of at least one basic solution to the sample, a detectable signal, namely, a chemiluminescent signal, indicative of the presence of anti-HCV antibody (where capture is with an antigen) or antigen (where capture is with an antibody) is generated. The basic solution contains at least one base and has a pH greater than or equal to 10, preferably, greater than or equal to 12. Examples of basic solutions include, but are not limited to, sodium hydroxide, potassium hydroxide, calcium hydroxide, ammonium hydroxide, magnesium hydroxide, sodium carbonate, sodium bicarbonate, calcium hydroxide, calcium carbonate, and calcium bicarbonate. The amount of basic solution added to the sample depends on the concentration of the basic solution. Based on the concentration of the basic solution used, one skilled in the art can easily determine the amount of basic solution to add to the sample.

The chemiluminescent signal that is generated can be detected using routine techniques known to those skilled in the art. Based on the intensity of the signal generated, the amount of anti-HCV antibody and/or antigen in the sample can be quantified. Specifically, the amount of anti-HCV antibody and/or in the sample is proportional to the intensity of the signal generated. The amount of anti-HCV antibody and/or antigen present can be quantified by comparing the amount of light generated to a standard curve for anti-HCV antibody and/or antigen or by comparison to a reference standard. The standard curve can be generated using serial dilutions or solutions of known concentrations of anti-HCV antibody by mass spectroscopy, gravimetric methods, and other techniques known in the art.

Anti-HCV antibody and/or antigen immunoassays can be conducted using any suitable format known in the art. Generally speaking, a sample being tested for (for example, suspected of containing) anti-HCV antibodies can be contacted with a capture antigen and at least one detection antibody

(which can be a second detection antibody or a third detection antibody), such as labeled anti-IgG and anti-IgM antibodies, either simultaneously or sequentially and in any order. Similarly, the test for presence of an antigen can be contacted with a captured antibody which binds the antigen in the test sample and the bound antigen may then be detected by a detection antibody.

For example, the test sample can be first contacted with at least one capture antigen and then (sequentially) with at least one detection antibody. Alternatively, the test sample can be 10 first contacted with at least one detection antibody and then (sequentially) with at least one capture antibody. In yet another alternative, the test sample can be contacted simultaneously with a capture antigen and a detection antibody.

In the sandwich assay format, a sample suspected of containing anti-HCV antibodies (or a fragment thereof) is first brought into contact with an at least one first capture antigen under conditions that allow the formation of a first capture antigen/anti-HCV antibody complex. In the combination assay, the same is repeated or simultaneously conducted with 20 a second, third or more capture antigens. If more than one capture antigen is used, multiple first capture antigen/anti-HCV antibody complexes are formed. In a sandwich assay, the antigen(s), preferably, the at least one capture antigen, is/are used in molar excess amounts of the maximum amount of anti-HCV antibodies expected in the test sample. For example, from about 5 µg to about 1 mg of antigen per mL of buffer (e.g., microparticle coating buffer) can be used.

Competitive inhibition immunoassays, which are often used to measure small analytes, comprise sequential and classic formats. In a sequential competitive inhibition immunoassay the one or more capture antigen(s) (i.e., a polypeptide, and preferably a pair of polypeptides, as described herein) to an antibody of interest (i.e., an anti-HCV antibody) is/are coated onto a well of a microtiter plate. When the sample containing 35 the antibody/antibodies of interest is added to the well, the antibody of interest binds to the capture antigen(s). After washing, a known amount of labeled (e.g., biotin or horseradish peroxidase (HRP)) antibody is added to the well. A substrate for an enzymatic label is necessary to generate a 40 signal. An example of a suitable substrate for HRP is 3,3',5, 5'-tetramethylbenzidine (TMB). After washing, the signal generated by the labeled antibody is measured and is inversely proportional to the amount of antibody in the sample. In a classic competitive inhibition immunoassay anti-45 gen for an antibody of interest is coated onto a well of a microtiter plate. However, unlike the sequential competitive inhibition immunoassay, the sample containing the antibody of interest (i.e., an anti-HCV antibody) and the labeled antibody are added to the well at the same. Any antibody in the 50 sample competes with labeled antibody for binding to the capture antigen. After washing, the signal generated by the labeled analyte is measured and is inversely proportional to the amount of analyte in the sample.

Optionally, prior to contacting the test sample with the at least one capture antigen (for example, the first capture antigen), the at least one capture antigen can be bound to a solid support, which facilitates the separation of the first antigen/anti-HCV antibody complex from the test sample. The substrate to which the capture antigen is bound can be any suitable solid support or solid phase that facilitates separation of the capture antigen-anti-HCV antibody complex from the sample. Examples include a well of a plate, such as a microtiter plate, a test tube, a porous gel (e.g., silica gel, agarose, dextran, or gelatin), a polymeric film (e.g., polyacrylamide), 65 beads (e.g., polystyrene beads or magnetic beads), a strip of a filter/membrane (e.g., nitrocellulose or nylon), micropar-

32

ticles (e.g., latex particles, magnetizable microparticles (e.g., microparticles having ferric oxide or chromium oxide cores and homo- or hetero-polymeric coats and radii of about 1-10 microns). The substrate can comprise a suitable porous material with a suitable surface affinity to bind antigens and sufficient porosity to allow access by detection antibodies. A microporous material is generally preferred, although a gelatinous material in a hydrated state can be used. Such porous substrates are preferably in the form of sheets having a thickness of about 0.01 to about 0.5 mm, preferably about 0.1 mm. While the pore size may vary quite a bit, preferably the pore size is from about 0.025 to about 15 microns, more preferably from about 0.15 to about 15 microns. The surface of such substrates can be activated by chemical processes that cause covalent linkage of an antibody to the substrate. Irreversible binding, generally by adsorption through hydrophobic forces, of the antigen to the substrate results; alternatively, a chemical coupling agent or other means can be used to bind covalently the antigen to the substrate, provided that such binding does not interfere with the ability of the antigen to bind to anti-HCV antibodies.

Alternatively, the anti-HCV antibody from the test sample can be bound with microparticles, which have been previously coated with antigen. If desired, one or more capture reagents, such as a pair of polypeptides as described herein, each of which can be bound by an anti-HCV antibody, can be attached to solid phases in different physical or addressable locations (e.g., such as in a biochip conFIG.uration (see, e.g., U.S. Pat. No. 6,225,047, Intl Pat. App. Pub. No. WO 99/51773; U.S. Pat. No. 6,329,209; Intl Pat. App. Pub. No. WO 00/56934, and U.S. Pat. No. 5,242,828). If the capture reagent is attached to a mass spectrometry probe as the solid support, the amount of anti-HCV antibodies bound to the probe can be detected by laser desorption ionization mass spectrometry. Alternatively, a single column can be packed with different beads, which are derivatized with the one or more capture reagents, thereby capturing the anti-HCV antibody in a single place (see, antibody derivatized, bead-based technologies, e.g., the xMAP technology of Luminex (Aus-

After the test sample being assayed for anti-HCV antibodies is brought into contact with at least one capture antigen (for example, the first capture antigen), the mixture is incubated in order to allow for the formation of a first antigen (or multiple antigen)-anti-HCV antibody (or a fragment thereof) complex. The incubation can be carried out at a pH of from about 4.5 to about 10.0, at a temperature of from about 2° C. to about 45° C., and for a period from at least about one (1) minute to about eighteen (18) hours, preferably from about 1 to about 24 minutes, most preferably for about 4 to about 18 minutes. The immunoassay described herein can be conducted in one step (meaning the test sample, at least one capture antibody and at least one detection antibody are all added sequentially or simultaneously to a reaction vessel) or in more than one step, such as two steps, three steps, etc.

After or simultaneously with formation of the (first or multiple) capture antigen/anti-HCV antibody complex, the complex is then contacted with at least one detection antibody (under conditions which allow for the formation of a (first or multiple) capture antigen/anti-HCV antibody/first antibody detection complex). The at least one detection antibody can be the second, third, fourth, etc. antibodies used in the immunoassay. If the capture antigen/anti-HCV antibody complex is contacted with more than one detection antibody, then a (first or multiple) capture antigen/anti-HCV antibody/(multiple) detection antibody complex is formed. As with the capture antigen (e.g., the first capture antigen), when the at least

second (and subsequent) detection antibody is brought into contact with the capture antigen/anti-HCV antibody complex, a period of incubation under conditions similar to those described above is required for the formation of the (first or multiple) capture antigen/anti-HCV antibody/(second or 5 multiple) detection antibody complex. Preferably, at least one detection antibody contains a detectable label. The detectable label can be bound to the at least one detection antibody (e.g., the second detection antibody) prior to, simultaneously with, or after the formation of the (first or multiple) capture antigen/ 10 anti-HCV antibody/(second or multiple) detection antibody complex. Any detectable label known in the art can be used (see discussion above, including Polak and Van Noorden (1997) and Haugland (1996)).

The detectable label can be bound to the antibodies (or 15 antigens which may comprise detectable labels) either directly or through a coupling agent. An example of a coupling agent that can be used is EDAC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, hydrochloride), which is commercially available from Sigma-Aldrich, St. Louis, Mo. 20 Other coupling agents that can be used are known in the art. Methods for binding a detectable label to an antibody are known in the art. Additionally, many detectable labels can be purchased or synthesized that already contain end groups that facilitate the coupling of the detectable label to the antibody, 25 such as CPSP-Acridinium Ester (i.e., 9-[N-tosyl-N-(3-carboxypropyl)]-10-(3-sulfopropyl)acridinium carboxamide) or SPSP-Acridinium Ester (i.e., N10-(3-sulfopropyl)-N-(3-sulfopropyl)-acridinium-9-carboxamide).

The (first or multiple) capture antigen/anti-HCV antibody/ 30 (second or multiple) detection antibody complex can be, but does not have to be, separated from the remainder of the test sample prior to quantification of the label. For example, if the at least one capture antigen (e.g., the first capture antigen) is bound to a solid support, such as a well or a bead, separation 35 can be accomplished by removing the fluid (of the test sample) from contact with the solid support. Alternatively, if the at least first capture antigen is bound to a solid support, it can be simultaneously contacted with the anti-HCV antibody-containing sample and the at least one second detection 40 antibody (or the labeled detection antigen) to form a first (multiple) antigen/anti-HCV antibody/second (multiple) antibody (and/or labeled detection antigen) complex, followed by removal of the fluid (test sample) from contact with the solid support. If the at least one first capture antigen is not 45 HCV antibody and HCV antigen combination immunoasbound to a solid support, then the (first or multiple) capture antigen/anti-HCV antibody/(second or multiple) detection antibody (and/or detection antigen for the captured antibody) complex does not have to be removed from the test sample for quantification of the amount of the label.

After formation of the labeled capture antigen/anti-HCV antibody/detection antigen (and/or detection antibody) complex (e.g., the first capture antigen/anti-HCV antibody/first detection antigen complex optionally also with a second detection antibody), the amount of label in the complex is 55 quantified using techniques known in the art. For example, if an enzymatic label is used, the labeled complex is reacted with a substrate for the label that gives a quantifiable reaction such as the development of color. If the label is a radioactive label, the label is quantified using a scintillation counter. If the 60 label is a fluorescent label, the label is quantified by stimulating the label with a light of one color (which is known as the "excitation wavelength") and detecting another color (which is known as the "emission wavelength") that is emitted by the label in response to the stimulation. If the label is a chemilu- 65 minescent label, the label is quantified by detecting the light emitted either visually or by using luminometers, x-ray film,

34

high speed photographic film, a CCD camera, etc. Once the amount of the label in the complex has been quantified, the concentration of anti-HCV antibody or antigen in the test sample is determined by use of a standard curve that has been generated using serial dilutions of anti-HCV antibody or antigens of known concentration. Other than using serial dilutions of anti-HCV antibodies or HCV antigens, the standard curve can be generated gravimetrically, by mass spectroscopy and by other techniques known in the art.

In a chemiluminescent microparticle assay employing the ARCHITECT® analyzer, the conjugate diluent pH should be about 6.0+/-0.2, the microparticle coating buffer should be maintained at room temperature (i.e., at about 17 to about 27° C.), the microparticle coating buffer pH should be about 6.5+/-0.2, and the microparticle diluent pH should be about 6.5+/-0.2. Solids preferably are less than about 0.2%, such as less than about 0.15%, less than about 0.14%, less than about 0.13%, less than about 0.12%, or less than about 0.11%, such as about 0.10%

FPIAs are based on competitive binding immunoassay principles. A fluorescently labeled compound, when excited by a linearly polarized light, will emit fluorescence having a degree of polarization inversely proportional to its rate of rotation. When a fluorescently labeled tracer-antibody complex is excited by a linearly polarized light, the emitted light remains highly polarized because the fluorophore is constrained from rotating between the time light is absorbed and the time light is emitted. When a "free" tracer compound (i.e., a compound that is not bound to an antibody) is excited by linearly polarized light, its rotation is much faster than the corresponding tracer-antibody conjugate produced in a competitive binding immunoassay. FPIAs are advantageous over RIAs inasmuch as there are no radioactive substances requiring special handling and disposal. In addition, FPIAs are homogeneous assays that can be easily and rapidly per-

Commercially available anti-HCV antibodies as well as anti-IgG and anti-IgM antibodies can be used in the methods of assay and kits thereof. Commercially available antibodies include those available from Abnova (Walnut, Calif., and Taiwan) and GenWay Biotech, Inc. (San Diego, Calif.). See, also, European Pat. App. EP2099825 A2 regarding the preparation of anti-HCV antibodies.

Any suitable control composition can be used in the antisays. The control composition generally comprises anti-HCV antibodies and known antigens and any desirable additives.

Thus, in view of the above, a method of determining the presence, amount, or concentration of anti-HCV antibodies 50 or antigens in a test sample is provided. The method comprises assaying the test sample for anti-HCV antibodies or antigens by an assay:

(i) employing an immunodiagnostic reagent comprising at least an isolated or purified polypeptide comprising HCV antigens, and at least one detectable label, and comparing a signal generated by the detectable label as a direct or indirect indication of the presence, amount or concentration of anti-HCV antibodies in the test sample to a signal generated as a direct or indirect indication of the presence, amount or concentration of anti-HCV antibodies in a control or calibrator, which is optionally part of a series of calibrators in which each of the calibrators differs from the other calibrators in the series by the concentration of anti-HCV antibodies. The method can comprise the following steps:

(i) contacting the test sample with the immunodiagnostic reagent comprising one of more recombinant HCV antigens so as to form first, second and third specific capture binding

partner/anti-HCV antibody complexes with HCV antibodies that may be present in the test sample,

(ii) contacting the first, second and third specific capture binding partner/first, second and third anti-HCV antibody complexes with at least one detectably labeled second specific binding partner for anti-HCV antibody (e.g., anti-IgG antibody and anti-IgM antibody or polypeptides as described herein) so as to form first specific binding partner/first, second and third anti-HCV antibody, respectively/second specific binding partner complexes, and

(iii) determining the presence, amount or concentration of anti-HCV antibodies in the test sample by detecting or measuring the signal generated by the detectable label in the first specific binding partner/anti-HCV antibody/second specific binding partner complexes formed in (ii).

Optionally or preferably, in addition to, or instead of, use of the anti-IgG and IgM antibodies, the second step comprises addition of first, second and third detection antigens that will specifically bind the anti-HCV antibodies that have been specifically captured by the first, second and third capture antigens, respectively so as to form first specific binding partner/anti-HCV antibody/second specific binding partner complexes, and the third step comprises:

(iii) determining the presence, amount or concentration of anti-HCV antibodies in the test sample by detecting or measuring the signal generated by the detectable label in the first, second and third specific capture binding partner/first, second and third anti-HCV antibodies/first, second and third specific detection binding partner complexes formed in (ii).

Alternatively, the method can comprise the following 30 steps:

(i) contacting the test sample with the immunodiagnostic reagent comprising one of more recombinant antigens and simultaneously or sequentially, in either order, contacting the test sample with at least one detectably labeled second specific binding partner, which can compete with anti-HCV antibody for binding to the at least one pair of first specific binding partners and which comprises detectably labeled anti-HCV antibodies, wherein any anti-HCV antibody present in the test sample and the at least one detectably 40 labeled second specific binding partner compete with each other to form first specific binding partner/anti-HCV antibody complexes and first specific binding partner/second specific binding partner/second specific binding partner/second specific binding partner complexes, respectively, and

(ii) determining the presence, amount or concentration of 45 anti-HCV antibodies in the test sample by detecting or measuring the signal generated by the detectable label in the first specific binding partner/second specific binding partner complex formed in (ii), wherein the signal generated by the detectable label in the first specific binding partner/second specific 50 binding partner complex is inversely proportional to the amount or concentration of anti-HCV antibodies in the test sample. The recombinant antigens of which the immunodiagnostic reagent is comprised can be coated on microparticles. In this regard, the antigens of which the immunodiagnostic reagent is comprised can be co-coated on the same microparticles as additional HCV antigens. When the polypeptides of which the immunodiagnostic reagent is comprised are co-coated on the same microparticles (e.g., a microparticle suspension containing 4% solids (4% weight/ 60 volume microparticles or 4 gr microparticles/100 mL microparticle suspension)), preferably the polypeptides are co-coated on the same microparticles in a ratio of about 1:2 to about 1:6, wherein, when the polypeptides are co-coated on the same microparticles in a ratio of about 1:2, the concen- 65 tration of an isolated or purified antigen of the present invention (e.g., those described in Table 1) is at least about 40

36

 μ g/mL and the concentration of the other isolated or purified polypeptide is at least about 80 μ g/mL. If the test sample was obtained from a patient, the method may further comprise diagnosing, prognosticating, or assessing the efficacy of a therapeutic/prophylactic treatment of the patient. If the method further comprises assessing the efficacy of a therapeutic/prophylactic treatment of the patient, the method optionally can further comprise modifying the therapeutic/prophylactic treatment of the patient as needed to improve efficacy. The method can be adapted for use in an automated system or a semi-automated system.

Also, in view of the above, a method of determining the presence, amount, or concentration of anti-HCV antibodies or HCV antigens or proteins in a test sample is provided. The method comprises assaying the test sample by an assay:

(i) employing: an immunodiagnostic reagent comprising at least one HCV antigen (and preferably two, three or more antigens) at least one detectable label (preferably each antigen being detectably labeled), and

(ii) comparing a signal generated by the detectable label as a direct or indirect indication of the presence, amount or concentration of anti-HCV antibodies in the test sample to a signal generated as a direct or indirect indication of the presence, amount or concentration of anti-HCV antibodies in a control or calibrator, which is optionally part of a series of calibrators in which each of the calibrators differs from the other calibrators in the series by the concentration of anti-HCV antibodies. The method can comprise the following steps:

(i) contacting the test sample with the immunodiagnostic reagent comprising at least one, two, three or more recombinant HCV antigens invention so as to form first specific capture binding partner/anti-HCV antibody complexes,

(ii) contacting the first specific capture binding partner/anti-HCV antibody complexes with at least one detectably labeled second specific binding partner for anti-HCV antibody (e.g., anti-IgG antibody and anti-IgM antibody or labeled antigens that bind the anti-HCV antibodies) so as to form first specific binding partner/anti-HCV antibody/second specific binding partner complexes, and

(iii) determining the presence, amount or concentration of anti-HCV antibodies in the test sample by detecting or measuring the signal generated by the detectable label in the first specific binding partner/anti-HCV antibody/second specific binding partner complexes formed in (ii). Alternatively, the method can comprise the following steps:

(i) contacting the test sample with the immunodiagnostic reagent comprising at least one, two, three or more different HCV antigens and simultaneously or sequentially, in either order, contacting the test sample with at least one detectably labeled second specific binding partner, which can compete with anti-HCV antibody for binding to the at least one pair of first specific binding partners and which comprises detectably labeled anti-HCV antibodies, wherein any anti-HCV antibody present in the test sample and the at least one second specific binding partner compete with each other to form first specific binding partner/anti-HCV antibody complexes and a first specific binding partner/second specific binding partner complexes, respectively, and

(ii) determining the presence, amount or concentration of anti-HCV antibodies in the test sample by detecting or measuring the signal generated by the detectable label in the first specific binding partner/second specific binding partner complex formed in (ii), wherein the signal generated by the detectable label in the first specific binding partner/second specific binding partner complex is inversely proportional to the amount or concentration of anti-HCV antibodies in the test

sample. The polypeptides of which the immunodiagnostic reagent is comprised can be coated on microparticles. In this regard, the polypeptides of which the immunodiagnostic reagent is comprised can be co-coated on the same microparticles. When the polypeptides of which the immunodiagnos- 5 tic reagent is comprised are co-coated on the same microparticles (e.g., a microparticle suspension containing 4% solids (4% weight/volume microparticles or 4 gr microparticles/100 mL microparticle suspension)), preferably the polypeptides are co-coated on the same microparticles in a ratio of about 10 1:2 to about 1:6, wherein, when the polypeptides are cocoated on the same microparticles in a ratio of about 1:2, the concentration of an isolated or purified polypeptide comprising the recombinant HCV antigen is at least about 40 μg/mL and the concentration of the other isolated or purified 15 polypeptide is at least about 80 μg/mL. If the test sample was obtained from a patient, the method can further comprise diagnosing, prognosticating, or assessing the efficacy of a therapeutic/prophylactic treatment of the patient. If the method further comprises assessing the efficacy of a thera-20 peutic/prophylactic treatment of the patient, the method optionally can further comprise modifying the therapeutic/ prophylactic treatment of the patient as needed to improve efficacy. The method can be adapted for use in an automated system or a semi-automated system.

Generally, a predetermined level can be employed as a benchmark against which to assess results obtained upon assaying a test sample for anti-HCV antibodies. Generally, in making such a comparison, the predetermined level is obtained by running a particular assay a sufficient number of 30 times and under appropriate conditions such that a linkage or association of analyte presence, amount or concentration with a particular stage or endpoint of a disease, disorder or condition (e.g., preeclampsia or cardiovascular disease) or with particular indicia can be made. Typically, the predetermined level is obtained with assays of reference subjects (or populations of subjects).

In particular, with respect to a predetermined level as employed for monitoring disease progression and/or treatment, the amount or concentration of anti-HCV antibodies 40 may be "unchanged," "favorable" (or "favorably altered"), or "unfavorable" (or "unfavorably altered"). "Elevated" or "increased" refers to an amount or a concentration in a test sample that is higher than a typical or normal level or range (e.g., predetermined level), or is higher than another reference 45 antigens; level or range (e.g., earlier or baseline sample). The term "lowered" or "reduced" refers to an amount or a concentration in a test sample that is lower than a typical or normal level or range (e.g., predetermined level), or is lower than another reference level or range (e.g., earlier or baseline sample). The 50 term "altered" refers to an amount or a concentration in a sample that is altered (increased or decreased) over a typical or normal level or range (e.g., predetermined level), or over another reference level or range (e.g., earlier or baseline

The typical or normal level or range for anti-HCV antibodies or HCV antigens is defined in accordance with standard practice. Because the levels of anti-HCV antibodies and/or HCV antigens in some instances will be very low, a so-called altered level or alteration can be considered to have occurred 60 when there is any net change as compared to the typical or normal level or range, or reference level or range, that cannot be explained by experimental error or sample variation. Thus, the level measured in a particular sample will be compared with the level or range of levels determined in similar samples 65 from a so-called normal subject. In this context, a "normal subject" is an individual with no detectable hepatitis, for

38

example, and a "normal" (sometimes termed "control") patient or population is/are one(s) that exhibit(s) no detectable hepatitis, for example. Furthermore, given that anti-HCV antibodies and HCV antigens are not routinely found at a high level in the majority of the human population, a "normal subject" can be considered an individual with no substantial detectable increased or elevated amount or concentration of anti-HCV antibodies or HCV antigens, and a "normal" (sometimes termed "control") patient or population is/are one(s) that exhibit(s) no substantial detectable increased or elevated amount or concentration of anti-HCV antibodies. An "apparently normal subject" is one in which anti-HCV antibodies or HCV antigen has not been or is being assessed. The level of an analyte is said to be "elevated" when the analyte is normally undetectable (e.g., the normal level is zero, or within a range of from about 25 to about 75 percentiles of normal populations), but is detected in a test sample, as well as when the analyte is present in the test sample at a higher than normal level. Thus, inter alia, the disclosure provides a method of screening for a subject having, or at risk of having. hepatitis, for example, as defined herein.

Accordingly, the methods described herein also can be used to determine whether or not a subject has or is at risk of developing hepatitis. Specifically, such a method can comprise the steps of:

- (a) determining the concentration or amount in a test sample from a subject of anti-HCV antibodies and/or HCV antigens (e.g., using the methods described herein, or methods known in the art); and
- (b) comparing the concentration or amount of anti-HCV antibodies and HCV antigens determined in step (a) with a predetermined level, wherein, if the concentration or amount of anti-HCV antibodies and/or HCV antigens determined in step (a) is favorable with respect to a predetermined level, then the subject is determined not to have or be at risk for hepatitis. However, if the concentration or amount of anti-HCV antibodies and/or HCV antigens determined in step (a) is unfavorable with respect to the predetermined level, then the subject is determined to have or be at risk for hepatitis.

Additionally, provided herein is method of monitoring the progression of disease in a subject. Optimally the method comprising the steps of:

- (a) determining the concentration or amount in a test sample from a subject of anti-HCV antibodies and/or HCV antigens;
- (b) determining the concentration or amount in a later test sample from the subject of anti-HCV antibodies and/or HCV antigens; and $\,$
- (c) comparing the concentration or amount of anti-HCV antibodies and/or HCV antigens as determined in step (b) with the concentration or amount of anti-HCV antibodies and/or HCV antigens determined in step (a), wherein if the concentration or amount determined in step (b) is unchanged or is unfavorable when compared to the concentration or amount of anti-HCV antibodies and/or antigens determined in step (a), then the disease in the subject is determined to have continued, progressed or worsened. By comparison, if the concentration or amount of anti-HCV antibodies and/or antigens as determined in step (b) is favorable when compared to the concentration or amount of anti-HCV antibodies and/or antigens as determined in step (a), then the disease in the subject is determined to have discontinued, regressed or improved

Optionally, the method further comprises comparing the concentration or amount of anti-HCV antibodies and/or HCV antigens as determined in step (b), for example, with a predetermined level. Further, optionally the method comprises

treating the subject with one or more pharmaceutical compositions for a period of time if the comparison shows that the concentration or amount of anti-HCV antibodies and/or anti-HCV antigens as determined in step (b), for example, is unfavorably altered with respect to the predetermined level.

Still further, the methods can be used to monitor treatment in a subject receiving treatment with one or more pharmaceutical compositions. Specifically, such methods involve providing a first test sample from a subject before the subject has been administered one or more pharmaceutical compositions. 10 Next, the concentration or amount in a first test sample from a subject of anti-HCV antibodies and/or HCV antigens is determined (e.g., using the methods described herein or as known in the art). After the concentration or amount of anti-HCV antibodies and/or HCV antigens is determined, option- 15 ally the concentration or amount of anti-HCV antibodies is then compared with a predetermined level. If the concentration or amount of anti-HCV antibodies and/or HCV antigens as determined in the first test sample is lower than the predetermined level, then the subject is not treated with one or more 20 pharmaceutical compositions. However, if the concentration or amount of anti-HCV antibodies and/or HCV antigens as determined in the first test sample is higher than the predetermined level, then the subject is treated with one or more pharmaceutical compositions for a period of time. The period 25 of time that the subject is treated with the one or more pharmaceutical compositions can be determined by one skilled in the art (for example, the period of time can be from about seven (7) days to about two years, preferably from about fourteen (14) days to about one (1) year).

During the course of treatment with the one or more pharmaceutical compositions, second and subsequent test samples are then obtained from the subject. The number of test samples and the time in which said test samples are obtained from the subject are not critical. For example, a 35 second test sample could be obtained seven (7) days after the subject is first administered the one or more pharmaceutical compositions, a third test sample could be obtained two (2) weeks after the subject is first administered the one or more pharmaceutical compositions, a fourth test sample could be 40 obtained three (3) weeks after the subject is first administered the one or more pharmaceutical compositions, a fifth test sample could be obtained four (4) weeks after the subject is first administered the one or more pharmaceutical compositions, a fifth test sample could be obtained four (4) weeks after the subject is first administered the one or more pharmaceutical compositions, etc.

After each second or subsequent test sample is obtained from the subject, the concentration or amount of anti-HCV antibodies and/or HCV antigens is determined in the second or subsequent test sample is determined (e.g., using the methods described herein or as known in the art). The concentra- 50 tion or amount of anti-HCV antibodies and/or HCV antigens as determined in each of the second and subsequent test samples is then compared with the concentration or amount of anti-HCV antibodies and/or HCV antigens as determined in the first test sample (e.g., the test sample that was originally 55 optionally compared to the predetermined level). If the concentration or amount of anti-HCV antibodies and/or HCV antigens as determined in step (c) is favorable when compared to the concentration or amount of anti-HCV antibodies and/or HCV antigens as determined in step (a), then the 60 disease in the subject is determined to have discontinued, regressed or improved, and the subject should continue to be administered the one or pharmaceutical compositions of step (b). However, if the concentration or amount determined in step (c) is unchanged or is unfavorable when compared to the 65 concentration or amount of anti-HCV antibodies and/or HCV antigens as determined in step (a), then the disease in the

40

subject is determined to have continued, progressed or worsened, and the subject should be treated with a higher concentration of the one or more pharmaceutical compositions administered to the subject in step (b) or the subject should be treated with one or more pharmaceutical compositions that are different from the one or more pharmaceutical compositions administered to the subject in step (b). Specifically, the subject can be treated with one or more pharmaceutical compositions that are different from the one or more pharmaceutical compositions that the subject had previously received to decrease or lower said subject's anti-HCV antibodies and/or HCV antigens level.

Generally, for assays in which repeat testing may be done (e.g., monitoring disease progression and/or response to treatment), a second or subsequent test sample is obtained at a period in time after the first test sample has been obtained from the subject. Specifically, a second test sample from the subject can be obtained minutes, hours, days, weeks or years after the first test sample has been obtained from the subject. For example, the second test sample can be obtained from the subject at a time period of about 1 minute, about 5 minutes, about 10 minutes, about 15 minutes, about 30 minutes, about 45 minutes, about 60 minutes, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 21 weeks, about 22 weeks, about 23 weeks, about 24 weeks, about 25 weeks, about 26 weeks, about 27 weeks, about 28 weeks, about 29 weeks, about 30 weeks, about 31 weeks, about 32 weeks, about 33 weeks, about 34 weeks, about 35 weeks, about 36 weeks, about 37 weeks, about 38 weeks, about 39 weeks, about 40 weeks, about 41 weeks, about 42 weeks, about 43 weeks, about 44 weeks, about 45 weeks, about 46 weeks, about 47 weeks, about 48 weeks, about 49 weeks, about 50 weeks, about 51 weeks, about 52 weeks, about 1.5 years, about 2 years, about 2.5 years, about 3.0 years, about 3.5 years, about 4.0 years, about 4.5 years, about 5.0 years, about 5.5. years, about 6.0 years, about 6.5 years, about 7.0 years, about 7.5 years, about 8.0 years, about 8.5 years, about 9.0 years, about 9.5 years or about 10.0 years after the first test sample from the subject is obtained. When used to monitor disease progression, the above assay can be used to monitor the progression of disease in subjects suffering from acute conditions. Acute conditions, also known as critical care conditions, refer to acute, life-threatening diseases or other critical medical conditions involving, for example, the cardiovascular system or excretory system. Typically, critical care conditions refer to those conditions requiring acute medical intervention in a hospital-based setting (including, but not limited to, the emergency room, intensive care unit, trauma center, or other emergent care setting) or administration by a paramedic or other field-based medical personnel. For critical care conditions, repeat monitoring is generally done within a shorter time frame, namely, minutes, hours or days (e.g., about 1 minute, about 5 minutes, about 10 minutes, about 15 minutes, about 30 minutes, about 45 minutes, about 60 minutes, about 2 hours, about 3 hours, about 4 hours, 4 about 5 hours, about 6 hours, about 7 hours, about 8

hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days or about 7 days), and the initial assay likewise is generally done within a shorter timeframe, e.g., about minutes, hours or days of the onset of the disease or condition.

The assays also can be used to monitor the progression of disease in subjects suffering from chronic or non-acute conditions. Non-critical care or, non-acute conditions, refers to conditions other than acute, life-threatening disease or other critical medical conditions involving, for example, the cardiovascular system and/or excretory system. Typically, nonacute conditions include those of longer-term or chronic duration. For non-acute conditions, repeat monitoring generally is done with a longer timeframe, e.g., hours, days, weeks, months or years (e.g., about 1 hour, about 2 hours, about 3 20 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 25 hours, about 23 hours, about 24 hours, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 21 weeks, about 22 weeks, about 23 weeks, about 24 weeks, about 25 weeks, about 26 weeks, about 27 weeks, about 28 weeks, about 29 weeks, about 30 weeks, about 31 weeks, about 32 weeks, about 33 weeks, about 34 weeks, about 35 weeks, about 36 weeks, about 37 weeks, about 38 weeks, about 39 weeks, about 40 weeks, about 41 about 45 weeks, about 46 weeks, about 47 weeks, about 48 weeks, about 49 weeks, about 50 weeks, about 51 weeks, about 52 weeks, about 1.5 years, about 2 years, about 2.5 years, about 3.0 years, about 3.5 years, about 4.0 years, about 4.5 years, about 5.0 years, about 5.5. years, about 6.0 years, 45 about 6.5 years, about 7.0 years, about 7.5 years, about 8.0 years, about 8.5 years, about 9.0 years, about 9.5 years or about 10.0 years), and the initial assay likewise generally is done within a longer time frame, e.g., about hours, days, months or years of the onset of the disease or condition.

Furthermore, the above assays can be performed using a first test sample obtained from a subject where the first test sample is obtained from one source, such as urine, serum or plasma. Optionally the above assays can then be repeated using a second test sample obtained from the subject where 55 the second test sample is obtained from another source. For example, if the first test sample was obtained from urine, the second test sample can be obtained from serum or plasma. The results obtained from the assays using the first test sample and the second test sample can be compared. The comparison 60 can be used to assess the status of a disease or condition in the subject.

Moreover, the present disclosure also relates to methods of determining whether a subject predisposed to or suffering from hepatitis will benefit from treatment. In particular, the 65 disclosure relates to HCV companion diagnostic methods and products. Thus, the method of "monitoring the treatment of

42

disease in a subject" as described herein further optimally also can encompass selecting or identifying candidates for therapy.

Thus, in particular embodiments, the disclosure also provides a method of determining whether a subject having, or at risk for, hepatitis is a candidate for therapy. Generally, the subject is one who has experienced some symptom of hepatitis or who has actually been diagnosed as having, or being at risk for, hepatitis and/or who demonstrates an unfavorable concentration or amount of anti-HCV antibodies or a fragment thereof and/or HCV antigens, as described herein.

The method optionally comprises an assay as described herein, where analyte is assessed before and following treatment of a subject with one or more pharmaceutical compositions (e.g., particularly with a pharmaceutical related to a mechanism of action involving HCV), with immunosuppressive therapy, or by immunoabsorption therapy, with antiangiogenic therapy, or where analyte is assessed following such treatment and the concentration or the amount of analyte is compared against a predetermined level. An unfavorable concentration of amount of analyte observed following treatment confirms that the subject will not benefit from receiving further or continued treatment, whereas a favorable concentration or amount of analyte observed following treatment confirms that the subject will benefit from receiving further or continued treatment. This confirmation assists with management of clinical studies, and provision of improved patient

Adaptation of Kit and Method

The kit (or components thereof), as well as the method of determining the concentration of anti-HCV antibodies and/or HCV antigens in a test sample by an immunoassay as described herein, can be adapted for use in a variety of automated and semi-automated systems (including those wherein the solid phase comprises a microparticle), as described, e.g., in U.S. Pat. Nos. 5,089,424 and 5,006,309, and as commercially marketed, e.g., by Abbott Laboratories (Abbott Park, Ill.) as ARCHITECT®.

Some of the differences between an automated or semiweeks, about 42 weeks, about 43 weeks, about 44 weeks, 40 automated system as compared to a non-automated system (e.g., ELISA) include the substrate to which the first specific binding partner (e.g., antigen) is attached (which can impact sandwich formation and analyte reactivity), and the length and timing of the capture, detection and/or any optional wash steps. Whereas a non-automated format such as an ELISA may require a relatively longer incubation time with sample and capture reagent (e.g., about 2 hours), an automated or semi-automated format (e.g., ARCHITECT®, Abbott Laboratories) may have a relatively shorter incubation time (e.g., approximately 18 minutes for ARCHITECT®). Similarly, whereas a non-automated format such as an ELISA may incubate a detection antibody such as the conjugate reagent for a relatively longer incubation time (e.g., about 2 hours), an automated or semi-automated format (e.g., ARCHITECT®) may have a relatively shorter incubation time (e.g., approximately 4 minutes for the ARCHITECT®).

Other platforms available from Abbott Laboratories include, but are not limited to, AxSYM®, IMx® (see, e.g., U.S. Pat. No. 5,294,404, which is hereby incorporated by reference in its entirety), PRISM®, EIA (bead), and Quantum™ II, as well as other platforms. Additionally, the assays, kits and kit components can be employed in other formats, for example, on electrochemical or other hand-held or point-of-care assay systems. The present disclosure is, for example, applicable to the commercial Abbott Point of Care (i-STAT®, Abbott Laboratories) electrochemical immunoassay system that performs sandwich immunoassays Immunosensors and

their methods of manufacture and operation in single-use test devices are described, for example in, U.S. Pat. No. 5,063, 081, U.S. Pat. App. Pub. No. 2003/0170881, U.S. Pat. App. Pub. No. 2004/0018577, U.S. Pat. App. Pub. No. 2005/0054078, and U.S. Pat. App. Pub. No. 2006/0160164, which are incorporated in their entireties by reference for their teachings regarding same.

In particular, with regard to the adaptation of an assay to the I-STAT® system, the following conFIG.uration is exemplary. A microfabricated silicon chip is manufactured with a pair of gold amperometric working electrodes and a silver-silver chloride reference electrode. On one of the working electrodes, polystyrene beads (0.2 mm diameter) with immobilized capture antibody are adhered to a polymer coating of patterned polyvinyl alcohol over the electrode. This chip is assembled into an I-STAT® cartridge with a fluidics format suitable for immunoassay. On a portion of the wall of the sample-holding chamber of the cartridge there is a layer comprising the detection antibody labeled with alkaline phosphatase (or other label). Within the fluid pouch of the cartridge is an aqueous reagent that includes p-aminophenol 20 phosphate.

In operation, a sample suspected of containing anti-HCV antibody and/or HCV antigens is added to the holding chamber of the test cartridge and the cartridge is inserted into the I-STAT® reader. After the detection antibody or detectably labeled detection antigen has dissolved into the sample, a pump element within the cartridge forces the sample into a conduit containing the chip. Here it is oscillated to promote formation of the sandwich between the capture antigen (or capture antibody), anti-HCV antibody (or HCV antigen), and the labeled detection antibody (and/or detection antigen). In the penultimate step of the assay, fluid is forced out of the pouch and into the conduit to wash the sample off the chip and into a waste chamber. In the final step of the assay, the alkaline phosphatase label reacts with p-aminophenol phosphate to cleave the phosphate group and permit the liberated p-ami- 35 nophenol to be electrochemically oxidized at the working electrode. Based on the measured current, the reader is able to calculate the amount of anti-HCV antibody or HCV antigen in the sample by means of an embedded algorithm and factory-determined calibration curve.

The methods and kits as described herein encompass other reagents and methods for carrying out the immunoassay. For instance, encompassed are various buffers such as are known in the art and/or which can be readily prepared or optimized to be employed, e.g., for washing, as a conjugate diluent, and/or 45 as a calibrator diluent. An exemplary conjugate diluent is ARCHITECT® conjugate diluent employed in certain kits (Abbott Laboratories, Abbott Park, Ill.) and containing 2-(Nmorpholino)ethanesulfonic acid (MES), a salt, a protein blocker, an antimicrobial agent, and a detergent. An exemplary calibrator diluent is ARCHITECT® human calibrator diluent employed in certain kits (Abbott Laboratories, Abbott Park, Ill.), which comprises a buffer containing MES, other salt, a protein blocker, and an antimicrobial agent. Additionally, as described in U.S. Patent Application No. 61/142,048 filed Dec. 31, 2008, and U.S. patent application Ser. No. 55 12/650,241, improved signal generation may be obtained, e.g., in an I-STAT® cartridge format, using a nucleic acid sequence linked to the signal antibody as a signal amplifier.

EXAMPLES

Example 1

Cloning and Expression of HCV NS3 9NB49H

The nucleotide sequence (Seq ID # 1) encoding amino acids 1192-1457 of HCV-1(Seq ID #) 2) was codon optimized

44

for *E. coli* expression and cloned into a modified pET32a vector wherein the sequence encoding a thioredoxin fusion protein was eliminated, and replaced with Methionine (M). In addition, a carboxy-terminal hexahistidine tag (SEQ ID NO: 90) was included to facilitate purification via immobilized metal affinity chromatography (IMAC). *E. coli* BL21(DE3) cells were transformed with purified plasmid DNA and transformants screened. The resulting plasmid was designated p9NB49H and the protein expressed therefrom was designated as 9NB49H.

Protein expression was achieved by culturing the p9NB49H-transformed E. coli BL21(DE3) cells in terrific broth (TB) medium. Cells were grown in shake flasks to an OD600 nm of 0.50 and then induced with 1 mM IPTG and grown at 25-37° C. for approximately three hours until an OD600 nm of approximately 3.5 was obtained. Cells were harvested by centrifugation, and suspended in lysis buffer (50 mM KPO4, 300 mM KCl, 5 mM Imidazole, pH 8.0) supplemented with protease inhibitors. The cell suspension was frozen and thawed, benzonase was added, and the cells were lysed by sonication on ice. The lysate was divided into soluble and insoluble fractions by centrifugation. SDS-PAGE revealed that the NS3 9NB49H protein was present in the soluble fraction. IMAC purification was performed on the lysate soluble fraction using the Native IMAC Buffer Kit and Profinity IMAC cartridge (BioRad) according to the manufacture's protocol. Buffer exchange of the purified protein into PBS was accomplished by a desalting column or by dialysis. All buffers used throughout the purification procedure contained 20 mM beta-mercaptoethanol (βME).

Example 2

Cloning and Expression of HCV NS3 Nbt-9NB49H

The nucleotide sequence encoding the NS3 9NB49H protein described in Example 1 was subcloned into a modified pET32a plasmid wherein the open reading frame encodes an amino-terminal biotinylation tag (MSGLNDIFEAQKIE-WHE) (SEQ ID NO: 91) with a GSGSNSM-linker (SEQ ID NO: 92) sequence upstream of the NS3-encoding sequence followed by a carboxyl-terminal hexahistidine tag (SEQ ID NO: 90) followed by a stop codon. The resulting plasmid was designated pNbt-9NB49H. The biotinylation tag, described by Beckett et al. (Protein Science, 8(4):921-929, 1999) permits site-specific biotin incorporation via a biotin ligase enzyme encoded by the E. coli BirA gene. E. coli BL21(DE3) cells were co-transformed with the pNbt-9NB49H expression plasmid and a second plasmid (pBirAcm) expressing the biotin ligase under control of an IPTG inducible promoter. Cells were grown in shake flasks at 37° C. in Terrific Broth with biotin added to 0.050 mM final concentration to an OD600 nm of 0.50 and then induced with 1 mM IPTG and grown at 25° C. overnight. Cells were then collected via centrifugation and resuspended in lysis buffer and sonicated to disrupt the cells. In some instances, to further ensure a high level of site-specific biotinylation, ATP and biotin were added to the lysed cells (3mM and 0.25 mM final concentrations, respectively) and incubated at room temperature for 2 hours. Recombinant protein was then purified via IMAC as 60 described in Example 1.

Example 3

Cloning and Expression of HCV NS3 9NB49H-Cbt

The nucleotide sequence encoding the NS3 9NB49H protein described in Example 1, was subcloned into a modified

pET32a vector wherein the open reading frame encodes N-terminal methionine followed by NS3 followed by a GSGSG-linker (SEQ ID NO: 93) and a hexahistidine tag (SEQ ID NO: 90) followed by a GG-linker and the biotinylation tag (GLNDIFEAQKIEWHE) (SEQ ID NO: 94) and 5 finally the stop codon. The resulting plasmid was designated p9NB49H-Cbt. Protein expression and biotinylation was performed as described in Examples 1 and 2.

Example 4

Cloning and Expression of HCV NS3h and Variants Thereof

Recombinant HCV NS3 helicase variants were constructed by using the same amino terminus expressed by p9NB49H (i.e. amino acids 1192-1215 of the HCV polyprotein) fused to various regions of the HCV NS3 helicase as described in the table 2 below and as shown in FIG.. 1. Nucleotide sequences encoding the helicase constructs were cloned into a modified pET32a vector (minus thioredoxin fusion) with either a carboxyl-terminal GSGSG-hexahistidine tag (SEQ ID NO: 95) as described in Example 1 or a carboxyl-terminal GSGSG-hexahistidine-GG-biotinylation 25 tag (SEQ ID NO: 96) as described in Example 2. Protein expression with or without biotinylation and purification were performed as described in Examples 1 and 2.

TABLE 2

Region of HCV Polyprotein	Region of HCV NS3	Plasmid Designation	Expressed Protein Designation	Seq ID# (nucleotide, amino acid)
1216-1658	190-632	pNS3h(±Cbt)	NS3h (helicase) (- ±Cbt)	19, 20

Example 5

Fermentation, Protein Expression and Purification

The NS3 recombinant proteins (e.g. 9NB49H or NS3h or variants thereof) were expressed in E. coli BL21(DE3) cells 45 cultured in 10 L fermenters. An 120 mL seed culture grown in a shake flask containing Superbroth (SB) Media (rich media with glycerol as a carbon source) was used to inoculate a 10 L fermenter containing SB media. Cells were grown at 37° C. until an optical density at 600 nm of 8-12 was reached. Protein 50 expression was induced by adding isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 1 mM. The culture was then grown an additional 4 hours at 25-37° C. Cells were then harvested from the fermenter and then passed through a hollow fiber membrane filter to concentrate the 55 harvest from the starting volume of 10 L to 1-2 liters. The concentrated cells were then pelleted via centrifugation, the supernatant removed, and the resulting pellets were stored at -80° C. until used for protein purification.

In vivo biotinylation of recombinant HCV NS3 proteins 60 containing either an amino-terminal or carboxyl-terminal biotinylation tag sequence (see Examples 2 and 3) was achieved by conducting fermentation as described above except that biotin was added to a final concentration of 0.05 mM at the time of induction. The culture was then grown an 65 additional 4 hours at 25-37° C. and processed as described in the above paragraph.

Frozen E. coli cell pellets containing expressed soluble HCV NS3 recombinant antigens were thawed then resuspended in chilled lysis buffer (40 mM NaPO₄, 300 mM NaCl, 1.5 mM MgCl₂, 5% Glycerol, 5 mM beta-mercaptoethanol, pH 7.2) followed by lysis via continuous flow sonication at 0° C. for 45 minutes. After centrifugation to remove insoluble material, GE nickel sepharose Fast Flow resin was added to the supernatant and incubated overnight at 2-8° C. (shaking at 125 rpm). The resin containing bound antigen was then washed under mild vacuum with wash buffer (40 mM NaPO₄, pH 7.2, 500 mM NaCl, 1 mM EDTA, 20 mM imidizole, 5 mM beta-mercaptoethanol) and bound antigen was eluted using buffer containing 40 mM NaPO₄, 150 mM NaCl, 1 mM EDTA, 500 mM imidizole, 10 mM DTT, pH 7.2. The antigen was further purified via anion exchange chromatography as follows: antigen was bound to a GE Q HP anion exchange resin in 20 mM Tris pH 8.4, followed by gradient elution with 20 mM Tris, pH 8.4, 1 M NaCl, 5 mM EDTA. The eluted protein was then desalted using a GE Sephadex G25 column into final buffer containing 10 mM Phosphate, 150 mM NaCl, 5 mM EDTA, pH 7.2. The purified NS3 protein was stored at -70° C.

Example 6

Preparation of Acridinium-Bovine Serum Albumin (Acr-BSA)

A 30% solution (300 mg/mL) of bovine serum albumin 30 (BSA) containing 0.1% sodium azide as preservative was purchased from a commercial source (Proliant Biologicals, Ankeny, Iowa). One milliliter (300 mg) of the 30% BSA solution was diluted with 2.0 mL of 0.1M PBS pH 8.0, transferred to a 0.5-3.0 mL Slide-A-Lyzer dialysis cassette (Ther-35 moFisher, Waltham, Mass.) and dialyzed against 0.1 M PBS pH 8.0 (2 exchanges, 600 mL/exchange) overnight at 2-8° C. The concentration of the dialyzed BSA solution was 97.1 mg/mL based on UV absorbance at 280 nm. Two hundred milligrams (2.060 mL, 3.0 umol, 1.0 mol equivalent) of the 40 97.1 mg/mL BSA solution was added to an amber glass vial containing 10.181 mL of 0.1M PBS pH 8.0. To this mixture was added 39 mg (1.092 mL, 45 umol, 15.0 mol equivalent) of SPSP-acridinium active ester in DMF [N,N-dimethylformamide. The reaction vial was capped; the solution was mixed by stirring at 350 rpm for 30 min, and then placed at room temperature overnight (20-26 h). After incubation, free acridinium and aggregates were removed chromatographically (Sephacryl HR S-200 column, GE Healthsciences, PA) using 0.01M PBS/0.1% CHAPS pH 6.3 running buffer. Fractions corresponding to monomeric Acr-BSA conjugate were pooled and characterized by UV spectrophotometry (240-600 $\,$ nm scan). Absorbance values at 280 nm and 370 nm were used to determine protein concentration and to calculate incorporation of acridinium per BSA molecule. The calculated protein concentration was 6.779 mg/mL with an average number of 6.2 acridiniums per BSA molecule.

Example 7

Preparation of Maleimide-Activated Acr-BSA

Preparation of Maleimide-Activated Acr-BSA. Acr-BSA (Example 8; 13.5 milligrams, 202 nmoles, 1.0 mol equivalent) 1.99 mL in PBS/0.1% CHAPS pH 6.3 was added to an amber glass vial and treated with 0.254 mL of 0.4M phosphate/8 mM EDTA/1.6% CHAPS pH 7.4 to adjust reaction pH to 7.4. To the homogeneous solution was added 0.040 mL

(0.35 mg, 4.0 mole equivalents) of a fresh 0.02M aqueous solution of Succinimidyl 4-(N maleimidomethyl)-cyclohexane-1-carboxylate (Sulfo-SMCC, Pierce Chemical Co., Rockford, Ill.). The reaction vial was capped; the solution was stirred for 20 min without foaming and then allowed to incubate statically at room temperature for 60-90 minutes in the dark. The reaction mixture was desalted to remove unincorporated sulfo-SMCC by applying to a Zeba spin column (Pierce, Rockford, Ill.) pre-equilibrated with 0.1M PBS/0.1% CHAPS/5 mM EDTA pH 6.7. The absorbance of the eluted Acr-BSA-Mal reagent was measured at 280 and 370 nm to estimate protein concentration. The calculated protein concentration was 6.28 mg/mL. The Acr-BSA-Mal was used immediately in the conjugation of HCV NS3 antigen.

Conjugation of Recombinant 9NB49H to Acr-BSA-Mal. Acr-BSA-Mal (5.6 milligrams, 84 nmoles, 2.0 mole equivalents) in 0.789 mL of 0.1M PBS/0.1% CHAPS/5 mM EDTA pH 6.7 was added to a polypropylene tube. To this was added 1.2 mg (1.3 mL, 42 nmoles, 1.0 mol equivalent) of recombinant 9NB49H antigen in 0.01M PBS/5 mM EDTA pH 7.2. The solution was stirred for 30 min without foaming, and then allowed to incubate statically at room temperature overnight in dark. The conjugate was purified either at this stage or after carboxymethylation of 9NB49H free cysteines. In the case of 25 carboxymethylation, the crude conjugate solution was treated with 0.270 mL of 0.5M phosphate buffer pH 11.0 to adjust pH to 8.0. The mixture was stirred for 5 min, then 0.94 mg (0.020 mL, 120 mole equivalents) of a fresh 0.25M iodoacetic (IAA) solution in 1N NaOH or 0.25M aqueous iodoacetaminde (IAM) was added under mixing to effect 9NB49H free Cyscarboxymethylation. The mixture was reacted statically at room temperature and dark for 60 min, and then passed thru a PD10 column equilibrated in 0.01 M PBS/0.1% CHAPS/5 mM EDTA pH 6.3 (3.0 mL elution volume).

The Acr-BSA-9NB49H conjugate protein concentration was determined from the 280 nm absorbance of the conjugate after subtracting the 280 nm absorbance contributed by the Acr-BSA. The absorbance of a 1% (w/v) solution of 9NB49H $_{\rm 40}$ of 0.52 was used to calculate the protein concentration. The 9NB49H concentration calculated as described was 0.406 mg/mL.

Example 8

Preparation of Acridinium-BSA-NS3h Conjugate

Preparation of (LC)Maleimide-Activated Acr-BSA. Acr-BSA (Example 8; 3.0 mg, 0.443 mL, 45 nmol, or 1.0 mol 50 equivalent) in PBS/0.1% CHAPS pH 6.3 was added to an amber glass vial and treated with 0.058 ml of 0.4M phosphate/8 mM EDTA/1.6% CHAPS pH 7.4 buffer to adjust the reaction pH to 7.4. To the homogeneous solution was added 0.018 mL (0.080 mg, 180 nmoles, 4.0 mol equivalent) of a 55 fresh 0.01 M solution of Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxy-(6-amidocaproate) Chain or LC-SMCC, Pierce Chemical Co., Rockford, Ill.) in dimethylsulfoxide (DMSO, Sigma Aldrich, St Louis, Mo.). The reaction vial was capped; the solution was stirred for 20 60 min without foaming and then allowed to incubate statically at room temperature for 60 minutes in dark. The reaction mixture was desalted to remove unincorporated LC-SMCC by applying to a Zeba spin column (Pierce, Rockford, Ill.) pre-equilibrated with 0.1M PBS/0.1% CHAPS/5 mM EDTA 65 pH 6.7. The absorbance of the eluted Acr-BSA-Mal reagent was measured at 280 and 370 nm to estimate protein concen48

tration. The calculated protein concentration was 5.25 mg/mL. The Acr-BSA-(LC)Mal was used immediately in the next conjugation step.

Conjugation of Recombinant NS3h to Acr-BSA-(LC)Mal. 1.20 mL (3.12 mg) of a 2.6 mg/mL solution of NS3h in 0.025M phosphate/0.25M NaCl/5 mM beta-mercaptoethanol/5 mM EDTA pH 8.0 was passed through a PD10 desalting column to remove the beta-mercaptoethanol. The NS3h protein was eluted with 2.5 mL of 0.01 M PBS/5 mM EDTA pH 7.2 and the concentration of the eluent was calculated to be 2.9 mg/mL by absorbance at 280 nm. To a polypropylene tube were added 1.56 mg (0.297 mL, 23.4 nmoles, 2.0 mol equivalent) of Acr-BSA-(LC)Mal in 0.1M PBS/0.1% CHAPS/5 mM EDTA pH 6.7 followed by 0.60 mg (0.518 mL, 11.7 nmoles, 1.0 mol equivalent) of recombinant NS3h antigen in 0.01 M PBS/5 mM EDTA pH 7.2. The solution was stirred for 30 min without foaming, and then allowed to incubate statically at room temperature overnight in dark. To the conjugate solution was added 0.093 mL of 0.5M phosphate buffer pH 11.0 to adjust mixture pH to 8.0. The mixture was stirred for 5 min, then 0.56 mg (0.012 mL, 120 mole equivalent) of a fresh 0.25M iodoacetic (IAA, Thermofisher Scientific, Waltham, Mass.) solution in 1N NaOH was added under mixing to effect NS3 free Cys-carboxymethylation. The mixture was reacted statically at room temperature and dark for 60 min, the final volume adjusted to 1.0 ml with 0.080 mL of 0.01M PBS/0.1% CHAPS/5 mM EDTA pH 6.3 and passed thru a PD10 column equilibrated in 0.01M PBS/0.1% CHAPS/5 mM EDTA pH 6.3 (2.5 mL elution volume). The desalted conjugate was next purified by SEC chromatography (TosoHaas G3000SW×I column, Toso Bioscience LLC, King of Prussia, Pa.) to remove undesired aggregates. The Acr-BSA-NS3h conjugate protein concentration was determined from the 280 nm absorbance of the conjugate after subtracting the 280 nm absorbance contributed by the Acr-BSA. The absorbance of a 1% (w/v) solution of NS3h of 0.95 was used to calculate the protein concentration.

Example 9

Automated Magnetic Microparticle-Based Immunoassays

The HCV NS3-derived proteins were tested for their ability 45 to detect anti-HCV NS3 antibodies using an automated immunoanalyzer that utilizes paramagnetic microparticles and chemiluminescent conjugates (ARCHITECT® system: Abbott Laboratories; see "Bulk Reagent Random-Access Analyzer: ARCHITECT i2000" Frank A. Quinn, pages 363-367. In The Immunoassay Handbook, Third Edition, edited by David Ward, Nature Publishing Group, London, UK; U.S. Pat. No. 5,795,784 and U.S. Pat. No. 5,856,194). Assay formats examined included a 2-step format or a 1-step format. Assays can generally be described as comprising two formats: 2-step and 1-step (also described as 'pseudo' 1-step). In the 2-step format, human samples, assay specific diluent buffer and recombinant antigen coated paramagnetic microparticles are mixed into a reaction vessel, vortexed, and incubated for 18 min, wherein antibodies directed against the recombinant antigen are captured by the microparticles. Following this incubation, the microparticle/immune complexes are sequestered at the side of the reaction vessel using a magnet and the reaction supernatant is removed. The microparticles are then washed with water/detergent solution. In the second step, antibodies from the sample bound to the microparticles are detected by suspension and incubation (4 min) of the particles in buffer containing acridinium-labeled

conjugate. The conjugate may be an acridinium-labeled antibody directed against human immunoglobulin(s) or an acridinium-labeled recombinant antigen. Incubation with conjugate is followed by a second wash step and finally an activation of the acridinium and simultaneous measurement of light output, which is proportional to the amount of conjugate bound onto the microparticles.

In the 1-step format, human samples, recombinant antigen coated paramagnetic microparticles and an assay specific diluent buffer containing a conjugate comprised of acridinium-labeled recombinant antigen were mixed into a reaction vessel. Following an 18-minute incubation, wherein antibodies directed against the recombinant antigen were simultaneously captured by the magnetic microparticles and 15 bound to the acridinium-labeled recombinant antigen. Subsequently, the microparticle/immune complexes were sequestered at the side of the reaction vessel using a magnet and washed with a water/detergent mixture. Particles were then released from the vessel wall and suspended in diluent 20 and incubated for 4 minutes. Incubation was followed by a second wash step and finally an activation of the acridinium and simultaneous measurement of light output, which was proportional to the amount of conjugate bound onto the microparticles.

Biotin-capture immunoassays. Biotin capture mediated immunoassays on the Architect analyzer used biotinylated NS3 protein (e.g, Nbt or Cbt as described in Example 2-6, or NS3 protein to which biotin has been coupled by chemical means in a non-site-specific manner) and a biotin capture 30 protein (e.g. avidin, Streptavidin, Neutravidin, or anti-biotin antibody) coated paramagnetic particles. In this format, immune complexes formed between NS3 antibodies present in the sample and biotinyl-NS3 were captured onto the microparticle surface via the biotin capture protein immobilized 35 onto the microparticle surface. A conjugate consisting of an acridinylated NS3 recombinant antigen can be added to the first step or the second step (i.e. following the capture step) to detect captured anti-NS3. Alternatively, an anti-human antibody acridinium conjugate can be added to the second step to 40 detect captured anti-NS3.

Example 10

Immunoassay Formats

The following human specimens were used:

Negative control sample is recalcified nonreactive human plasma (nonreactive for HBsAg, and negative for anti-HCV, HIV-1 RNA or HIV-1 Ag, anti-HIV-1/HIV-2 and anti-HTLV-50 I/HTLV-II).

Positive control sample known as 'Panel B' is a human recalcifed human plasma sample reactive for a single anti-HCV marker as determined by Chiron RIBA HCV 3.0 SIA (2+ or greater c33 band intensity and nonreactive for other 55 bands). This panel is diluted in recalcified nonreactive human plasma (nonreactive for HBsAg, and negative for anti-HCV, HIV-1 RNA or HIV-1 Ag, anti-HIV-1/HIV-2 and anti-HTLV-I/HTLV-II) containing disodium-EDTA and sodium azide.

Blood samples: A panel of commercially available human 60 blood samples, referred to as seroconversion panels was obtained from SeraCare (Gaithersburg, Md.) and Zeptometrix (Franklin, Mass.). The seroconversion panels consist of serial blood samples obtained from an individual who is negative for antibodies to HCV in early bleed dates, but 65 reactive for antibodies in the later bleed dates. Seroconversion panels are utilized to determine the sensitivity of various

50

antibody tests, and antigen/antibody tests. More sensitive tests detect exposure to HCV at an earlier time than less sensitive tests

Core Antigen specimen ST5 1:10 is human plasma that is HCV RNA positive and HCV antibody negative and has been diluted 1:10 in recalcified nonreactive human plasma (nonreactive for HBsAg, and negative for anti HCV, HIV-1 RNA or HIV-1 Ag, anti HIV 1/HIV-2 and anti-HTLV-I/HTLV-II) containing disodium-EDTA and sodium azide.

CAL is a recalcified human plasma reactive for antibody to HCV core, NS3 and NS4 and diluted into recalcified nonreactive human plasma (nonreactive for HBsAg, and negative for anti HCV, HIV-1 RNA or HIV-1 Ag, anti HIV 1/HIV-2 and anti-HTLV-I/HTLV-II) containing disodium-EDTA and sodium azide.

Example 11

HCV Antigen/Antibody (Combo) Assay Format

Described herein is a method for detection of Hepatitis C(HCV) core antigen and antibody in a single reaction on the ARCHITECT immunoassay platform developed at Abbott Laboratories. A prototype chemiluminescent immunoassay was developed for simultaneous detection of HCV core antigen and antibody to HCV (anti-HCV) in sera and plasma. The prototype combination assay is a 2-step (18'/4'), 3 bottle assay on the ARCHITECT instrument platform. The HCV combo test provides detection of human antibodies to the core, NS3 and NS4 proteins of HCV in addition to detection of HCV core antigen that may be present in the blood of HCV infected individuals.

In the first step, the instrument dispenses 110 ul of specimen plus 50 ul of the reaction mixture from bottle 1 plus 50 ul of streptavidin/neutravidin or anti-biotin paramagnetic microparticles from bottle 2 diluted in a detergent containing microparticle diluent (20 mM MES, pH 6.6, 0.15 M NaCl, 5 mM EDTA, 13.6% Sucrose, 0.1% Nipasept, 0.0005% Quinolone, and 5 mM DTT & 5 mM glutathione and containing 24.3 mM SB3-14 (N-Tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate). Bottle 1 contains a mixture of both biotin and acridinium labeled HCV specific reagents (peptides, proteins, and antibodies as well as various detergents and buffers) that enable immune complex formation with HCV antibody or antigen present in the serum or plasma. Specifically, bottle 1 contains: Acridinylated—Core peptide 5 (aa 15-68³4⁴8), Biotinylated-Core peptide 5 (aa 15-68³4⁴⁸), Acridinylated-NS3 recombinant antigen (9NB49H or NS3h), Biotinylated-NS3 recombinant antigen (9NB49H-Cbt or NS3h-Cbt), Acridinylated-NS4 peptide aa 1694-1735, Biotinylated-NS4 peptide aa 1694-1735, and Biotinylated-c11-7 monoclonal antibody in 80 mM Bis-Tris, pH 6.3, 0.92 M NaCl, 8% Sucrose, 1.7% Dextran 2000, 3% BSA, 0.3% Triton X100, 0.04% Methylcellulose, 7 mM EDTA, 0.04% sodium azide). The first step of the reaction therefore includes 110 ul specimen plus 50 ul of the reaction mixture from bottle 1 plus 50 ul of streptavidin/neutravidin/ anti-biotin microparticles from bottle 2 and extends for 18 minutes—allowing various immune complexes to form.

The first step of the antibody detection assays are described as follows. Specifically, for anti-Core detection, one biotin labeled Core peptide and one acridinium labeled Core peptide need be present in the reaction mixture that can be bound by anti-Core antibody present in the specimen. This immune complex then binds to the solid phase coated with a biotin binding protein, in this case neutravidin, but could alternatively be streptavidin or anti-biotin. The process for the anti-NS3 reaction follows that one biotin labeled NS3 protein plus one acridinium labeled NS3 protein need be present in the reaction mixture that can be bound by anti-NS3 antibody present in the specimen. Likewise for anti-NS4, one biotin

labeled NS4 peptide and one acridinium NS4 labeled peptide need be present in the reaction mixture that can be bound by anti-NS4 antibody present in the specimen.

The first step of the antigen detection assay is described as follows. For the Core antigen detection reaction, a biotin labeled monoclonal antibody (Mab c11-7) capable of binding to HCV Core antigen in serum or plasma is present in the 1st reaction (bottle 1). This immune complex then binds to the solid phase, also via the biotin moiety.

The second step of the antibody and antigen reactions are as follows. After an 18 minute incubation step, the microparticles are washed to remove unbound reactants from the mixture. The microparticles are then incubated with the conjugate *Ac-DBA c11-9/c11-14 conjugate from bottle 3 diluted in buffered solution containing various detergents and proteins (80 mM Bis Tris, pH 6.3, 0.924 M NaCl, 3.0% Sucrose, 5.0% Sorbitol, 7 mM EDTA, 1.7% Dextran 2000, 0.8% PVSA (25% solution), 3.0% BSA, 0.02% Benzethonium Chloride, 55,000 units/L Heparin Sodium, 0.2% Sodium Flouride, 0.3% Triton X-100, 0.3% Glycine, 0.2% SB3-12, 0.4% SB3-16, 0.2% SB3-18, 0.15% CHAPS, 0.2% Saponin, 0.35% 20 CTAB, 0.02% TTAB, 0.1% Sodium Azide, 0.1% Nipasept, 1% A56620, 0.04% Methylcellulos). In this step, any immune-complexed Core antigen on the solid phase will be conjugated. After the 4 minute incubation of the 2nd step, the microparticles complete with labeled immune complexes 25 intact are again washed and separated from unreacted components by a magnet. The reaction is then triggered and chemiluminescent signal generated from the acridinium-labeled conjugates bound to the solid phase via immune complexes is read proportional to the amount of analyte that was 30 present in the sample being tested.

Example 12

Core Peptide Design

Detection of HCV infection requires the use of multiple HCV proteins for antibody detection (including HCV core, 52

NS3 and in some cases, NS4 and NS5 peptides or proteins). Detection of HCV core antigen requires the use of antibodies that bind to the HCV core antigen, and such antibodies may bind to the HCV core protein utilized in the antibody side of the HCV combo test. Research scientists have identified the amino acid sequences on the HCV core antigen that are targeted by the antibodies used in the core antigen test—both for those utilized to capture the HCV core antigen (in this assay C-11-7), and those utilized to generate a signal (C11-9/C11-14). For each of the sites recognized by the antibodies, the amino acids comprising that recognition site must be modified by amino acid substitution or amino acid deletion.

A modified Core peptide was generated by removing 5 amino acids (amino acid residues 32-34, and 47-48) from the core protein, thus, avoiding recognition by the two monoclonal (C11-14 and C11-9) used in the ARCHITECT HCV Core Antigen test. An unwanted result of removing these 5 amino acids is that human antibody response to the core protein was compromised by the loss of these amino acids.

Thus, a series of Core peptides were generated to determine if minimal modifications can be made to the core protein—so that the minimally-modified peptides are not recognized by the antibodies utilized in the core antigen test—but allow adequate detection of antibodies to the core protein. These modified peptides were designed to restore some of the lost reactivity observed with the Core peptide that had five amino acids deleted. It was postulated that certain deletions/substitutions in the known epitope binding regions for the monoclonal antibody c11-9 (aa 29-37) and c11-14 (aa 45-49) could be designed that would evade detection by this conjugate.

The design of the Core peptides involves targeted amino acid deletions and/or substitutions in distinct regions of the Core sequence of HCV whereby these deletion/substitutions successfully avoid detection by the *Ac-DBA c11-9/c11-14 conjugate used for detection of Core Ag in an HCV Combo assay.

TABLE 3

	TABLE 3							
	New HCV Core Peptides Synthesized aa 15-68							
Peptide 1:	TNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATRKTSERSQPRGRRQPIPKA (SEQ ID NO: 97)							
Peptide 2:	TNRRPQDVKFPGGGQIVYLLPRRGPRLGVTRKTSERSQPRGRRQPIPKA (SEQ ID NO: 98)							
Peptide 3:	TNRRPQDVKFPGGGQIVGG-YLLPRRGPRLGVTRKTSERSQPRGRRQPIPKA (SEQ ID NO: 99)							
Peptide 4:	TNRRPQDVKFPGGGQIVGG-YLLPRRGPRLGV-ATRKTSERSQPRGRRQPIPKA (SEQ ID NO: 100)							
Peptide 5:	thm:thm:podvkfpggqqivgg-yllprrgprlgvr-trktsersqprgrrqpipka (SEQ ID NO: 101)							
Peptide 6:	thm:thm:podvkfpggqqivgg-yllprrgprlgviatrktsersoprgrropipka (SEQ ID NO: 102)							
Peptide 7:	TNRRPQDVKFPGGGQIVGGGYLLPRRGPRLGVTRKTSERSQPRGRRQPIPKA (SEQ ID NO: 103)							
Peptide 8:	TNRRPQDVKFPGGGQIVGGGYLLPRRGPRLGV-ATRKTSERSQPRGRRQPIPKA (SEQ ID NO: 104)							
Peptide 9:	thm:thm:podvkfpggqqivgggyllprrgprlgvr-trktsersqprgrrqpipka (SEQ ID NO: 105)							
Peptide 10:	thm:thm:podvkfpggqlivgggyllprrgprlgviatrktsersqprgrrqpipka (SEQ ID NO: 106)							

Each of the newly synthesized Core peptides was coated onto neutravidin paramagnetic microparticles and probed with the *Ac-DBA c11-9/c11-14 conjugate. As shown below (table 4), peptide 1 (intact sequence between amino acids 15-68) provides high signal to noise (S/N) values when reacted with the *Ac-DBA c11-9/c11-14 conjugate. NOTE: the negative controls include microparticles that do NOT contain either on the solid phase or in liquid phase any HCV core epitope recognition molecules. These negative controls produce low S/N (signal to noise) values. The positive control (6C37 coated microparticles) contains HCV recombinant protein (compromising amino acids 1-150 of the HCV core protein) produces high S/N values due to its recognition by the *Ac-DBA c11-9/c11-14 conjugate.

two peptides (only aa's 34 and 48 are deleted), peptide 5 was chosen as the peptide of choice for HCV Combo development. Thus, peptide 5, which successfully avoids detection by the *Ac-DBA c11-9/c11-14 conjugate and is immunoreactive for human specimens infected with HCV was considered as the candidate peptide for HCV Combo.

Example 13

Monoclonal Antibodies

The HCV combo test utilizes three monoclonal antibodies (C11-7, C11-14, and C11-9). Two of the monoclonal antibod-

TABLE 4

	IADLE 4												
	Detection by *Ac-c11-9/c11-14 Conjugate												
		ative trols	Positive Control										
S/N	Neut	BSA	6C37					HCV	Core Per	otides			
Summary Sample	uparts S/N	uparts S/N	uparts S/N	1 S/N	2 S/N	3 S/N	4 S/N	5 S/N	6 S/N	7 S/N	8 S/N	9 S/N	10 S/N
Architect wash buffer	1.0	1.1	18465.9	15176.8	1.6	0.5	10.0	1.1	2456.3	1695.2	2697.6	2666.0	10030.5

Peptide 1 above represents the intact amino acid sequence between amino acids 15-68 that has been previously used to 30 detect antibodies to the HCV core protein. Peptide 2 above has a total of 5 amino acids deleted, 3 of these amino acids (32, 33, and 34) representing part of the epitope recognition site for the C 11-9 monoclonal antibody, and 2 of these amino acids (47 and 48) representing the epitope recognition site for the C 11-14 monoclonal antibody. The signal for Peptide 1 is high since it is recognized by the HCV core conjugate, *Ac-DBA c11-9/c11-14. The S/N values for peptides 4 and 6-10 have S/N values >3.0 and are not candidates for use in the HCV combination assay since they are also recognized by the core conjugate. The S/N values for Peptides 2, 3 and 5 are very low, similar to the S/N values noted for the negative control, and thus, are not recognized by the HCV core antigen conjugate thereby making their design useful for the HCV combo test.

TABLE 5

Immunoreactivity of core peptides 2, 3 and 5 with Human Specimens Indirect Anti-Human Assay - S/N Summary									
	Negative Controls Positive								
	Neutra- vidin	Control 6C37		HCV	Core Pe	ptides			
Sample	uparts S/N	uparts S/N	uparts S/N	1 S/N	2 S/N	3 S/N	4 S/N	5 S/N	
CAL	2.5	2.9	205.3	24.4	9.5	21.4	15.2	13.1	

Shown above in Table 5, peptides 2, 3 & 5 all show immunoreactivity with human specimens reactive for anti-HCV in an Indirect Assay format. The S/N values for the human samples containing antibodies to HCV were slightly higher 65 with both peptides 3 and 5 over that seen with peptide 2, but since peptide 5 contains the most minimal deletion of these

ies (C11-7, C11-14) have been previously described in the Abbott US patent "Methods for the simultaneous detection of HCV Antigens and HCV antibodies". U.S. Pat. No. 6,727,092 by Shah et al., issued Apr. 27, 2004. However, the original disclosure of these two monoclonal antibodies was cited in U.S. Pat. No. 6,623,921 by Aoyagi et al., issued Sep. 23, 2003. The third monoclonal antibody was disclosed in publications (Morota et al., J. Virol. Meth 157:8 (2009) and is discussed in Patent Application number 20120009196 by Muerhoff, et al. (publication date 2012-01-12).

Example 14

Preparation of Microparticles

The HCV Combo assay uses one type of paramagnetic microparticle capable of capturing biotin-labeled proteins (streptavidin, neutravidin, and anti-biotin). Briefly, Dynal M270 Carboxylic Acid raw particles are washed with 2 50 exchanges into MES-Chaps Buffer, pH 5.5 (25 mM 2-(N-Morpholino)ethanesulfonic acid (MES), 0.1% 3[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate (Chaps)). Particles are pre-activated with EDAC(N-Ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride) at 55 0.25 mg/mL for 30 minutes at 1% solids. Particles are washed with 1 exchange into MES-Chaps Buffer, pH 5.5. Neutravidin/Streptavidin/anti-Biotin Ab stock solution is added to the particles at 0.40 mg/mL for 60 minutes at 1% solids. Particles are washed with 3 exchanges into PBS-Chaps Buffer, pH 7.2 (phosphate buffered saline (PBS), 0.1% Chaps). Final particle concentration is 1% solids in PBS-Chaps Buffer, pH 7.2. These microparticles are subsequently diluted to 0.075% solids in microparticle diluent (20 mM MES, pH 6.6, 0.15 M NaCl, 5 mM EDTA, 13.6% Sucrose, 0.1% Nipasept, 0.0005% Quinolone, and 5 mM DTT & 1.54 g/L glutathione and containing 24 mM SB3-14 (N-Tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate).

55 Example 15

56 Example 18

HCV Core Peptide

Preparation of Acr-BSA-Core Peptide Conjugate

The synthetic peptides were manufactured by AnaSpec 5 (Fremont, Calif.). Purity level >95%.

Six milligrams (1.01 mL, 90 nmoles, 1.0 mol equivalent) of Acr-BSA in 0.1M PBS/0.1% CHAPS pH 6.3 (from Example

(SEO ID NO: 101)

Biotin-TNRRPODVKFPGGGOIVGGYLLPRRGPRLGVRTRKTSERSOPRGRROPIPKA

2. Acridinylated labeled HCV core peptide 5 was used as a conjugate for the assay and is represented as follows:

1) was added to a polypropylene tube. To this solution was added 0.431 mL (4.31 mg, 22.5 umol, 250 mol equivalents) of

(SEQ ID NO: 101)

TNRRPQDVKFPGGGQIVGGYLLPRRGPRLGVRTRKTSERSQPRGRRQPIPKA

The acridinylation process for Core peptide 5 is described in Example 18.

Example 16

NS4 Peptides (Amino Acids 1694-1735)

These synthetic peptides were manufactured by Ana Spec 25 (Fremont Calif.). Purity level >95%.

The HCV combo test utilized the HCV NS4 peptide in two

1. Biotinylated NS4 peptide was captured on streptavidin coated microparticles as follows:

a fresh 10 mg/mL 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDAC) solution in water and 0.259 ²⁰ mL (2.58 mg, 22.5 umol, 250 mol equivalent) of a fresh 10 mg/mL N-hydroxysuccinimide (NHS) solution in water. The mixture was vortexed gently and then allowed to react stati-cally at room temperature and dark for 10 min. To the activated Acr-BSA conjugate solution was added 4.4 mg (0.881 mL, 0.72 umol, 8 mol equivalent) of a fresh 5.0 mg/mL Core peptide (AnaSpec, Fremont, Calif.) solution in 0.01 M PBS pH 7.2. The solution was vortexed gently and allowed to react at room temperature in dark overnight. The conjugate was purified by SEC chromatography on a TosoHaas G3000SWxI column (Tosoh Bioscience LLC., King of Prussia, Pa.) using 0.01 M PBS/0.1% CHAPS pH 6.3 to remove aggregates. The

(SEQ ID NO: 107)

Biotin-IIPDREVLYREFDEMEECSQHLPYIEQGMMLAEQFKQKALGL

gate for the assay and is represented as follows:

2. Acridinylated labeled NS4 peptide was used as a conju- 35 fractions corresponding to the major conjugate peak were pooled. The absorbance of the Acr-BSa-NS4 peptide conju-

(SEO ID NO: 108)

45

Acridinium - IIPDREVLYREFDEMEECSQHLPYIEQGMMLAEQFKQKALGLC

The acridinylation process for the NS4 is described in Example 17.

Example 17

Preparation of Acr-BSA-NS4 Peptide Conjugate

Thirteen milligrams (2.0 mL, 0.196 umol, 1.0 mol equivalent) of Acr-BSA-Mal in 0.1M PBS/0.1% CHAPS/5 mM EDTA pH 6.7 (from Example 2) was added to a polypropylene tube. To this solution was added 0.100 mL (4.02 mg, 0.784 umol, 4.0 mol equivalent) of a fresh 41 mg/mL solution of C-terminal cysteine NS4 peptide (AnaSpec, Fremont, Calif.) in dimethylsulfoxide (DMSO, Sigma Aldrich, St Louis, Mo.). The reaction vial was capped, the solution vor- 55 texed briefly without foaming and allowed to incubate at room temperature in dark overnight. The crude conjugate was next treated for about 30 min with a 0.25M mercaptoethylamine HCl (MEA) aqueous solution to a final 1.14 mM MEA reaction concentration to quench unreacted maleimide groups. The conjugate was immediately purified by SEC chromatography on a TosoHaas G3000SW column (Tosoh Bioscience LLC., King of Prussia, Pa.) using 0.01M PBS/ 0.1% CHAPS pH 6.3. The fractions corresponding to the main conjugate peak were pooled. The absorbance of the conjugate pool was measured at 280 and 370 nm and used to 65 determine a corrected 280 nm absorbance value. The conjugate was stored at -20° C. between uses.

gate pool was measured at 280 and 370 nm and used to determine a corrected 280 nm absorbance value. The conjugate was stored at -20° C. between uses.

Example 19 Preparation of Biotinylated C11-7 Monoclonal Antibody

Thirteen milligrams (1.0 mL, 86.6 nmoles, 1.0 mol equivalent) of a 13.1 mg/mL solution of C11-7 monoclonal antibody (mÁb) in 0.01 MPBS pH 7.2 was added to an amber glass vial containing 0.916 mL of 0.01 M PBS pH 7.2 buffer. To this solution was added 0.144 mL of 0.133M phosphate/0.376M NaCl/7.5% CHAPS pH 8.0 to adjust the reaction pH to 7.4-7.5 and the mixture was stirred for 5 min without foaming. To the stirring C11-7 mAb solution was added 0.350 mg (0.100mL, 433 nmoles, 5.0 mol equivalent) of a 5.71 mg/mL solution of Chromalink Biotin (CLB, SoluLink, San Diego, Calif.) in anhydrous dimethylformamide (DMF, Sigma Aldrich, St Louis, Mo.). The mixture was stirred for 30 min, then reacted statically at room temperature overnight in dark. The crude conjugate mixture was passes. The reaction mixture was desalted to remove unincorporated CLB biotin by passing thru a Zeba spin column (Pierce, Rockford, Ill.) equilibrated with 0.01 M PBS/0.1% CHAPS pH 7.2. The absorbance of the eluted C11-7 mAb-CLB conjugate was measured at 280 and 354 nm to estimate protein concentration and calculate incorporation of histing are artibated. tion and calculate incorporation of biotin per antibody molecule. The calculated protein concentration was 4.03 mg/mL with an average number of 4.12 biotins per C11-7 mAb mol-

Example 20 Preparation of the Dextran-BSA

1.068 mL of a 100 mg/mL solution of sodium periodate (Sigma Chemical Co., St. Louis, Mo.) prepared in distilled water was added to a solution of dextran that was prepared by dissolving 117.48 mg of dextran (150,000 MW GPC Grade, Pharmacosmos, Holbaek, Denmark) in 2.1 mL of distilled water and incubated in a 23° C. waterbath in the dark, with stirring for 120 minutes. At the end of the 120 minutes, 6.408 mL of a 55 mg/mL solution of BSA (Proliant Biologicals, Boone, Iowa) equilibrated in 150 mM HEPBS (Sigma Chemical, St. Louis, Mo.) buffer, pH 8.9 was added to the oxidized dextran solution and the reaction continued for an additional 120 minutes at 23° C. in the dark. At the end of the incubation 1.06 g of borane-dimethylamine complex (97%, Sigma-Aldrich, St. Louis, Mo.) was added to the dextran-BSA solution for 60 minutes at 23° C. in the dark followed by addition of 1.34 mL of a 0.65 M Tris-HCl (Sigma Chemical Co., St. Louis, Mo.)), pH 7.5 buffer for 16-20 hours at 23° C The resulting solution was purified using a HiPrep Sephacryl S300 26/60 column (GE Healthcare, Uppsala, Sweden) that 20 was equilibrated in PBS at 2.6 mL/min. The crude dextran-BSA was loaded onto the column and run at 2.6 mL/min. while monitoring the absorbance at 280 nm. 2.6 mL fractions were collected and the voided fractions were pooled. The pooled fractions were then concentrated to less than 10 mL using Amicon Ultra-15 centrifugal concentrators (50,000 25 MWCO, EMD Millipore Corporation, Billerica, Mass.). The concentrated dextran-BSA was spiked with a solution of sodium azide and CHAPS (Sigma Chemical Co., St. Louis, Mo.) to a final concentration of 0.1% sodium azide and 0.5% CHAPS. This solution was heat stressed in a 45° C. oven for 7 days and stored at 2-8° C. prior to additional HiPrep Sephacryl S400 column purification. A HiPrep Sephacryl S400 26/60 column (GE Healthcare, Uppsala, Sweden) was equilibrated with PBS at a flow rate of 2.6 mL/min. and the heat stressed dextran-BSA was loaded onto the column. Fractions were pooled in order to eliminate high molecular weight 35 aggregate and low molecular weight degradation products.

The pooled fractions were concentrated to greater than 5 mg/mL using Amicon Ultra-15 centrifugal concentrators (as above) and the solution stored at 2-8° C. until used to prepare the conjugate.

Example 21 Preparation of the C11-9/C11-14 Dextran-BSA Conjugate

6 mg of the purified, heat stressed dextran-BSA solution 45 (from above) was reacted with 1.62 mg of acridinium SPSP 9-[[[4-[4-oxo-4-(2,3,4,5,6-pentafluorophenoxy)butyl]phenyl[sulfonyl](3-sulfopropyl)amino]carbonyl]-10-(3-sulfopropyl) in a conjugation buffer containing sodium phosphate, 150 mM NaCl, 1 mM EDTA (Sigma Chemical Co., St. Louis, Mo.), 0.2% CHAPS (Sigma Chemical Co., St. Louis, Mo.), pH 7.4. The reaction was allowed to proceed overnight at room temperature in the dark. At the end of the overnight reaction, 2.7 mg of Sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sSMCC, ThermoFisher Scientific, Rockford, Ill.) was added to the SPSP-dextran- 55 BSA solution and incubation continued for 60 minutes at room temperature in the dark. The unreacted SPSP and sSMCC were removed by gel filtration using a column equilibrated with a buffer containing sodium phosphate, NaCl, 1 mM EDTA, 0.5% CHAPS, pH 6.0. The final solution was concentrated to greater than $10\,\mathrm{mg/mL}$ using Amicon Ultra-4 centrifugal concentrators (30,000 MWCO) and the absorbance at 280 nm and 370 nm was determined.

8.76 mg of a 2.5:1 (mg:mg) mixture of C11-9:C11-14 F(ab')2 fragments in a conjugation buffer containing sodium phosphate, NaCl, 1 mM EDTA, pH 6.0 was equilibrated at 65 37° C. in a waterbath. 0.39 mL of a 120 mM solution of cysteamine HCl (Sigma-Aldrich, St. Louis, Mo.) prepared in

58

sodium phosphate buffer containing EDTA at pH 6.0 was added to the temperature equilibrated antibody fragments and incubated at 37° C. for 90 minutes. After reduction of the fragments, excess cysteamine HCl was removed by gel filtration using a column equilibrated with a buffer containing sodium phosphate, NaCl, 1 mM EDTA, 0.5% CHAPS, pH 6.0 and the solution was concentrated to greater than 8 mg/mL using Amicon Ultra-4 centrifugal concentrators (10,000 MWCO). A final conjugation reaction containing 5 mg/mL of the SPSP and sSMCC labeled dextran-BSA and 4 mg/mL of the reduced fragments was incubated in the sodium phosphate, NaCl, 1 mM EDTA, 0.5% CHAPS, pH 6.0 buffer at 2-8° C. 16-24 in the dark.

After blocking any unreacted maleimide groups with excess cysteamine HCl, the crude conjugation reaction was purified using a HiPrep Sephacryl S400 column (GE Healthcare, Uppsala, Sweden) equilibrated in PBS with 0.1% CHAPS, pH 6.3. Fractions were pooled from the main conjugate peak in order to eliminate high molecular weight material and any unbound antibody fragments. The concentration of the conjugate was expressed as the amount of antibody fragments and was determined using the absorbance at 280 nm and 370 nm of the conjugate compared to the absorbances of the SPSP and sSMCC labeled dextran-BSA.

Example 22

Assay Diluent Formulations

In order to enable detection of Core antigen in the HCV Combo format, exposure of the Core capsid proteins is required. This exposure requires the use of a detergent present in either the outer ring bottle (bottle 1) or the middle ring bottle (bottle 2), and this detergent can be of non-ionic classification and/or contain alkyl chain groups with amines. (Aoyagi et al: G01N 33/576, WO 00/07023, Feb. 10, 2000).

The detergents required to detect HCV core antigen have a negative impact on the ability of antibodies to bind to the NS3 protein utilized in the HCV combo assay. This loss of anti-NS3 signal is reproducible, and has been monitored during the assay development process using an anti-NS3 "only sample that contains antibodies to NS3, but not to other HČV proteins. The sample utilized in our studies is referred to as Panel B, and is prepared by diluting a highly reactive sample in normal human plasma that is negative for antibodies to NS3. Panel B is diluted to contain a moderate reactivity, and serves as a surrogate marker for the capacity of the immunoassay to detect antibodies to NS3 in patient samples. In monitoring the anti-NS3 reactivity, the signal to noise (S/N) ratio is utilized to denote relative reactivity, with high S/N's being desirable. Previous experience with anti-HCV assays has shown that a viable antibody assay should provide an S/N value of >20.

Example 23

Effect of Detergents on HCV Combo Assay

Using the Combo format described in Example 11 (and all the capture reagents of the combo assay described herein), the data in Table 6 shows the effect of varying hydrocarbon chain length of zwitterionic detergent sulfobetaine (SB3) in the detection of anti-NS3 (Panel B) and core antigen in the HCV combo assay format. When no detergent is present in the reaction, Panel B detection is high (S/N=39.6) but detection of Core antigen is low (S/N=3.8). When a hydrocarbon chain length of 8 (SB3-8) is used in the reaction, both Panel B and Core antigen detection are low. As the hydrocarbon chain length is increased, particularly to 12 or 14, Core antigen reactivity improves. However, when the chain length is 16, both Core antigen detection and Panel B reactivity decline suggesting that the optimal hydrocarbon chain length to strike a suitable balance between Panel B detection and Core antigen detection appears to be 12 to 14.

TABLE 6

Effect of different zwitterionic detergents in the detection of anti-NS3 and core antigen in the HCV combo assay format (S/N: Ratio of sample rlu/negative plasma rlu)

samples	control diluent - no detergents S/N	control diluent + SB3-8 S/N	control diluent + SB3- 10 S/N	control diluent + SB3-12 S/N	control diluent + SB3-14 S/N	control diluent + SB3-16 S/N
Panel B	39.6	9.8	36.9	26.9	26.4	15.2
core antigen ST5 1:10	3.8	1.5	4.2	72.1	94.9	62.0

Table 7 shows the use of various detergents and their effect 15 Panel B and Core antigen (C7BzO). The best detection is seen on both Panel B detection and Core antigen detection. The control diluent with no detergent shows good detection of Panel B (S/N=63.9) but virtually no detection of Core antigen (S/N=2.2). Other detergents show moderate detection of both

with detergent SB3-14 where detection of both Panel B and Core antigen is the highest at an S/N of 71.7 and 81.9, respectively.

TABLE 7

samples	control diluent - no detergent S/N	control diluent + SB3- 14 S/N	control diluent + CHAPS S/N	control diluent + C7BzO S/N	control diluent + Empigen BB S/N	control diluent + TSP16 S/N	control diluent + ASB- 16 S/N	control diluent + NDSB256 sulfobetaine S/N	control diluent + NDSB201 sulfobetaine S/N
Panel B: anti-NS3	63.9	71.7	46.8	56.4	32.5	58.3	35.2	46.2	26.8
core antigen ST5 1:10	2.2	81.9	5.1	56.2	40.4	10.3	43.6	1.9	1.8

Summary of detergents used in study: The detergents SB3-14, CHAPŠ, C7BzO (3-(4-Heptyl)phenyl-3-hydroxypropyl) 35 dimethylammoniopropanesulfonate), Empigen BB (EMPI-**GEN®** BB. Sigma-Aldrich), **ASB-16** and (Amidosulfobetaine-16) are classified as zwitterionic surfactants; they possess a neutral charge resulting from the presence of equal numbers of positive and negative charged chemical groups within the molecule. This group of detergents possesses the ability to solubilize membrane proteins (Sigmaalrich.com). TSP-16 is classified as a non-ionic surfactant, which contains an uncharged hydrophilic headgroup. The sulfobetaines, NDSB256 (Dimethylbenzylammonium propane sulfonate; N-phenyl-methyl-N,N-dimethylammo-₄₅ nium-propane-sulfonate), and NDSB201 (3-(1-Pyridino)-1propane Sulfonate), are classified as non-detergent sulfobetaines which are zwitterionic compounds that can reduce aggregation and aid in refolding of proteins. They are not considered detergents because they cannot aggregate to form micelles.

Shown in Table 8 is a titration of detergent SB3-14 from 0 to 100 mM in the microparticle diluent (bottle 2, middle ring). The concentration of SB3-14 detergent for optimal detection of both Panel B and Core antigen appears to be between 25-75 mM, with acceptable Panel B (S/N>20) and core Ag (S/N>20) sensitivity.

TABLE 8

samples	control							
	diluent -	diluent +						
	no	0.1 mM	1 mM	10 mM	25 mM	50 mM	75 mM	100 mM
	detergent	SB3-14						
	S/N							
Panel B: anti-NS3	28.5	32.4	33.9	33.2	27.2	25.1	22.2	8.8
core antigen ST5 1:10	4.1	4.5	4.4	8.1	35.8	38.3	43.7	56.8

Example 24

Assay Performance—Placement of Detergent
Table 9 shows the HCV Combo assay performance on
select seroconversion panels where the detergent used for

62

Core antigen detection is placed in the outer ring (bottle 1) or, alternatively, placed in the middle ring (bottle 2). Performance remains roughly the same with the total number of bleeds detected being 19/23.

TABLE 9

		НС				en SB3-14 i	s in the outer:	ring	
Panel	Sample	Bleed Date	Days from 0	PCR	RNA Copies/ ml (Vendor)	RIBA 3.0	Anti-HCV Antibody Data by 6C37 Assay S/CO	HCV Antibody/Antigen Combination Assay (HCV Combo) - Detergent in Outer Ring (bottle 1) S/CO	HCV combo blend CoF - Detergent in Middle ring (bottle 2) S/CO
PHV-	1	6-Jan-	0	+	40,000	_	0.23	0.6	0.8
912 Genotype 2b/3	2	96 10- Jan- 96	4	+	>500,000	_	0.16	3.4	17.6
	3	13- Jan-	7	+	40,000	core	7.91	15.7	18.7
PHV- 919	1	96 31- Dec-	0	-	BLD	_	0.32	0.8	0.6
	2	99 7-Jan-	7	-	BLD	_	0.48	0.7	0.8
Genotype 1a	3	00 12- Jan-	12	-	BLD	_	0.26	0.7	0.5
	4	00 25- Jan-	25	+	200,000	_	0.46	2.5	3.3
	5	00 28- Jan-	28	+	20,000	core/NS3	2.76	12.2	13.9
	6	00 1-Feb- 00	32	+	100,000	core/NS3	13.99	8.8	9.7
	7	4-Feb- 00	35	+	100,000	core/NS3	13.90	5.7	6.0
BCP 6214	1	13- Jan- 96	0	+	246,000	_	0.12	1.6	2.3
	2	15- Jan- 96	2	+	181,000	_	0.12	3.2	7.1
Genotype 1a	3	21- Jan- 96	8	+	241,000	_	0.09	3.9	4.7
	4	23- Jan- 96	10	+	186,000	_	0.11	3.1	2.3
	5	29- Jan- 96	16	+	290,000	_	0.10	2.1	4.0
	6	31- Jan-	18	+	177,000	_	0.08	2.2	1.8
	7	96 5-Feb- 96	23	+	312,000	_	0.27	3.0	3.5
	8	7-Feb- 96	25	+	408,000	_	0.56	6.5	7.6
	9	12- Feb- 96	30	+	290,000	NS3	3.51	3.1	4.6
	10	14- Feb- 96	32	+	632,000	NS3	4.44	3.5	4.6
	11	2-Mar- 96	49	+	228,000	NS3/NS4	13.07	1.8	2.7

TABLE 9-continued

		НС				en SB3-14 is dle ring bott	s in the outer le (bottle 2)	ring	
Panel	Sample	Bleed Date	Days from 0	PCR	RNA Copies/ ml (Vendor)	RIBA 3.0	Anti-HCV Antibody Data by 6C37 Assay S/CO	HCV Antibody/Antigen Combination Assay (HCV Combo) - Detergent in Outer Ring (bottle 1) S/CO	HCV combo blend CoF - Detergent in Middle ring (bottle 2) S/CO
	12	6-Mar- 96	53	+	228,000	NS3/NS4	13.21	2.5	3.9
	13	9-Mar- 96	56	+	193,000	NS3/NS4	13.00	4.1	4.7

S/CO: 10 NC used for cutoff calculation S/CO >/=1.0 is considered reactive

Example 25

Assay Stability of SB3-14 in Different Reagent Bottle

As mentioned above, the detergent(s) necessary for Core antigen detection can be located either in the outer ring bottle (bottle 1) or in the middle ring bottle (bottle 2) with equivalent performance. However, stability testing over a 62 day period showed an approximate 67% drop in retention of rlu's for an 30 NS3 specimen (Panel B) when the detergent was kept in the outer ring bottle vs. no apparent loss in rlu retention when the detergent was moved into the middle ring bottle (Table 10).

Table 10: The Assay Stability of SB3-14 in different reagent bottle. RLU of NS3 panel over time when reagent stored at 2 to 8 degree C.

TABLE 10

	SB3-14 in C	uter Ring bottle	SB3-14 in Middle Ring bottle		
	RLU	% retention	RLU	% retention	
Day 1	157668		157894		
Day 3	144312	91.5%	158378	100.3%	
Day 8	132705	84.2%	157401	99.7%	
Day 15	103128	65.4%	162609	102.9%	
Day 35	84415	53.5%	163996	103.8%	
Day 62	51064	32.4%	161422	102.2%	

Example 26

Performance of the HCV Combination Assay on Seroconversion Panels

A total of 9 seroconversion panels, PHV-907, PHV-909, PHV-912, PHV-913, PHV-914, PHV-919 (commercially available from SeraCare) and BCP 6214, BCP 6229 and BCP 9044 (commercially available from ZeptoMetrix) were tested by an anti-HCV only assay (Abbott ARCHITECT LN6C37) and the HCV Combo Assay (described above). The results are expressed in terms of S/CO (sample/cutoff) where an S/CO of 1.0 or greater is considered reactive. As shown in Table 11, the HCV Combo assay detects evidence of infection in these panels earlier than that detected by the Antibody only assay (6C37). Shown below (Table 12) is the average window period reduction in days for seroconversion panels that were RNA positive on the 1st bleed of the series. The HCV Combo assay showed detection, on average, approximately 18.4 days earlier than the antibody only assay and roughly equivalent to that detected by RNA. The single seroconversion panel shown above that became RNA positive during the course of collection (PHV-919) shows detection by the HCV Combo assay at the same time as RNA and 3 days ahead of detection by the antibody only assay.

These data demonstrate the value of the HCV antigen/ antibody Combo test in detection of exposure to HCV earlier than antibody only tests.

TABLE 11

Panel	Sample	Bleed Date	Days from 0	PCR	RNA Copies/ml (Vendor)	RIBA 3.0	Anti-HCV Antibody Data by 6C37 Assay S/CO	HCV Antibody/Antigen Combination Assay (HCV Combo) S/CO
PHV- 907	1	6-Apr-96	0	+	>500,000	_	0.07	14.0
	2	10-Apr-96	4	+	>500,000	_	0.06	24.8
Genotype 1b	3	13-Apr-96	7	+	>500,000	_	0.06	14.3
	4	19-Apr-96	13	+	>500,000	core	0.46	7.4
	5	24-Apr-96	18	+	>500,000	core	2.37	3.1
	6	27-Apr-96	21	+	>500,000	core/NS3	2.55	4.1
	7	17-Sep-96	164	+	40,000	core, NS3, NS4	12.56	23.3

TABLE 11-continued

Panel	Sample	Bleed Date	Days from 0	PCR	RNA Copies/ml (Vendor)	RIBA 3.0	Anti-HCV Antibody Data by 6C37 Assay S/CO	HCV Antibody/Antigen Combination Assay (HCV Combo) S/CO
PHV-	1	18-Jan-96	0		10,000	_	0.12	8.6
909	1	16-Jan-90	Ü	+	10,000	_	0.12	6.0
Genotype 3	2	15-Feb-96	28	+	40,000	core	1.37	3.3
	3	17-Feb-96	30	+	20,000	core	1.13	2.7
PHV- 912	1	6-Jan-96	0	+	40,000	_	0.23	0.6
Genotype 2b/3	2	10-Jan-96	4	+	>500,000	_	0.16	3.4
	3	13-Jan-96	7	+	40,000	core	7.91	15.7
PHV-	1	27-Feb-97	0	+	>500,000	_	0.07	13.7
913	2	1.14 07	2		> 500 000		0.22	150
Genotype	2 3	1-Mar-97 6-Mar-97	2 7	+ +	>500,000 >500,000	core	0.23 2.50	15.0 10.9
2b	3	0-IVIAI-97	,	-	~300,000	Core	2.50	10.9
20	4	8-Mar-97	9	+	>500,000	core	1.12	6.1
PHV-	1	9-Apr-97	0	+	>500,000	_	0.05	7.6
914								
C	2	14-Apr-97	5	+	>500,000	_	0.05	11.3
Genotype 2b	3	18-Apr-97	9	+	>500,000	_	0.06	7.8
20	4	21-Apr-97	12	+	>500,000	_	0.10	7.7
	5	25-Apr-97	16	+	>500,000	core	0.75	4.6
	6	28-Apr-97	19	+	>500,000	core	2.24	6.3
	7	3-May-97	24	+	>500,000	core	3.82	3.4
	8	9-May-97	30	+	>500,000		5.02	7.5
	9	12-May-97	33	+	>500,000	core/NS3	7.84	13.7
PHV- 919	1	31-Dec-99	0	-	BLD	_	0.32	0.8
	2	7-Jan-00	7	_	BLD	_	0.48	0.7
Genotype 1a	3	12-Jan-00	12	-	BLD	_	0.26	0.7
	4	25-Jan-00	25	+	200,000	_	0.46	2.5
	5	28-Jan-00	28	+	20,000	core/NS3	2.76	12.2
	6	1-Feb-00	32	+	,	core/NS3	13.99	8.8
DOD	7	4-Feb-00	35	+	100,000		13.90	5.7
BCP 6214	1	13-Jan-96	0	+	246,000	_	0.12	1.6
Constant	2	15-Jan-96	2	+	181,000	_	0.12	3.2
Genotype 1a	3	21-Jan-96	8	+	241,000	_	0.09	3.9
	4	23-Jan-96	10	+	186,000		0.11	3.1
	5	29-Jan-96	16	+	290,000		0.10	2.1
	6	31-Jan-96	18	+	177,000		0.08	2.2
	7 8	5-Feb-96 7-Feb-96	23 25	+ +	312,000 408,000		0.27 0.56	3.0 6.5
	9	12-Feb-96	30	+	290,000		3.51	3.1
	10	14-Feb-96	32	+	632,000		4.44	3.5
	11	2-Mar-96	49	+		NS3/NS4	13.07	1.8
	12	6-Mar-96	53	+		NS3/NS4	13.21	2.5
	13	9-Mar-96	56	+		NS3/NS4	13.00	4.1
BCP 6229	1	14-Nov-96	0	+	>5,000,000	_	0.35	31.8
Genotype	2 3	17-Nov-96 21-Nov-96	3 7	++	>5,000,000 >5,000,000		0.36 0.18	30.2 23.8
1a	4	24 No 06	10	,	>5 000 000		0.43	20.2
	4 5	24-Nov-96	10	+	>5,000,000 >5,000,000		0.42 1.22	38.3
	5 6	1-Dec-96 4-Dec-96	17 20	+	>5,000,000			20.9
	7	4-Dec-96 8-Dec-96	20	+ +	>5,000,000		1.56 2.65	27.5 17.3
	8	12-Dec-96	28	+	>5,000,000		7.02	15.7
BCP 9044	1	14-Apr-97	0	+	2,030,000	_	0.07	26.0
J J T T	2	18-Apr-97	4	+		_	0.03	21.9
Genotype	3	1-May-97	17	+		_	0.07	30.9
1a	4	5-May-97	21	+		_	0.62	33.4
	5	9-May-97	25	+		NS3	3.00	29.9
	6	13-May-97	29	+		NS3	5.58	24.9

BLD: Below limit of Detection

S/CO: 10 NC used for cutoff calculation

S/CO >/=1.0 is considered reactive

50

55

67 Example 27

Table 12 Window Period Reduction by HCV Combo Assay. Time (days) to detection of HCV Ag or Ab in HCV seroconversion panels with HCV RNA detected in the 1st 5 bleed.

TABLE 12

	TIMBLE 12									
		First D	ay to Det	ection of:	RNA- Combo	HCV Combo-	10			
Panel	Genotype	RNA	Anti- HCV Assay	HCV Combo Assay	Differ- ential (Days)	Ab Differential (Days)				
PHV-907	1b	0	18	0	0	18	15			
PHV-909	3	0	28	0	0	28				
PHV-912	2b/3	0	7	4	4	3				
PHV-913	2b	0	7	0	0	7				
PHV-914	2b	0	19	0	0	19				
BCP 6214	1a	0	30	0	0	30				
BCP 6229	1a	0	17	0	0	17	20			
BCP 9044	1a	0	25	0	0	25				
M	Iean window	period	reduction		0.5	18.4				

Average window period reduction by HCV Combo: 18.4 days

Example 28

Table 13 shows that the highest number of seroconversion bleeds detected by any format is by the Capture-on-the-Fly HCV Combo Assay format with a total number of 17 bleeds detected (out of a potential 21 bleeds). The 6C37 antibody only assay detected 11 bleeds while the Murex HCV Combo (MiDAS Report, Health Protection Agency-Centre for Infections, Report PER06007, February, 2007.) detected 9 bleeds. Table 14 shows the S/CO information on both seroconversion panels shown in table 13. Further, in Table 14, the S/CO values are shown for Panel B (anti-NS3 only sample). The Capture-on-the-fly format is more robust, S/CO of 6.19 vs. that of 6C37 at S/CO of 3-4 indicating that the Capture-on-the Fly format for HCV Combo is the most suitable assay format for detection of HCV seroconversion panels.

TABLE 13

Table 13: Sensitivity comparison of different assay formats for 2 key seroconversion panels								
	6C37 Anti- HCV Only Assay	Murex HCV Combo Assay	HCV Combo in Capture-on- the-Fly Format					
BCP6212	8	2	9					
BCP6213	3	7	8					
Total Bleeds Detected	11	9	17					

Number of reactive bleeds from each seroconversion panel (10 NC used as cutoff)

TABLE 14

	S/	'CO information	n		
	RIBA Data	Anti-HCV 6C37 S/CO	HCV combo Murex S/CO	HCV combo CotF format S/CO*	60
Panel B (anti-NS3)	NS3	3~4		6.19	
BCP6212-1 BCP6212-2	_	0.07 1.49	0.795 0.407	1.18 2.36	65

68
TABLE 14-continued

		S/	CO information	n	
			Anti-HCV 6C37	HCV combo Murex	HCV combo CotF format
		RIBA Data	S/CO	S/CO	S/CO*
	BCP6212-3	_	2.12	0.417	2.24
`	BCP6212-4	NS3	6.48	0.499	2.69
,	BCP6212-5	NS3	7.97	0.489	6.96
	BCP6212-6	NS3	8.13	0.529	5.18
	BCP6212-7	NS3	8.17	0.509	4.95
	BCP6212-8	NS3	11.80	1.071	18.5
	BCP6212-9	NS3	12.23	1.245	19.5
•	BCP6213-1	_	0.09	0.348	0.22
	BCP6213-2	_	0.09	0.371	0.22
	BCP6213-3	_	0.11	0.470	0.20
	BCP6213-4	_	0.09	0.532	0.30
	BCP6213-5	_	0.08	0.969	1.27
)	BCP6213-6	_	0.09	1.110	2.11
	BCP6213-7	_	0.09	2.233	3.52
	BCP6213-8	_	0.08	5.609	4.69
	BCP6213-9	_	0.14	2.608	5.05
	BCP6213-10	_	1.47	4.489	10.30
5	BCP6213-11	Core/NS3	10.48	9.192	12.27
	BCP6213-12	Core/NS3	10.30	6.860	6.13

S/CO*: 10 NC used for cutoff calculation

Example 29

Seroconversion Sensitivity of 9NB49H and NS3h

The NS3 recombinant antigens 9NB49H (Acr-BSA-9NB49H and 9NB49H-Cbt) and NS3h (NS3h-Cbt and Acr-BSA-NS3h) were examined in the HCV Ag/Ab Combo format for their ability to detect antibodies among individual serum samples from a seroconversion panel from an HCV infected individual. The results are expressed in terms of S/CO (sample/cutoff) where samples with S/CO 1.0 are considered to be reactive and samples with S/CO<1.0 are considered to be non-reactive. The assay using NS3h resulted in greater seroconversion sensitivity, i.e. most reactive bleeds detected with the highest S/CO values, as compared to the assay using 9NB49H and the Murex HCV Ag/Ab Combo.

TABLE 15

)	Panel Member	Bleed Date	ARCHI- TECT Anti-HCV S/CO	Murex HCV Ag/Ab Combo S/CO	HCV Ag/Ab Combo (9NB49H) S/CO	HCV Ag/Ab Combo (NS3h) S/CO
5	6228-1	20 Nov. 1996	0.03	0.58	nd	0.49
	6228-2	22 Nov. 1996	0.03	0.42	0.19	0.23
	6228-3	27 Nov. 1996	0.04	1.03	0.82	1.06
	6228-4	29 Nov. 1996	0.03	0.58	0.31	0.35
	6228-5	4 Dec. 1996	0.04	0.35	0.13	0.18
	6228-6	6 Dec. 1996	0.03	0.30	0.08	0.11
)	6228-7	11 Dec. 1996	0.09	0.49	0.34	0.41
	6228-8	14 Dec. 1996	0.10	0.61	0.42	0.67
	6228-9	18 Dec. 1996	1.37	0.56	nd	3.04
	6228-10	21 Dec. 1996	4.52	1.09	0.29	15.39
	6228-11	26 Dec. 1996	6.62	1.67	0.39	17.01
5	6228-12	28 Dec. 1996	7.12	1.53	0.30	17.12

nd: not determined

SEQUENCE LISTING

```
<160> NUMBER OF SEQ ID NOS: 125
<210> SEQ ID NO 1
<211> LENGTH: 798
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     polynucleotide
<400> SEQUENCE: 1
qctqttqact ttatcccqqt tqaaaatctc qaqactacta tqcqttctcc qqttttcact
                                                                       60
gacaactett eteegeeggt tgtteegeag tettteeagg ttgeteacet geatgeteeg
                                                                      120
actggttctg gtaaatctac taaagttcca gctgcttacg ctgctcaggg ttacaaagtt
                                                                      180
                                                                      240
ctggttctga accegtctgt tgctgctact ctgggtttcg gcgcctacat gtctaaagct
caeggtateg accegaacat tegtactggt gtacgtacta teactactgg tteteegate
                                                                      300
acttactcta cttacggtaa attcctggct gacggtggtt gctctggtgg tgcttacgat
                                                                      360
atcatcatct gcgacgaatg ccactctact gacgctactt ctatcctggg tatcggtacc
                                                                      420
gttctggacc aggctgaaac tgcaggtgct cgtctggttg ttctggctac tgctactccg
                                                                      480
ccgggttctg ttactgttcc gcacccgaac atcgaagaag ttgctctgtc gactactggt
                                                                      540
gaaatcccgt tctacggtaa agctatcccg ctcgaggtta tcaaaggtgg tcgtcacctg
                                                                      600
attttctgcc actctaaaaa aaaatgcgac gaactggctg ctaagcttgt tgctctgggt
                                                                      660
atcaacgctg ttgcttacta ccgtggtctg gacgtttctg ttatcccgac ttctggtgac
                                                                      720
gttgttgttg tggccactga cgctctgatg actggttaca ctggtgactt cgactctgtt
                                                                      780
atcgattgca acacttgc
                                                                      798
<210> SEQ ID NO 2
<211> LENGTH: 266
<212> TYPE: PRT
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223 > OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     polypeptide
<400> SEQUENCE: 2
Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser
Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe
Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys
Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn
                        55
Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala
                    70
His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr
Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly
           100
                                105
Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His
                           120
Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln
                        135
    130
                                            140
```

-continued

```
Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro
145
                   150
                                       155
Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu
Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu
                               185
Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys
Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val
Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp
Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp
Phe Asp Ser Val Ile Asp Cys Asn Thr Cys
           260
<210> SEQ ID NO 3
<211> LENGTH: 798
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     polvnucleotide
<400> SEQUENCE: 3
gctgttgact ttatcccggt tgaaaatctc gagactacta tgcgttctcc ggttttcact
                                                                      60
gacaactett eteegeeggt tgtteegeag tettteeagg ttgcteacet geatgeteeg
                                                                     120
actggttctg gtaaatctac taaagttcca gctgcttacg ctgctcaggg ttacaaagtt
                                                                     180
ctggttctga acccgtctgt tgctgctact ctgggtttcg gcgcctacat gtctaaagct
                                                                     240
cacggtatcg acccgaacat tcgtactggt gtacgtacta tcactactgg ttctccgatc
                                                                     300
acttactcta cttacggtaa attcctggct gacggtggta gctctggtgg tgcttacgat
                                                                     360
atcatcatct gcgacgaatg ccactctact gacgctactt ctatcctggg tatcggtacc
gttctggacc aggctgaaac tgcaggtgct cgtctggttg ttctggctac tgctactccg
ccgggttctg ttactgttcc gcacccgaac atcgaagaag ttgctctgtc gactactggt
gaaatcccgt tctacggtaa agctatcccg ctcgaggtta tcaaaggtgg tcgtcacctg
attttctgcc actctaaaaa aaaatgcgac gaactggctg ctaagcttgt tgctctgggt
atcaacgctg ttgcttacta ccgtggtctg gacgtttctg ttatcccgac ttctggtgac
gttgttgttg tggccactga cgctctgatg actggttaca ctggtgactt cgactctgtt
atcgattgca acacttgc
<210> SEQ ID NO 4
<211> LENGTH: 266
<212> TYPE: PRT
<213 > ORGANISM: Artificial Sequence
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     polypeptide
<400> SEQUENCE: 4
Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser
                                   10
```

Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe 20 25 30

_																	
Gln	Val	Ala 35	His	Leu	His	Ala	Pro 40	Thr	Gly	Ser	Gly	Lув 45	Ser	Thr	ГЛа		
Val	Pro 50	Ala	Ala	Tyr	Ala	Ala 55	Gln	Gly	Tyr	Lys	Val 60	Leu	Val	Leu	Asn		
Pro 65	Ser	Val	Ala	Ala	Thr 70	Leu	Gly	Phe	Gly	Ala 75	Tyr	Met	Ser	Lys	Ala 80		
His	Gly	Ile	Asp	Pro 85	Asn	Ile	Arg	Thr	Gly 90	Val	Arg	Thr	Ile	Thr 95	Thr		
Gly	Ser	Pro	Ile 100	Thr	Tyr	Ser	Thr	Tyr 105	Gly	Lys	Phe	Leu	Ala 110	Asp	Gly		
Gly	Ser	Ser 115	Gly	Gly	Ala	Tyr	Asp 120	Ile	Ile	Ile	CAa	Asp 125	Glu	Cys	His		
Ser	Thr 130	Asp	Ala	Thr	Ser	Ile 135	Leu	Gly	Ile	Gly	Thr 140	Val	Leu	Asp	Gln		
Ala 145	Glu	Thr	Ala	Gly	Ala 150	Arg	Leu	Val	Val	Leu 155	Ala	Thr	Ala	Thr	Pro 160		
Pro	Gly	Ser	Val	Thr 165	Val	Pro	His	Pro	Asn 170	Ile	Glu	Glu	Val	Ala 175	Leu		
Ser	Thr	Thr	Gly 180	Glu	Ile	Pro	Phe	Tyr 185	Gly	Lys	Ala	Ile	Pro 190	Leu	Glu		
Val	Ile	Lys 195	Gly	Gly	Arg	His	Leu 200	Ile	Phe	Сув	His	Ser 205	Lys	Lys	Lys		
Cys	Asp 210	Glu	Leu	Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val		
Ala 225	Tyr	Tyr	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240		
Val	Val	Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp		
Phe	Asp	Ser	Val 260	Ile	Asp	CÀa	Asn	Thr 265	СЛа								
<21: <21: <21: <22: <22:		ENGTI YPE : RGAN: EATUI THER olyni	H: 79 DNA ISM: RE: INFO	Art: ORMA'	TION		_		n of	Art:	ific	ial :	Seque	ence:	: Syntl	neti	С
gct	gttga	act 1	ttat	cccg	gt to	gaaa	atcto	gaç	gacta	acta	tgc	gttci	tee 9	ggttt	tcact		60
gac	aacto	ctt «	ctcc	gaag	gt to	gttc	cgcag	g tơ	ttc	cagg	ttg	ctca	cct q	gcato	gctccg		120
act	ggtto	ctg q	gtaaa	atct	ac ta	aaagt	tcca	a gct	gctt	acg	ctg	ctca	ggg 1	ttaca	aagtt		180
ctg	gttct	ga a	accc	gtct	gt to	gctg	ctact	cte	gggtt	tcg	gcg	ccta	cat q	gtcta	aagct		240
cac	ggtat	cg a	accc	gaac	at to	cgta	ctggt	gta	acgta	acta	tcad	ctact	gg 1	ttctc	ccgatc		300
act	cacto	cta «	ctta	eggt	aa at	tcct	gget	gad	eggt	ggtt	gct	ctggi	tgg 1	tgctt	acgat		360
atc	atcat	ca q	gcga	cgaat	tg co	cacto	ctact	gad	egeta	actt	ctat	cct	ggg 1	tatco	ggtacc		420
gtt	ctgga	acc a	aggci	tgaa	ac to	gcag	gtgct	c cgt	ctg	gttg	ttct	ggcı	tac 1	tgcta	actccg		480
ccg	ggtto	ctg 1	ttacı	gtt	ee go	cacco	cgaad	c ato	cgaaq	gaag	ttg	ctct	gtc (gacta	actggt		540
gaa	atcc	egt 1	tcta	ggt	aa a	gctai	cccg	g cto	cgag	gtta	tcaa	aaggt	igg 1	tegte	cacctg		600
att	tctç	gcc a	actci	taaa	aa aa	aaat	gcgad	c gaa	actg	gctg	ctaa	agcti	tgt 1	tgcto	tgggt		660

-continued

atcaacgctg ttgcttacta ccgtggtctg gacgtttctg ttatcccgac ttctggtgac gttgttgttg tggccactga cgctctgatg actggttaca ctggtgactt cgactctgtt 780 atcgattgca acacttgc 798 <210> SEQ ID NO 6 <211> LENGTH: 266 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 6 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly 105 Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Ser Asp Glu Cys His Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln 135 Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu 170 Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys 260 <210> SEQ ID NO 7 <211 > LENGTH: 798 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polynucleotide

<400> SEQUENCE: 7

gctgttgact	ttatcccggt	tgaaaatctc	gagactacta	tgcgttctcc	ggttttcact	60
gacaactctt	ctccgccggt	tgttccgcag	tetttecagg	ttgctcacct	gcatgctccg	120
actggttctg	gtaaatctac	taaagttcca	gctgcttacg	ctgctcaggg	ttacaaagtt	180
ctggttctga	acccgtctgt	tgctgctact	ctgggtttcg	gcgcctacat	gtctaaagct	240
cacggtatcg	acccgaacat	tcgtactggt	gtacgtacta	tcactactgg	ttctccgatc	300
acttactcta	cttacggtaa	attectgget	gacggtggtt	gctctggtgg	tgcttacgat	360
atcatcatct	gcgacgaaag	ccactctact	gacgctactt	ctatcctggg	tatcggtacc	420
gttctggacc	aggctgaaac	tgcaggtgct	cgtctggttg	ttctggctac	tgctactccg	480
ccgggttctg	ttactgttcc	gcacccgaac	atcgaagaag	ttgctctgtc	gactactggt	540
gaaatcccgt	tctacggtaa	agctatcccg	d ctcgaggtta	tcaaaggtgg	tcgtcacctg	600
attttctgcc	actctaaaaa	aaaatgcgac	gaactggctg	ctaagcttgt	tgctctgggt	660
atcaacgctg	ttgcttacta	ccgtggtctg	gacgtttctg	ttatcccgac	ttctggtgac	720
gttgttgttg	tggccactga	cgctctgatg	actggttaca	ctggtgactt	cgactctgtt	780
atcgattgca	acacttgc					798
<220> FEAT <223> OTHE poly	TH: 266 : PRT NISM: Artif JRE: R INFORMATI peptide	icial Seque ON: Descrip		ificial Sequ	uence: Syntheti	Lc
<400> SEQUI	ENCE: 8					
Ala Val As _]	Phe Ile P 5	ro Val Glu	Asn Leu Glu 10	Thr Thr Met	Arg Ser 15	
Pro Val Pho	Thr Asp A	sn Ser Ser	Pro Pro Val 25	Val Pro Gln 30	ser Phe	
Gln Val Ala	a His Leu H	is Ala Pro 40	Thr Gly Ser	Gly Lys Ser 45	Thr Lys	
Val Pro Ala 50	a Ala Tyr A	la Ala Gln 55	Gly Tyr Lys	Val Leu Val 60	. Leu Asn	
Pro Ser Va 65		hr Leu Gly O	Phe Gly Ala 75	Tyr Met Ser	Lys Ala 80	
His Gly Ile	e Asp Pro A 85	sn Ile Arg	Thr Gly Val 90	Arg Thr Ile	Thr Thr 95	
Gly Ser Pro	o Ile Thr T 100	yr Ser Thr	Tyr Gly Lys 105	Phe Leu Ala		
Gly Cys Se:		la Tyr Asp 120	Ile Ile Ile	Cys Asp Glu 125	ı Ser His	
Ser Thr Asp 130	Ala Thr S	er Ile Leu 135	Gly Ile Gly	Thr Val Leu 140	ı Asp Gln	
Ala Glu Th	_	la Arg Leu 50	Val Val Leu 155	Ala Thr Ala	Thr Pro 160	
Pro Gly Se	r Val Thr V 165	al Pro His	Pro Asn Ile 170	Glu Glu Val	. Ala Leu 175	
			m al t	Ala Ile Pro	I ou Clu	

Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val

Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Lys 195 200 205

-continued

210 215 Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp 225 230 235 Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp 245 250 Phe Asp Ser Val Ile Asp Cys Asn Thr Cys 260 <210> SEQ ID NO 9 <211> LENGTH: 798 <212> TYPE: DNA <213 > ORGANISM: Artificial Sequence <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polynucleotide <400> SEQUENCE: 9 gctqttqact ttatcccqqt tgaaaatctc qaqactacta tqcqttctcc qqttttcact 60 qacaactett eteeqeeqqt tqtteeqeaq tettteeaqq ttqcteacet qeatqcteeq 120 actggttctg gtaaatctac taaagttcca gctgcttacg ctgctcaggg ttacaaagtt 180 ctggttctga acccgtctgt tgctgctact ctgggtttcg gcgcctacat gtctaaagct 240 cacggtatcg accegaacat tegtactggt gtacgtacta teactactgg tteteegate 300 acttactcta cttacggtaa attcctggct gacggtggtt gctctggtgg tgcttacgat 360 atcatcatct gcgacgaatg ccactctact gacgctactt ctatcctggg tatcggtacc 420 gttctggacc aggctgaaac tgcaggtgct cgtctggttg ttctggctac tgctactccg 480 ccgggttctg ttactgttcc gcacccgaac atcgaagaag ttgctctgtc gactactggt 540 gaaatcccgt tctacggtaa agctatcccg ctcgaggtta tcaaaggtgg tcgtcacctg 600 attttcagcc actctaaaaa aaaatgcgac gaactggctg ctaagcttgt tgctctgggt 660 atcaacgctg ttgcttacta ccgtggtctg gacgtttctg ttatcccgac ttctggtgac 720 gttgttgttg tggccactga cgctctgatg actggttaca ctggtgactt cgactctgtt 780 atcgattgca acacttgc 798 <210> SEQ ID NO 10 <211> LENGTH: 266 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 10 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe 25 Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn 55 Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr 85

```
Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly
           100
                                105
Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His
Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln
Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro
Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu
Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu
Val Ile Lys Gly Gly Arg His Leu Ile Phe Ser His Ser Lys Lys
Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val
Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp
Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp
Phe Asp Ser Val Ile Asp Cys Asn Thr Cys
           260
<210> SEQ ID NO 11
<211> LENGTH: 798
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     polynucleotide
<400> SEQUENCE: 11
gctgttgact ttatcccggt tgaaaatctc gagactacta tgcgttctcc ggttttcact
                                                                      60
gacaactett eteegeeggt tgtteegeag tettteeagg ttgeteacet geatgeteeg
                                                                     120
actggttctg gtaaatctac taaagttcca gctgcttacg ctgctcaggg ttacaaagtt
                                                                     180
ctggttctga acccgtctgt tgctgctact ctgggtttcg gcgcctacat gtctaaagct
                                                                     240
cacggtatcg accegaacat tegtactggt gtacgtacta teactactgg ttetecgate
                                                                     300
acttactcta cttacggtaa attcctggct gacggtggtt gctctggtgg tgcttacgat
atcatcatct gcgacgaatg ccactctact gacgctactt ctatcctggg tatcggtacc
gttctggacc aggctgaaac tgcaggtgct cgtctggttg ttctggctac tgctactccg
cogggttotg ttactgttoc gcaccogaac atogaagaag ttgctotgto gactactggt
qaaatcccqt tctacqqtaa aqctatcccq ctcqaqqtta tcaaaqqtqq tcqtcacctq
                                                                     600
attttctqcc actctaaaaa aaaaaqcqac qaactqqctq ctaaqcttqt tqctctqqqt
                                                                     660
atcaacgctg ttgcttacta ccgtggtctg gacgtttctg ttatcccgac ttctggtgac
                                                                     720
gttgttgttg tggccactga cgctctgatg actggttaca ctggtgactt cgactctgtt
atcqattqca acacttqc
                                                                     798
<210> SEQ ID NO 12
<211> LENGTH: 266
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
```

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic

-continued

polypeptide

< 400)> SE	EQUE	ICE :	12													
Ala 1	Val	Asp	Phe	Ile 5	Pro	Val	Glu	Asn	Leu 10	Glu	Thr	Thr	Met	Arg 15	Ser		
Pro	Val	Phe	Thr 20	Asp	Asn	Ser	Ser	Pro 25	Pro	Val	Val	Pro	Gln 30	Ser	Phe		
Gln	Val	Ala 35	His	Leu	His	Ala	Pro 40	Thr	Gly	Ser	Gly	Lys 45	Ser	Thr	Lys		
Val	Pro 50	Ala	Ala	Tyr	Ala	Ala 55	Gln	Gly	Tyr	Lys	Val 60	Leu	Val	Leu	Asn		
Pro 65	Ser	Val	Ala	Ala	Thr 70	Leu	Gly	Phe	Gly	Ala 75	Tyr	Met	Ser	Lys	Ala 80		
His	Gly	Ile	Asp	Pro 85	Asn	Ile	Arg	Thr	Gly 90	Val	Arg	Thr	Ile	Thr 95	Thr		
Gly	Ser	Pro	Ile 100	Thr	Tyr	Ser	Thr	Tyr 105	Gly	Lys	Phe	Leu	Ala 110	Asp	Gly		
Gly	Cys	Ser 115	Gly	Gly	Ala	Tyr	Asp 120	Ile	Ile	Ile	Cys	Asp 125	Glu	Cys	His		
Ser	Thr 130	Asp	Ala	Thr	Ser	Ile 135	Leu	Gly	Ile	Gly	Thr 140	Val	Leu	Asp	Gln		
Ala 145	Glu	Thr	Ala	Gly	Ala 150	Arg	Leu	Val	Val	Leu 155	Ala	Thr	Ala	Thr	Pro 160		
Pro	Gly	Ser	Val	Thr 165	Val	Pro	His	Pro	Asn 170	Ile	Glu	Glu	Val	Ala 175	Leu		
Ser	Thr	Thr	Gly 180	Glu	Ile	Pro	Phe	Tyr 185	Gly	Lys	Ala	Ile	Pro 190	Leu	Glu		
Val	Ile	Lys 195	Gly	Gly	Arg	His	Leu 200	Ile	Phe	Cys	His	Ser 205	Lys	Lys	Lys		
Ser	Asp 210	Glu	Leu	Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val		
Ala 225	Tyr	Tyr	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240		
Val	Val	Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp		
Phe	Asp	Ser	Val 260	Ile	Asp	Cys	Asn	Thr 265	Cys								
<211 <212 <213 <220)> FE 3> O'I	ENGTH PE: RGANI EATUR PHER	H: 79 DNA ESM: RE:	98 Art: DRMA:			-		ı of	Arti	lfici	ial s	Seque	ence:	: Synth	netic	3
<400)> SE	EQUE	ICE:	13													
gct	gttga	ect t	tato	ccgg	gt to	jaaaa	atcto	gag	jacta	ecta	tgcg	gttct	caa g	ggttt	tcact		60
gaca	aacto	tt d	ctccç	geegg	gt to	jttco	egcaç	g tct	ttcc	agg	ttg	ctcac	ect g	gcate	gctccg	1	L20
acto	ggtto	tg g	gtaaa	atcta	ac ta	aagt	tcca	gct	gctt	acg	ctg	ctcaç	ggg t	taca	aaagtt	1	180
ctg	gttct	ga a	accc	gtata	gt to	gctgo	ctact	cto	ggtt	tcg	gcg	cctac	cat ç	gtcta	aaagct	2	240
cacç	ggtat	.cg a	acccg	gaaca	at to	gtac	tggt	gta	cgta	ecta	tcac	ctact	gg t	tctc	ecgate	3	300
actt	acto	cta d	cttac	ggta	aa at	tcct	ggct	gac	ggtg	gta	gcto	etggt	gg t	gctt	acgat	3	360

atcatcatca gegacgaaag ceaetetaet gaegetaett etateetggg tateggtaee

-continued

gttctggad	c agget	gaaac to	gcaggtgct	cgtct	ggttg	ttctgg	ctac	tgcta	actccg	480
ccgggttct	g ttact	gttcc go	cacccgaad	c atcga	ıagaag	ttgctc	tgtc	gacta	actggt	540
gaaatcccc	t tctac	ggtaa ag	gctatccc	g ctcga	ıggtta	tcaaag	gtgg	tegte	cacctg	600
attttctgc	c actct	aaaaa aa	aaatgcgad	c gaact	ggctg	ctaagc	ttgt	tgcto	ctgggt	660
atcaacgct	g ttgct	tacta co	egtggtetg	g gacgt	ttctg	ttatcc	cgac	ttctg	ggtgac	720
gttgttgtt	g tggcc	actga co	gctctgato	g actgo	ıttaca	ctggtg	actt	cgact	ctgtt	780
atcgattgo	a acacti	tgc								798
_	GTH: 260 PE: PRT GANISM: A TURE: MER INFO	6 Artifici RMATION: e	_		of Art:	ificial	Sequ	ence:	: Synthet	ic
<400> SEQ			Wal Clu	Agn Le	u Glu	тьк ть	r Met	Δrα	Car	
1		5	vai Giu	10		1111 111	ı mec	15	sei	
Pro Val E	he Thr 2	Asp Asn	Ser Ser	Pro Pr 25	o Val	Val Pr	o Gln 30	Ser	Phe	
Gln Val A	ala His 1 5	Leu His	Ala Pro 40	Thr Gl	y Ser	Gly Ly 45	s Ser	Thr	ГЛа	
Val Pro F 50	la Ala '	Tyr Ala	Ala Gln 55	Gly Ty	r Lys	Val Le 60	u Val	Leu	Asn	
Pro Ser V 65	al Ala i	Ala Thr 70	Leu Gly	Phe Gl	y Ala 75	Tyr Me	t Ser	Lys	Ala 80	
His Gly I	_	Pro Asn 85	Ile Arg	Thr Gl	_	Arg Th	r Ile	Thr 95	Thr	
Gly Ser F	ro Ile '	Thr Tyr	Ser Thr	Tyr Gl 105	y Lys.	Phe Le	u Ala 110	_	Gly	
Gly Ser S	er Gly (Gly Ala	Tyr Asp 120	Ile Il	e Ile	Ser As	_	Ser	His	
Ser Thr A	sp Ala'	Thr Ser	Ile Leu 135	Gly Il	e Gly	Thr Va	l Leu	Asp	Gln	
Ala Glu 1 145	hr Ala (Gly Ala 150	Arg Leu	Val Va	ıl Leu 155	Ala Th	r Ala	Thr	Pro 160	
Pro Gly S		Thr Val	Pro His	Pro As		Glu Gl	u Val	Ala 175	Leu	
Ser Thr T	hr Gly (Glu Ile	Pro Phe	Tyr Gl 185	.y Lys	Ala Il	e Pro 190	Leu	Glu	
Val Ile I	ys Gly (.95	Gly Arg	His Leu 200	Ile Ph	ie Cys	His Se		Lys	Lys	
Cys Asp C	lu Leu I	Ala Ala	Lys Leu 215	Val Al	a Leu	Gly I1 220	e Asn	Ala	Val	
Ala Tyr T	yr Arg	Gly Leu 230	Asp Val	Ser Va	l Ile 235	Pro Th	r Ser	Gly	Asp 240	
Val Val V		Ala Thr 245	Asp Ala	Leu Me		Gly Ty	r Thr	Gly 255	Asp	

Phe Asp Ser Val Ile Asp Cys Asn Thr Cys 260 265

	-continued

<211> LENGTH: 798 <212> TYPE: DNA

<213 > ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polynucleotide

<400> SEQUENCE: 15

gctgttgact	ttatcccggt	tgaaaatctc	gagactacta	tgcgttctcc	ggttttcact	60
gacaactctt	ctccgccggt	tgttccgcag	tctttccagg	ttgctcacct	gcatgctccg	120
actggttctg	gtaaatctac	taaagttcca	gctgcttacg	ctgctcaggg	ttacaaagtt	180
ctggttctga	acccgtctgt	tgctgctact	ctgggtttcg	gcgcctacat	gtctaaagct	240
cacggtatcg	acccgaacat	tcgtactggt	gtacgtacta	tcactactgg	ttctccgatc	300
acttactcta	cttacggtaa	attcctggct	gacggtggtt	gctctggtgg	tgcttacgat	360
atcatcatct	gcgacgaatg	ccactctact	gacgctactt	ctatcctggg	tatcggtacc	420
gttctggacc	aggctgaaac	tgcaggtgct	cgtctggttg	ttctggctac	tgctactccg	480
ccgggttctg	ttactgttcc	gcacccgaac	atcgaagaag	ttgctctgtc	gactactggt	540
gaaatcccgt	tctacggtaa	agctatcccg	ctcgaggtta	tcaaaggtgg	tegteacetg	600
attttcagcc	actctaaaaa	aaaaagcgac	gaactggctg	ctaagcttgt	tgctctgggt	660
atcaacgctg	ttgcttacta	ccgtggtctg	gacgtttctg	ttatcccgac	ttctggtgac	720
gttgttgttg	tggccactga	cgctctgatg	actggttaca	ctggtgactt	cgactctgtt	780
atcgattgca	acacttgc					798

<210> SEQ ID NO 16

<211> LENGTH: 266 <212> TYPE: PRT

<213 > ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide

<400> SEQUENCE: 16

Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1 $$ 5 $$ 10 $$ 15

Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe 20 25 30

Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys 35 40 45

Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn 50 $\,$ 60 $\,$

Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala 65 70 75 80

His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr 85 90 95

Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly 100 \$105\$

Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His 115 120 125

Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln 130 135 140

Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro 145 150 150 160

Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu

-continued

170 Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu 180 185 190 Val Ile Lys Gly Gly Arg His Leu Ile Phe Ser His Ser Lys Lys 200 Ser Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys <210> SEQ ID NO 17 <211> LENGTH: 798 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polynucleotide <400> SEOUENCE: 17 gctgttgact ttatcccggt tgaaaatctc gagactacta tgcgttctcc ggttttcact 60 qacaactett eteeqeeqqt tqtteeqeaq tettteeaqq ttqcteacet qeatqeteeq 120 actggttctg gtaaatctac taaagttcca gctgcttacg ctgctcaggg ttacaaagtt 180 ctggttctga acccgtctgt tgctgctact ctgggtttcg gcgcctacat gtctaaagct 240 cacggtatcg accegaacat tegtactggt gtacgtacta teactactgg tteteegate 300 acttactcta cttacggtaa attcctggct gacggtggta gctctggtgg tgcttacgat 360 atcatcatca gcgacgaaag ccactctact gacgctactt ctatcctggg tatcggtacc 420 gttctggacc aggctgaaac tgcaggtgct cgtctggttg ttctggctac tgctactccg 480 ccgggttctg ttactgttcc gcacccgaac atcgaagaag ttgctctgtc gactactggt 540 gaaatcccgt tctacggtaa agctatcccg ctcgaggtta tcaaaggtgg tcgtcacctg 600 attttcagcc actctaaaaa aaaaagcgac gaactggctg ctaagcttgt tgctctgggt atcaacgctg ttgcttacta ccgtggtctg gacgtttctg ttatcccgac ttctggtgac gttgttgttg tggccactga cgctctgatg actggttaca ctggtgactt cgactctgtt atcgattgca acacttgc <210> SEQ ID NO 18 <211> LENGTH: 266 <212> TYPE: PRT <213 > ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 18 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 5 10 Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe 25 Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys

40

Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn 50 55 60	
Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala 65 70 75 80	
His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr 85 90 95	
Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly 100 105 110	
Gly Ser Ser Gly Gly Ala Tyr Asp Ile Ile Ile Ser Asp Glu Ser His 115 120 125	
Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln 130 135 140	
Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro 145 150 155 160	
Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu 165 170 175	
Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu 180 185 190	
Val Ile Lys Gly Gly Arg His Leu Ile Phe Ser His Ser Lys Lys Lys 195 200 205	
Ser Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 210 215 220	
Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp 225 230 235 240	
Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp	
245 250 255 Phe Asp Ser Val Ile Asp Cys Asn Thr Cys	
260 265	
<210> SEQ ID NO 19 <211> LENGTH: 1401 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence	
<220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Syntheti-polynucleotide	а
<400> SEQUENCE: 19	
gctgttgact ttatcccggt tgaaaatctc gagactacta tgcgttctcc ggttttcact	60
gacaactett eteegeeggt tgtteegeag tettteeagg ttgeteacet geatgeteeg	120
actggttctg gtaaatctac taaagttcca gctgcttacg ctgctcaggg ttacaaagtt	180
ctggttctga acccgtctgt tgctgctact ctgggtttcg gcgcctacat gtctaaagct	240
	300
33 33 33 33 3 33 3	360
	420
	480
	540
	600
	660
	720
gttgttgttg tggccactga cgctctgatg actggttaca ctggtgactt cgactctgtt	780

atcgattgca	acacttgcg	gt tactc	agacc	gta	gatt	tta	gcct	ggad	cc q	gactt	tcact	840
atcgaaacga	tcaccctgo	ec geagg	atgca	gtt	tece	gta	ccca	agcgt	.cg	tggcd	gtacc	900
ggtcgcggca	aaccgggta	at ttacc	gtttc	gtg	gege	cgg	gcga	agcgt	cc .	atcco	ggtatg	960
ttcgatagct	ctgttctgt	g tgagt	gttat	gac	gegg	gtt	gcg	gtgg	gta ·	cgaad	etgact	1020
ccggctgaaa	ctactgtac	eg eetge	gtgca	tac	atga	ata	cgc	gggt	ct	gccgg	gtgtgt	1080
caagaccacc	tggaatttt	g ggaag	gtgtc	ttt	actg	gcc	tgad	ccat	at	cgacç	gcacac	1140
tttctgtccc	agactaaac	ca gtctg	gtgaa	aac	ctgc	cgt	acct	ggtg	gc (gtato	caagcc	1200
actgtgtgcg	cccgtgcgc	ca ggcgc	cgcca	ccg	agct	999	acca	aaato	gtg	gaagt	gcctg	1260
atccgtctga	aaccgacco	ct gcacg	gtccg	acg	ccac	tgc	tgta	accgo	ct	gggtg	gcagtg	1320
cagaacgaaa	tcacgctga	ac gcacc	cggtc	act	aaat	aca	ttat	gact	tg	catga	agcgca	1380
gacctggaag	tggtgactt	c c										1401
<pre><210> SEQ : <211> LENG' <212> TYPE <213> ORGAI <220> FEATI <223> OTHEI polyj</pre>	TH: 467 : PRT NISM: Arti URE:		-		of.	Arti	lfici	ial S	sequ	ence:	: Syntl	netic
<400> SEQUI	ENCE: 20											
Ala Val As _l 1	Phe Ile 5	Pro Val	Glu .		Leu 10	Glu	Thr	Thr	Met	Arg 15	Ser	
Pro Val Pho	e Thr Asp 20	Asn Ser		Pro 25	Pro '	Val	Val	Pro	Gln 30	Ser	Phe	
Gln Val Ala	a His Leu	His Ala	Pro 40	Thr	Gly	Ser	Gly	Lys 45	Ser	Thr	Lys	
Val Pro Ala	a Ala Tyr	Ala Ala 55	Gln	Gly	Tyr	Lys	Val 60	Leu	Val	Leu	Asn	
Pro Ser Vai	l Ala Ala	Thr Leu 70	Gly	Phe		Ala 75	Tyr	Met	Ser	Lys	Ala 80	
His Gly Ile	e Asp Pro 85	Asn Ile	Arg		Gly 90	Val	Arg	Thr	Ile	Thr 95	Thr	
Gly Ser Pro	o Ile Thr 100	Tyr Ser		Tyr 105	Gly :	Lys	Phe	Leu	Ala 110	Asp	Gly	
Gly Cys Se:		Ala Tyr	Asp 120	Ile	Ile	Ile	СЛа	Asp 125	Glu	CÀa	His	
Ser Thr Asp	o Ala Thr	Ser Ile 135	Leu	Gly	Ile	Gly	Thr 140	Val	Leu	Asp	Gln	
Ala Glu Th	r Ala Gly	Ala Arg 150	Leu '	Val		Leu 155	Ala	Thr	Ala	Thr	Pro 160	
Pro Gly Se:	r Val Thr 165	Val Pro	His		Asn 170	Ile	Glu	Glu	Val	Ala 175	Leu	
Ser Thr Th	r Gly Glu 180	Ile Pro		Tyr 185	Gly :	Lys	Ala	Ile	Pro 190	Leu	Glu	
Val Ile Ly:		Arg His	Leu 200	Ile	Phe	Cys	His	Ser 205	Lys	Lys	Lys	
Cys Asp Gli 210	ı Leu Ala	Ala Lys 215	Leu '	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val	
Ala Tyr Ty:	r Arg Gly	Leu Asp 230	Val	Ser		Ile 235	Pro	Thr	Ser	Gly	Asp 240	
Val Val Va	l Val Ala	Thr Asp	Ala	Leu	Met	Thr	Gly	Tyr	Thr	Gly	Asp	

Continued												
245 250 255												
Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp 260 265 270												
Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Ile Thr Leu Pro Gln 275 280 285												
Asp Ala Val Ser Arg Thr Gln Arg Gly Arg Thr Gly Arg Gly Lys 290 295 300												
Pro Gly Ile Tyr Arg Phe Val Ala Pro Gly Glu Arg Pro Ser Gly Met 305 310 315 320												
Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala Gly Cys Ala Trp 325 330 335												
Tyr Glu Leu Thr Pro Ala Glu Thr Thr Val Arg Leu Arg Ala Tyr Met 340 345 350												
Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu Glu Phe Trp Glu 355 360 365												
Gly Val Phe Thr Gly Leu Thr His Ile Asp Ala His Phe Leu Ser Gln 370 375 380												
Thr Lys Gln Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr Gln Ala 385 390 395 400												
Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met 405 410 415												
Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro 420 425 430												
Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Ile Thr Leu Thr His 435 440 445												
Pro Val Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val 450 455 460												
Val Thr Ser 465												
<400> SEQUENCE: 21												
gctgttgact ttatcccggt tgaaaatctc gagactacta tgcgttctcc ggttttcact 60												
gacaactett eteegeeggt tgtteegeag tettteeagg ttgeteacet geatgeteeg 120												
actggttctg gtaaatctac taaagttcca gctgcttacg ctgctcaggg ttacaaagtt 180												
ctggttctga accegtctgt tgctgctact ctgggtttcg gcgcctacat gtctaaagct 240												
cacggtatcg accegaacat tegtactggt gtacgtacta teactactgg tteteegate 300												
acttactcta cttacggtaa attcctggct gacggtggtt gctctggtgg tgcttacgat 360												
atcatcatct gcgacgaatg ccactctact gacgctactt ctatcctggg tatcggtacc 420												
gttctggacc aggctgaaac tgcaggtgct cgtctggttg ttctggctac tgctactccg 480												
ccgggttctg ttact 495												
<210> SEQ ID NO 22 <211> LENGTH: 165 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:												

```
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     polypeptide
<400> SEQUENCE: 22
Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser
                 10
Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe
Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys
Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn
Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala
His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr
Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly
                             105
Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His
                          120
Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln
                      135
Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro
145
                   150
Pro Gly Ser Val Thr
<210> SEQ ID NO 23
<211> LENGTH: 375
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     polynucleotide
<400> SEQUENCE: 23
gctgttgact ttatcccggt tgaaaatctc gagactacta tgcgttctcc ggttttcact
                                                                     60
gacaactett etgtteegea eeegaacate gaagaagttg etetgtegae taetggtgaa
atcoogttct acggtaaagc tatcoogctc gaggttatca aaggtggtcg tcacctgatt
ttctgccact ctaaaaaaa atgcgacgaa ctggctgcta agcttgttgc tctgggtatc
aacgctgttg cttactaccg tggtctggac gtttctgtta tcccgacttc tggtgacgtt
gttgttgtgg ccactgacgc tctgatgact ggttacactg gtgacttcga ctctgttatc
gattqcaaca cttqc
<210> SEQ ID NO 24
<211> LENGTH: 125
<212> TYPE: PRT
<213 > ORGANISM: Artificial Sequence
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     polypeptide
<400> SEQUENCE: 24
Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser
                                   10
Pro Val Phe Thr Asp Asn Ser Ser Val Pro His Pro Asn Ile Glu Glu
          20
                      25
```

-continued

Val Ala Leu Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp Val Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys <210> SEQ ID NO 25 <211> LENGTH: 513 <212> TYPE: DNA <213 > ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polynucleotide <400> SEQUENCE: 25 qctqttqact ttatcccqqt tqaaaatctc qaqactacta tqcqttctcc qqttttcact 60 gacaactctt ctttcgatag ctctgttctg tgtgagtgtt atgacgcggg ttgcgcgtgg 120 tacgaactga ctccggctga aactactgta cgcctgcgtg catacatgaa tacgccgggt 180 ctgccggtgt gtcaagacca cctggaattt tgggaaggtg tctttactgg cctgacccat 240 ategacgeae actitetgie ecagactaaa eagietggig aaaacetgee giacetggig 300 gcgtatcaag ccactgtgtg cgcccgtgcg caggcgccgc caccgagctg ggaccaaatg 360 tggaagtgee tgateegtet gaaacegaee etgeaeggte egaegeeaet getgtaeege 420 ctgggtgcag tgcagaacga aatcacgctg acgcacccgg tcactaaata cattatgact 480 tgcatgagcg cagacctgga agtggtgact tcc 513 <210> SEQ ID NO 26 <211> LENGTH: 171 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 26 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Phe Asp Ser Ser Val Leu Cys Glu 25 Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr 40 Thr Val Arg Leu Arg Ala Tyr Met Asn Thr Pro Gly Leu Pro Val Cys 55 Gln Asp His Leu Glu Phe Trp Glu Gly Val Phe Thr Gly Leu Thr His 70 Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ser Gly Glu Asn Leu 90 Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala 100 105 110

```
Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys
                           120
Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val
                       135
Gln Asn Glu Ile Thr Leu Thr His Pro Val Thr Lys Tyr Ile Met Thr
                   150
Cys Met Ser Ala Asp Leu Glu Val Val Thr Ser
               165
<210> SEQ ID NO 27
<211> LENGTH: 978
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     polynucleotide
<400> SEQUENCE: 27
qctqttqact ttatcccqqt tqaaaatctc qaqactacta tqcqttctcc qqttttcact
                                                                    60
                                                                   120
gacaactett etgtteegea eeegaacate gaagaagttg etetgtegae taetggtgaa
atcccqttct acqqtaaaqc tatcccqctc qaqqttatca aaqqtqqtcq tcacctqatt
                                                                   180
ttctgccact ctaaaaaaaa atgcgacgaa ctggctgcta agcttgttgc tctgggtatc
                                                                   240
aacgctgttg cttactaccg tggtctggac gtttctgtta tcccgacttc tggtgacgtt
                                                                   300
gttgttgtgg ccactgacgc tctgatgact ggttacactg gtgacttcga ctctgttatc
                                                                   360
gattgcaaca cttgcgttac tcagaccgta gattttagcc tggacccgac tttcactatc
                                                                   420
gaaacgatca ccctgccgca ggatgcagtt tcccgtaccc agcgtcgtgg ccgtaccggt
                                                                   480
cgcggcaaac cgggtattta ccgtttcgtg gcgccgggcg agcgtccatc cggtatgttc
                                                                   540
gatagetetg ttetgtgtga gtgttatgae gegggttgeg egtggtaega aetgaeteeg
                                                                   600
getgaaaeta etgtaegeet gegtgeatae atgaataege egggtetgee ggtgtgteaa
                                                                    660
gaccacctgg aattttggga aggtgtcttt actggcctga cccatatcga cgcacacttt
                                                                    720
ctgtcccaga ctaaacagtc tggtgaaaac ctgccgtacc tggtggcgta tcaagccact
                                                                    780
gtgtgcgccc gtgcgcaggc gccgccaccg agctgggacc aaatgtggaa gtgcctgatc
                                                                    840
aacgaaatca cgctgacgca cccggtcact aaatacatta tgacttgcat gagcgcagac
ctggaagtgg tgacttcc
                                                                    978
<210> SEQ ID NO 28
<211> LENGTH: 326
<212> TYPE: PRT
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     polypeptide
<400> SEQUENCE: 28
Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser
                                   1.0
Pro Val Phe Thr Asp Asn Ser Ser Val Pro His Pro Asn Ile Glu Glu
Val Ala Leu Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile
                           40
Pro Leu Glu Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser
```

												COII	CIII	aca		
	50					55					60					
Lуз 65	ГÀа	Lys	Cys	Asp	Glu 70	Leu	Ala	Ala	Lys	Leu 75	Val	Ala	Leu	Gly	Ile 80	
Asn	Ala	Val	Ala	Tyr 85	Tyr	Arg	Gly	Leu	Asp 90	Val	Ser	Val	Ile	Pro 95	Thr	
Ser	Gly	Asp	Val 100	Val	Val	Val	Ala	Thr 105	Asp	Ala	Leu	Met	Thr 110	Gly	Tyr	
Thr	Gly	Asp 115		Asp	Ser	Val	Ile 120	Asp	Сув	Asn	Thr	Сув 125	Val	Thr	Gln	
Thr	Val 130	Asp	Phe	Ser	Leu	Asp 135	Pro	Thr	Phe	Thr	Ile 140	Glu	Thr	Ile	Thr	
Leu 145	Pro	Gln	Asp	Ala	Val 150	Ser	Arg	Thr	Gln	Arg 155	Arg	Gly	Arg	Thr	Gly 160	
Arg	Gly	ГÀа	Pro	Gly 165	Ile	Tyr	Arg	Phe	Val 170	Ala	Pro	Gly	Glu	Arg 175	Pro	
Ser	Gly	Met	Phe 180	Asp	Ser	Ser	Val	Leu 185	Cys	Glu	CAa	Tyr	Asp 190	Ala	Gly	
Cys	Ala	Trp 195		Glu	Leu	Thr	Pro 200	Ala	Glu	Thr	Thr	Val 205	Arg	Leu	Arg	
Ala	Tyr 210	Met	Asn	Thr	Pro	Gly 215	Leu	Pro	Val	Cys	Gln 220	Asp	His	Leu	Glu	
Phe 225	Trp	Glu	Gly	Val	Phe 230	Thr	Gly	Leu	Thr	His 235	Ile	Asp	Ala	His	Phe 240	
Leu	Ser	Gln	Thr	Lys 245	Gln	Ser	Gly	Glu	Asn 250	Leu	Pro	Tyr	Leu	Val 255	Ala	
Tyr	Gln	Ala	Thr 260	Val	CAa	Ala	Arg	Ala 265	Gln	Ala	Pro	Pro	Pro 270	Ser	Trp	
Asp	Gln	Met 275	Trp	Lys	CAa	Leu	Ile 280	Arg	Leu	Lys	Pro	Thr 285	Leu	His	Gly	
Pro	Thr 290	Pro	Leu	Leu	Tyr	Arg 295	Leu	Gly	Ala	Val	Gln 300	Asn	Glu	Ile	Thr	
Leu 305	Thr	His	Pro	Val	Thr 310	Lys	Tyr	Ile	Met	Thr 315	Cys	Met	Ser	Ala	Asp 320	
Leu	Glu	Val	Val	Thr 325	Ser											
<213 <213 <213 <220	0 > FI 3 > O	ENGTI PE: RGANI EATUI	H: 50 DNA ISM: RE: INFO	34 Art: ORMA					ı of	Art:	ific	ial :	Sequ	ence	: Synt	chetic
< 400	O> SI	EQUEI	NCE:	29												
gct	gttga	act t	ttat	cccg	gt to	gaaaa	atcto	gag	gacta	acta	tgc	gttc	taa q	ggttt	tcact	: 60
gaca	aacto	ctt (ctgti	taag	ca co	ccgaa	acato	gaa	agaaq	gttg	ctct	tgtc	gac '	tacto	ggtgaa	120
atco	ccgtt	cct a	acggi	taaaq	gc ta	atcc	cgcto	gaç	ggtta	atca	aag	gtgg	cg ·	tcaco	tgatt	180
ttct	gcca	act o	ctaa	aaaa	aa at	gega	acgaa	a ctç	ggct	gcta	agct	ttgt	tgc ·	tctg	ggtato	240
aac	gctgt	tg d	ctta	ctac	cg t	ggtct	ggad	gtt	tate	gtta	tcc	cgac	ttc '	tggt	gacgtt	300
gtt	gttgt	gg (ccact	tgac	gc to	ctgat	gact	ggt	taca	actg	gtga	actt	cga ·	ctctç	gttato	360
gati	gcaa	aca (cttg	cgtta	ac to	caga	ccgta	a gat	ttta	agcc	tgga	accc	gac ·	tttca	actato	420
gaaa	acgat	ca d	ccct	geeg	ca g	gatgo	cagtt	tco	ccgta	accc	agc	gtcg	gg ·	ccgta	accggt	480

-continued

cgcggcaaac cgggtattta ccgtttcgtg gcgccgggcg agcgtccatc cggt 534 <210> SEQ ID NO 30 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 30 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Val Pro His Pro Asn Ile Glu Glu Val Ala Leu Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln 120 Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Ile Thr Leu Pro Gln Asp Ala Val Ser Arg Thr Gln Arg Arg Gly Arg Thr Gly 155 150 Arg Gly Lys Pro Gly Ile Tyr Arg Phe Val Ala Pro Gly Glu Arg Pro Ser Gly <210> SEQ ID NO 31 <211> LENGTH: 957 <212> TYPE: DNA <213 > ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polynucleotide <400> SEQUENCE: 31 gctgttgact ttatcccggt tgaaaatctc gagactacta tgcgttctcc ggttttcact gacaactett eteegeeggt tgtteegeag tettteeagg ttgeteacet geatgeteeg 120 actgqttctq qtaaatctac taaaqttcca qctqcttacq ctqctcaqqq ttacaaaqtt 180 ctggttctga acccgtctgt tgctgctact ctgggtttcg gcgcctacat gtctaaagct 240 cacggtateg accegaacat tegtactggt gtacgtacta teactactgg tteteegate acttactcta cttacggtaa attcctggct gacggtggtt gctctggtgg tgcttacgat 360 atcatcatct gcgacgaatg ccactctact gacgctactt ctatcctggg tatcggtacc 420 qttctqqacc aqqctqaaac tqcaqqtqct cqtctqqttq ttctqqctac tqctactccq 480 ccgggttctg ttactgttcc gcacccgaac atcgaagaag ttgctctgtc gactactggt 540 qaaatcccqt tctacqqtaa aqctatcccq ctcqaqqtta tcaaaqqtqq tcqtcacctq

attttc	tgcc	actc	taaaa	aa aa	aaat	gcga	c gaa	actg	gctg	cta	agcti	tgt '	tgct	ctgggt	660
atcaac	gctg	ttgc	ttact	a co	egtg	gtct	g gad	gtti	ctg	ttai	taaa	gac ·	ttct	ggtgac	720
gttgtt	gttg	tggc	cacto	ga c	gata	tgat	g act	ggtt	caca	ctg	gtga	ctt (cgact	ctgtt	780
atcgat	tgca	acac	ttgcç	gt ta	actca	agaco	gta	agatt	tta	gcct	tgga	ecc (gacti	tcact	840
atcgaa	acga	tcac	cctg	ec go	cagg	atgca	a gtt	tcc	gta	ccca	agcgi	cg ·	tggc	egtacc	900
ggtcgc	ggca	aacc	gggta	at ti	tacc	gttt	gtg	ggcg	ccgg	gcga	agcgt	tcc .	atcc	ggt	957
	LENGT TYPE : ORGAN FEATU	H: 3: PRT IISM: IRE:	19 Art: ORMA:			-		n of	Art:	ific	ial :	Sequ	ence	: Synth	etic
<400>															
Ala Va 1	l Asp) Phe	Ile 5	Pro	Val	Glu	Asn	Leu 10	Glu	Thr	Thr	Met	Arg 15	Ser	
Pro Va	l Ph∈	Thr 20	Asp	Asn	Ser	Ser	Pro 25	Pro	Val	Val	Pro	Gln 30	Ser	Phe	
Gln Va	1 Ala 35	His	Leu	His	Ala	Pro 40	Thr	Gly	Ser	Gly	Lys 45	Ser	Thr	ГÀа	
Val Pr 50		Ala	Tyr	Ala	Ala 55	Gln	Gly	Tyr	Lys	Val 60	Leu	Val	Leu	Asn	
Pro Se	r Val	. Ala	Ala	Thr 70	Leu	Gly	Phe	Gly	Ala 75	Tyr	Met	Ser	Lys	Ala 80	
His Gl	y Ile	a Asp	Pro 85	Asn	Ile	Arg	Thr	Gly 90	Val	Arg	Thr	Ile	Thr 95	Thr	
Gly Se	r Pro	Ile 100		Tyr	Ser	Thr	Tyr 105	Gly	Lys	Phe	Leu	Ala 110	Asp	Gly	
Gly Cy	s Ser		Gly	Ala	Tyr	Asp 120	Ile	Ile	Ile	Cys	Asp 125	Glu	Сув	His	
Ser Th		Ala	Thr	Ser	Ile 135	Leu	Gly	Ile	Gly	Thr 140	Val	Leu	Asp	Gln	
Ala Gl 145	u Thi	Ala	Gly	Ala 150	Arg	Leu	Val	Val	Leu 155	Ala	Thr	Ala	Thr	Pro 160	
Pro Gl	y Sei		Thr 165	Val	Pro	His		Asn 170		Glu	Glu	Val	Ala 175	Leu	
Ser Th	r Thi	Gly 180	Glu	Ile	Pro	Phe	Tyr 185	Gly	Lys	Ala	Ile	Pro 190	Leu	Glu	
Val Il	e Lys 195		Gly	Arg	His	Leu 200	Ile	Phe	Cys	His	Ser 205	Lys	Lys	Lys	
Cys As	_	ı Leu	Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val	
Ala Ty 225	r Tyı	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240	
Val Va	l Val	. Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp	
Phe As	p Sei	Val 260	Ile	Asp	CAa	Asn	Thr 265	Сув	Val	Thr	Gln	Thr 270	Val	Asp	
Phe Se	r Leu 275	_	Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln	
Asp Al	a Val	. Ser	Arg	Thr	Gln	Arg	Arg	Gly	Arg	Thr	Gly	Arg	Gly	Lys	

	290					295					300					
Pro 305		Ile	Tyr	Arg	Phe 310	Val	Ala	Pro	Gly	Glu 315		Pro	Ser	Gly		
<211 <212 <213 <220	<pre><210> SEQ ID NO 33 <211> LENGTH: 675 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polynucleotide</pre>															
< 400	<400> SEQUENCE: 33 gctgttgact ttatcccggt tgaaaatctc gagactacta tgcgttctcc ggttttcact 60															
gct	gttga	act t	tato	cccg	gt to	gaaaa	itcto	gag	jacta	ıcta	tgcg	gttct	caa q	ggttt	tcac	t 60
gaca	aacto	ctt o	etgtt	tacto	ca ga	accgt	agat	ttt	agco	tgg	acco	egact	tt d	cacta	atcga	a 120
acga	atcad	ccc t	gee	gcago	ga to	gcagt	ttcc	c cgt	acco	agc	gtcg	gtggd	ccg t	tacco	ggtcg	c 180
ggca	aaaco	gg g	gtatt	taco	eg tt	tcgt	ggcg	g ccc	ggcg	jagc	gtco	catco	cgg t	tatgt	tcga	t 240
agct	cctgt	tc t	gtgt	gagt	g tt	atga	cgcg	g ggt	tgcg	ıcgt	ggta	acgaa	act ç	gacto	ccggc	t 300
gaaa	actac	ctg t	cacgo	ectgo	g to	gcata	cato	g aat	acgo	cgg	gtct	gccg	ggt g	gtgto	caaga	c 360
caco	ctgga	aat t	ttg	ggaag	gg to	gtett	tact	ggo	ctga	ccc	atat	cgad	ege a	acact	ttct	g 420
teed	cagao	cta a	aacaq	gtcto	gg to	gaaaa	ccts	g ccc	jtacc	tgg	tggd	gtat	ca a	agcca	actgt	g 480
tgc	geeeg	gtg (cgcaq	ggcgo	cc go	cacc	gago	tgg	gaco	aaa	tgtg	ggaag	gtg (cctga	atccg	t 540
ctga	aaaco	ga d	ccct	gcaco	gg to	cgac	gcca	a ctç	gctgt	acc	gcct	gggt	gc a	agtgo	cagaa	c 600
gaaa	atcad	ege t	gac	gcaco	ec gg	gtcac	taaa	a tac	atta	ıtga	ctto	gcato	gag d	cgcaç	gacct	g 660
gaag	gtggt	ga	cttco	2												675
	<210> SEQ ID NO 34 <211> LENGTH: 225 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide															
<212 <213 <220 <223	2 > T 3 > OF 0 > FF 3 > OT po	ENGTH PE: RGAN: EATUR THER DIYPE	H: 22 PRT ISM: RE: INF(∋ptic	25 Art: ORMA: de			-		ı of	Arti	ifici	ial S	Seque	ence:	: Syn	thetic
<212 <213 <220 <223	2 > TY 3 > OF 0 > FF 3 > OT po	ENGTH PE: RGAN: EATUR THER Olype	H: 22 PRT ISM: RE: INFO Pptic	Art: DRMA: de	rion :	: Des	crip	otion								thetic
<212 <213 <220 <223	2 > TY 3 > OF 0 > FF 3 > OT po	ENGTH PE: RGAN: EATUR THER Olype	H: 22 PRT ISM: RE: INFO Pptic	Art: DRMA: de	rion :		crip	otion								thetic
<212 <213 <220 <223 <400 Ala	2 > TY 3 > OP 0 > FF 3 > OY po 0 > SF Val	ENGTH (PE: RGAN: EATUH THER DIYPH EQUEN	H: 22 PRT ISM: RE: INFO Pptic	Art: DRMA: de 34 Ile 5	rion: Pro	: Des	- scri <u>r</u> Glu	otior Asn	Leu 10	Glu	Thr	Thr	Met	Arg 15	Ser	thetic
<212 <213 <220 <223 <400 Ala 1	2 > TY 3 > OF 0 > FF 3 > OT po 0 > SF Val	ENGTH (PE: RGANI EATUR THER Dlype EQUER Asp	H: 22 PRT ISM: RE: INFO Phe Thr 20	Art: DRMAT de 34 Ile 5 Asp	Pro Asn	Des	- scrip Glu Ser	Asn Val 25	Leu 10 Thr	Glu Gln	Thr Thr	Thr Val	Met Asp 30	Arg 15 Phe	Ser	thetic
<212 <213 <220 <223 <400 Ala 1 Pro	2> TY 3> OF 0> FF 3> OT po 0> SF Val Val	ENGTH (PE: RGANI EATUR THER OLYPO EQUER Asp Phe Pro 35	H: 22 PRT ISM: ISM: RE: INFO Phe Thr 20 Thr	Art: DRMAT de 34 Ile 5 Asp	Pro Asn Thr	Des Val Ser	Glu Ser Glu 40	Asn Val 25 Thr	Leu 10 Thr	Glu Gln Thr	Thr Thr Leu	Thr Val Pro 45	Met Asp 30	Arg 15 Phe Asp	Ser Ser Ala	thetic
<212 <213 <220 <223 <400 Ala 1 Pro Leu	22> TY 33> OF 33> OF po 20> SE Val Val Ser 50	ENGTHER CONTROL OF THE CONTROL OF TH	H: 22 PRT ISM: ISM: INF(eptic NCE: Phe Thr 20 Thr	Art: DRMA: 34 Ile 5 Asp Phe Gln	Pro Asn Thr	Val Ser Ile	Glu Ser Glu 40	Asn Val 25 Thr	Leu 10 Thr Ile	Glu Gln Thr	Thr Thr Leu Arg	Thr Val Pro 45 Gly	Met Asp 30 Gln Lys	Arg 15 Phe Asp	Ser Ser Ala	thetic
<212<213<222<4000 Ala 1 Pro Leu Val Ile 65	22> TY 33> OF 50> FF 50> SF Val Val Asp Ser 50	ENGTH (PE: GAN: CREATURE AND PHER CAUSE AND PHER Pro 35 Arg	H: 22 PRT ISM: ISM: ISM: INFC Eptic NCE: Phe Thr 20 Thr	Art: Art: Art: Art: Art: Art: Val	Pro Asn Thr Arg Ala 70	Val Ser Ile Arg	Glu Ser Glu 40 Gly	Asn Val 25 Thr Arg	Leu 10 Thr Ile Thr	Glu Gln Thr Gly Pro 75	Thr Leu Arg 60	Thr Val Pro 45 Gly	Met Asp 30 Gln Lys	Arg 15 Phe Asp Pro	Ser Ser Ala Gly Asp	thetic
<212<213 222</223</400 Ala 1 Pro Leu Val Ile 65 Ser</td <td>22> TY 33> OF 50> FI 33> OT pc Val Val Asp Ser 50</td> <td>ENGTH (PE:: CGAN: FHER clype CQUEI Asp Phe Pro 35 Arg Val</td> <td>H: 22 PRT ISM: RE: INF Phe Thr 20 Thr Thr Leu</td> <td>Art: DRMA: de 34 Ile 5 Asp Phe Gln Val Cys 85</td> <td>Pro Asn Thr Arg Ala 70 Glu</td> <td>Val Ser Ile Arg 55</td> <td>Glu Ser Glu 40 Gly Gly</td> <td>Asn Val 25 Thr Arg Glu Asp</td> <td>Leu 10 Thr Ile Thr Arg</td> <td>Glu Gln Thr Gly Pro 75 Gly</td> <td>Thr Leu Arg 60 Ser Cys</td> <td>Thr Val Pro 45 Gly Gly</td> <td>Met Asp 30 Gln Lys Met</td> <td>Arg 15 Phe Asp Pro Phe Tyr 95</td> <td>Ser Ser Ala Gly Asp 80 Glu</td> <td>thetic</td>	22> TY 33> OF 50> FI 33> OT pc Val Val Asp Ser 50	ENGTH (PE:: CGAN: FHER clype CQUEI Asp Phe Pro 35 Arg Val	H: 22 PRT ISM: RE: INF Phe Thr 20 Thr Thr Leu	Art: DRMA: de 34 Ile 5 Asp Phe Gln Val Cys 85	Pro Asn Thr Arg Ala 70 Glu	Val Ser Ile Arg 55	Glu Ser Glu 40 Gly Gly	Asn Val 25 Thr Arg Glu Asp	Leu 10 Thr Ile Thr Arg	Glu Gln Thr Gly Pro 75 Gly	Thr Leu Arg 60 Ser Cys	Thr Val Pro 45 Gly Gly	Met Asp 30 Gln Lys Met	Arg 15 Phe Asp Pro Phe Tyr 95	Ser Ser Ala Gly Asp 80 Glu	thetic
<212<213<220<223<4400 Ala 1 Pro Leu Val Ile 65 Ser Leu	22> Ty 3> OF Popular No. 10 Popular	ENGTH (PE: CARCALLINE PROPERTY OF THE PROPERTY	H: 22 PRT ISM: ISM: ISM: ISM: INFC Pptic Thr 20 Thr Thr Phe Leu Ala 100	Art: DRMA: de 34 Ile 5 Asp Phe Gln Val Cys 85 Glu	Pro Asn Thr Arg Ala 70 Glu Thr	Val Ser Ile Arg 55 Pro	Glu Ser Glu 40 Gly Gly Tyr	Asn Val 25 Thr Arg Glu Asp	Leu 10 Thr Ile Thr Arg Ala 90 Leu	Glu Gln Thr Gly Pro 75 Gly	Thr Leu Arg 60 Ser Cys	Thr Val Pro 45 Gly Gly Ala	Met Asp 30 Gln Lys Met Trp Met 110	Arg 15 Phe Asp Pro Phe Tyr 95 Asn	Ser Ser Ala Gly Asp 80 Glu Thr	thetic
<212<213<220<223<4400 Ala 1 Pro Leu Val Ile 65 Ser Leu Pro	22> TY 33> OF 50> FF 50> FF 50> SF 70> SF Val Val Val Val Tyr Thr	ENGTH (PE: (PE: (PE: (PE: (PE: (PE: (PE: (PE:	H: 22 PRT PRT PRT PRT PRT INFC PPT Thr Thr Phe Leu Ala 100 Pro	Art: Art: DRMA: 34 Ile 5 Asp Phe Gln Val Cys 85 Glu Val	Pro Asn Thr Arg Ala 70 Glu Thr Cys	Val Ser Ile Arg 55 Pro Cys	Glu Ser Glu 40 Gly Tyr Val Asp	Asn Val 25 Thr Arg Glu Asp Arg 105	Leu 10 Thr Ile Thr Arg Ala 90 Leu	Glu Gln Thr Gly Pro 75 Gly Arg	Thr Leu Arg 60 Ser Cys Ala	Thr Val Pro 45 Gly Gly Ala Tyr Trp 125	Met Asp 30 Gln Lys Met Trp Met 110 Glu	Arg 15 Phe Asp Pro Phe Tyr 95 Asn	Ser Ser Ala Gly Asp 80 Glu Thr	thetic

-continued

145 150 155 Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met Trp Lys 165 170 175 Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro Leu Leu 185 Tyr Arg Leu Gly Ala Val Gln Asn Glu Ile Thr Leu Thr His Pro Val Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val Val Thr 215 Ser 225 <210> SEQ ID NO 35 <211> LENGTH: 1401 <212> TYPE: DNA <213 > ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polynucleotide <400> SEQUENCE: 35 gctgttgact ttatcccggt tgaaaatctc gagactacta tgcgttctcc ggttttcact 60 gacaactett eteegeeggt tgtteegeag tettteeagg ttgeteacet geatgeteeg 120 actggttctg gtaactctac taaagttcca gctgcttacg ctgctcaggg ttacaaagtt 180 ctggttctga acccgtctgt tgctgctact ctgggtttcg gcgcctacat gtctaaagct 240 cacggtatcg accegaacat tegtactggt gtacgtacta teactactgg tteteegate 300 acttactcta cttacggtaa attcctggct gacggtggtt gctctggtgg tgcttacgat 360 atcatcatct gcgacgaatg ccactctact gacgctactt ctatcctggg tatcggtacc 420 gttctggacc aggctgaaac tgcaggtgct cgtctggttg ttctggctac tgctactccg 480 cogggttctg ttactgttcc gcacccgaac atcgaagaag ttgctctgtc gactactggt 540 gaaatcccgt tctacggtaa agctatcccg ctcgaggtta tcaaaggtgg tcgtcacctg 600 attttctgcc actctaaaaa aaaatgcgac gaactggctg ctaagcttgt tgctctgggt 660 atcaacgctg ttgcttacta ccgtggtctg gacgtttctg ttatcccgac ttctggtgac 720 gttgttgttg tggccactga cgctctgatg actggttaca ctggtgactt cgactctgtt 780 atcgattgca acacttgcgt tactcagacc gtagatttta gcctggaccc gactttcact 840 atogaaacga toaccotgoo goaggatgoa gtttocogta cocagogtog tggoogtaco 900 ggtcgcggca aaccgggtat ttaccgtttc gtggcgccgg gcgagcgtcc atccggtatg ttcgataget etgttetgtg tgagtgttat gaegegggtt gegegtggta egaactgaet ccggctgaaa ctactgtacg cctgcgtgca tacatgaata cgccgggtct gccggtgtgt 1080 caaqaccacc tqqaattttq qqaaqqtqtc tttactqqcc tqacccatat cqacqcacac 1140 tttctgtccc agactaaaca gtctggtgaa aacctgccgt acctggtggc gtatcaagcc 1200 actgtgtgcg cccgtgcgca ggcgccgcca ccgagctggg accaaatgtg gaagtgcctg atccgtctga aaccgaccct gcacggtccg acgccactgc tgtaccgcct gggtgcagtg 1320 cagaacgaaa tcacgctgac gcacccggtc actaaataca ttatgacttg catgagcgca 1380 1401 gacctggaag tggtgacttc c

<210> SEQ ID NO 36 <211> LENGTH: 467

-010 mV	ישת השת												
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic													
	HER INFO		N: De	scri	ption	n of	Art:	ific	ial :	Seque	ence	: Synthetic	
<400> SE	QUENCE :	36											
Ala Val 1	Asp Phe	Ile Pr 5	o Val	Glu	Asn	Leu 10	Glu	Thr	Thr	Met	Arg 15	Ser	
Pro Val	Phe Thr 20	Asp As	n Ser	Ser	Pro 25	Pro	Val	Val	Pro	Gln 30	Ser	Phe	
Gln Val	Ala His 35	Leu Hi	s Ala	Pro 40	Thr	Gly	Ser	Gly	Asn 45	Ser	Thr	ГЛа	
Val Pro 50	Ala Ala	Tyr Al	a Ala 55	Gln	Gly	Tyr	Lys	Val 60	Leu	Val	Leu	Asn	
Pro Ser 65	Val Ala	Ala Th	r Leu	Gly	Phe	Gly	Ala 75	Tyr	Met	Ser	Lys	Ala 80	
His Gly	Ile Asp	Pro As 85	n Ile	Arg	Thr	Gly 90	Val	Arg	Thr	Ile	Thr 95	Thr	
Gly Ser	Pro Ile 100	Thr Ty	r Ser	Thr	Tyr 105	Gly	Lys	Phe	Leu	Ala 110	Asp	Gly	
Gly Cha	Ser Gly 115	Gly Al	a Tyr	Asp 120	Ile	Ile	Ile	CAa	Asp 125	Glu	CAa	His	
Ser Thr 130	Asp Ala	Thr Se	r Ile 135	Leu	Gly	Ile	Gly	Thr 140	Val	Leu	Asp	Gln	
Ala Glu 145	Thr Ala	Gly Al 15		Leu	Val	Val	Leu 155	Ala	Thr	Ala	Thr	Pro 160	
Pro Gly	Ser Val	Thr Va 165	l Pro	His	Pro	Asn 170	Ile	Glu	Glu	Val	Ala 175	Leu	
Ser Thr	Thr Gly 180	Glu Il	e Pro	Phe	Tyr 185	Gly	Lys	Ala	Ile	Pro 190	Leu	Glu	
Val Ile	Lys Gly 195	Gly Ar	g His	Leu 200	Ile	Phe	Сув	His	Ser 205	Lys	Lys	Lys	
Cys Asp 210	Glu Leu	Ala Al	a Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val	
Ala Tyr 225	Tyr Arg	Gly Le 23		Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240	
Val Val	Val Val	Ala Th 245	r Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp	
Phe Asp	Ser Val 260	Ile As	b CAa	Asn	Thr 265	CAa	Val	Thr	Gln	Thr 270	Val	Aap	
Phe Ser	Leu Asp 275	Pro Th	r Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln	
Asp Ala 290	Val Ser	Arg Th	r Gln 295	Arg	Arg	Gly	Arg	Thr 300	Gly	Arg	Gly	Lys	
Pro Gly 305	Ile Tyr	Arg Ph		Ala	Pro	Gly	Glu 315	Arg	Pro	Ser	Gly	Met 320	
Phe Asp	Ser Ser	Val Le 325	u Cys	Glu	Cys	Tyr 330	Asp	Ala	Gly	Cys	Ala 335	Trp	
Tyr Glu	Leu Thr 340	Pro Al	a Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met	
Asn Thr	Pro Gly 355	Leu Pr	o Val	GAa	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu	
Gly Val 370	Phe Thr	Gly Le	u Thr 375	His	Ile	Asp	Ala	His 380	Phe	Leu	Ser	Gln	

-continued

Thr Lys Gln Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Ile Thr Leu Thr His Pro Val Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val Val Thr Ser <210> SEQ ID NO 37 <211> LENGTH: 1401 <212> TYPE: DNA <213 > ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polynucleotide <400> SEQUENCE: 37 qctqttqact ttatcccqqt tqaaaatctc qaqactacta tqcqttctcc qqttttcact 60 qacaactett eteeqeeqqt tqtteeqeaq tettteeaqq ttqcteacet qeatqcteeq 120 actggttctg gtaaagcgac taaagttcca gctgcttacg ctgctcaggg ttacaaagtt 180 ctggttctga acccgtctgt tgctgctact ctgggtttcg gcgcctacat gtctaaagct 240 cacggtatcg accegaacat tegtactggt gtacgtacta teactactgg tteteegate 300 acttactcta cttacggtaa attcctggct gacggtggtt gctctggtgg tgcttacgat 360 atcatcatct gegacgaatg ccactctact gacgctactt ctatcctggg tateggtacc 420 gttctggacc aggctgaaac tgcaggtgct cgtctggttg ttctggctac tgctactccg 480 ccgggttctg ttactgttcc gcacccgaac atcgaagaag ttgctctgtc gactactggt 540 gaaatcccgt tctacggtaa agctatcccg ctcgaggtta tcaaaggtgg tcgtcacctg 600 attttctgcc actctaaaaa aaaatgcgac gaactggctg ctaagcttgt tgctctgggt 660 atcaacgctg ttgcttacta ccgtggtctg gacgtttctg ttatcccgac ttctggtgac 720 gttgttgttg tggccactga cgctctgatg actggttaca ctggtgactt cgactctgtt 780 atcgattgca acacttgcgt tactcagacc gtagatttta gcctggaccc gactttcact 840 atogaaacga toaccotgoo goaggatgoa gtttocogta cocagogtog tggoogtaco ggtcgcggca aaccgggtat ttaccgtttc gtggcgccgg gcgagcgtcc atccggtatg ttegataget etgttetgtg tgagtgttat gaegegggtt gegegtggta egaactgaet 1020 1080 ccqqctqaaa ctactqtacq cctqcqtqca tacatqaata cqccqqqtct qccqqtqtqt caagaccacc tggaattttg ggaaggtgtc tttactggcc tgacccatat cgacgcacac 1140 tttctgtccc agactaaaca gtctggtgaa aacctgccgt acctggtggc gtatcaagcc actgtgtgcg cccgtgcgca ggcgccgcca ccgagctggg accaaatgtg gaagtgcctg 1260 atccgtctga aaccgaccct gcacggtccg acgccactgc tgtaccgcct gggtgcagtg 1320 1380 caqaacqaaa tcacqctqac qcacccqqtc actaaataca ttatqacttq catqaqcqca gacctggaag tggtgacttc c 1401

<211 <212 <213 <220	<210> SEQ ID NO 38 <211> LENGTH: 467 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide														
< 400)> SI	EQUE	ICE :	38											
Ala 1	Val	Asp	Phe	Ile 5	Pro	Val	Glu	Asn	Leu 10	Glu	Thr	Thr	Met	Arg 15	Ser
Pro	Val	Phe	Thr 20	Asp	Asn	Ser	Ser	Pro 25	Pro	Val	Val	Pro	Gln 30	Ser	Phe
Gln	Val	Ala 35	His	Leu	His	Ala	Pro 40	Thr	Gly	Ser	Gly	Lys 45	Ala	Thr	Lys
Val	Pro 50	Ala	Ala	Tyr	Ala	Ala 55	Gln	Gly	Tyr	Lys	Val 60	Leu	Val	Leu	Asn
Pro 65	Ser	Val	Ala	Ala	Thr 70	Leu	Gly	Phe	Gly	Ala 75	Tyr	Met	Ser	Tàa	Ala 80
His	Gly	Ile	Asp	Pro 85	Asn	Ile	Arg	Thr	Gly 90	Val	Arg	Thr	Ile	Thr 95	Thr
Gly	Ser	Pro	Ile 100	Thr	Tyr	Ser	Thr	Tyr 105	Gly	Lys	Phe	Leu	Ala 110	Asp	Gly
Gly	Сув	Ser 115	Gly	Gly	Ala	Tyr	Asp 120	Ile	Ile	Ile	Cys	Asp 125	Glu	Cys	His
Ser	Thr 130	Asp	Ala	Thr	Ser	Ile 135	Leu	Gly	Ile	Gly	Thr 140	Val	Leu	Asp	Gln
Ala 145	Glu	Thr	Ala	Gly	Ala 150	Arg	Leu	Val	Val	Leu 155	Ala	Thr	Ala	Thr	Pro 160
Pro	Gly	Ser	Val	Thr 165	Val	Pro	His	Pro	Asn 170	Ile	Glu	Glu	Val	Ala 175	Leu
Ser	Thr	Thr	Gly 180	Glu	Ile	Pro	Phe	Tyr 185	Gly	Lys	Ala	Ile	Pro 190	Leu	Glu
Val	Ile	Lys 195	Gly	Gly	Arg	His	Leu 200	Ile	Phe	Cys	His	Ser 205	Lys	Lys	Lys
CÀa	Asp 210	Glu	Leu	Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val
Ala 225	Tyr	Tyr	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240
Val	Val	Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp
Phe	Asp	Ser	Val 260	Ile	Asp	CÀa	Asn	Thr 265	СЛа	Val	Thr	Gln	Thr 270	Val	Asp
Phe	Ser	Leu 275	Asp	Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln
Asp	Ala 290	Val	Ser	Arg	Thr	Gln 295	Arg	Arg	Gly	Arg	Thr 300	Gly	Arg	Gly	Lys
Pro 305	Gly	Ile	Tyr	Arg	Phe 310	Val	Ala	Pro	Gly	Glu 315	Arg	Pro	Ser	Gly	Met 320
Phe	Asp	Ser	Ser	Val 325	Leu	Сув	Glu	Cys	Tyr 330	Asp	Ala	Gly	Сув	Ala 335	Trp
Tyr	Glu	Leu	Thr 340	Pro	Ala	Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met
Asn	Thr	Pro 355	Gly	Leu	Pro	Val	360 CAa	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu

-continued

Gly Val Phe Thr Gly Leu Thr His Ile Asp Ala His Phe Leu Ser Gln 370 375 Thr Lys Gln Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Ile Thr Leu Thr His Pro Val Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val Val Thr Ser <210> SEQ ID NO 39 <211> LENGTH: 1401 <212> TYPE: DNA <213 > ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polvnucleotide <400> SEQUENCE: 39 getgttgact ttatcccggt tgaaaatctc gagactacta tgcgttctcc ggttttcact 60 gacaactett eteegeeggt tgtteegeag tettteeagg ttgeteacet geatgeteeg 120 actggttctg gtaaatctga gaaagttcca gctgcttacg ctgctcaggg ttacaaagtt 180 ctggttctga acccgtctgt tgctgctact ctgggtttcg gcgcctacat gtctaaagct 240 cacggtatcg acccgaacat tcgtactggt gtacgtacta tcactactgg ttctccgatc 300 acttactcta cttacggtaa attcctggct gacggtggtt gctctggtgg tgcttacgat 360 atcatcatct gegacgaatg ccactctact gacgctactt ctatcctggg tatcggtacc 420 gttctggacc aggctgaaac tgcaggtgct cgtctggttg ttctggctac tgctactccg 480 ccgggttctg ttactgttcc gcacccgaac atcgaagaag ttgctctgtc gactactggt 540 gaaatcccgt tctacggtaa agctatcccg ctcgaggtta tcaaaggtgg tcgtcacctg 600 attttctgcc actctaaaaa aaaatgcgac gaactggctg ctaagcttgt tgctctgggt 660 atcaacgctg ttgcttacta ccgtggtctg gacgtttctg ttatcccgac ttctggtgac 720 gttgttgttg tggccactga cgctctgatg actggttaca ctggtgactt cgactctgtt 780 atcgattgca acacttgcgt tactcagacc gtagatttta gcctggaccc gactttcact atogaaacga toaccotgoo goaggatgoa gtttocogta cocagogtog tggoogtaco ggtcgcggca aaccgggtat ttaccgtttc gtggcgccgg gcgagcgtcc atccggtatg 960 ttogatagot otgitotgig igagigitat gaogoggit gogogiggia ogaacigaci 1020 ccggctgaaa ctactgtacg cctgcgtgca tacatgaata cgccgggtct gccggtgtgt 1080 caagaccacc tggaattttg ggaaggtgtc tttactggcc tgacccatat cgacgcacac tttctgtccc agactaaaca gtctggtgaa aacctgccgt acctggtggc gtatcaagcc 1200 actgtgtgcg cccgtgcgca ggcgccgcca ccgagctggg accaaatgtg gaagtgcctg 1260 atccgtctga aaccgaccct gcacggtccg acgccactgc tgtaccgcct gggtgcagtg 1320 cagaacgaaa tcacgctgac gcacccggtc actaaataca ttatgacttg catgagcgca 1380 gacctggaag tggtgacttc c 1401

<210> SEQ ID NO 40 <211> LENGTH: 467 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide														
<400> SEQUENCE: 40														
Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1 5 10 15														
Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe 20 25 30														
Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Glu Lys 35 40 45														
Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn 50 55 60														
Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala 65 70 75 80														
His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr 85 90 95														
Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly 100 105 110														
Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His 115 120 125														
Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln 130 135 140														
Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro 145 150 155 160														
Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu 165 170 175														
Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu 180 185 190														
Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys 195 200 205														
Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 210 215 220														
Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp 225 230 235 240														
Val Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp 245 250 255														
Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp 260 265 270														
Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Ile Thr Leu Pro Gln 275 280 285														
Asp Ala Val Ser Arg Thr Gln Arg Arg Gly Arg Thr Gly Arg Gly Lys 290 295 300														
Pro Gly Ile Tyr Arg Phe Val Ala Pro Gly Glu Arg Pro Ser Gly Met 305 310 315 320														
Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala Gly Cys Ala Trp 325 330 335														
Tyr Glu Leu Thr Pro Ala Glu Thr Thr Val Arg Leu Arg Ala Tyr Met 340 345 350														
Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu Glu Phe Trp Glu														

-continued

-continued														
355 360 365														
Gly Val Phe Thr Gly Leu Thr His Ile Asp Ala His Phe Leu Ser Gln 370 375 380														
Thr Lys Gln Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr Gln Ala 385 390 395 400														
Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met 405 410 415														
Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro 420 425 430														
Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Ile Thr Leu Thr His 435 440 445														
Pro Val Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val 450 455 460														
Val Thr Ser 465														
<210> SEQ ID NO 41 <211> LENGTH: 1401 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polynucleotide <400> SEQUENCE: 41														
qctqttqact ttatcccqqt tqaaaatctc qaqactacta tqcqttctcc qqttttcact	60													
gacaactett eteegeeggt tgtteegeag tettteeagg ttgeteacet geatgeteeg	120													
actggttctg gtaaatctac taaagttcca gctgcttacg ctgctcaggg ttacaaagtt	180													
ctggttctga accegtctgt tgctgctact ctgggtttcg gegecageat gtctaaaget	240													
cacggtatcg accegaacat tegtactggt gtacgtacta teactactgg ttetecgate	300													
acttactcta cttacggtaa attcctggct gacggtggtt gctctggtgg tgcttacgat	360													
atcatcatct gcgacgaatg ccactctact gacgctactt ctatcctggg tatcggtacc	420													
gttctggacc aggctgaaac tgcaggtgct cgtctggttg ttctggctac tgctactccg	480													
ccgggttctg ttactgttcc gcacccgaac atcgaagaag ttgctctgtc gactactggt	540													
gaaatcccgt tctacggtaa agctatcccg ctcgaggtta tcaaaggtgg tcgtcacctg	600													
attttctgcc actctaaaaa aaaatgcgac gaactggctg ctaagcttgt tgctctgggt	660													
atcaacgctg ttgcttacta ccgtggtctg gacgtttctg ttatcccgac ttctggtgac	720													
gttgttgttg tggccactga cgctctgatg actggttaca ctggtgactt cgactctgtt	780													
ategattgea acaettgegt taeteagace gtagatttta geetggacee gaettteaet	840													
ategaaaega teaccetgee geaggatgea gttteeegta eecagegteg tggeegtaee	900													
ggtcgcggca aaccgggtat ttaccgtttc gtggcgccgg gcgagcgtcc atccggtatg	960													
ttcgatagct ctgttctgtg tgagtgttat gacgcgggtt gcgcgtggta cgaactgact 1	020													
ccggctgaaa ctactgtacg cctgcgtgca tacatgaata cgccgggtct gccggtgtgt 1	080													
caagaccacc tggaattttg ggaaggtgtc tttactggcc tgacccatat cgacgcacac 1	140													
tttctgtccc agactaaaca gtctggtgaa aacctgccgt acctggtggc gtatcaagcc 1	200													
actgtgtgcg cccgtgcgca ggcgccgcca ccgagctggg accaaatgtg gaagtgcctg 1	260													

atccgtctga aaccgaccct gcacggtccg acgccactgc tgtaccgcct gggtgcagtg

cagaacgaaa tcacgctgac gcacccggtc actaaataca ttatgacttg catgagegca

1320

1380

125 126

-continued

gacctggaag tggtgacttc c <210> SEQ ID NO 42 <211> LENGTH: 467 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 42 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Ser Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His 120 Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln 135 Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro 150 155 Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu 185 Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Ile Thr Leu Pro Gln 280 Asp Ala Val Ser Arg Thr Gln Arg Arg Gly Arg Thr Gly Arg Gly Lys 295 Pro Gly Ile Tyr Arg Phe Val Ala Pro Gly Glu Arg Pro Ser Gly Met 310 Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala Gly Cys Ala Trp 330 Tyr Glu Leu Thr Pro Ala Glu Thr Thr Val Arg Leu Arg Ala Tyr Met 345

-continued

Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu Glu Phe Trp Glu Gly Val Phe Thr Gly Leu Thr His Ile Asp Ala His Phe Leu Ser Gln 370 Thr Lys Gln Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Ile Thr Leu Thr His Pro Val Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val Val Thr Ser 465 <210> SEQ ID NO 43 <211> LENGTH: 1401 <212> TYPE: DNA <213 > ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polynucleotide <400> SEQUENCE: 43 gctgttgact ttatcccggt tgaaaatctc gagactacta tgcgttctcc ggttttcact 60 gacaactett eteegeeggt tgtteegeag tettteeagg ttgeteacet geatgeteeg 120 actggttctg gtaaatctac taaagttcca gctgcttacg ctgctcaggg ttacaaagtt 180 ctggttctga accegtctgt tgctgctact ctgggtttcg gcgcctacat gtctaaagct 240 cacggtateg accegaacat tegtactggt gtacgtacta teactactgg tteteegate 300 acttactcta cttacggtaa attcctggct gacggtggtt gctctggtgg tgcttacgat 360 atcatcatct gcaacgaatg ccactctact gacgctactt ctatcctggg tatcggtacc 420 gttetggace aggetgaaac tgeaggtget egtetggttg ttetggetae tgetaeteeg 480 cogggttctg ttactgttcc gcacccgaac atcgaagaag ttgctctgtc gactactggt 540 gaaatcccgt tctacggtaa agctatcccg ctcgaggtta tcaaaggtgg tcgtcacctg 600 attttctgcc actctaaaaa aaaatgcgac gaactggctg ctaagcttgt tgctctgggt 660 atcaacgctg ttgcttacta ccgtggtctg gacgtttctg ttatcccgac ttctggtgac gttgttgttg tggccactga cgctctgatg actggttaca ctggtgactt cgactctgtt ategattgca acaettgcgt tactcagacc gtagatttta gcctggaccc gactttcact 840 900 ategaaacga teaccetqee qeaqqatqea qtttcccqta cecaqcqteq tqqccqtace ggtcgcggca aaccgggtat ttaccgtttc gtggcgccgg gcgagcgtcc atccggtatg 960 ttcgataget etgttetgtg tgagtgttat gaegegggtt gegegtggta egaactgaet ccggctgaaa ctactgtacg cctgcgtgca tacatgaata cgccgggtct gccggtgtgt 1080 caagaccacc tggaattttg ggaaggtgtc tttactggcc tgacccatat cgacgcacac 1140 tttctqtccc aqactaaaca qtctqqtqaa aacctqccqt acctqqtqqc qtatcaaqcc 1200 actgtgtgcg cccgtgcgca ggcgccgcca ccgagctggg accaaatgtg gaagtgcctg 1260 atcoqtctqa aaccqaccct qcacqqtccq acqccactqc tqtaccqcct qqqtqcaqtq

-continued

cagaacgaaa tcacgctgac gcacccggtc actaaataca ttatgacttg catgagcgca 1380 gacctggaag tggtgacttc c 1401 <210> SEQ ID NO 44 <211> LENGTH: 467 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 44 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn 55 Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala 65 70 75 80 His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly 105 Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asn Glu Cys His 120 Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro 155 Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp 265 Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Ile Thr Leu Pro Gln 280 Asp Ala Val Ser Arg Thr Gln Arg Arg Gly Arg Thr Gly Arg Gly Lys Pro Gly Ile Tyr Arg Phe Val Ala Pro Gly Glu Arg Pro Ser Gly Met 310 315 Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala Gly Cys Ala Trp 325

-continued

Tyr Glu Leu Thr Pro Ala Glu Thr Thr Val Arg Leu Arg Ala Tyr Met 340 Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu Glu Phe Trp Glu Gly Val Phe Thr Gly Leu Thr His Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Ile Thr Leu Thr His Pro Val Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val Val Thr Ser 465 <210> SEQ ID NO 45 <211> LENGTH: 1401 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polynucleotide <400> SEQUENCE: 45 gctgttgact ttatcccggt tgaaaatctc gagactacta tgcgttctcc ggttttcact 60 gacaactett eteegeeggt tgtteegeag tettteeagg ttgeteacet geatgeteeg 120 actggttctg gtaaatctac taaagttcca gctgcttacg ctgctcaggg ttacaaagtt 180 ctggttctga accegtctgt tgctgctact ctgggtttcg gegcctacat gtctaaagct 240 cacggtatcg acccgaacat tcgtactggt gtacgtacta tcactactgg ttctccgatc 300 acttactcta cttacggtaa attcctggct gacggtggtt gctctggtgg tgcttacgat 360 atcatcatct gcgaccagtg ccactctact gacgctactt ctatcctggg tatcggtacc 420 gttetggace aggetgaaac tgeaggtget egtetggttg ttetggetae tgetaeteeg 480 ccgggttctg ttactgttcc gcacccgaac atcgaagaag ttgctctgtc gactactggt gaaatcccgt tctacggtaa agctatcccg ctcgaggtta tcaaaggtgg tcgtcacctg attttctgcc actctaaaaa aaaatgcgac gaactggctg ctaagcttgt tgctctgggt atcaacgctg ttgcttacta ccgtggtctg gacgtttctg ttatcccgac ttctggtgac gttgttgttg tggccactga cgctctgatg actggttaca ctggtgactt cgactctgtt 780 840 ategattqca acaettqcqt tactcaqacc qtaqatttta qcctqqaccc qactttcact ategaaaega teaccetgee geaggatgea gttteeegta eeeagegteg tggeegtace 900 ggtcgcggca aaccgggtat ttaccgtttc gtggcgccgg gcgagcgtcc atccggtatg ttcgatagct ctgttctgtg tgagtgttat gacgcgggtt gcgcgtggta cgaactgact 1020 ccggctgaaa ctactgtacg cctgcgtgca tacatgaata cgccgggtct gccggtgtgt 1080 caagaccacc tggaattttg ggaaggtgtc tttactggcc tgacccatat cgacgcacac 1140 tttctgtccc agactaaaca gtctggtgaa aacctgccgt acctggtggc gtatcaagcc 1200

actgtgtgcg cccgtgcgca ggcgccgcca ccgagctggg accaaatgtg gaagtgcctg

																	_
atccg	tct	ga a	acc	gacco	ct go	cacg	gtac	g ac	gcca	ctgc	tgta	accg	cct q	gggtg	gcagtg	132	0
cagaa	cga	aa t	cacç	gctga	ac go	cacco	cggt	c act	caaat	caca	ttai	gac	ttg (catga	agcgca	138	0
gacct	gacctggaag tggtgacttc c 1401																
<211><212><213><220>	<210> SEQ ID NO 46 <211> LENGTH: 467 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 46																
<400>	SE	QUEN	ICE :	46													
Ala V 1	al.	Asp	Phe	Ile 5	Pro	Val	Glu	Asn	Leu 10	Glu	Thr	Thr	Met	Arg 15	Ser		
Pro V	al	Phe	Thr 20	Asp	Asn	Ser	Ser	Pro 25	Pro	Val	Val	Pro	Gln 30	Ser	Phe		
Gln V		Ala 35	His	Leu	His	Ala	Pro 40	Thr	Gly	Ser	Gly	Lуs 45	Ser	Thr	Lys		
Val P	ro 0	Ala	Ala	Tyr	Ala	Ala 55	Gln	Gly	Tyr	Lys	Val 60	Leu	Val	Leu	Asn		
Pro S 65	er	Val	Ala	Ala	Thr 70	Leu	Gly	Phe	Gly	Ala 75	Tyr	Met	Ser	Lys	Ala 80		
His G	ly	Ile	Asp	Pro 85	Asn	Ile	Arg	Thr	Gly 90	Val	Arg	Thr	Ile	Thr 95	Thr		
Gly S	er	Pro	Ile 100	Thr	Tyr	Ser	Thr	Tyr 105	Gly	Lys	Phe	Leu	Ala 110	Asp	Gly		
Gly C		Ser 115	Gly	Gly	Ala	Tyr	Asp 120	Ile	Ile	Ile	CAa	Asp 125	Gln	CAa	His		
Ser T	hr .	Asp	Ala	Thr	Ser	Ile 135	Leu	Gly	Ile	Gly	Thr 140	Val	Leu	Asp	Gln		
Ala G 145	lu	Thr	Ala	Gly	Ala 150	Arg	Leu	Val	Val	Leu 155	Ala	Thr	Ala	Thr	Pro 160		
Pro G	ly	Ser	Val	Thr 165	Val	Pro	His	Pro	Asn 170	Ile	Glu	Glu	Val	Ala 175	Leu		
Ser T	'hr	Thr	Gly 180	Glu	Ile	Pro	Phe	Tyr 185	Gly	Lys	Ala	Ile	Pro 190	Leu	Glu		
Val I		Lys 195		Gly			Leu 200		Phe	Cys		Ser 205		Lys	Lys		
Cys A	sp 10	Glu	Leu	Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val		
Ala T 225	yr	Tyr	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240		
Val V	al '	Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Aap		
Phe A	ap	Ser	Val 260	Ile	Asp	Сув	Asn	Thr 265	Суз	Val	Thr	Gln	Thr 270	Val	Asp		
Phe S		Leu 275	Asp	Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln		
Asp A	la 90	Val	Ser	Arg	Thr	Gln 295	Arg	Arg	Gly	Arg	Thr	Gly	Arg	Gly	Lys		
Pro G	ly	Ile	Tyr	Arg	Phe 310	Val	Ala	Pro	Gly	Glu 315	Arg	Pro	Ser	Gly	Met 320		
Phe A	ap	Ser	Ser	Val	Leu	Cys	Glu	Cys	Tyr	Asp	Ala	Gly	Cys	Ala	Trp		

-continued

325 330 Tyr Glu Leu Thr Pro Ala Glu Thr Thr Val Arg Leu Arg Ala Tyr Met 340 345 Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu Glu Phe Trp Glu 360 Gly Val Phe Thr Gly Leu Thr His Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Ile Thr Leu Thr His Pro Val Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val 455 450 Val Thr Ser 465 <210> SEO ID NO 47 <211> LENGTH: 1401 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polynucleotide <400> SEQUENCE: 47 getgttgact ttateceggt tgaaaatete gagactacta tgegttetee ggtttteact 60 gacaactett eteegeeggt tgtteegeag tettteeagg ttgeteacet geatgeteeg 120 actggttctg gtaaatctac taaagttcca gctgcttacg ctgctcaggg ttacaaagtt 180 ctggttctga acccgtctgt tgctgctact ctgggtttcg gcgcctacat gtctaaagct 240 cacggtatcg acccgaacat tcgtactggt gtacgtacta tcactactgg ttctccgatc 300 acttactcta cttacggtaa attcctggct gacggtggtt gctctggtgg tgcttacgat 360 atcatcatct gcgacgaaag ccactctact gacgctactt ctatcctggg tatcggtacc 420 gttctggacc aggctgaaac tgcaggtgct cgtctggttg ttctggctac tgctactccg ccgggttctg ttactgttcc gcacccgaac atcgaagaag ttgctctgtc gactactggt gaaatcccgt tctacggtaa agctatcccg ctcgaggtta tcaaaggtgg tcgtcacctg attttctgcc actctaaaaa aaaatgcgac gaactggctg ctaagcttgt tgctctgggt atcaacgctg ttgcttacta ccgtggtctg gacgtttctg ttatcccgac ttctggtgac 720 780 qttqttqttq tqqccactqa cqctctqatq actqqttaca ctqqtqactt cqactctqtt ategattgca acaettgcgt tactcagace gtagatttta geetggacee gaettteact 840 atogaaacga toaccotgoo goaggatgoa gtttocogta cocagogtog tggoogtaco ggtcgcggca aaccgggtat ttaccgtttc gtggcgccgg gcgagcgtcc atccggtatg 960 ttcgatagct ctgttctgtg tgagtgttat gacgcgggtt gcgcgtggta cgaactgact 1020 ccqqctqaaa ctactqtacq cctqcqtqca tacatqaata cqccqqqtct qccqqtqtqt 1080 caagaccacc tggaattttg ggaaggtgtc tttactggcc tgacccatat cgacgcacac 1140

tttctqtccc aqactaaaca qtctqqtqaa aacctqccqt acctqqtqqc qtatcaaqcc

1200

-continued

actgtgtgcg cccgtgcgca ggcgccgcca ccgagctggg accaaatgtg gaagtgcctg atcogtotga aaccgaccot gcacggtocg acgccactgo tgtaccgcot gggtgcagtg cagaacgaaa tcacgctgac gcacccggtc actaaataca ttatgacttg catgagcgca 1401 gacctggaag tggtgacttc c <210> SEQ ID NO 48 <211> LENGTH: 467 <212> TYPE: PRT <213 > ORGANISM: Artificial Sequence <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 48 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala 65 70 75 80 His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly 105 Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Ser His 120 Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro 150 155 Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp 265 Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Ile Thr Leu Pro Gln 280 Asp Ala Val Ser Arg Thr Gln Arg Arg Gly Arg Thr Gly Arg Gly Lys 295 300 Pro Gly Ile Tyr Arg Phe Val Ala Pro Gly Glu Arg Pro Ser Gly Met 310 315

Phe	Asp	Ser	Ser	Val 325	Leu	CAa	Glu	Cys	Tyr 330	Asp	Ala	Gly	Cys	Ala 335	Trp	
Tyr	Glu	Leu	Thr 340	Pro	Ala	Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met	
Asn	Thr	Pro 355	Gly	Leu	Pro	Val	Cys 360	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu	
Gly	Val 370	Phe	Thr	Gly	Leu	Thr 375	His	Ile	Asp	Ala	His 380	Phe	Leu	Ser	Gln	
Thr 385	Lys	Gln	Ser	Gly	Glu 390	Asn	Leu	Pro	Tyr	Leu 395	Val	Ala	Tyr	Gln	Ala 400	
Thr	Val	CÀa	Ala	Arg 405	Ala	Gln	Ala	Pro	Pro 410	Pro	Ser	Trp	Asp	Gln 415	Met	
Trp	Lys	СЛа	Leu 420	Ile	Arg	Leu	Lys	Pro 425	Thr	Leu	His	Gly	Pro 430	Thr	Pro	
Leu	Leu	Tyr 435	Arg	Leu	Gly	Ala	Val	Gln	Asn	Glu	Ile	Thr 445	Leu	Thr	His	
Pro	Val 450	Thr	Lys	Tyr	Ile	Met 455	Thr	Cys	Met	Ser	Ala 460	Asp	Leu	Glu	Val	
Val 465	Thr	Ser														
-210	ı CE	70 TI	OM C	40												
<210> SEQ ID NO 49 <211> LENGTH: 1401 <212> TYPE: DNA																
<pre><212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:</pre>																
	s> 01	THER	INF	ORMA'		: De	scrip	tion	n of	Art:	ific	ial s	Sequ	ence	Synt	hetic
< 400	-	-	NCE :													
gcto	ıttga	act 1	ttat	cccg	gt t	gaaa	atcto	gaç	gacta	acta	tgc	gttct	taa q	ggttt	tcact	: 60
gaca	acto	ctt «	ctcc	gccg	gt t	gttc	cgcag	j tct	ttc	cagg	ttg	ctcac	ect (gcate	geteeg	120
acto	gtto	ctg (gtaa	atcta	ac t	aaagi	tcca	ı gct	gctt	acg	ctg	ctcaç	999	ttaca	aagtt	180
ctgg	jttct	ga a	accc	gtct	gt t	gctg	ctact	ctg	gggtt	tcg	gcg	ctac	cat (gtcta	aagct	240
caco	ıgtat	cg a	accc	gaaca	at t	cgta	ctggt	gta	acgta	acta	tcad	ctact	gg :	ttct	cgato	300
actt	acto	cta (ctta	eggta	aa a	ttcci	ggct	gad	ggtg	ggtt	gcto	etggt	gg ·	tgctt	acgat	360
atca	tcat	ct (gcga	cgaat	tg c	gcct	ctact	gad	egeta	actt	ctat	cct	999	tatco	ggtaco	: 420
gtto	tgga	acc a	aggci	tgaaa	ac t	gcag	gtgct	: cgt	ctg	gttg	ttct	ggct	tac '	tgcta	actccc	4 80
ccgc	gtto	ctg 1	ttacı	gtt	cc g	cacc	cgaac	ato	gaag	gaag	ttg	ctctq	gtc	gacta	ectggt	540
gaaa	tccc	gt 1	tcta	eggta	aa a	gcta	caag	g cto	gagg	gtta	tcaa	aaggt	gg ·	tcgt	caccto	j 600
attt	tcts	gcc a	actci	taaa	aa a	aaat	gcgac	gaa	actgo	gctg	ctaa	agctt	tgt '	tgct	tgggt	660
atca	acgo	ctg 1	ttga	ttaci	ta c	cgtg	gtete	g gad	gttt	ctg	ttat	caaq	gac	ttctç	ggtgad	720
gttg	ıttgt	tg 1	tggc	cact	ga c	gete	gatg	g act	ggtt	aca	ctg	gtgad	ctt (cgact	ctgtt	780
atco	gatto	gca a	acact	ttgc	gt t	actc	agaco	gta	agatt	tta	gcct	ggad	ccc (gactt	tcact	840
atco	jaaac	ega 1	tcac	cctg	ee g	cagg	atgca	gtt	tec	gta	ccca	agcgt	teg :	tggc	gtaco	900
ggto	gege	gca a	aacc	gggta	at t	tacc	gtttc	gtg	ggcgo	ccgg	gcga	agcgt	tcc .	atcc	ggtato	960
ttcg	jatag	gct (ctgti	tatgi	tq t	gagt	gttat	gad	gegg	ggtt	gcg	gtgg	gta :	cqaa	rtaact	1020
					_								_	_	regue	
ccgg	ıctga	aaa «	ctaci				gtgca	ı tad	catga		cgc				gtgtgt	
				tgta	eg e	ctgc				aata		egggt	tet (geeg		1080

ttt	ctgto	ccc a	agact	caaac	ca gt	ctg	gtgaa	a aad	cctgo	ccgt	acct	ggt	ggc (gtato	caagcc	1200
acto	gtgtç	geg d	ccgt	gcg	ca go	geged	egeca	a cc	gaget	ggg	acca	aaat	gtg (gaagt	gcctg	1260
atco	egtet	ga a	acco	gacco	ct go	cacgo	gtaco	g aco	gccad	ctgc	tgta	accg	cct (gggtg	gcagtg	1320
caga	aacga	aaa t	cacç	gctga	ac go	cacco	eggto	act	aaat	aca	ttat	gact	ttg (catga	agcgca	1380
gaco	tgga	aag t	ggtg	gactt	c c											1401
<211 <212 <213 <220		ENGTH (PE : RGAN) EATUR	H: 46 PRT ISM: RE: INFO	57 Art: DRMA:			-		n of	Arti	ific	ial :	Seque	ence:	: Synthe	etic
< 400)> SE	EQUE	ICE :	50												
Ala 1	Val	Asp	Phe	Ile 5	Pro	Val	Glu	Asn	Leu 10	Glu	Thr	Thr	Met	Arg 15	Ser	
Pro	Val	Phe	Thr 20	Asp	Asn	Ser	Ser	Pro 25	Pro	Val	Val	Pro	Gln 30	Ser	Phe	
Gln	Val	Ala 35	His	Leu	His	Ala	Pro 40	Thr	Gly	Ser	Gly	Lys 45	Ser	Thr	Lys	
Val	Pro 50	Ala	Ala	Tyr	Ala	Ala 55	Gln	Gly	Tyr	Lys	Val 60	Leu	Val	Leu	Asn	
Pro 65	Ser	Val	Ala	Ala	Thr 70	Leu	Gly	Phe	Gly	Ala 75	Tyr	Met	Ser	Lys	Ala 80	
His	Gly	Ile	Asp	Pro 85	Asn	Ile	Arg	Thr	Gly 90	Val	Arg	Thr	Ile	Thr 95	Thr	
Gly	Ser	Pro	Ile 100	Thr	Tyr	Ser	Thr	Tyr 105	Gly	Lys	Phe	Leu	Ala 110	Asp	Gly	
Gly	Cys	Ser 115	Gly	Gly	Ala	Tyr	Asp 120	Ile	Ile	Ile	CAa	Asp 125	Glu	Cys	Ala	
Ser	Thr 130	Asp	Ala	Thr	Ser	Ile 135	Leu	Gly	Ile	Gly	Thr 140	Val	Leu	Asp	Gln	
Ala 145	Glu	Thr	Ala	Gly	Ala 150	Arg	Leu	Val	Val	Leu 155	Ala	Thr	Ala	Thr	Pro 160	
Pro	Gly	Ser	Val	Thr 165	Val	Pro	His	Pro	Asn 170	Ile	Glu	Glu	Val	Ala 175	Leu	
Ser	Thr	Thr	Gly 180	Glu	Ile	Pro	Phe	Tyr 185	Gly	Lys	Ala	Ile	Pro 190	Leu	Glu	
Val	Ile	Lys 195	Gly	Gly	Arg	His	Leu 200	Ile	Phe	Cys	His	Ser 205	Lys	Lys	Lys	
Сув	Asp 210	Glu	Leu	Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val	
Ala 225	Tyr	Tyr	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240	
Val	Val	Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp	
Phe	Asp	Ser	Val 260	Ile	Asp	Cys	Asn	Thr 265	Cys	Val	Thr	Gln	Thr 270	Val	Asp	
Phe	Ser	Leu 275	Asp	Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln	
Asp	Ala 290	Val	Ser	Arg	Thr	Gln 295	Arg	Arg	Gly	Arg	Thr 300	Gly	Arg	Gly	Lys	

-continued

Pro Gly Ile Tyr Arg Phe Val Ala Pro Gly Glu Arg Pro Ser Gly Met 305 310 315 Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr Thr Val Arg Leu Arg Ala Tyr Met Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu Glu Phe Trp Glu Gly Val Phe Thr Gly Leu Thr His Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Ile Thr Leu Thr His Pro Val Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val 455 460 450 Val Thr Ser 465 <210> SEO TD NO 51 <211> LENGTH: 1401 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polynucleotide <400> SEQUENCE: 51 gctgttgact ttatcccggt tgaaaatctc gagactacta tgcgttctcc ggttttcact 60 gacaactett eteegeeggt tgtteegeag tettteeagg ttgeteacet geatgeteeg 120 actggttctg gtaaatctac taaagttcca gctgcttacg ctgctcaggg ttacaaagtt 180 ctggttctga acccgtctgt tgctgctact ctgggtttcg gcgcctacat gtctaaagct 240 cacggtatcg accegaacat tegtactggt gtacgtacta teactactgg ttetecgate 300 acttactcta cttacggtaa attcctggct gacggtggtt gctctggtgg tgcttacgat atcatcatct gcgacgaatg ccactctact gacgctactt ctatcctggg tatcggtacc gttctggacc aggctgaaac tgcaggtgct cgtctggttg ttctggctac tgctactccg cogggttotg ttactgttoc gcaccogaac atogaagaag ttgctotgto gactactggt qaaatcccqt tctacqqtaa aqctatcccq ctcqaqqtta tcaaaqqtqq tcqtcacctq 600 attttctqcc actctaaaaa aaaaaqcqac qaactqqctq ctaaqcttqt tqctctqqqt 660 atcaacgctg ttgcttacta ccgtggtctg gacgtttctg ttatcccgac ttctggtgac 720 gttgttgttg tggccactga cgctctgatg actggttaca ctggtgactt cgactctgtt atcgattgca acacttgcgt tactcagacc gtagatttta gcctggaccc gactttcact 840 atogaaacga tcaccctgcc gcaggatgca gtttcccgta cccagcgtcg tggccgtacc 900 qqtcqcqqca aaccqqqtat ttaccqtttc qtqqcqccqq qcqaqcqtcc atccqqtatq 960 ttcgatagct ctgttctgtg tgagtgttat gacgcgggtt gcgcgtggta cgaactgact 1020 coqqctqaaa ctactqtacq cctqcqtqca tacatqaata cqccqqqtct qccqqtqtqt

-continued

																	_
caaç	gacca	acc 1	tggaa	attti	tg g	gaag	gtgto	c ttt	cacto	ggcc	tga	cccat	tat «	cgac	gcacac	114	0
tttc	ctgt	ccc a	agact	taaa	ca gt	ctg	gtgaa	a aac	cctgo	ccgt	acci	tggt	ggc (gtato	caagcc	120	0
acto	gtgt	gcg (cccgt	tgcg	ca g	gege	egeca	a ccg	gagct	ggg	acca	aaat	gtg (gaagt	tgcctg	126	0
atco	egtet	tga a	aacc	gacco	ct go	cacg	gtee	g aco	gccad	ctgc	tgt	accg	ect (gggt	gcagtg	132	0
caga	aacga	aaa 1	tcac	gctga	ac go	cacco	eggto	c act	caaat	aca	ttai	tgacı	ttg (catga	agcgca	138	0
gaco	ctgga	aag 1	tggt	gacti	tc c											140	1
<211 <212 <213 <220 <223	1 > LI 2 > T 3 > OI 0 > FI 3 > O' po	ENGTI YPE: RGAN: EATUI THER Olype	ISM: RE: INFO	Art: DRMA:	ific: TION				n of	Art:	ific	ial :	Seque	ence	: Syntl	netic	
			MCE:														
Ala 1	Val	Asp	Phe	Ile 5	Pro	Val	Glu	Asn	Leu 10	Glu	Thr	Thr	Met	Arg 15	Ser		
Pro	Val	Phe	Thr 20	Asp	Asn	Ser	Ser	Pro 25	Pro	Val	Val	Pro	Gln 30	Ser	Phe		
Gln	Val	Ala 35	His	Leu	His	Ala	Pro 40	Thr	Gly	Ser	Gly	Lys 45	Ser	Thr	ГЛа		
Val	Pro 50	Ala	Ala	Tyr	Ala	Ala 55	Gln	Gly	Tyr	Lys	Val 60	Leu	Val	Leu	Asn		
Pro 65	Ser	Val	Ala	Ala	Thr 70	Leu	Gly	Phe	Gly	Ala 75	Tyr	Met	Ser	Lys	Ala 80		
His	Gly	Ile	Asp	Pro 85	Asn	Ile	Arg	Thr	Gly 90	Val	Arg	Thr	Ile	Thr 95	Thr		
Gly	Ser	Pro	Ile 100	Thr	Tyr	Ser	Thr	Tyr 105	Gly	Lys	Phe	Leu	Ala 110	Asp	Gly		
Gly	Cys	Ser 115	Gly	Gly	Ala	Tyr	Asp 120	Ile	Ile	Ile	Cys	Asp 125	Glu	Cys	His		
Ser	Thr 130	Asp	Ala	Thr	Ser	Ile 135	Leu	Gly	Ile	Gly	Thr 140	Val	Leu	Asp	Gln		
Ala 145	Glu	Thr	Ala	Gly	Ala 150	Arg	Leu	Val	Val	Leu 155	Ala	Thr	Ala	Thr	Pro 160		
Pro	Gly	Ser	Val	Thr 165	Val	Pro	His	Pro	Asn 170	Ile	Glu	Glu	Val	Ala 175	Leu		
Ser	Thr	Thr	Gly 180	Glu	Ile	Pro	Phe	Tyr 185	Gly	Lys	Ala	Ile	Pro 190	Leu	Glu		
Val	Ile	Lys 195	Gly	Gly	Arg	His	Leu 200	Ile	Phe	Cys	His	Ser 205	Lys	ГЛа	ГЛа		
Ser	Asp 210	Glu	Leu	Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val		
Ala 225	Tyr	Tyr	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240		
Val	Val	Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp		
Phe	Asp	Ser	Val 260	Ile	Asp	СЛа	Asn	Thr 265	СЛа	Val	Thr	Gln	Thr 270	Val	Asp		
Phe	Ser	Leu 275	Asp	Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln		

Asp Ala Val Ser Arg Thr Gln Arg Arg Gly Arg Thr Gly Arg Gly Lys

290 295 300	
Pro Gly Ile Tyr Arg Phe Val Ala Pro Gly Glu Arg Pro Ser Gly Met 305 310 315 320	
Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala Gly Cys Ala Trp 325 330 335	
Tyr Glu Leu Thr Pro Ala Glu Thr Thr Val Arg Leu Arg Ala Tyr Met 340 345 350	
Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu Glu Phe Trp Glu 355 360 365	
Gly Val Phe Thr Gly Leu Thr His Ile Asp Ala His Phe Leu Ser Gln 370 375 380	
Thr Lys Gln Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr Gln Ala 385 390 395 400	
Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met	
Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro	
420 425 430 Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Ile Thr Leu Thr His	
435 440 445 Pro Val Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val	
450 455 460 Val Thr Ser	
465	
<211> LENGTH: 1401 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polynucleotide	
<400> SEQUENCE: 53	
gctgttgact ttatcccggt tgaaaatctc gagactacta tgcgttctcc ggttttcact 60	
gacaactett eteegeeggt tgtteegeag tettteeagg ttgeteacet geatgeteeg 120	
actggttctg gtaaatctac taaagttcca gctgcttacg ctgctcaggg ttacaaagtt 180	
ctggttctga acccgtctgt tgctgctact ctgggtttcg gcgcctacat gtctaaagct 240	
cacggtatcg accegaacat tegtactggt gtacgtacta teactactgg tteteegate 300	
acttactcta cttacggtaa attcctggct gacggtggtt gctctggtgg tgcttacgat 360	
atcatcatct gcgacgaatg ccactctact gacgctactt ctatcctggg tatcggtacc 420	
gttctggacc aggctgaaac tgcaggtgct cgtctggttg ttctggctac tgctactccg 480	
cogggttotg ttactgttoc gcacocgaac atogaagaag ttgototgto gactactggt 540	
gaaatcccgt tctacggtaa agctatcccg ctcgaggtta tcaaaggtgg tcgtcacctg 600	
attttctgcc actctaaaaa aaaatgcgac gaactggctg ctaagcttgt tgctctgggt 660	
atcaacgctg ttgcttacta ccgtggtctg gacgtttctg ttatcccgac ttctggtgac 720	
gttgttgttg tggccactga cgctctgatg actggttacg gtggtgactt cgactctgtt 780	
ategattgea acaettgegt tacteagace gtagatttta geetggacee gaettteaet 840	
atcgaaacga tcaccctgcc gcaggatgca gtttcccgta cccagcgtcg tggccgtacc 900	
ggtcgcggca aaccgggtat ttaccgtttc gtggcgccgg gcgagcgtcc atccggtatg 960	
ttcgatagct ctgttctgtg tgagtgttat gacgcgggtt gcgcgtggta cgaactgact 1020	

ccggctgaa	aa cta	ctgta	cg c	ctgc	gtgca	a tao	catga	aata	cgc	cggg1	tot (gccg	gtgtgt	10	080
caagacca	cc tgg	aattt	tg g	gaag	gtgto	e tti	tacto	ggcc	tga	cccat	tat «	cgac	gcacac	1	140
tttctgtc	cc aga	ctaaa	ca g	tatg	gtgaa	a aa	cctgo	ccgt	acci	tggt	ggc (gtat	caagcc	1:	200
actgtgtg	cg ccc	gtgcg	ca g	gaga	egeca	a cc	gagct	ggg	acca	aaat	gtg (gaagi	tgcctg	1:	260
atccgtct	ga aac	cgacc	ct g	cacg	gtee	g acq	gccad	ctgc	tgta	accg	ect (gggt	gcagtg	13	320
cagaacgaa	aa tca	cgctg	ac g	cacco	eggto	c act	aaat	aca	ttai	tgact	ttg (catg	agcgca	13	380
gacctgga	ag tgg	tgact	tc c											1	401
<210 > SE(<211 > LEI<211 > TYI<212 > TYI<213 > OR(<220 > FE<223 > OTIpoi	NGTH: PE: PR GANISM ATURE:	467 T : Art FORMA			_		ı of	Art:	ific	ial :	Seque	ence	: Synt	hetio	С
<400> SE	QUENCE	: 54													
Ala Val i	Asp Ph	e Ile 5	Pro	Val	Glu	Asn	Leu 10	Glu	Thr	Thr	Met	Arg 15	Ser		
Pro Val I	Phe Th 20	_	Asn	Ser	Ser	Pro 25	Pro	Val	Val	Pro	Gln 30	Ser	Phe		
Gln Val	Ala Hi 35	s Leu	His	Ala	Pro 40	Thr	Gly	Ser	Gly	Lys 45	Ser	Thr	Lys		
Val Pro 2	Ala Al	a Tyr	Ala	Ala 55	Gln	Gly	Tyr	Lys	Val 60	Leu	Val	Leu	Asn		
Pro Ser 7	Val Al	a Ala	Thr 70	Leu	Gly	Phe	Gly	Ala 75	Tyr	Met	Ser	Lys	Ala 80		
His Gly	Ile As	p Pro 85	Asn	Ile	Arg	Thr	Gly 90	Val	Arg	Thr	Ile	Thr 95	Thr		
Gly Ser 1	Pro Il 10		Tyr	Ser	Thr	Tyr 105	Gly	Lys	Phe	Leu	Ala 110	Asp	Gly		
Gly Cys :	Ser Gl 115	y Gly	Ala	Tyr	Asp 120	Ile	Ile	Ile	CAa	Asp 125	Glu	Cys	His		
Ser Thr 2	Asp Al	a Thr	Ser	Ile 135	Leu	Gly	Ile	Gly	Thr 140	Val	Leu	Asp	Gln		
Ala Glu 1 145	Thr Al	a Gly	Ala 150	Arg	Leu	Val	Val	Leu 155	Ala	Thr	Ala	Thr	Pro 160		
Pro Gly	Ser Va	l Thr 165		Pro	His	Pro	Asn 170	Ile	Glu	Glu	Val	Ala 175	Leu		
Ser Thr	Thr Gl 18	-	Ile	Pro	Phe	Tyr 185	Gly	Lys	Ala	Ile	Pro 190	Leu	Glu		
Val Ile I	Lys Gl 195	y Gly	Arg	His	Leu 200	Ile	Phe	Cys	His	Ser 205	Lys	Lys	Lys		
Cys Asp (Glu Le	u Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val		
Ala Tyr 1	Tyr Ar	g Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240		
Val Val ^v	Val Va	1 Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Gly	Gly 255	Asp		
Phe Asp	Ser Va 26		Asp	Сув	Asn	Thr 265	Сув	Val	Thr	Gln	Thr 270	Val	Asp		
Phe Ser 1	Leu As 275	p Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln		

Asp	Ala 290	Val	Ser	Arg	Thr	Gln 295	Arg	Arg	Gly	Arg	Thr 300	Gly	Arg	Gly	Lys	
Pro 305	Gly	Ile	Tyr	Arg	Phe 310	Val	Ala	Pro	Gly	Glu 315	Arg	Pro	Ser	Gly	Met 320	
Phe	Asp	Ser	Ser	Val 325	Leu	CAa	Glu	Cys	Tyr 330	Asp	Ala	Gly	Сув	Ala 335	Trp	
Tyr	Glu	Leu	Thr 340	Pro	Ala	Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met	
Asn	Thr	Pro 355	Gly	Leu	Pro	Val	Сув 360	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu	
Gly	Val 370	Phe	Thr	Gly	Leu	Thr 375	His	Ile	Asp	Ala	His 380	Phe	Leu	Ser	Gln	
Thr 385	Lys	Gln	Ser	Gly	Glu 390	Asn	Leu	Pro	Tyr	Leu 395	Val	Ala	Tyr	Gln	Ala 400	
Thr	Val	Cys	Ala	Arg 405	Ala	Gln	Ala	Pro	Pro 410	Pro	Ser	Trp	Asp	Gln 415	Met	
Trp	Lys	Cys	Leu 420	Ile	Arg	Leu	Lys	Pro 425	Thr	Leu	His	Gly	Pro 430	Thr	Pro	
Leu	Leu	Tyr 435	Arg	Leu	Gly	Ala	Val 440	Gln	Asn	Glu	Ile	Thr 445	Leu	Thr	His	
Pro	Val 450	Thr	Lys	Tyr	Ile	Met 455	Thr	Cys	Met	Ser	Ala 460	Asp	Leu	Glu	Val	
Val 465	Thr	Ser														
/ L I	.> LE	NGTH) NO I: 14													
<212 <213 <220 <223	P TY P OR P FE P OT	PE: GANI ATUR HER Jynu	H: 14 DNA SM: E: INFO	:01 Arti ORMAT	ION:		eque crip		of	Arti	fici	al S	Seque	ence:	Syr	nthetic
<212 <213 <220 <223	2 > TY 3 > OR 0 > FE 3 > OI pc 0 > SE	PE: GANI ATUR HER Olynu	H: 14 DNA SM: EE: INFO ICLE:	O1 Arti ORMAT Otide	'ION :	Des	scrip	tion					_			
<212 <213 <220 <223 <400	:> TY :> OR :> OT :> OT :> SE ::ttga	PE: GANI ATUR HER Jynu QUEN	I: 14 DNA SM: RE: INFO ICLE:	Arti Arti RMAT tide 55	ION:	Des Jaaaa	scrip	tion	jacta	ıcta	tgcg	ttct	ac g	ence: ggttt gcatg	tcac	t 60
<212 <213 <220 <223 <400 gcts	:> TY :> OR :> OR :> OT :> OT :> pc :> SE	PE: GANI ATUR HER Jynu QUEN ct t	I: 14 DNA SM: EE: INFO ICLE: tato	Arti Arti RMAT 55 ccgg	iON:	Des Jaaaa Jatco	ecrip stete	gag	jacta ttcc	icta :agg	tgcg	ttet	ccc g	ggttt	tcac	et 60 eg 120
<212<213<220<223<400 <gcts< td=""><td>2> TY 3> OR 0> FE 3> OT pc 0> SE gttga</td><td>PE: GANI ATUR HER Lynu QUEN act t</td><td>H: 14 DNA SM: RE: INFO ICE: tato</td><td>Arti Arti RMAT otide 55 ccege gcege</td><td>rION:</td><td>Des gaaaa gttcc gaagt</td><td>scrip stctc gcag</td><td>gag tet</td><td>jacta ttec</td><td>icta agg acg</td><td>tgcg ttgc</td><td>ttet teac</td><td>ect g</td><td>ggttt gcatg</td><td>tcac</td><td>et 60 eg 120 et 180</td></gcts<>	2> TY 3> OR 0> FE 3> OT pc 0> SE gttga	PE: GANI ATUR HER Lynu QUEN act t	H: 14 DNA SM: RE: INFO ICE: tato	Arti Arti RMAT otide 55 ccege gcege	rION:	Des gaaaa gttcc gaagt	scrip stctc gcag	gag tet	jacta ttec	icta agg acg	tgcg ttgc	ttet teac	ect g	ggttt gcatg	tcac	et 60 eg 120 et 180
<212<213<220<223<400 <gctg< td=""><td>2> TY 3> OR 0> FE 3> OT pc 0> SE gttga actc</td><td>PE: GANI ATUR HER Olynu CQUEN Act t</td><td>H: 14 DNA SM: RE: INFO ICLE: tato</td><td>Arti Arti ORMAT 55 ccgg gccgg tcta</td><td>PION:</td><td>Des Jaaaa Jittoo Jaagt Jotgo</td><td>scrip stoto sgcag stoca</td><td>gag tet get</td><td>jacta ttcc gctt jggtt</td><td>acta agg acg tcg</td><td>tgeg ttge etge gege</td><td>ttct tcac tcac</td><td>ccc g cct g ggg t</td><td>ggttt gcatg ctaca</td><td>tcac ctcc aagt</td><td>et 60 eg 120 et 180</td></gctg<>	2> TY 3> OR 0> FE 3> OT pc 0> SE gttga actc	PE: GANI ATUR HER Olynu CQUEN Act t	H: 14 DNA SM: RE: INFO ICLE: tato	Arti Arti ORMAT 55 ccgg gccgg tcta	PION:	Des Jaaaa Jittoo Jaagt Jotgo	scrip stoto sgcag stoca	gag tet get	jacta ttcc gctt jggtt	acta agg acg tcg	tgeg ttge etge gege	ttct tcac tcac	ccc g cct g ggg t	ggttt gcatg ctaca	tcac ctcc aagt	et 60 eg 120 et 180
<212 213</220</220</220</220</220</220</220</22</td <td>2> TY 3> OR 0> FE 3> OT pc 0> SE gttga actc ggttc gttct</td> <td>PE: GANI ATUR HER JYNU CUEN CUEN CUE CUE CUE CUE CUE CUE CUE CUE CUE CUE</td> <td>II: 14 DNA SM: RE: INFO ICLE: INFO ICLE: Itato</td> <td>Arti Arti RMAT tide 55 cccgg ccgg tcta gtctg gaaca</td> <td>TION:</td> <td>Des Jaaaa Jittee Jaagt Jetge</td> <td>scrip stctc sgcag stcca stact</td> <td>gag tet get</td> <td>jacta ttec gett jggtt</td> <td>acta agg acg tcg</td> <td>tgeg ttge etge gege teac</td> <td>ttct tcac tcac ctac</td> <td>cee geet geet geet geet geet geet geet g</td> <td>ggttt gcatg ctaca gtcta</td> <td>tcac letec laagt laagc</td> <td>et 60 eg 120 et 180 et 240</td>	2> TY 3> OR 0> FE 3> OT pc 0> SE gttga actc ggttc gttct	PE: GANI ATUR HER JYNU CUEN CUEN CUE	II: 14 DNA SM: RE: INFO ICLE: INFO ICLE: Itato	Arti Arti RMAT tide 55 cccgg ccgg tcta gtctg gaaca	TION:	Des Jaaaa Jittee Jaagt Jetge	scrip stctc sgcag stcca stact	gag tet get	jacta ttec gett jggtt	acta agg acg tcg	tgeg ttge etge gege teac	ttct tcac tcac ctac	cee geet geet geet geet geet geet geet g	ggttt gcatg ctaca gtcta	tcac letec laagt laagc	et 60 eg 120 et 180 et 240
<212	<pre>2</pre>	PE: GANI ATUR HER lynu cquen ct t tt c ttg g ga a ccg a ta c	II: 14 DNA SM: SE: INFO colect ICE: ttato ttato deccog deccog	Arti Arti RMAT ttide 55 cccgg gccgg gccgg gccgg gccgg gcgg gcg gcg gcgg gcgg gcg g	rion: t tg t tg t tg t tg t tg t tg	Des Jaaaa Jttcc Jaagt Jetgc Jetgc	scrip stete geag teea stact stggt	gag tet get etg	jacta ttcc gctt iggtt icgta	agg agg teg teg	tgeg ttge etge gege teac	tcac tcac ctac tact	ect g ggg t gat g	ggttt gcatg ctaca gtcta	tcac etec aagt aagc	et 60 eg 120 et 180 et 240 ec 300 et 360
<212 <213 <220 <223 <400 gets gaca acts ctgs cacs actt atca	<pre>2</pre>	PE: GANI ATUR HER lynu ct t tt c tg g ga a cg a ct c ct g	II: 14 DNA SM: SM: SE: INFO Collect CCE: tato tece tece tece ttac gegac	Arti RMAT tide 55 cccgg ccgg ccgg gccgg	TION: type	Des Jettec Jettec Jetge Jetge Jetec	ecrip detecte egeag teca etact etagt egget	gag tet get etg gta gac	Jacta ttec gett Jegtt Jegta Jegte	acta agg acg teg icta igtt	tgcg ttgc ctgc gcgc tcac gctc	tcac tcac ctac tact tggt	ccc gagg tagg tagg tagg	ggttt gcatg ctaca gtcta ctctc	tcac aagt aagg cgat acga	et 60 eg 120 et 180 et 240 et 300 et 360 ec 420
<212 <213 <220 <223 <400 gets gaca acts cass cass gaca gtts	<pre>2> TYS 3> OR 3> FE 3> OR 4> OT 5 po 6 po 7 po 8 po 9 po 8 po 8 po 9 po 9</pre>	PE: GANI ATUR HER lynu cquen ctt c ga a cg a cg a cct g cct g	II: 14 DNA SM: RE: INFC INFC INFC INFC INFC INFC INFC INFC	Artii Artii RMAT tide 55 cccgg tcta tcta ggaaca ggaaa	TION: ty ty ty ty ty ty ty ty ty t	Des Jaaaaa Jaaagt Jetge Jetge Jeaggtae	ecrip detect d detect detect detect detect detect detect detect detect detect d	gae tet get ete gta gae	decta gett ggtt eggta eggte egeta etgg	acta acg acg tcg cta gtt	tgeg ttge etge gege teac gete etat ttet	tcac tcac cctac tact tctggt cctg	ggg t ggg t ggg t ggg t	ggttt gcatg ttaca gtcta ctctc cgctt	tcac aagt aagc cgat acga gtac	et 60 eg 120 et 180 et 240 ec 300 et 360 ec 420
<212 <213 <220 <400 gets gaca acts ctgs cacs gatta atca gtts ccgs	<pre>2> TY 3> OR 3> FE 3> OI pc c pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc pc p</pre>	PE: GANI GANI LATUR THER CLYNU CCT t ttt c ttt c ctg g a a ccg a cct g	I: 14 DNA SM: EE: INFC ICE: INFC ICE: Itato Itat	Arti Arti Arti RMAI 55 cccgg cccgg tcta atctg aaca ggta ggaat ggaaa ggttc	rion: t tg gt tg	Des per	ecrip geag tteca ttect ttegt ttect ttegt ttect geaac	gag tet get gta gac gac	ttee gett ggtt eggte ggte eggte etge	acta agg acg tcg acta gtt actt	ttgcg tttgc cttgc gcgc tcac gctc ctat ttct	tcac cctac tact tact ggt ccctg	e de centre de c	ggsttt ttaca gtcta ctctc cgctt catcg	tcac etec aagt aagc cgat acga acga ctcc	et 60 eg 120 et 180 et 240 et 300 et 360 et 420 ec 420 eg 480 eg 480
<212 <213 <220 <220 <400 gets gaca acts cass gtts acts gtts cogg gaaa	2> TYP 3> OR 3> FE 5> OT pc	PE: GANI ATUR HER Ilynu QUEN ct t ttt c gga a ccg a tta c cct g ccc a ttg t	I: 14 DNA CSM: CSM: CSM: CSM: CSM: CSM: CSM: CSM:	Arti Arti Arti Arti Arti Arti Arti Arti	rion:	Des Jaaaaa Jaaagt Jotgo Jotgo Jotat Jotat	actip ggcag ttcca ttact ggct ttact ggct ttact gtgct	gage gta gac gac atc	dacta ttcc gett gggtt cgta ggtg gcta ctgg	acgacta acg tcg cta acgt tcg acta acgt tcg acg acg acg acg acg acg acg acg acg a	tgcg ttgc ctgc gcgc tcac gctc ttttc tttgc tcaa	tcac tcac tcac tcac tact tggt cctc ggct tctcc	gg t tagg t	gggttt ggatg ttaca gtcta catcg	teac aagt aagg egat aega gtac etec	et 60 eg 120 et 180 et 240 ec 300 et 420 ec 420 eg 480 et 540
<212 <213 <220 <223 <400 gets cass cass cass gets cass gets actt atca gets ggaaa attt	<pre>2> TY >> OR >> FE >> OT pc pc pc actc actc actc tcat tcat tcat</pre>	PE: GANICATURE CAND CAND CAND CAND CAND CAND CAND CAND	I: 14 DNA CSM: CSM: CSM: INFO CCCCC CCCCC CCCCC CCCCC CCCCC CCCCC CCCC	Arti Artii RMAT ttide 55 cccgg cccgg tcta aaca ggta ggaat ggaaa ggtc	TION: t tg gt tg gt tg gt tg c ta a at cg cc cc tg cc tg cc ta a ag aaaaaaaaaaaaaaaaaaaaaaaaa	Des passassing petge getge teet acte acte acce acce acce acce	acrip detector detect	gagget etc.	ttee gett ggtt eggte geta etge gaae	acta agg accg accta agtt actt actt actt	tgcg ttgc ctgc gcgc tcac gctc ctat ttct ttgc tcaa	tcac ctac ctac cctac cct	cccc cccc cccc cccc cccc cccc cccc cccc cccc	gggttt ggatg gtota gtota toto ggtt atog ggta gacta	tead octor aaagd aagd acgat acgat acct	et 60 eg 120 et 180 et 240 ec 300 et 360 ec 420 eg 480 eg 600 eg 660
<212 <213 <220 <400 gctc gaca actc ccacc gact atca atta atca atta att	2> TY 3> OR 3> FE 4> OR 4> OR 5> FE 6> PE 6 7 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	PE: GANITATURE HER LINE LINE LINE LINE LINE LINE LINE LINE	I: 14 DNA SER: INFO CCICE: tato tacce tacce gracece ttacc gracece ttact cctac dcttact tact tact tact tact	Artii RMAT ttide 55 cccgg cccgg tcta gaaca ggaat ggaat ggaat gggta aaaaa tact	TION: type to the text of the text to the	Des	acrip tctc cgcag tcca tact ctact ctact ggct cccg ggac cccg gcgac	gac	ttcc gett ggtt eggta ggta etgg gaag	acta agg accg acta gtt actt actt actt ac	tgcg ttgc ctgc gcgc tcac gctc ttat ttct ttgc tcaa ttat	tcac tcac tcac tcac tcac tcac tcac tcac	ggg t ggg t ggg t t ggc t	gggttt taca gtcta cgctt ggcta ggcta gacta cccgtc	tcac detect aagt aagg cgat acga gtac ctcc ctgg gtga	et 60 eg 120 et 180 et 240 ec 300 et 420 ec 420 eg 480 ec 420 ed 660 ec 720
<212 <213 <220 <223 <400 gcts gaca acts acts gtts acta atta atta atta atta	<pre>2> TY 3> OR 3> FE 6> OT pc /pre>	PE: GANIR ATURE HER COLUMN COL	I: 14 DNA ESM: ESM: ESM: INFO Colclect	Arti Artii RMAI Etide 55 cccgg gccgg tcta gaaca ggta ggaat ggaa ggta aaaa tact	rion: t tg t tg t tg t tg t tg c ta a at c g cc c gc a ag a ag a ac c ga c g	Des per	acrip detector detect	gac gac gac gac gac gac gac gac gac atc	gett gett eggtt eggage geta etge gaage etge gaage	acta aagg accg accta ggtt actt ggtt actt gtta accg acca acca	tgcg ttgc ctgc ctgc tcac gctc ctat ttct tcaa ctaa ttat	tteteteace ectee eccee eccee ectee eccee ectee eccee ectee eccee e	gg t ggg t ggg t ggg t ggg t t	ggsttt taca ttaca ttaca ttaca ttaca tcaca	tcac ctcc aaagt aaagc cgat acga ctcc ctcc	et 60 eg 120 et 180 et 240 ec 300 et 360 ec 420 et 540 eg 600 et 720 et 780
<212 <213 <220 <400 gets sector cases actt atca gtts actg gaaa attt atca gtts accg gaaa attt atca	2> TY 3> OR 3> FE 5> OT pc pc actc actc actc tcat tcat tctgga actc tctgga tcct tctgga actc	PE: GANICATURE CATURE C	I: 14 DNA DNA GNA: SSM: SSM: SSM: SSM: SSM: SSM: SSM: SS	Artii Artii RMAT ttide 55 cccgg cccgg tcta gaaca ggta ggaat ggaat cggta aaaa atact	rion: gt tg gt tg gt tg gc ta a at cc ta a ac gc cc gc aa ag aa aa aa cc ga cg	Des	derip de de la companya de la compan	gage gage gage gage gage gage gage gage	gett ggtt cgta ctgg gcta ctgg gaag gttt ggtt gg	acta aagg acg tcg ccta agtt actt tttg aaag tcta actt ttta actt ttta actt ttta actt ttta	tgcg ttgc ctgc gcgc tcac gctc ctat ttct ttgc tcaa ctaa ct	tcace gent	at gag t tagg t	gggttt taca gtcta catcg catcg catcg catca catca catca catca catca catca catca catca	aagt aagg acgat acce acce acce acce acce acce acce ac	24 60 25 120 25 240 25 25 26 26 26 27 20 25 28 240 25 26 26 26 27 20 25 26 26 26 26 26 26 26 26 26 26 26 26 26

																1000
		_	_	_	-		=	-		-			=	-	etgaet	1020
	_			_	_				_		_			-	gtgtgt	1080
	-									-	-			-	gcacac	1140
	_		-		_				_	-				=	caagcc	1200
acto	gtgt	gcg (cccgt	tgcg	ca g	gege	egee	a cc	gagct	999	acca	aaat	gtg 9	gaagt	geetg	1260
atco	egtet	ga a	aacc	gacc	ct go	cacg	gtcc	g acq	gcca	ctgc	tgta	accg	ect o	gggtg	gcagtg	1320
caga	acga	aaa 1	tcac	gatg	ac go	cacco	eggt	c act	caaat	caca	ttai	tgac	ttg (catga	agcgca	1380
gaco	tgga	aag 1	tggt	gacti	tc c											1401
<213 <213 <213 <220 <223	L> LI 2> T 3> OI 0> FI 3> O	ENGTI YPE: RGAN: EATUI THER Dlype	ISM: RE:	Art: ORMA' de	ific: FION		_		n of	Art:	ific	ial :	Seque	ence	: Synthe	etic
					Dese	17	G1	7	T	G1	mla sa	TI la sa	Mat	7	Com	
AIA 1	vai	Asp	Pne	11e 5	Pro	vai	GIU	Asn	Leu 10	GIU	Thr	Thr	мес	Arg 15	ser	
Pro	Val	Phe	Thr 20	Asp	Asn	Ser	Ser	Pro 25	Pro	Val	Val	Pro	Gln 30	Ser	Phe	
Gln	Val	Ala 35	His	Leu	His	Ala	Pro 40	Thr	Gly	Ser	Gly	Lуs 45	Ser	Thr	Lys	
Val	Pro 50	Ala	Ala	Tyr	Ala	Ala 55	Gln	Gly	Tyr	Lys	Val 60	Leu	Val	Leu	Asn	
Pro 65	Ser	Val	Ala	Ala	Thr 70	Leu	Gly	Phe	Gly	Ala 75	Tyr	Met	Ser	ГÀа	Ala 80	
His	Gly	Ile	Asp	Pro 85	Asn	Ile	Arg	Thr	Gly 90	Val	Arg	Thr	Ile	Thr 95	Thr	
Gly	Ser	Pro	Ile 100	Thr	Tyr	Ser	Thr	Tyr 105	Gly	Lys	Phe	Leu	Ala 110	Asp	Gly	
Gly	Сла	Ser 115	Gly	Gly	Ala	Tyr	Asp 120	Ile	Ile	Ile	CÀa	Asp 125	Glu	CÀa	His	
Ser	Thr 130	Asp	Ala	Thr	Ser	Ile 135	Leu	Gly	Ile	Gly	Thr 140	Val	Leu	Asp	Gln	
Ala 145	Glu	Thr	Ala	Gly	Ala 150	Arg	Leu	Val	Val	Leu 155	Ala	Thr	Ala	Thr	Pro 160	
Pro	Gly	Ser	Val	Thr 165	Val	Pro	His	Pro	Asn 170	Ile	Glu	Glu	Val	Ala 175	Leu	
Ser	Thr	Thr	Gly 180	Glu	Ile	Pro	Phe	Tyr 185	Gly	Lys	Ala	Ile	Pro 190	Leu	Glu	
Val	Ile	Lys 195	Gly	Gly	Arg	His	Leu 200	Ile	Phe	Cys	His	Ser 205	ГЛа	ГÀа	Lys	
CAa	Asp 210	Glu	Leu	Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val	
Ala 225	Tyr	Tyr	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240	
Val	Val	Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp	
Phe	Asp	Ser	Val 260	Ile	Asp	СЛа	Asn	Thr 265	Сув	Val	Thr	Gln	Thr 270	Val	Asp	

Phe Ser	Leu 275	Asp	Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln		
Asp Ala 290	Val	Ser	Arg	Thr	His 295	Arg	Arg	Gly	Arg	Thr 300	Gly	Arg	Gly	Lys		
Pro Gly 305	Ile	Tyr	Arg	Phe 310	Val	Ala	Pro	Gly	Glu 315	Arg	Pro	Ser	Gly	Met 320		
Phe Asp	Ser	Ser	Val 325	Leu	Cys	Glu	Сув	Tyr 330	Asp	Ala	Gly	Cys	Ala 335	Trp		
Tyr Glu	Leu	Thr 340	Pro	Ala	Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met		
Asn Thr	Pro 355	Gly	Leu	Pro	Val	Сув 360	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu		
Gly Val 370	Phe	Thr	Gly	Leu	Thr 375	His	Ile	Asp	Ala	His 380	Phe	Leu	Ser	Gln		
Thr Lys 385	Gln	Ser	Gly	Glu 390	Asn	Leu	Pro	Tyr	Leu 395	Val	Ala	Tyr	Gln	Ala 400		
Thr Val	Cya	Ala	Arg 405	Ala	Gln	Ala	Pro	Pro 410	Pro	Ser	Trp	Asp	Gln 415	Met		
Trp Lys	CÀa	Leu 420	Ile	Arg	Leu	Lys	Pro 425	Thr	Leu	His	Gly	Pro 430	Thr	Pro		
Leu Leu	Tyr 435	Arg	Leu	Gly	Ala	Val 440	Gln	Asn	Glu	Ile	Thr 445	Leu	Thr	His		
Pro Val 450	Thr	Lys	Tyr	Ile	Met 455	Thr	Cys	Met	Ser	Ala 460	Asp	Leu	Glu	Val		
Val Thr 465	Ser															
<210 > S <211 > L <212 > T <213 > O <220 > F <223 > O	ENGTI YPE: RGAN EATUI THER	H: 1. DNA ISM: RE: INF	401 Art:	rion		_		n of	Art:	ific:	ial :	Seque	ence	: Synt:	hetic	
<400> S	EQUE	NCE:	57													
gctgttg	act '	ttat	cccg	gt t	gaaa	atcto	ga	gact	acta	tgc	gttci	tee q	ggttt	tcact	60	
gacaact	ctt ·	ctcc	geeg	gt t	gttc	egeag	g te	ttc	cagg	ttg	ctca	ect q	gcato	gctccg	120	
actggtt	ctg (gtaa	atcta	ac t	aaag	tcca	a gc	gcti	tacg	ctg	ctcaç	ggg t	taca	aagtt	180	
ctggttc	tga .	accc	gtct	gt t	gctg	ctact	ct	gggti	ttcg	gcg	ccta	cat o	gtcta	aagct	240	
cacggta	tcg .	accc	gaaca	at t	cgta	ctggt	gt	acgt	acta	tca	ctact	egg t	tctc	ccgatc	300	
acttact	cta ·	ctta	cggta	aa a	ttcc	gget	ga	eggt	ggtt	gct	ctggi	tgg t	gctt	acgat	360	
atcatca	tct (gcga	cgaat	tg c	cact	ctact	ga	cgct	actt	ctai	tact	ggg t	atco	ggtacc	420	
gttctgg	acc .	aggc	tgaaa	ac t	gcag	gtgct	c cg	catg	gttg	ttc	tggc1	tac t	gcta	actccg	480	
ccgggtt	ctg ·	ttac	tgtt	cc g	cacc	cgaad	c at	gaa	gaag	ttg	ctct	gtc (gacta	actggt	540	
gaaatcc	cgt ·	tcta	cggta	aa a	gcta	caaq	g ct	gag	gtta	tcaa	aaggi	tgg t	cgt	cacctg	600	
attttct	gee .	actc	taaa	aa a	aaat	gcgad	ga:	actg	gctg	ctaa	agcti	tgt t	get	tgggt	660	
atcaacg	ctg	ttgc	ttacı	ta c	cgtg	gtate	g ga	egtti	tctg	ttai	taca	gac t	tctç	ggtgac	720	
gttgttg	ttg ·	tggc	cact	ga c	gete	gato	g act	ggti	taca	ctg	gtga	ett o	egaet	ctgtt	780	
atcgatt	gca .	acac	ttgc	gt ta	actca	agaco	gt	agati	ttta	gcci	tgga	ecc ç	gactt	tcact	840	
atcgaaa	cga ·	tcac	cctg	cc g	cagg	atgca	a gti	tcc	cgta	ccca	agcgi	cg t	ggcg	gcgacc	900	

-continued

ggto	geg	gca	aacco	gggta	at tt	cacco	gttto	gtg	gege	cgg	gcga	agcgt	cc.	atcco	ggtatg	2	960
ttc	gataç	gct	ctgtt	ctgt	g to	gagto	gttat	gad	gege	gtt	gcgo	gtg	gta	cgaad	etgact	10	020
ccg	gctga	aaa	ctact	gtad	eg co	ctgcg	gtgca	a tac	catga	ata	cgc	egggt	ct (geegg	gtgtgt	10	080
caaç	gacca	acc	tggaa	attt	g gg	gaagg	gtgto	ttt	acto	gcc	tgad	ccat	at ·	cgaco	gcacac	11	L40
ttt	ctgt	ccc .	agact	caaac	ca gt	ctg	gtgaa	a aac	cctgo	ccgt	acct	ggt	ggc (gtato	caagcc	12	200
acto	gtgtg	gcg	cccgt	gcg	ca go	gege	egeca	a ccc	gaget	999	acca	aaat	gtg (gaagt	geetg	12	260
atco	egtet	ga	aacco	gacco	ct go	cacgo	gtac	g acc	gccac	etge	tgta	accgo	cct (gggtg	gcagtg	13	320
caga	aacga	aaa	tcacç	gctga	ac go	cacco	eggto	c act	aaat	aca	ttat	gact	tg	catga	agcgca	13	380
gaco	ctgga	aag	tggtg	gactt	c c											14	101
<211 <212 <213 <220	L> LI 2> T: 3> OI 0> FI 3> O:	ENGT: YPE: RGAN EATU: THER	ISM: RE:	57 Art: DRMA:			_		n of	Art:	ifici	ial S	Sequ	ence:	: Synt	hetio	e e
<400)> SI	EQUE	NCE:	58													
Ala 1	Val	Asp	Phe	Ile 5	Pro	Val	Glu	Asn	Leu 10	Glu	Thr	Thr	Met	Arg 15	Ser		
Pro	Val	Phe	Thr 20	Asp	Asn	Ser	Ser	Pro 25	Pro	Val	Val	Pro	Gln 30	Ser	Phe		
Gln	Val	Ala 35	His	Leu	His	Ala	Pro 40	Thr	Gly	Ser	Gly	Lys 45	Ser	Thr	Lys		
Val	Pro 50	Ala	Ala	Tyr	Ala	Ala 55	Gln	Gly	Tyr	Lys	Val 60	Leu	Val	Leu	Asn		
Pro 65	Ser	Val	Ala	Ala	Thr 70	Leu	Gly	Phe	Gly	Ala 75	Tyr	Met	Ser	ГÀа	Ala 80		
His	Gly	Ile	Asp	Pro 85	Asn	Ile	Arg	Thr	Gly 90	Val	Arg	Thr	Ile	Thr 95	Thr		
Gly	Ser	Pro	Ile 100	Thr	Tyr	Ser	Thr	Tyr 105	Gly	Lys	Phe	Leu	Ala 110	Asp	Gly		
Gly	Сла	Ser 115	Gly	Gly	Ala	Tyr	Asp 120	Ile	Ile	Ile	CAa	Asp 125	Glu	CAa	His		
Ser	Thr 130	Asp	Ala	Thr	Ser	Ile 135	Leu	Gly	Ile	Gly	Thr 140	Val	Leu	Asp	Gln		
Ala 145	Glu	Thr	Ala	Gly	Ala 150	Arg	Leu	Val	Val	Leu 155	Ala	Thr	Ala	Thr	Pro 160		
Pro	Gly	Ser	Val	Thr 165	Val	Pro	His	Pro	Asn 170	Ile	Glu	Glu	Val	Ala 175	Leu		
Ser	Thr	Thr	Gly 180	Glu	Ile	Pro	Phe	Tyr 185	Gly	Lys	Ala	Ile	Pro 190	Leu	Glu		
Val	Ile	Lys 195	Gly	Gly	Arg	His	Leu 200	Ile	Phe	Сув	His	Ser 205	Lys	Lys	Lys		
CAa	Asp 210	Glu	Leu	Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val		
Ala 225	Tyr	Tyr	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240		
Val	Val	Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp		

Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp

			260					265					270			
Phe	Ser	Leu 275	Asp	Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln	
Asp	Ala 290	Val	Ser	Arg	Thr	Gln 295	Arg	Arg	Gly	Ala	Thr 300	Gly	Arg	Gly	ГÀа	
Pro 305	Gly	Ile	Tyr	Arg	Phe 310	Val	Ala	Pro	Gly	Glu 315	Arg	Pro	Ser	Gly	Met 320	
Phe	Asp	Ser	Ser	Val 325	Leu	CAa	Glu	Сув	Tyr 330	Asp	Ala	Gly	Cys	Ala 335	Trp	
Tyr	Glu	Leu	Thr 340	Pro	Ala	Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met	
Asn	Thr	Pro 355	Gly	Leu	Pro	Val	Cys	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu	
Gly	Val 370	Phe	Thr	Gly	Leu	Thr 375	His	Ile	Asp	Ala	His 380	Phe	Leu	Ser	Gln	
Thr 385	Lys	Gln	Ser	Gly	Glu 390	Asn	Leu	Pro	Tyr	Leu 395	Val	Ala	Tyr	Gln	Ala 400	
Thr	Val	CÀa	Ala	Arg 405	Ala	Gln	Ala	Pro	Pro 410	Pro	Ser	Trp	Asp	Gln 415	Met	
Trp	Lys	Cys	Leu 420	Ile	Arg	Leu	Lys	Pro 425	Thr	Leu	His	Gly	Pro 430	Thr	Pro	
Leu	Leu	Tyr 435	Arg	Leu	Gly	Ala	Val 440	Gln	Asn	Glu	Ile	Thr 445	Leu	Thr	His	
Pro	Val 450	Thr	Lys	Tyr	Ile	Met 455	Thr	Cys	Met	Ser	Ala 460	Asp	Leu	Glu	Val	
Val 465	Thr	Ser														
<211 <212 <213 <220	L> LE 2> T\ 3> OF 0> FE 3> OT	EATUF CHER	H: 14 DNA ISM: RE: INFO	401 Art:	rion	ial s	_		ı of	Art:	ific	ial :	Seque	ence	: Synth	etic
< 400)> SI	EQUE	ICE :	59												
gcto	gttga	act t	tato	cccg	gt to	gaaaa	atcto	gaç	gacta	acta	tgcg	gttci	caa g	ggttt	tcact	60
gaca	acto	ett o	etec	geegg	gt to	gttc	gcaç	g tơi	ttco	agg	ttg	ctca	ect o	gcate	gctccg	120
acto	gtto	etg g	gtaaa	atcta	ac ta	aaagt	tcca	a gct	gctt	acg	ctg	ctcaç	ggg t	taca	aagtt	180
ctg	gttct	ga a	accc	gtete	gt t	gctg	ctact	ctę	gggtt	tcg	gcg	ccta	cat o	gteta	aagct	240
caco	ggtat	cg a	accc	gaaca	at to	cgta	ctggt	gta	acgta	acta	tcad	ctact	gg t	tct	ecgate	300
actt	acto	cta d	cttac	eggta	aa a	ttcct	gget	gad	ggtg	ggtt	gct	ctggi	gg t	gett	acgat	360
atca	tcat	ct ç	gcgad	cgaat	g c	cacto	ctact	gad	egeta	actt	ctat	cct	ggg t	tato	ggtacc	420
gtto	etgga	acc a	aggct	tgaaa	ac t	gcag	gtgct	. cgt	ctg	gttg	ttct	ggct	ac t	gcta	actccg	480
ccgg	gtto	ctg t	tact	tgtto	cc g	cacco	cgaac	ato	gaag	gaag	ttg	ctct	gtc (gacta	actggt	540
gaaa	atccc	gt t	cta	eggta	aa a	gctat	caaq	g cto	gagg	gtta	tcaa	aaggi	gg t	cgt	cacctg	600
attt	tctç	gee a	actct	taaaa	aa a	aaat	gegae	gaa	actgo	gctg	ctaa	agcti	gt t	gcto	tgggt	660
atca	acgo	ctg t	tgct	tact	a c	cgtg	gtata	g gad	gttt	ctg	ttat	caaq	gac t	tctç	ggtgac	720
gtto	gttgt	tg t	ggc	cacto	ga c	getet	gato	g act	ggtt	aca	ctg	gtga	ctt o	cgact	ctgtt	780
atco	gatto	gca a	acact	ttgcg	gt ta	actca	agaco	gta	agatt	tta	gcct	gga	ccc (gactt	tcact	840

-continued

atco	jaaad	ga t	caco	cctg	cc go	cagga	atgca	a gti	tece	gta	ccca	agcgi	tag 1	tggc	gtacc	900
ggta	aagg	gca a	aacco	gggta	at tt	acc	gttt	gt	ggcgo	ccgg	gcga	agcgt	tee a	atcco	ggtatg	960
ttcg	jataç	get d	ctgtt	ctg	g to	gagt	gttat	gad	gegg	ggtt	gcg	gtg	gta (cgaad	ctgact	1020
ccgg	ıctga	aaa o	ctact	gta	eg co	ctgc	gtgca	a tao	catga	aata	cgc	gggt	tat (gccg	gtgtgt	1080
caaç	jacca	acc t	ggaa	attti	g gg	gaag	gtgto	tt!	cacto	ggcc	tgad	cccat	tat (cgac	gcacac	1140
tttc	tgto	ecc a	agact	caaa	ca gt	ctg	gtgaa	a aa	cctgo	ccgt	acct	ggt	ggc (gtato	caagcc	1200
acto	ıtgtç	geg (cccgt	gcg	ca go	gege	egeca	a cc	gaget	ggg	acca	aaat	gtg (gaagt	geetg	1260
atco	gtct	ga a	aacco	gacco	ct go	cacg	gtcc	g ac	gccad	ctgc	tgta	accg	cct q	gggtg	gcagtg	1320
caga	acga	aaa t	caco	gatga	ac go	cacco	eggto	c act	caaat	aca	ttat	gact	ttg (catga	agcgca	1380
gaco	tgga	ag t	ggt	gacti	cc c											1401
<211 <212 <213 <220	.> LH: > T: > OH:	ENGTE (PE: RGAN: EATUE THER	ISM: RE:	Art: ORMA	ific: FION:		-		n of	Art:	ific	ial :	Seque	ence	: Synth	netic
< 400)> SI	EQUEI	ICE:	60												
Ala 1	Val	Asp	Phe	Ile 5	Pro	Val	Glu	Asn	Leu 10	Glu	Thr	Thr	Met	Arg 15	Ser	
Pro	Val	Phe	Thr 20	Asp	Asn	Ser	Ser	Pro 25	Pro	Val	Val	Pro	Gln 30	Ser	Phe	
Gln	Val	Ala 35	His	Leu	His	Ala	Pro 40	Thr	Gly	Ser	Gly	Lys 45	Ser	Thr	Lys	
Val	Pro 50	Ala	Ala	Tyr	Ala	Ala 55	Gln	Gly	Tyr	Lys	Val 60	Leu	Val	Leu	Asn	
Pro 65	Ser	Val	Ala	Ala	Thr 70	Leu	Gly	Phe	Gly	Ala 75	Tyr	Met	Ser	ГЛа	Ala 80	
His	Gly	Ile	Asp	Pro 85	Asn	Ile	Arg	Thr	Gly 90	Val	Arg	Thr	Ile	Thr 95	Thr	
Gly	Ser	Pro	Ile 100	Thr	Tyr	Ser	Thr	Tyr 105	Gly	Lys	Phe	Leu	Ala 110	Asp	Gly	
Gly	Cys	Ser 115	Gly	Gly	Ala	Tyr	Asp 120	Ile	Ile	Ile	CÀa	Asp 125	Glu	CÀa	His	
Ser	Thr 130	Asp	Ala	Thr	Ser	Ile 135	Leu	Gly	Ile	Gly	Thr 140	Val	Leu	Asp	Gln	
Ala 145	Glu	Thr	Ala	Gly	Ala 150	Arg	Leu	Val	Val	Leu 155	Ala	Thr	Ala	Thr	Pro 160	
Pro	Gly	Ser	Val	Thr 165	Val	Pro	His	Pro	Asn 170	Ile	Glu	Glu	Val	Ala 175	Leu	
Ser	Thr	Thr	Gly 180	Glu	Ile	Pro	Phe	Tyr 185	Gly	Lys	Ala	Ile	Pro 190	Leu	Glu	
Val	Ile	Lys 195	Gly	Gly	Arg	His	Leu 200	Ile	Phe	Cys	His	Ser 205	Lys	Lys	Lys	
Cys	Asp 210	Glu	Leu	Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val	
Ala 225	Tyr	Tyr	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240	
Val	Val	Val	Val	Ala	Thr	Asp	Ala	Leu	Met	Thr	Gly	Tyr	Thr	Gly	Asp	

250

Phe	Asp	Ser	Val 260	Ile	Asp	Cys	Asn	Thr 265	Cys	Val	Thr	Gln	Thr 270	Val	Asp	
Phe	Ser	Leu 275	Asp	Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln	
Asp	Ala 290	Val	Ser	Arg	Thr	Gln 295	Arg	Arg	Gly	Arg	Thr 300	Gly	Lys	Gly	Lys	
Pro 305	Gly	Ile	Tyr	Arg	Phe 310	Val	Ala	Pro	Gly	Glu 315	Arg	Pro	Ser	Gly	Met 320	
Phe	Asp	Ser	Ser	Val 325	Leu	Сла	Glu	Сла	Tyr 330	Asp	Ala	Gly	CÀa	Ala 335	Trp	
Tyr	Glu	Leu	Thr 340	Pro	Ala	Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met	
Asn	Thr	Pro 355	Gly	Leu	Pro	Val	Сув 360	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu	
Gly	Val 370	Phe	Thr	Gly	Leu	Thr 375	His	Ile	Asp	Ala	His 380	Phe	Leu	Ser	Gln	
Thr 385	ГÀа	Gln	Ser	Gly	Glu 390	Asn	Leu	Pro	Tyr	Leu 395	Val	Ala	Tyr	Gln	Ala 400	
Thr	Val	Cys	Ala	Arg 405	Ala	Gln	Ala	Pro	Pro 410	Pro	Ser	Trp	Asp	Gln 415	Met	
Trp	ГÀа	Cys	Leu 420	Ile	Arg	Leu	Lys	Pro 425	Thr	Leu	His	Gly	Pro 430	Thr	Pro	
Leu	Leu	Tyr 435	Arg	Leu	Gly	Ala	Val 440	Gln	Asn	Glu	Ile	Thr 445	Leu	Thr	His	
Pro	Val 450	Thr	ГЛа	Tyr	Ile	Met 455	Thr	Сла	Met	Ser	Ala 460	Asp	Leu	Glu	Val	
Val 465	Thr	Ser														
<213 <213 <213 <220	0 > FI 3 > O	ENGTI (PE : RGAN: EATUI THER	H: 14 DNA ISM: RE:	101 Art: DRMA			_		ı of	Art:	ific	ial :	Seque	ence:	: Synt	hetic
< 40	0> SI	EQUEI	NCE:	61												
gct	gttga	act 1	ttato	cccg	gt to	gaaaa	atcto	gag	gacta	acta	tgc	gttci	cac é	ggttt	tcact	60
gac	aacto	ctt «	ctcc	gccg	gt to	gttco	cgcag	g tct	ttco	cagg	ttg	ctca	cct q	gcato	gctccg	120
act	ggtto	ctg (gtaaa	atcta	ac ta	aaagt	tcca	a gct	gatt	acg	ctg	ctcaç	ggg 1	ttaca	aagtt	180
ctg	gttct	ga a	accc	gtct	gt to	gctgo	ctact	cte	gggtt	tcg	gcg	ccta	cat o	gtcta	aagct	240
cac	ggtat	cg a	accc	gaaca	at to	cgtac	ctggt	gta	acgta	acta	tcad	ctaci	gg 1	ttctc	ccgatc	300
acti	tacto	cta (cttad	cggta	aa at	tcct	egget	gad	ggtg	ggtt	gcto	ctggi	gg 1	tgatt	acgat	360
atc	atcat	ct	gcgad	cgaat	eg co	cacto	ctact	gad	egeta	actt	ctat	cct	ggg 1	tatco	ggtacc	420
gtt	ctgga	acc a	aggct	gaaa	ac to	gcago	gtgct	c cgt	ctg	gttg	ttct	ggc1	ac 1	tgcta	actccg	480
ccg	ggtto	ctg 1	ttact	gtt	ec go	cacco	cgaad	ato	gaag	gaag	ttg	ctct	gtc	gacta	actggt	540
gaa	atcco	gt 1	tctad	ggt	aa aq	gctat	caaq	g cto	gagg	gtta	tcaa	aaggt	gg 1	tegte	cacctg	600
att	ttctç	gcc a	actct	caaaa	aa aa	aaatg	gcgad	gaa	ectg	gctg	ctaa	agcti	gt 1	tgcto	tgggt	660
atc	aacgo	ctg 1	ttgct	tacı	ca co	gtgg	gtctg	g gad	gttt	ctg	ttat	ccc	gac 1	ttctç	ggtgac	720
gtt	gttgt	tg 1	tggc	cact	ga co	getet	gato	g act	ggtt	aca	ctg	gtga	ett «	cgact	ctgtt	780

### Acceptance acceptance gragatitus georgaacce gactiticate 840 atcagaacqs teaccetace gragataga gittcocqta cocagegicq tggccqtacc 900 ggtcgggaa aaccgggtat ttaccgttic gtgggcgcgg ggagggtcc atccggtaty 960 ticgatagct cigtitigtg tgagtgtat gacgcgggta ggaggggtc atcaggtast 1020 ccggctgaaa ctactgaacg cctgcgtgca tacatgaata cgccgggtta ggagggtggt 1080 caagaccacc tggaattitg ggaaggtgte titactggcc tgacccatat cgacgcacac 140 titctgtccc agactaaaca gtctggtggaa aacctgcgtg gaccaatat ggaggacgc 1200 actgtgtgcg cccggacgacgacgacaccaccaccaccaccaccaccacc		
### Secretary Se	atcgattgca acacttgcgt tactcagacc g	gtagatttta gcctggaccc gactttcact 840
cegactagact ctgttctgtg tgagtgttat gacgegggta gegegtggta cegactgact ceggetgaaa ctactgtacg cetgegtgca tacatgaata cecegggtet geoggtgtgt caagaccacc tggaattttg ggaaggtgt tttactggce tgacccatat egacgcacac 1200 actgtgtgce agactaaaca gtetggtgaa aacctgcegt acetggtgge gtatcaagce 1200 actgtgtgcg ceegtgega ggegeegeca eegagetggg accaaatgt gaagtgeetg 1260 actegttga aaccgacet geaceggte actaaataca ttatgacttg eatgagegea 1320 cagaacgaaa teacgetgac geaceceggte actaaataca ttatgacttg eatgagegea 1320 cagaacgaaa teacgetgac geaceceggte actaaataca ttatgacttg eatgagegea 1340 cagaacgaaa tggtgacttc c 1401 <pre><210</pre>	atcgaaacga tcaccctgcc gcaggatgca g	gtttcccgta cccagcgtcg tggccgtacc 900
Coggetqaaa ctactgtaeg ctgogtgca tacatgaata cgcogggtct gccggtgtgt 1080	ggtcgcggca aaccgggtat ttaccgtttc g	gtggcgccgg gcgagcgtcc atccggtatg 960
caagaccacc tggaattttg ggaaggtgtc tttactggcc tgacccatat cgacgcacac 1200 actgtgtgcc cagctacacac gcttggtga aacctgccgt acctggtggc gtatcaagcc 1200 actgtgtgcg cccgtgcgca ggcgccgca ccgagctggg accaaatgtg gaagtgcctg 1260 atccgtctga aaccgacct gcacggtccg acgcactgc tgtaccgcct gggtgcagtg 1320 cagaacgaaa tcacgctgac gcacccggtc actaaataca ttatgacttg catgagcgca 1380 gacctggaag tggtgacttc c 1401 <pre> <pre> <pre> <pre></pre></pre></pre></pre>	ttcgataget etgttetgtg tgagtgttat g	gacgcgggta gcgcgtggta cgaactgact 1020
thictgives agactaases givingsigas accidency accignings giateaages 1260 actignings coccidency accidency acc	ccggctgaaa ctactgtacg cctgcgtgca t	acatgaata cgccgggtct gccggtgtgt 1080
actgygtgcg cccgtgcgca ggcgccgca ccgagctggg accaaatgtg gaagtgcctg 1200 atccgtcga aaccgacct gcaccggtccg acgccatgc tgtaccgcct gggtgcagtg 1320 cagaacgaaa tcacgctgac gcacccggtc actaaataca ttatgacttg catgagcgca 1380 gacctggaag tggtgacttc c 1401 <pre> <210> SEQ ID NO 62 <211> IENNTH: 467 <212> TYPE: PRT <212> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INNORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 62 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1</pre>	caagaccacc tggaattttg ggaaggtgtc t	ttactggcc tgacccatat cgacgcacac 1140
cagaacgaaa tcacgctgac gcaccggtc actaaataca ttatgacttg catgaggacg 1380 gacctggaag tggtgacttc c 1401 <pre> <a< td=""><td>tttctgtccc agactaaaca gtctggtgaa a</td><td>acctgccgt acctggtggc gtatcaagcc 1200</td></a<></pre>	tttctgtccc agactaaaca gtctggtgaa a	acctgccgt acctggtggc gtatcaagcc 1200
Cagaacgaaa tcacgctgac gcacccggtc actaaataca ttatgacttg catgagcgca	actgtgtgcg cccgtgcgca ggcgccgcca c	cgagctggg accaaatgtg gaagtgcctg 1260
SEQ ID NO 62	atccgtctga aaccgaccct gcacggtccg a	acgccactgc tgtaccgcct gggtgcagtg 1320
C210 SEQ ID NO 62	cagaacgaaa tcacgctgac gcacccggtc a	actaaataca ttatgacttg catgagcgca 1380
<pre> <211> LENGTH: 467 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <222> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide </pre> <pre> <400> SEQUENCE: 62 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1</pre>	gacctggaag tggtgacttc c	1401
Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1 Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe 20	<211> LENGTH: 467 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Descripti	
1	<400> SEQUENCE: 62	
20	<u>-</u>	
Yal Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Ash So Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala So Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala So Ser Gly Ile Ash Pro Ash Ile Arg Thr Gly Val Arg Thr Ile Thr Thr Ser Thr Tyr Gly Lys Phe Leu Ala Ash Gly Gly Gly Ala Tyr Ash Ile Ile Gly Thr Val Leu Ash Gly Gly Ala Tyr Ash Ile Gly Thr Val Leu Ash Gln Ila Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Pro Ile Ile Gly Thr Val Leu Ash Gln Info	=	
50		
65		
90 95 Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly 110 110 110 110 110 110 110 110 110 11		
100		
Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln 130 Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro 145 Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu 175 Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu 180 Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Lys 195 Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 210 Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp		
Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro 145 Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu 175 Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu 180 Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Lys 195 Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 210 Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp		
Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu 175 Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu 180 Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Lys 195 Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 210 Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp		
Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu 180 Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Lys Lys 195 Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 210 Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp		
Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Lys 195 200 205 Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 210 215 220 Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp		
Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 210 215 220 Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp		
Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 210 215 220 Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp		
Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp	Cys Asp Glu Leu Ala Ala Lys Leu Va	al Ala Leu Gly Ile Asn Ala Val
	Ala Tyr Tyr Arg Gly Leu Asp Val Se	er Val Ile Pro Thr Ser Gly Asp

Val	Val	Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp	
Phe	Asp	Ser	Val 260	Ile	Asp	CAa	Asn	Thr 265	Cys	Val	Thr	Gln	Thr 270	Val	Asp	
Phe	Ser	Leu 275	Asp	Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln	
Asp	Ala 290	Val	Ser	Arg	Thr	Gln 295	Arg	Arg	Gly	Arg	Thr 300	Gly	Arg	Gly	Lys	
Pro 305	Gly	Ile	Tyr	Arg	Phe 310	Val	Ala	Pro	Gly	Glu 315	Arg	Pro	Ser	Gly	Met 320	
Phe	Asp	Ser	Ser	Val 325	Leu	Cys	Glu	Сув	Tyr 330	Asp	Ala	Gly	Ser	Ala 335	Trp	
Tyr	Glu	Leu	Thr 340	Pro	Ala	Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met	
Asn	Thr	Pro 355	Gly	Leu	Pro	Val	360	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu	
Gly	Val 370	Phe	Thr	Gly	Leu	Thr 375	His	Ile	Asp	Ala	His 380	Phe	Leu	Ser	Gln	
Thr 385	Lys	Gln	Ser	Gly	Glu 390	Asn	Leu	Pro	Tyr	Leu 395	Val	Ala	Tyr	Gln	Ala 400	
Thr	Val	Cys	Ala	Arg 405	Ala	Gln	Ala	Pro	Pro 410	Pro	Ser	Trp	Asp	Gln 415	Met	
Trp	Lys	Сув	Leu 420	Ile	Arg	Leu	Lys	Pro 425	Thr	Leu	His	Gly	Pro 430	Thr	Pro	
Leu	Leu	Tyr 435	Arg	Leu	Gly	Ala	Val 440	Gln	Asn	Glu	Ile	Thr 445	Leu	Thr	His	
Pro	Val 450	Thr	Lys	Tyr	Ile	Met 455	Thr	Cys	Met	Ser	Ala 460	Asp	Leu	Glu	Val	
Val 465	Thr	Ser														
<21: <21: <21: <22: <22:	1 > LI 2 > T 3 > OI 0 > FI 3 > O' po	ENGTI YPE : RGAN: EATUI THER olyni	ISM: RE: INFO	Art: Art: ORMA: otide	rion				ı of	Art:	ific	ial S	Seque	ence:	: Syntl	netic
gct	gttga	act 1	ttat	cccg	gt to	gaaaa	atcto	gaç	gacta	acta	tgc	gttct	caa q	ggttt	tcact	60
gaca	aacto	ctt (ctcc	geegg	gt to	gttc	egeag	g tci	ttc	cagg	ttg	ctcac	ect (gcato	gctccg	120
act	ggtt	ctg (gtaa	atcta	ac ta	aaagt	ttcca	a gct	gcti	acg	ctg	ctcaç	ggg 1	ttaca	aagtt	180
ctg	gttct	iga a	accc	gtct	gt to	gctg	ctact	cte	gggti	tcg	gcg	ccta	cat q	gtcta	aagct	240
cac	ggtat	cg a	accc	gaaca	at to	cgta	ctggt	gta	acgta	acta	tcad	ctact	gg 1	ttctc	ecgate	300
act	tacto	cta «	ctta	eggta	aa at	tcci	tggct	gad	ggt	ggtt	gct	ctggt	gg 1	tgctt	acgat	360
atc	atcat	ct q	gcga	cgaat	g c	cacto	ctact	gad	egeta	actt	ctat	cct	ggg 1	tatco	ggtacc	420
gtt	ctgga	acc a	aggci	tgaaa	ac to	gcag	gtgct	c cgt	ctg	gttg	ttct	ggct	cac 1	tgcta	actccg	480
ccg	ggtto	ctg 1	ttacı	tgtto	ec go	cacco	cgaad	c ato	cgaaq	gaag	ttg	ctctç	gtc	gacta	actggt	540
gaa	atcc	egt 1	tcta	cggta	aa aq	gctai	tccc	g cto	gag	gtta	tcaa	aaggt	gg 1	tegte	cacctg	600
atti	tctç	gcc a	actci	taaaa	aa aa	aaat	gcgad	gaa	actg	gctg	ctaa	agctt	gt 1	tgcto	tgggt	660
atc	aacgo	ctg 1	ttgci	ttact	ca co	egtg	gtct	g gad	egtti	ctg	ttat	caaq	gac 1	ttate	ggtgac	720

ategattgated tagecataga egetetgateg actgattaca etagateatt egactetgat 840 ategaatega acacttgat tacteagace gragattta goetgacce gactttoact 840 ategaacaga teacectage gragagataga gittecepta cecagegiteg tagecagate 900 ggtegeggea acaceggata tracegitite gigageggeaga gaageggate atecagatagat 1020 teegaage tetgitegit gageggaggate atecaggateg 1020 cegagegaacacac tagattgag gedgaggata tacatgaata egeogggited geoggaggate caacagaacace tagaattitig ggaaggage titactgage tagacegaacacac 1140 acacagacacac tagaattitig ggaaggage titactgage gacceatat egacgacaca 1200 actgatige dactagagaa aacctgacga accagatigag gaatteaga 1200 actgatigag agacagagaa accagactig egaggaggagga accaaatiga gaagtgacig 1220 cagaacgaaa teacgatiga ggaccegga accaagateg titacagace accagaacgaa taccigatiga gaaccaggate actaaataca tatagactig gaagtgadig 1320 cagaacgaaa teacgatiga geacceggic actaaataca tatagactig agaatgacig 1320 cagaacgagaa teacgatiga geacceggic actaaataca tatagactig agaatgacig 1320 cagaacgagaa teacgatiga geacceggic actaaataca tatagactig agaatgacig 1320 cagaacgagaa taccigatiga geacceggic actaaataca tatagactig agaatgacig 1320 cagaacgagaa taccigatiga geacceggic actaaataca tatagactig agaatgacig 1320 cagaacgagaa taccigtiga gacceggic actaaataca tatagactig agaatgacig 1320 cagaacgagaa taccigtiga geacceggic actaaataca tatagactig agaatgacig 1320 cagaacgagaa taccigtiga gacceggic accaagactiga gacceggic accaggiciga accaaatig gaagtgacig 1220 cagaacgagaactigaa gacceggic accaagacace tigaacgacig gaccacgacacac tigaacagaacace tigaacgacacacacacacacacacacacacacacacacac		
getogogoa aacoggetat ttacogttc gtgogogog gogagogtcc atcoggtaty getogogoga aacoggetat ttacogttc gtgogogog gogagogtcc atcoggtaty peopogogog togagogogogogogogogogogogogogogogogogogo	gttgttgttg tggccactga cgctctgatg actggttaca ctggtgactt cgactctgtt	780
### Secretary 960 atogattgca acacttgcgt tactcagacc gtagatttta gcctggaccc gactttcact	840	
ttegataget etgttetgtg tgagtgttat gacgegggt gegggggta egaactgact 1020 ceggetgaaa etactgtaeg cetgegtgta tacatgaata egeegggtet geeggtgtt 1080 caagaccace tggaattttg ggaagtgte tttactgge tgaccatat egaeggacac 1140 tttetgtee agactaaaca gtetggtgaa aacetgeegt acetggtge gtatecaage 1200 actgtgtgeg eeggegegegegegegegegegegegegege	atcgaaacga tcaccctgcc gcaggatgca gtttcccgta cccagcgtcg tggccgtacc	900
cagactagaa ctactgtacg cctgcgtgca tacatgaata cgccgggtct gccggtgtgt 1800 caagaccacc tggaattttg ggaaggtgtc tttactggcc tgacccatat cgacgcacac 1140 tttetgtecc agactaaaca gtetggtga aacctgccgt acctggtgg gtatcaagcc 1200 actgtgtgcg cccgtgcga ggcgccgcca ccgagctgg accaaatgt gaagtgcctg 1260 atccgtctga aaccgacct gcacggtccg acgacactgc tgtaccgcct gggtgcagtg 1320 cagaacgaaa tcacgctgac gcaccggtc actaaataca ttatgacttg catgagcgc 1380 gacctggaag tggtgacttc c 1401 c210 SEO ID NO 64 c211 LEMOTH: 467 c212 TYPE: PRT c213 ORGANISM: Artificial Sequence c220 FEATURE: c223 OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide c400 SEQUENCE: 64 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1	ggtcgcggca aaccgggtat ttaccgtttc gtggcgccgg gcgagcgtcc atccggtatg	960
casgaccac tggaattttg ggaaggtgtc tttactggcc tgacccatat cgacgcacac 1140 tttetgtocc agactaaaca gtetggtgaa aacctgccgt acctggtggc gtatcaagcc 1200 actgtgtgcg cccgtgcgca ggcgccgcca ccgagctggg accaaatgtg gaagtgcctg 1260 atccgtctga aaccgacct gcacggtccg acgacctgc tgtaccgct gggtgcagtg 1320 cagaacgaaa tcacgctgac gcacccggtc actaaataca ttatgacttg catgagcgca 1380 gacctggaag tggtgacttc c 1401 <pre> <210 > SEO ID NO 64 <2212 > TYPE: PRT <2123 > ORSANISM: Arrificial Sequence <220 > FEATURE: <2223 > OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400 > SEQUENCE: 64 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1</pre>	ttcgatagct ctgttctgtg tgagtgttat gacgcgggtt gcgcggcgta cgaactgact	1020
actggtgcg cccgtgcgca ggcgccgca ccgagctgg acaaagtg gaagtgcctg 1260 actggtgcg cccgtgcgca ggcgccgca ccgagctgg acaaagtg gaagtgcctg 1260 atccgtctga aaccgacct gcacggtccg acgccactgc tgtaccgcct gggtgcagtg 1320 cagaacgaaa tcacgctgac gcaccggtc actaaataca ttatgacttg catgagcgca 1380 gacctggaag tggtgacttc c 1401 <210 > SEQ ID NO 64 <211 > LENGTH: 467 <212 > TTPE PRT <2123 > TTPE PRT <213 > ORGANISM: Artificial Sequence <220 > FEATURE: <223 > TOHER IMPORNATION: Description of Artificial Sequence: Synthetic polypeptide <400 > SEQUENCE: 64 Ala Val Amp Phe Ile Pro Val Glu Amn Leu Glu Thr Thr Met Arg Ser 1	ccggctgaaa ctactgtacg cctgcgtgca tacatgaata cgccgggtct gccggtgtgt	1080
actggtgtgcg cccgtgcgca ggcgccgca ccgagctggg accaaatgtg gaagtgcctg 1260 atccgtctga aaccgacct gcaccggtccg acgccatcg tgtaccgcct gggtgcagtg 1320 cagaacgaaa tcacgctgac gcacccggtc actaaataca ttatgacttg catgagcgca 1380 gacctggaag tggtgacttc c 1401 <210 > SEQ ID NO 64 <211 > LENGTH: 467 <212 > TTPE: PRT <212 > ORGANISM: Artificial Sequence <220 > FEATURE: <222 > FOTHER INDOMMATION: Description of Artificial Sequence: Synthetic polypeptide <400 > SEQUENCE: 64 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1	caagaccacc tggaattttg ggaaggtgtc tttactggcc tgacccatat cgacgcacac	1140
cagaccgaaa tcacgccct gcaccggtccg acgccactgc tgtaccgcct gggtgcagtg 1320 cagaacgaaa tcacgctgac gcacccggtc actaaataca ttatgacttg catgagcgca 1380 gacctggaag tggtgacttc c 1401 <210 > SEQ ID NO 64 <211 > LENGTH: 467 <212 > TTPE: PRT <212 > TTPE: PRT <212 > TTPE: PRT <213 > ORGANISM: Artificial Sequence <220 > FEATURE: <222 > OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <4400 > SEQUENCE: 64 Ala Val Agp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1	tttctgtccc agactaaaca gtctggtgaa aacctgccgt acctggtggc gtatcaagcc	1200
gacctggaag tggtgacttc c 1401 <pre> cagaacggaag tggtgacttc c 1401 <pre> cagaacggaag tggtgacttc c 1401 cagactggaag tggtgactc cagactggaag agactgag tggtgactetegacectgactggaag acctggaag agactgactgactgactggaag agactgactgactgactgactgactgactgactgactgac</pre></pre>	actgtgtgcg cccgtgcgca ggcgccgcca ccgagctggg accaaatgtg gaagtgcctg	1260
210 SEQ ID NO 64 2211 LENGTH: 467 212 TYPE: PRT 2121 JENGTH: 467 220 FEATURE: 2220 FEATURE: 2223 OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide 2400 SEQUENCE: 64 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1	atccgtctga aaccgaccct gcacggtccg acgccactgc tgtaccgcct gggtgcagtg	1320
<pre> <210> SEQ ID NO 64 <211> LENGTH: 467 <212> TYPE: PRT <212> TYPE: PRT <212> ORGANISM: Attificial Sequence <220> FEATURE: <222> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide </pre> <pre> <400> SEQUENCE: 64 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1</pre>	cagaacgaaa tcacgctgac gcacccggtc actaaataca ttatgacttg catgagcgca	1380
C211 LENGTH: 467 C212 TYPE: PRT C213 ORGANISM: Artificial Sequence C220 FEATURE: C223 ORGANISM: Artificial Sequence C223 ORGANISM: Artificial Sequence C223 ORGANISM: Artificial Sequence: Synthetic polypeptide C400 SEQUENCE: 64	gacctggaag tggtgacttc c	1401
<pre>2211> LEMOTH: 467 2212> TYPE: PRT 2213> ORGANISM: Artificial Sequence 2220> FEATURE: 2223> OTHER INPORMATION: Description of Artificial Sequence: Synthetic polypeptide 2400> SEQUENCE: 64 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1</pre>		
C212> TYPE: PRT		
<pre><220> FEATURE:</pre>	<212> TYPE: PRT	
Polypeptide C400> SEQUENCE: 64	<u>-</u>	
Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1		etic
Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1 10 15 Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe 20 25 25 25 26 26 26 26 27 27 28 20 26 27 28 20 20 20 20 20 20 20 20 20 20 20 20 20	* ** *	
1		
20	-	
Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Ash So Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala So Ala Gln Gly Thr Gly Val Arg Thr Thr Ser Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly Gly Gly Ala Tyr Asp The Thr Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Ala Arg Thr Leu Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Ala Arg Leu Val Val Leu Ala Thr Pro Ala Glu Thr Val Pro His Pro Ash Thr Ala Thr Ala Leu Ala Thr Ala Thr Tyr Ser Thr Tyr Gly Lys Ala Thr Ala Thr Ala Thr Ala Thr Ala Thr Tro Thr Thr Gly Glu Thr Tyr Gly Lys Ala Thr Ala Thr Ala Leu Ala Thr Thr Gly Glu Thr Tyr Gly Lys Ala Thr Tyr Tyr Gly Lys Ala Thr Tyr Leu Glu Tyr Tyr Tyr Gly Lys Ala Thr Lys Ly	-	
50 55 60 Pro Ser Val Ala Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala 80 His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr 85 Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly 1100 Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His 115 Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln 130 Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro 160 Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu 175 Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu 180 Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Lys 195 Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 210		
His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr 85 Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly 110 Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His 115 Cys Thr 120 Cys Asp Glu Cys His 125 Cys Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln 130 Cys His 150 Cys Cys Lys Dro 160 Cys		
Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly 110 Cys Ser Gly Gly Ala Tyr Asp 120 Ile Ile Cys Asp Glu Cys His 125 Ile Leu Gly Ile Gly Thr Val Leu Asp Gln 130 Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro 145 Ile Cys Asp Glu Cys His 155 Ile Cys Asp Glu Cys His 150 Ile Gly Thr Val Leu Asp Gln 140 Ile Cys Asp Glu Cys His 125 Ile Gly Thr Val Leu Asp Gln 140 Ile Cys Asp Glu Cys His 125 Ile Gly Thr Val Leu Asp Gln 140 Ile Gly Thr Ala Thr Pro 160 Ile Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu 175 Ile Cys Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu 180 Ile Cys Asp Glu Leu Ala Ala Leu 118 Ile Phe Cys His Ser Lys Lys Lys 195 Ile Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asp Ala Val 210 Ile Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asp Ala Val 220 Ile Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asp Ala Val 220 Ile Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asp Ala Val 220 Ile Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asp Ala Val 220 Ile Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asp Ala Val 220 Ile Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asp Ala Val 220 Ile Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asp Ala Val 220 Ile Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asp Ala Val 220 Ile Cys His Ser Lys Lys Lys Lys Lys 220 Ile Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asp Ala Val 220 Ile Cys His Ser Lys Lys Lys Lys 220 Ile Cys His Ser Lys Lys Lys Lys 220 Ile Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asp Ala Val 220 Ile Cys His Ser Lys Lys Lys Ile Cys His Ser Lys Lys Lys Ile Cys His Ile		
Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His 115 Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln 130 Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro 145 Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu 175 Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu 180 Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Lys 195 Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 210 Ser Thr Thr Gly Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 220 Ser Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 220 Ser Thr Thr Gly Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 220 Ser Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 220 Ser Thr Thr Gly Gly Arg His Leu Val Ala Leu Gly Ile Asn Ala Val 220 Ser Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 220 Ser Thr Thr Gly Gly Arg His Leu Val Ala Leu Gly Ile Asn Ala Val 220 Ser Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val		
Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His 115 Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln 130 Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro 145 150 Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu 175 Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu 180 Thr Ala Ile Pro Leu Glu 185 Cys Asp Glu Leu Ala Ala Leu Val Ala Leu Gly Ile Pro Phe Cys His Ser Lys Lys Lys 195 Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 210 Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 220	Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly	
Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln 130 Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Pro 145 Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu 170 Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu 180 Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys 195 Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 210	100 105 110	
Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro 145 Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu 175 Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu 180 Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Lys 195 Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 210		
Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu 175 Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu 185 Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Lys 205 Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 210		
Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu 180		
Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Lys 195 Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 210		
195 200 205 Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 210 215 220		
Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 210 215 220		
	Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val	

225	230	235		240
			Gly Tyr Thr Gly	
	245	250	255	•
Phe Asp Ser Val 260	Ile Asp Cys A	sn Thr Cys Val 265	Thr Gln Thr Val 270	Asp
Phe Ser Leu Asp 275		hr Ile Glu Thr 80	Ile Thr Leu Pro 285	Gln
Asp Ala Val Ser 290	Arg Thr Gln A	rg Arg Gly Arg	Thr Gly Arg Gly	Lys
Pro Gly Ile Tyr 305	Arg Phe Val A	la Pro Gly Glu 315	Arg Pro Ser Gly	Met 320
Phe Asp Ser Ser	Val Leu Cys G 325	lu Cys Tyr Asp 330	Ala Gly Cys Ala 335	Ala
Tyr Glu Leu Thr	Pro Ala Glu T	hr Thr Val Arg 345	Leu Arg Ala Tyr 350	Met
Asn Thr Pro Gly		ys Gln Asp His 60	Leu Glu Phe Trp	Glu
Gly Val Phe Thr	Gly Leu Thr H	is Ile Asp Ala	His Phe Leu Ser	Gln
		eu Pro Tyr Leu 395	Val Ala Tyr Gln	Ala 400
			Ser Trp Asp Gln 415	
		ys Pro Thr Leu	His Gly Pro Thr	Pro
			430 Ile Thr Leu Thr	His
435		40 hr Cyc Met Ser	445 Ala Asp Leu Glu	Val
450	455	nr cys met ser	460	vai
Val Thr Ser 465				
<pre><210> SEQ ID NO <211> LENGTH: 1 <2112> TYPE: DNA <213> ORGANISM: <220> FEATURE: <223> OTHER INF polynucle</pre>	401 Artificial Se ORMATION: Desc	_	ificial Sequence	: Synthetic
<400> SEQUENCE:	65			
gctgttgact ttat	cccggt tgaaaat	ctc gagactacta	tgcgttctcc ggttt	tcact 60
gacaactctt ctcc	geeggt tgtteeg	cag tettteeagg	ttgctcacct gcate	gctccg 120
actggttctg gtaa	atctac taaagtt	cca gctgcttacg	ctgctcaggg ttaca	aaagtt 180
ctggttctga acco	gtctgt tgctgct	act ctgggtttcg	gcgcctacat gtcta	aaagct 240
cacggtatcg acco	gaacat tegtaet	ggt gtacgtacta	tcactactgg ttct	ecgate 300
acttactcta ctta	cggtaa attcctg	gct gacggtggtt	getetggtgg tgett	acgat 360
atcatcatct gcga	cgaatg ccactct	act gacgctactt	ctatcctggg tatcg	ggtacc 420
gttctggacc aggc	tgaaac tgcaggt	get egtetggttg	ttctggctac tgcta	actccg 480
ccgggttctg ttac	tgttcc gcacccg	aac atcgaagaag	ttgctctgtc gacta	actggt 540
gaaatcccgt tcta	cggtaa agctatc	ccg ctcgaggtta	tcaaaggtgg tcgto	cacctg 600
attttctgcc actc	taaaaa aaaatgo	gac gaactggctg	ctaagcttgt tgcto	etgggt 660

atcaacgctg	ttgcttacta d	ccgtggtctg	gacgtttctg	ttatcccgac	ttctggtgac 720
gttgttgttg	tggccactga d	gctctgatg	actggttaca	ctggtgactt	cgactctgtt 780
atcgattgca	acacttgcgt t	actcagacc	gtagatttta	gcctggaccc	gactttcact 840
atcgaaacga	tcaccctgcc (gcaggatgca	gtttcccgta	cccagcgtcg	tggccgtacc 900
ggtcgcggca	aaccgggtat t	taccgtttc	gtggcgccgg	gcgagcgtcc	atccggtatg 960
ttcgatagct	ctgttctgtg t	gagtgttat	gacgcgggtt	gcgcgtggta	cgaactgact 1020
ccggctgaaa	ctactgtacg (ectgegtgea	tacatgaata	cgccgggtct	geeggtgtet 1080
caagaccacc	tggaattttg 🤉	ggaaggtgtc	tttactggcc	tgacccatat	cgacgcacac 1140
tttctgtccc	agactaaaca 🤅	gtctggtgaa	aacctgccgt	acctggtggc	gtatcaagcc 1200
actgtgtgcg	cccgtgcgca (ggegeegeea	ccgagctggg	accaaatgtg	gaagtgeetg 1260
atccgtctga	aaccgaccct (gcacggtccg	acgccactgc	tgtaccgcct	gggtgcagtg 1320
cagaacgaaa	tcacgctgac (gcacccggtc	actaaataca	ttatgacttg	catgagegea 1380
gacctggaag	tggtgacttc (2			1401
<220> FEATU <223> OTHER	H: 467 PRT USM: Artific RE:	•		ificial Sequ	ence: Synthetic
<400> SEQUE	NCE: 66				
Ala Val Asp 1	Phe Ile Pro 5	Val Glu	Asn Leu Glu 10	Thr Thr Met	Arg Ser 15
Pro Val Phe	Thr Asp Asi 20		Pro Pro Val 25	Val Pro Gln 30	Ser Phe
Gln Val Ala	His Leu His	s Ala Pro ' 40	Thr Gly Ser	Gly Lys Ser 45	Thr Lys
Val Pro Ala 50	Ala Tyr Ala	a Ala Gln (55	Gly Tyr Lys	Val Leu Val	Leu Asn
Pro Ser Val	. Ala Ala Thi 70	Leu Gly	Phe Gly Ala 75	Tyr Met Ser	Lys Ala 80
His Gly Ile	Asp Pro Ası 85	ı Ile Arg '	Thr Gly Val	Arg Thr Ile	Thr Thr 95
Gly Ser Pro	Ile Thr Tyr		Tyr Gly Lys 105	Phe Leu Ala	
Gly Cys Ser	Gly Gly Ala	a Tyr Asp	Ile Ile Ile	Cys Asp Glu 125	. Cys His
Ser Thr Asp	Ala Thr Sei	Ile Leu (Gly Ile Gly	Thr Val Leu	. Asp Gln
Ala Glu Thr 145	Ala Gly Ala	_	Val Val Leu 155	Ala Thr Ala	Thr Pro
Pro Gly Ser	Val Thr Val	l Pro His	Pro Asn Ile 170	Glu Glu Val	Ala Leu 175
Ser Thr Thr	Gly Glu Ile		Tyr Gly Lys 185	Ala Ile Pro	
Val Ile Lys	Gly Gly Arg				
	Leu Ala Ala		Val Ala Leu		Ala Val

Ala 225	Tyr	Tyr	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240	
Val	Val	Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp	
Phe	Asp	Ser	Val 260	Ile	Asp	Cys	Asn	Thr 265		Val	Thr	Gln	Thr 270	Val	Asp	
Phe	Ser	Leu 275		Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln	
Asp	Ala 290	Val	Ser	Arg	Thr	Gln 295	Arg	Arg	Gly	Arg	Thr 300	Gly	Arg	Gly	Lys	
Pro 305	Gly	Ile	Tyr	Arg	Phe 310	Val	Ala	Pro	Gly	Glu 315	Arg	Pro	Ser	Gly	Met 320	
Phe	Asp	Ser	Ser	Val 325	Leu	Cys	Glu	Cys	Tyr 330	Asp	Ala	Gly	Сув	Ala 335	Trp	
Tyr	Glu	Leu	Thr 340	Pro	Ala	Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met	
Asn	Thr	Pro 355	Gly	Leu	Pro	Val	Ser 360	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu	
Gly	Val 370	Phe	Thr	Gly	Leu	Thr 375	His	Ile	Asp	Ala	His 380	Phe	Leu	Ser	Gln	
Thr 385	Lys	Gln	Ser	Gly	Glu 390	Asn	Leu	Pro	Tyr	Leu 395	Val	Ala	Tyr	Gln	Ala 400	
Thr	Val	Cys	Ala	Arg 405	Ala	Gln	Ala	Pro	Pro 410	Pro	Ser	Trp	Asp	Gln 415	Met	
Trp	Lys	Cys	Leu 420	Ile	Arg	Leu	Lys	Pro 425	Thr	Leu	His	Gly	Pro 430	Thr	Pro	
Leu	Leu	Tyr 435	Arg	Leu	Gly	Ala	Val 440	Gln	Asn	Glu	Ile	Thr 445	Leu	Thr	His	
Pro	Val 450	Thr	Lys	Tyr	Ile	Met 455	Thr	СЛа	Met	Ser	Ala 460	Asp	Leu	Glu	Val	
Val 465	Thr	Ser														
<211 <212 <213 <220 <223)> FE 3> O'I	ENGTH PE: RGANI EATUR PHER	H: 14 DNA ISM: RE: INFO	101 Arti	NOI		_		ı of	Arti	ifici	ial S	Seque	ence:	: Synthet	ic
)> SE				at to	aaaa	atcto	c gad	acta	icta	taco	attet	.cc c	aattt	tcact	60
															gctccg	120
acto	gtto	etg g	gtaaa	atcta	ac ta	aagt	tcca	a gct	gctt	acg	ctgo	ctcaç	ggg t	taca	aagtt	180
ctg	gttct	ga a	accc	gtctg	gt to	gctgo	ctact	ctg	ggtt	tcg	gcgo	ctac	cat o	gtcta	aagct	240
cacç	gtat	.cg a	accc	gaaca	at to	gtac	tggt	gta	acgta	ecta	tcac	ctact	gg t	tctc	ecgate	300
actt	acto	cta d	cttac	eggta	aa at	tcct	gget	gad	ggtg	gtt	gcto	etggt	gg t	gctt	acgat	360
atca	tcat	ct ç	gcgad	cgaat	g co	cacto	ctact	gad	egeta	ctt	ctat	cctç	ggg t	atco	ggtacc	420
gtto	tgga	acc a	aggct	gaaa	ac to	gcago	gtgct	. cgt	ctgg	gttg	ttct	ggct	ac t	gcta	actccg	480
ccgg	gtto	etg t	tact	gtto	ec go	cacco	gaac	ato	gaag	gaag	ttg	etete	gtc g	gacta	actggt	540
gaaa	atcco	gt t	ctac	eggta	aa aq	gctat	cccc	g cto	gagg	gtta	tcaa	aaggt	gg t	cgto	cacctg	600

attttctgcc	actct	aaaaa a	ıaaatgcga	ıc ga	actggct	g cta	agcttg	ıt tgct	ctgggt	660
atcaacgcto	ttgct	tacta c	cgtggtct	g ga	cgtttct	g tta	tcccga	c ttct	ggtgac	720
gttgttgttg	tggcc	actga c	gctctgat	gac	tggttad	a ctg	gtgact	t cgac	tctgtt	780
atcgattgca	acact	tgcgt t	actcagac	c gt	agatttt	a gcc	tggacc	c gact	ttcact	840
atcgaaacga	tcacc	ctgcc g	gcaggatgo	a gt	ttcccgt	a ccc	agcgtc	g tggc	cgtacc	900
ggtcgcggca	aaccg	ggtat t	taccgttt	c gt	ggcgccg	ig gcg	agcgtc	c atco	ggtatg	960
ttcgatagct	ctgtt	ctgtg t	gagtgtta	ıt ga	cgcgggt	t gcg	cgtggt	a cgaa	ctgact	1020
ccggctgaaa	ctact	gtacg c	ctgcgtgc	a ta	catgaat	a cgc	cgggtc	t gccg	gtgtgt	1080
caagaccacc	tggaa	ttttg g	gaaggtgt	c tt	tactggo	c tga	cccata	t cgac	gcacac	1140
tttctgtccc	agact	aaaca g	ıtctggtga	ıa aa	cctgccg	gt acc	tggtgg	c gtat	caagcc	1200
actgtgtgcg	cccgt	gcgca g	gegeegee	a cc	gagetge	g acc	aaatgt	g gaag	tgcctg	1260
atccgtctga	. aaccg	accct g	gcacggtco	g ac	gccacto	gc tgt	accgcc	t gggt	gcagtg	1320
cagaacgaaa	tcacg	ctgac g	ıcacccggt	c ac	taaatad	a tta	tgacta	g cate	agcgca	1380
gacctggaag	tggtg	acttc c	:							1401
<212> TYPE <213> ORGA <220> FEAT <223> OTHE poly <400> SEQU	NISM: . URE: R INFO peptid	RMATION e	-		n of Aı	rtific	ial Se	quence	: Synth	netic
Ala Val As	-	Ile Pro 5	Val Glu	ı Asn	Leu Gl	u Thr	Thr M	let Arg 15	Ser	
Pro Val Ph	e Thr . 20	Asp Asn	ı Ser Seı	Pro 25	Pro Va	al Val		ln Ser O	Phe	
Gln Val Al 35		Leu His	Ala Pro	Thr	Gly Se	er Gly	Lys S 45	er Thr	Lys	
Val Pro Al 50	a Ala	Tyr Ala	ı Ala Glr 55	gly	Tyr Ly	rs Val 60	Leu V	al Leu	Asn	
Pro Ser Va 65	l Ala.	Ala Thr 70	Leu Gly	7 Phe	Gly Al	-	Met S	er Lys	Ala 80	
His Gly Il		Pro Asn 85	ı Ile Arg	J Thr	Gly Va 90	ıl Arg	Thr I	le Thr 95	Thr	
Gly Ser Pr	o Ile 100	Thr Tyr	Ser Thr	Tyr 105	Gly Ly	s Phe		la Asp 10	Gly	
Gly Cys Se	-	Gly Ala	Tyr Asp 120		Ile I	e Cys.	Asp G 125	lu Cys	His	
Ser Thr As	p Ala	Thr Ser	Ile Leu 135	ı Gly	Ile G	y Thr. 140	Val L	eu Asp	Gln	
Ala Glu Th 145	r Ala	Gly Ala 150	_	ı Val	Val Le		Thr A	la Thr	Pro 160	
Pro Gly Se		Thr Val 165	. Pro His	Pro	Asn II	e Glu	Glu V	al Ala 175		
Ser Thr Th	r Gly	Glu Ile	Pro Phe		Gly Ly	rs Ala			Glu	
	180			185			1	.90		

CAa	Asp 210	Glu	Leu	Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val	
Ala 225	Tyr	Tyr	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240	
Val	Val	Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp	
Phe	Asp	Ser	Val 260	Ile	Asp	СЛа	Asn	Thr 265	СЛа	Val	Thr	Gln	Thr 270	Val	Asp	
Phe	Ser	Leu 275	Asp	Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln	
Asp	Ala 290	Val	Ser	Arg	Thr	Gln 295	Arg	Arg	Gly	Arg	Thr 300	Gly	Arg	Gly	Lys	
Pro 305	Gly	Ile	Tyr	Arg	Phe 310	Val	Ala	Pro	Gly	Glu 315	Arg	Pro	Ser	Gly	Met 320	
Phe	Asp	Ser	Ser	Val 325	Leu	CÀa	Glu	Cys	Tyr 330	Asp	Ala	Gly	Cya	Ala 335	Trp	
Tyr	Glu	Leu	Thr 340	Pro	Ala	Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met	
Asn	Thr	Pro 355	Gly	Leu	Pro	Val	360 CAa	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu	
Gly	Val 370	Phe	Thr	Gly	Leu	Thr 375	His	Ile	Asp	Ala	His 380	Phe	Leu	Ser	Gln	
Thr 385	Lys	Gln	Ser	Gly	Glu 390	Asn	Leu	Pro	Tyr	Leu 395	Val	Ala	Tyr	Gln	Ala 400	
Thr	Val	Cys	Ala	Arg 405	Ala	Gln	Ala		Pro 410	Pro	Ser	Trp	Asp	Gln 415	Met	
Trp	Lys	Сув	Leu 420	Ile	Arg	Leu		Pro 425	Thr	Leu	His	Gly	Pro 430	Thr	Pro	
Leu	Leu	Tyr 435	Arg	Leu	Gly	Ala	Val 440	Gln	Asn	Glu	Ile	Thr 445	Leu	Thr	His	
Pro	Val 450	Thr	Lys	Tyr	Ile	Met 455	Thr	Ser	Met	Ser	Ala 460	Asp	Leu	Glu	Val	
Val 465	Thr	Ser														
<213 <213 <213 <220)> FI 3> O'	ENGTI (PE : RGAN: EATUI THER	H: 14 DNA ISM: RE:	101 Art: DRMA					ı of	Art:	ific	ial :	Seque	ence:	: Synthet	ic
)> SI	_														
															ctcact	60 120
															aagtt	180
															aagct	240
cac	ggtat	cg a	accc	gaaca	at to	cgtac	ctggt	gta	acgta	acta	tcad	ctaci	gg t	tctc	ecgate	300
acti	acto	cta d	cttac	eggta	aa at	taat	ggct	gad	ggtg	ggtt	gct	ctggi	gg t	gctt	acgat	360
atca	atcat	ct q	gcgad	cgaat	eg eg	gccto	ctact	gad	cgcta	actt	ctat	cct	ggg t	atco	ggtacc	420
gtt	ctgga	acc a	aggct	gaaa	ac to	gcago	gtgct	cgt	ctg	gttg	ttct	ggct	ac t	gcta	actccg	480
ccg	ggtto	ctg t	tact	gtt	cc go	cacco	cgaac	c ato	cgaag	gaag	ttg	ctct	gtc (gacta	actggt	540

-continued

gaaatcccgt tctacggtaa agctatcccg ctcgaggtta tcaaaggtgg tcgtcacctg	600
attttctgcc actctaaaaa aaaatgcgac gaactggctg ctaagcttgt tgctctgggt	660
atcaacgctg ttgcttacta ccgtggtctg gacgtttctg ttatcccgac ttctggtgac	720
gttgttgttg tggccactga cgctctgatg actggttaca ctggtgactt cgactctgtt	780
ategattgea acaettgegt tacteagace gtagatttta geetggacee gaettteact	840
ategaaacga teaccetgee geaggatgea gttteeegta eeeagegteg tggegegaee	900
ggtegeggea aacegggtat ttacegttte gtggegeegg gegagegtee ateeggtatg	960
ttcgatagct ctgttctgtg tgagtgttat gacgcgggtt gcgcgtggta cgaactgact	1020
ccggctgaaa ctactgtacg cctgcgtgca tacatgaata cgccgggtct gccggtgtgt	1080
caagaccace tggaattttg ggaaggtgte tttactggce tgacccatat cgacgcacac	1140
tttctgtccc agactaaaca gtctggtgaa aacctgccgt acctggtggc gtatcaagcc	1200
actgtgtgcg cccgtgcgca ggcgccgcca ccgagctggg accaaatgtg gaagtgcctg	1260
atcogtotga aacogacoot goacggtoog acgocactgo tgtacogoot gggtgcagtg	1320
cagaacgaaa tcacgctgac gcacccggtc actaaataca ttatgacttg catgagcgca	1380
gacctggaag tggtgacttc c	1401
<210> SEQ ID NO 70 <211> LENGTH: 467 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthe polypeptide	tic
Polypopolas	
<400> SEQUENCE: 70	
<400> SEQUENCE: 70 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser	
<pre><400> SEQUENCE: 70 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1</pre>	
<pre><400> SEQUENCE: 70 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1</pre>	
<pre><400> SEQUENCE: 70 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1</pre>	
<pre><400> SEQUENCE: 70 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1</pre>	
<pre><400> SEQUENCE: 70 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1</pre>	
<pre><400> SEQUENCE: 70 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 15 Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe 20 Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys 40 Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn 50 Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala 80 His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr 90 Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly</pre>	
<pre><400> SEQUENCE: 70 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1</pre>	
<pre><400> SEQUENCE: 70 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1</pre>	
<pre><400> SEQUENCE: 70 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1</pre>	
<pre><400> SEQUENCE: 70 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 15 Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe 20 Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys 45 Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn 50 Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala 80 His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr 95 Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly 110 Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys Ala 125 Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln 130 Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Pro 145</pre>	

Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys

		195					200					205				
СЛа	Asp 210	Glu	Leu	Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val	
Ala 225	Tyr	Tyr	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240	
Val	Val	Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp	
Phe	Asp	Ser	Val 260	Ile	Asp	CAa	Asn	Thr 265	Cys	Val	Thr	Gln	Thr 270	Val	Asp	
Phe	Ser	Leu 275	Asp	Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln	
Asp	Ala 290	Val	Ser	Arg	Thr	Gln 295	Arg	Arg	Gly	Ala	Thr 300	Gly	Arg	Gly	Lys	
Pro 305	Gly	Ile	Tyr	Arg	Phe 310	Val	Ala	Pro	Gly	Glu 315	Arg	Pro	Ser	Gly	Met 320	
Phe	Asp	Ser	Ser	Val 325	Leu	CÀa	Glu	Cys	Tyr 330	Asp	Ala	Gly	Cys	Ala 335	Trp	
Tyr	Glu	Leu	Thr 340	Pro	Ala	Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met	
Asn	Thr	Pro 355	Gly	Leu	Pro	Val	360 Cys	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu	
Gly	Val 370	Phe	Thr	Gly	Leu	Thr 375	His	Ile	Asp	Ala	His 380	Phe	Leu	Ser	Gln	
Thr 385	Lys	Gln	Ser	Gly	Glu 390	Asn	Leu	Pro	Tyr	Leu 395	Val	Ala	Tyr	Gln	Ala 400	
Thr	Val	Cys	Ala	Arg 405	Ala	Gln	Ala	Pro	Pro 410	Pro	Ser	Trp	Asp	Gln 415	Met	
Trp	Lys	Сла	Leu 420	Ile	Arg	Leu	Lys	Pro 425	Thr	Leu	His	Gly	Pro 430	Thr	Pro	
Leu	Leu	Tyr 435	Arg	Leu	Gly	Ala	Val 440	Gln	Asn	Glu	Ile	Thr 445	Leu	Thr	His	
Pro	Val 450	Thr	Lys	Tyr	Ile	Met 455	Thr	Cys	Met	Ser	Ala 460	Asp	Leu	Glu	Val	
Val 465	Thr	Ser														
<213 <213 <213 <220		ENGTI (PE : RGAN: EATUI THER	H: 14 DNA ISM: RE:	401 Art: DRMA'	rion		_		ı of	Art:	ific	ial :	Seque	ence	: Synth	netic
< 400	O> SI	EQUEI	NCE:	71												
gct	gttga	act t	ttato	cccg	gt to	gaaaa	atcto	gag	gacta	acta	tgc	gttci	tac q	ggttt	tcact	60
gaca	aacto	ctt o	ctcc	geeg	gt to	gttc	cgcaç	g tct	ttc	cagg	ttg	ctca	cct (gcato	gctccg	120
act	ggtto	ctg (gtaa	atct	ac ta	aaagt	tcca	a gct	gatt	acg	ctg	ctca	ggg 1	ttaca	aaagtt	180
ctg	gttct	ga a	accc	gtct	gt to	gctg	ctact	ctg	gggti	tcg	gcg	ccta	cat q	gtcta	aaagct	240
cac	ggtat	.cg a	accc	gaac	at to	cgta	ctggt	gta	acgta	acta	tca	ctact	tgg 1	ttct	ccgatc	300
acti	acto	cta d	ctta	ggt	aa at	tcct	ggct	gad	ggt	ggtt	gct	ctggi	egg 1	tgctt	acgat	360
atca	atcat	ct	gcga	cgaa	ag co	cacto	ctact	gad	egeta	actt	ctai	teet	ggg 1	tato	ggtacc	420
gtt	ctgga	acc a	aggci	tgaa	ac to	gcag	gtgct	cgt	ctg	gttg	ttc	tggc1	tac 1	tgcta	actccg	480

-continued

ccgggttctg												
	ttact	gttcc	gcacc	cgaac	ato	gaagaa	g ttg	ctctc	gtc	gacta	ctggt	540
gaaatcccgt	tctac	ggtaa	a agcta	taaag	g ctc	gaggtt	a tca	aaggt	gg	tcgto	accto	600
attttctgcc	actct	aaaaa	a aaaaa	gcgac	gaa	ectggct	g cta	agctt	gt	tgcto	tgggt	660
atcaacgctg	ttgct	tacta	a ccgtg	gtctg	gac	gtttct	g tta	taaag	gac ·	ttctç	gtgad	720
gttgttgttg	tggcc	actga	a cgctc	tgatg	g act	ggttad	a ctg	gtgad	ett (cgact	ctgtt	780
atcgattgca	acact	tgcgt	tactc	agacc	gta	agatttt	a gcc	tggad	ccc (gactt	tcact	840
atcgaaacga	tcacc	etgec	gcagg:	atgca	gtt	tecegt	a ccc	agcgt	cg ·	tggco	gtaco	900
ggtcgcggca	aaccg	ggt at	ttacc	gtttc	gto	gegeeg	g gcg	agcgt	cc.	atcco	gtato	960
ttcgatagct	ctgtt	ctgtg	g tgagt	gttat	gac	gegggt	t gcg	egtge	gta ·	cgaad	tgact	1020
ccggctgaaa	ctact	gtacg	g cctgc	gtgca	ı tac	atgaat	a cgc	cgggt	ct	gccgg	gtgtgt	1080
caagaccacc	tggaa	ttttg	g ggaag	gtgtc	ttt	actgg	c tga	cccat	at	cgaco	gcacac	1140
tttctgtccc	agact	aaaca	a gtctg	gtgaa	aac	ectgeco	t acc	tggtg	ggc (gtato	aagco	1200
actgtgtgcg	cccgt	gegea	a ggcgc	egeca	cce	gagetge	g acc	aaato	gtg	gaagt	gcct	1260
atccgtctga	aaccg	jaccct	gcacg	gtaag	g acc	gecaete	c tgt	accgo	cct	gggtg	gcagto	1320
cagaacgaaa	tcacg	gctgac	gcacc	eggte	act	aaatad	a tta	tgact	tg	catga	igegea	a 1380
gacctggaag	tggtg	gactto	C C									1401
<pre><211> LENG <212> TYPE <213> ORGA <220> FEAT <223> OTHE</pre>	: PRT NISM: URE:	Artif		-								
	peptid	le		JCI IL	OCTO	n of Ai	tilic	ial S	Sequ	ence:	Synt	hetic
poly	_	le		oci ip	CIO	n of Ai	tilic	ial S	Sequ	ence:	Synt	hetic
	ENCE :	le 72										chetic
<400> SEQU	ENCE:	de 72 Ile F 5	Pro Val	Glu	Asn	Leu Gl	u Thr	Thr	Met	Arg 15	Ser	:hetic
<400> SEQU Ala Val As	ENCE: p Phe e Thr 20	de 72 Ile F 5 Asp A	Pro Val Asn Ser	Glu Ser	Asn Pro 25	Leu Gl 10 Pro Vá	u Thr l Val	Thr	Met Gln 30	Arg 15 Ser	Ser Phe	:hetic
<400> SEQU Ala Val As 1 Pro Val Ph Gln Val Al	ENCE: p Phe e Thr 20 a His	de 72 Ile F 5 Asp A	Pro Val Asn Ser His Ala	Glu Ser Pro 40	Asn Pro 25 Thr	Leu GJ 10 Pro Va Gly Se	u Thr l Val r Gly	Thr Pro Lys 45	Met Gln 30 Ser	Arg 15 Ser Thr	Ser Phe Lys	:hetic
<400> SEQUAL AS 1 Pro Val Ph Gln Val Al 35 Val Pro Al 50 Pro Ser Va	ENCE: p Phe e Thr 20 a His	de 72 Ile F 5 Asp A Leu F Tyr A	Pro Val Asn Ser His Ala Ala Ala 55 Chr Leu	Glu Ser Pro 40	Asn Pro 25 Thr	Leu Gl 10 Pro Va Gly Se Tyr Ly	u Thr l Val r Gly s Val 60 a Tyr	Thr Pro Lys 45 Leu	Met Gln 30 Ser Val	Arg 15 Ser Thr	Ser Phe Lys Asn	chetic
<400> SEQU Ala Val As 1 Pro Val Ph Gln Val Al 35 Val Pro Al	ENCE: p Phe e Thr 20 a His a Ala	le F Tyr A Ala T Pro A	Pro Val Asn Ser His Ala Ala Ala 55 Thr Leu	Glu Ser Pro 40 Gln	Asn Pro 25 Thr Gly	Leu Gl 10 Pro Va Gly Se Tyr Ly Gly Al 75 Gly Va	u Thr l Val r Gly s Val 60 a Tyr	Thr Pro Lys 45 Leu Met	Met Gln 30 Ser Val	Arg 15 Ser Thr Leu Lys	Ser Phe Lys Asn Ala	Chetic
<400> SEQUENTS AND	ENCE: p Phe e Thr 20 a His a Ala l Ala e Asp o Ile	Asp A Leu H Tyr A Ala T Pro A	Pro Val Asn Ser His Ala Ala Ala 55 Thr Leu 70 Asn Ile	Glu Ser Pro 40 Gln Gly	Asn Pro 25 Thr Gly Phe Thr	Leu Gl 10 Pro Va Gly Se Tyr Ly Gly Al 75 Gly Va 90	u Thr l Val r Gly s Val 60 a Tyr l Arg	Thr Pro Lys 45 Leu Met	Met Gln 30 Ser Val Ser Ile	Arg 15 Ser Thr Leu Lys Thr 95	Ser Phe Lys Asn Ala 80	chetic
<400> SEQUENTS AND SEQUENTS AND	ENCE: p Phe e Thr 20 a His a Ala l Ala e Asp o Ile 100	Ile F Asp A Leu F Tyr A Ala T Pro A 85	Asn Ser His Ala Ala Ala 55 Fhr Leu 70 Asn Ile	Glu Ser Pro 40 Gln Gly Arg	Asn Pro 25 Thr Gly Phe Thr	Leu Gl 10 Pro Va Gly Se Tyr Ly Gly Al 75 Gly Va 90 Gly Ly	u Thr l Val r Gly s Val 60 a Tyr l Arg	Thr Pro Lys 45 Leu Met Thr	Met Gln 30 Ser Val Ser Ile Ala 110	Arg 15 Ser Thr Leu Lys Thr 95 Asp	Ser Phe Lys Asn Ala 80 Thr	chetic
<400> SEQUAL AS 1 Pro Val Ph Gln Val Al 35 Val Pro Al 50 Pro Ser Va 65 His Gly II	ENCE: p Phe e Thr 20 a His a Ala l Ala e Asp o Ile 100 r Gly	Ile F Asp A Leu F Tyr A Ala T Pro A 85	Asn Ser His Ala Ala Ala 55 Fhr Leu 70 Asn Ile	Glu Ser Pro 40 Gln Gly Arg	Asn Pro 25 Thr Gly Phe Thr	Leu Gl 10 Pro Va Gly Se Tyr Ly Gly Al 75 Gly Va 90 Gly Ly	u Thr l Val r Gly s Val 60 a Tyr l Arg	Thr Pro Lys 45 Leu Met Thr	Met Gln 30 Ser Val Ser Ile Ala 110	Arg 15 Ser Thr Leu Lys Thr 95 Asp	Ser Phe Lys Asn Ala 80 Thr	Chetic
<pre><400> SEQU Ala Val As 1 Pro Val Ph Gln Val Al 35 Val Pro Al 50 Pro Ser Va 65 His Gly Il Gly Ser Pr Gly Cys Se</pre>	ENCE: p Phe e Thr 20 a His a Ala l Ala e Asp o Ile 100 r Gly 5	Ile F 5 Asp A Leu H Tyr A Ala T Pro A 5 Thr T	Asn Ser His Ala Ala Ala 55 Thr Leu 70 Asn Ile Tyr Ser	Glu Ser Pro 40 Gln Gly Arg Thr	Asn Pro 25 Thr Gly Phe Thr Tyr 105 Ile	Leu Gl 10 Pro Va Gly Se Tyr L Gly Al 75 Gly Va 90 Gly L Ile II	u Thr l Val r Gly S Val 60 a Tyr l Arg s Phe e Cys	Thr Pro Lys 45 Leu Met Thr Leu Asp 125	Met Gln 30 Ser Val Ser Ile Ala 110 Glu	Arg 15 Ser Thr Leu Lys Thr 95 Asp	Ser Phe Lys Asn Ala 80 Thr	Chetic
<pre><400> SEQU Ala Val As 1 Pro Val Ph Gln Val Al 35 Val Pro Al 50 Pro Ser Va 65 His Gly Il Gly Ser Pr Gly Cys Se 11 Ser Thr As</pre>	ENCE: p Phe e Thr 20 a His a Ala l Ala e Asp o Ile 100 r Gly p Ala	de 72 Ile F 5 Asp A Leu H Tyr A Ala T 7 Pro A 85 Thr T Gly A Thr S	Asn Ser His Ala Ala Ala 55 Fhr Leu 70 Asn Ile Fyr Ser Ala Tyr Ger Ile 135	Glu Ser Pro 40 Gln Gly Arg Thr Asp 120 Leu	Asn Pro 25 Thr Gly Phe Thr Tyr 105 Ile	Leu GI 10 Pro Va Gly Se Tyr Ly Gly AI 75 Gly Va 90 Gly Ly Ile II	u Thr l Val r Gly S Val 60 a Tyr l Arg s Phe e Cys y Thr 140 u Ala	Thr Pro Lys 45 Leu Met Thr Leu Asp 125 Val	Met Gln 30 Ser Val Ser Ile Ala 110 Glu Leu	Arg 15 Ser Thr Leu Lys Thr 95 Asp	Ser Phe Lys Asn Ala 80 Thr Gly His	Chetic
<pre><400> SEQU Ala Val As 1 Pro Val Ph Gln Val Al 35 Val Pro Al 50 Pro Ser Va 65 His Gly Il Gly Ser Pr Gly Cys Se 11 Ser Thr As 130</pre>	ENCE: p Phe e Thr 20 a His a Ala l Ala e Asp o Ile 100 r Gly p Ala r Ala	de 72 Ile F 5 Asp A Leu H Tyr A Ala T 7 Pro A 85 Thr T Gly A Thr S	Asn Ser His Ala Ala Ala 55 Thr Leu 70 Asn Ile Tyr Ser Ala Tyr Ser Ile 135 Ala Arg	Glu Ser Pro 40 Gln Gly Arg Thr Leu Leu	Asn Pro 25 Thr Gly Phe Thr Tyr 105 Ile Gly Val	Leu Gl 10 Pro Va Gly Se Tyr Ly Gly Al 75 Gly Va 90 Gly Ly Ile Il Ile Gl Val Le	u Thr l Val r Gly s Val 60 a Tyr l Arg es Phe e Cys y Thr 140 u Ala	Thr Pro Lys 45 Leu Met Thr Leu Asp 125 Val	Met Gln 30 Ser Val Ser Ile Ala 110 Glu Leu Ala	Arg 15 Ser Thr Leu Lys Thr 95 Asp Ser Asp	Ser Phe Lys Asn Ala 80 Thr Gly His Gln Pro 160	Chetic

Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu 180 $$185\$

Val	Ile	Lys 195	Gly	Gly	Arg	His	Leu 200	Ile	Phe	Cys	His	Ser 205	Lys	Lys	Lys		
Ser	Asp 210	Glu	Leu	Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val		
Ala 225	Tyr	Tyr	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240		
Val	Val	Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp		
Phe	Asp	Ser	Val 260	Ile	Asp	CÀa	Asn	Thr 265	Cys	Val	Thr	Gln	Thr 270	Val	Asp		
Phe	Ser	Leu 275	Asp	Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln		
Asp	Ala 290	Val	Ser	Arg	Thr	Gln 295	Arg	Arg	Gly	Arg	Thr 300	Gly	Arg	Gly	Lys		
Pro 305	Gly	Ile	Tyr	Arg	Phe 310	Val	Ala	Pro	Gly	Glu 315	Arg	Pro	Ser	Gly	Met 320		
Phe	Asp	Ser	Ser	Val 325	Leu	CAa	Glu	Cys	Tyr 330	Asp	Ala	Gly	Cys	Ala 335	Trp		
Tyr	Glu	Leu	Thr 340	Pro	Ala	Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met		
Asn	Thr	Pro 355	Gly	Leu	Pro	Val	Cys	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu		
Gly	Val 370	Phe	Thr	Gly	Leu	Thr 375	His	Ile	Asp	Ala	His 380	Phe	Leu	Ser	Gln		
Thr 385	Lys	Gln	Ser	Gly	Glu 390	Asn	Leu	Pro	Tyr	Leu 395	Val	Ala	Tyr	Gln	Ala 400		
Thr	Val	Cys	Ala	Arg 405	Ala	Gln	Ala	Pro	Pro 410	Pro	Ser	Trp	Asp	Gln 415	Met		
Trp	Lys	Cys	Leu 420	Ile	Arg	Leu	Lys	Pro 425	Thr	Leu	His	Gly	Pro 430	Thr	Pro		
Leu	Leu	Tyr 435	Arg	Leu	Gly	Ala	Val 440	Gln	Asn	Glu	Ile	Thr 445	Leu	Thr	His		
Pro	Val 450	Thr	Lys	Tyr	Ile	Met 455	Thr	Cys	Met	Ser	Ala 460	Asp	Leu	Glu	Val		
Val 465	Thr	Ser															
<213 <213 <213 <220)> FI 3> O	ENGTH (PE : RGAN] EATUR	H: 14 DNA ISM: RE: INFO	101 Art: DRMA			-		ı of	Art:	ifici	ial S	Seque	ence	: Syntl	netic	
<400)> SI	EQUE	ICE :	73													
gct	gttga	act t	tato	cccg	gt to	gaaa	atcto	gag	gacta	ecta	tgcg	gttct	ccc (ggtti	tcact	6	0
gaca	aacto	ctt o	ctcc	gccg	gt to	gttc	cgcaç	g tct	ttc	agg	ttgo	ctcac	cct q	gcato	geteeg	12	0
															aaagtt	18	
															aaagct	24	
															ecgate	30	
acti	acto	cta d	cttac	eggta	aa at	tcct	egget	gad	ggtg	gtt	gcto	ctggt	gg 1	tgctt	acgat	36	0
atca	atcat	ct g	gcgad	cgaaa	ag co	cacto	ctact	gad	egeta	ctt	ctat	cct	ggg 1	tatco	ggtacc	42	0

-continued

gttctggac														
	c aggc	tgaaa	c tg	cago	gtgct	cgt	ctg	gttg	ttct	ggct	ac	tgcta	actccg	480
ccgggttct	g ttac	tgttc	c go	acco	gaac	ato	gaaç	gaag	ttgo	etete	gtc	gacta	actggt	540
gaaatcccc	ıt tcta	cggta	a ag	ctat	cccg	cto	gagg	gtta	tcaa	aggt	gg	tcgto	cacctg	600
attttctgc	c actc	taaaa	ааа	aato	gegae	gaa	actgo	gctg	ctaa	gctt	gt	tgcto	tgggt	660
atcaacgct	g ttgc	ttact	асс	gtgg	gtetg	gad	gttt	ctg	ttat	cccc	jac	ttctc	ggtgac	720
gttgttgtt	g tggc	cactg	a cg	ıctct	gatg	, act	ggtt	aca	ctg	gtgad	tt	cgact	ctgtt	780
atcgattgo	a acac	ttgcg	t ta	ctca	agacc	gta	agatt	tta	gcct	ggad	cc	gactt	tcact	840
atcgaaacg	ja tcac	cctgc	c go	agga	atgca	gtt	teed	gta	ccca	ıgcgt	cg	tggco	gtacc	900
ggtcgcggc	a aacc	gggta	t tt	acco	gtttc	gto	gege	cgg	gcga	ıgcgt	cc.	atccc	ggtatg	960
ttcgatago	t ctgt	tctgt	g tg	agto	gttat	gad	gegg	ggta	gcgc	gtgg	jta	cgaac	etgact	1020
ccggctgaa	a ctac	tgtac	g cc	tgcc	gtgca	tac	catga	ata	cgcc	gggt	ct	gccgg	gtgtgt	1080
caagaccac	c tgga	atttt	a aa	aagg	gtgtc	ttt	acto	gcc	tgad	ccat	at	cgaco	gcacac	1140
tttctgtcc	c agac	taaac	a gt	ctgo	gtgaa	aac	cctgo	cgt	acct	ggtg	gc	gtato	caagco	1200
actgtgtgc	g cccg	tgcgc	a gg	lagad	gcca		gaget	ggg	acca	aato	gtg	gaagt	gcctg	1260
atccgtctc	ja aacc	gaccc	t go	acgo	gtaag	acç	gccac	etge	tgta	ccgc	ct	gggtç	gcagtg	1320
cagaacgaa	a tcac	gctga	c go	acco	ggto	act	aaat	aca	ttat	gact	tg	catga	agcgca	1380
gacctggaa	ıg tggt	gactt	c c											1401
<211> LEN <212> TYF <213> ORG <220> FEA <223> OTH pol <400> SEQ	PE: PRT ANISM: ATURE: MER INF Ypepti	Arti ORMAT de			-		ı of	Arti	lfici	al S	Jequ	ence:	: Synt	hetic
Ala Val A	sp Phe	Ile 5	Pro	Val	Glu	Asn	Leu 10	Glu	Thr	Thr	Met	Arg 15	Ser	
Pro Val F	he Thr 20	Asp	Asn	Ser	Ser	Pro 25	Pro	Val	Val	Pro	Gln 30	Ser	Phe	
Gln Val A	ala His 5	Leu	His	Ala	Pro	Thr								
	la Ala						GIY	Ser	Gly	Lys 45	Ser	Thr	Lys	
Val Pro A		Tyr	Ala	Ala 55		Gly	-			45			-	
		Ala		55	Gln		Tyr	Lys	Val 60	45 Leu	Val	Leu	Asn	
50 Pro Ser V	al Ala	Ala	Thr 70	55 Leu	Gln Gly	Phe	Tyr Gly	Lys Ala 75	Val 60 Tyr	45 Leu Met	Val Ser	Leu Lys	Asn Ala 80	
50 Pro Ser V 65	al Ala le Asp	Ala Pro 85	Thr 70 Asn	55 Leu Ile	Gln Gly Arg	Phe Thr	Tyr Gly Gly 90	Lys Ala 75 Val	Val 60 Tyr Arg	45 Leu Met Thr	Val Ser Ile	Leu Lys Thr	Asn Ala 80	
Fro Ser V 65 His Gly I Gly Ser F	Val Ala Tle Asp Pro Ile 100	Ala Pro 85 Thr	Thr 70 Asn Tyr	55 Leu Ile Ser	Gln Gly Arg Thr	Phe Thr Tyr 105	Tyr Gly Gly 90 Gly	Lys Ala 75 Val Lys	Val 60 Tyr Arg	45 Leu Met Thr	Val Ser Ile Ala 110	Leu Lys Thr 95 Asp	Asn Ala 80 Thr	
Fro Ser V 65 His Gly I Gly Ser F	Tal Ala Tal Asp Tro Ile 100 Ter Gly 15	Ala Pro 85 Thr	Thr 70 Asn Tyr Ala	55 Leu Ile Ser Tyr	Gln Gly Arg Thr Asp 120	Phe Thr Tyr 105 Ile	Tyr Gly Gly 90 Gly	Lys Ala 75 Val Lys	Val 60 Tyr Arg Phe	45 Leu Met Thr Leu Asp 125	Val Ser Ile Ala 110	Leu Lys Thr 95 Asp	Asn Ala 80 Thr Gly	
Fro Ser V 65 Fro Ser V 65 Fro Fro Ser Thr F	Yal Ala The Asp The Asp The 100 The Gly The State of the Asp The Asp The Asp The Asp The Asp	Ala Pro 85 Thr Gly Thr	Thr 70 Asn Tyr Ala Ser	55 Leu Ile Ser Tyr Ile 135	Gln Gly Arg Thr Asp 120 Leu	Phe Thr Tyr 105 Ile	Tyr Gly Gly 90 Gly Ile	Lys Ala 75 Val Lys Ile Gly	Val 60 Tyr Arg Phe Cys	45 Leu Met Thr Leu Asp 125 Val	Val Ser Ile Ala 110 Glu Leu	Leu Lys Thr 95 Asp Ser	Asn Ala 80 Thr Gly His	

Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu 165 170 175

_																
Ser	Thr	Thr	Gly 180	Glu	Ile	Pro	Phe	Tyr 185	Gly	Lys	Ala	Ile	Pro 190	Leu	Glu	
Val	Ile	Lys 195		Gly	Arg	His	Leu 200	Ile	Phe	Cys	His	Ser 205	Lys	Lys	Lys	
Сув	Asp 210	Glu	Leu	Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val	
Ala 225	Tyr	Tyr	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240	
Val	Val	Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp	
Phe	Asp	Ser	Val 260	Ile	Asp	Сув	Asn	Thr 265	Сув	Val	Thr	Gln	Thr 270	Val	Asp	
Phe	Ser	Leu 275	Asp	Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln	
Asp	Ala 290	Val	Ser	Arg	Thr	Gln 295	Arg	Arg	Gly	Arg	Thr 300	Gly	Arg	Gly	Lys	
Pro 305	Gly	Ile	Tyr	Arg	Phe 310	Val	Ala	Pro	Gly	Glu 315	Arg	Pro	Ser	Gly	Met 320	
Phe	Asp	Ser	Ser	Val 325	Leu	Cys	Glu	Cys	Tyr 330	Asp	Ala	Gly	Ser	Ala 335	Trp	
Tyr	Glu	Leu	Thr 340	Pro	Ala	Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met	
Asn	Thr	Pro 355		Leu	Pro	Val	Cys 360	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu	
Gly	Val 370	Phe	Thr	Gly	Leu	Thr 375	His	Ile	Asp	Ala	His 380	Phe	Leu	Ser	Gln	
Thr 385	Lys	Gln	Ser	Gly	Glu 390	Asn	Leu	Pro	Tyr	Leu 395	Val	Ala	Tyr	Gln	Ala 400	
Thr	Val	Cys	Ala	Arg 405	Ala	Gln	Ala	Pro	Pro 410	Pro	Ser	Trp	Asp	Gln 415	Met	
Trp	Lys	Cys	Leu 420	Ile	Arg	Leu		Pro 425	Thr	Leu	His	Gly	Pro 430	Thr	Pro	
Leu	Leu	Tyr 435	Arg	Leu	Gly	Ala	Val 440	Gln	Asn	Glu	Ile	Thr 445	Leu	Thr	His	
Pro	Val 450	Thr	ГÀа	Tyr	Ile	Met 455	Thr	Сла	Met	Ser	Ala 460	Asp	Leu	Glu	Val	
Val 465	Thr	Ser														
<211 <212 <213 <220	L> LE 2> TY 3> OF 0> FE 3> OT	ENGTI (PE : RGAN: EATUI THER	ISM: RE:	Art: ORMA	rion	ial S	-		ı of	Art:	ific	ial S	Seque	ence	: Synthe	etic
<400)> SI	EQUEI	NCE :	75												
															tcact	60
															geteeg aaagtt	120
															aaagct	240
															ecgate	300
actt	acto	cta d	cttad	eggta	aa at	taat	gget	gad	ggtg	ggtt	gct	ctggt	tgg t	gctt	acgat	360

-continued

	420
atcatcatct gegacgaaag ccactctact gacgetactt ctatcetggg tateggtace gttetggace aggetgaaac tgeaggtget egtetggttg ttetggetac tgetacteeg	480
cogggttctg ttactgttcc gcacccgaac atcgaagaag ttgctctgtc gactactggt	540
gaaatcccgt tctacggtaa agctatcccg ctcgaggtta tcaaaggtgg tcgtcacctg	600
attttctgcc actctaaaaa aaaatgcgac gaactggctg ctaagcttgt tgctctgggt	660
atcaacgetg ttgettaeta eegtggtetg gaegtttetg ttateeegae ttetggtgae	720
gttgttgttg tggccactga cgctctgatg actggttaca ctggtgactt cgactctgtt	780
ategattgea acaettgegt tacteagace gtagatttta geetggacee gaettteact	840
atogaaacga toaccotgoo goaggatgoa gtttooogta oocagogtog tggoogtaco	900
ggtcgcggca aaccgggtat ttaccgtttc gtggcgccgg gcgagcgtcc atccggtatg	960
ttcgatagct ctgttctgtg tgagtgttat gacgcgggtt gcgcgtggta cgaactgact	1020
ccggctgaaa ctactgtacg cctgcgtgca tacatgaata cgccgggtct gccggtgagt	1080
caagaccacc tggaattttg ggaaggtgtc tttactggcc tgacccatat cgacgcacac	1140
tttctgtccc agactaaaca gtctggtgaa aacctgccgt acctggtggc gtatcaagcc	1200
actgtgtgcg cccgtgcgca ggcgccgcca ccgagctggg accaaatgtg gaagtgcctg	1260
atccgtctga aaccgaccct gcacggtccg acgccactgc tgtaccgcct gggtgcagtg	1320
cagaacgaaa tcacgctgac gcaccoggtc actaaataca ttatgacttg catgagcgca	1380
gacctggaag tggtgacttc c	1401
<211> LENGTH: 467 <212> TYPE: PRT	
<213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthet polypeptide	ic
<pre><220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthet</pre>	ic
<pre><220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthet polypeptide</pre>	ic
<pre><220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthet</pre>	ic
<pre><220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthet polypeptide <400> SEQUENCE: 76 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1 5 10 15 Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe</pre>	ic
<pre><220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthet polypeptide <400> SEQUENCE: 76 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1</pre>	ic
<pre><220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthet polypeptide <400> SEQUENCE: 76 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser</pre>	ic
<pre><220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthet polypeptide <400> SEQUENCE: 76 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1</pre>	ic
<pre><220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthet polypeptide <400> SEQUENCE: 76 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1</pre>	ic
<pre><220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthet polypeptide <400> SEQUENCE: 76 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1</pre>	ic
<pre><220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthet polypeptide <400> SEQUENCE: 76 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1</pre>	ic
<pre><220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthet polypeptide <400> SEQUENCE: 76 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 1</pre>	ic

Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu

				165					170					175		
Ser	Thr	Thr	Gly 180	Glu	Ile	Pro	Phe	Tyr 185	Gly	Lys	Ala	Ile	Pro 190	Leu	Glu	
Val	Ile	Lys 195	Gly	Gly	Arg	His	Leu 200	Ile	Phe	Сув	His	Ser 205	Lys	Lys	Lys	
CÀa	Asp 210	Glu	Leu	Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val	
Ala 225	Tyr	Tyr	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240	
Val	Val	Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp	
Phe	Asp	Ser	Val 260	Ile	Asp	CÀa	Asn	Thr 265	Cys	Val	Thr	Gln	Thr 270	Val	Asp	
Phe	Ser	Leu 275	Asp	Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln	
Asp	Ala 290	Val	Ser	Arg	Thr	Gln 295	Arg	Arg	Gly	Arg	Thr 300	Gly	Arg	Gly	Lys	
Pro 305	Gly	Ile	Tyr	Arg	Phe 310	Val	Ala	Pro	Gly	Glu 315	Arg	Pro	Ser	Gly	Met 320	
Phe	Asp	Ser	Ser	Val 325	Leu	CAa	Glu	Cys	Tyr 330	Asp	Ala	Gly	Cya	Ala 335	Trp	
Tyr	Glu	Leu	Thr 340	Pro	Ala	Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met	
Asn	Thr	Pro 355	Gly	Leu	Pro	Val	Ser 360	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu	
Gly	Val 370	Phe	Thr	Gly	Leu	Thr 375	His	Ile	Asp	Ala	His 380	Phe	Leu	Ser	Gln	
Thr 385	Lys	Gln	Ser	Gly	Glu 390	Asn	Leu	Pro	Tyr	Leu 395	Val	Ala	Tyr	Gln	Ala 400	
Thr	Val	СЛа	Ala	Arg 405	Ala	Gln	Ala	Pro	Pro 410	Pro	Ser	Trp	Asp	Gln 415	Met	
Trp	Lys	CÀa	Leu 420	Ile	Arg	Leu	Lys	Pro 425	Thr	Leu	His	Gly	Pro 430	Thr	Pro	
Leu	Leu	Tyr 435	Arg	Leu	Gly	Ala	Val 440	Gln	Asn	Glu	Ile	Thr 445	Leu	Thr	His	
Pro	Val 450	Thr	Lys	Tyr	Ile	Met 455	Thr	Cys	Met	Ser	Ala 460	Asp	Leu	Glu	Val	
Val 465	Thr	Ser														
<213 <213 <213 <220		ENGTI PE: RGAN EATUI	H: 14 DNA ISM: RE: INFO	401 Art: DRMA	TION		_		n of	Art	ific	ial :	Seque	ence	: Syntl	hetic
< 40	0> SI	EQUEI	ICE :	77												
gct	gttga	act t	tato	cccg	gt to	gaaaa	atct	gag	gacta	acta	tgc	gtte	tcc (ggtti	ttcact	60
gac	aacto	ctt o	ctcc	gccg	gt to	gttc	cgca	g tet	ttc	cagg	ttg	ctca	cct (gcat	gctccg	120
act	ggtt	ctg (gtaaa	atcta	ac ta	aaagt	ttcc	a gct	gctt	acg	ctg	ctca	ggg 1	ttaca	aaagtt	180
ctg	gttct	iga a	accc	gtct	gt to	gctg	ctact	ctg	gggtt	tcg	gcg	ccta	cat 🤅	gtcta	aaagct	240
cac	ggtat	cg a	accc	gaaca	at to	cgta	ctggi	gta	acgta	acta	tca	ctac	tgg 1	ttct	ccgatc	300

-continued

actt	acto	cta «	cttac	eggta	ıa at	taat	ggct	gad	ggtg	ggtt	gcto	ctggt	gg .	tgctt	acga	ıt	360
atca	atcat	ct q	gcgad	cgaaa	ıg co	cacto	ctact	gad	egeta	actt	ctat	cctg	igg .	tatco	gtac	:c	420
gtto	ctgga	acc a	aggct	gaaa	ıc tç	gcago	gtgct	. cgt	ctg	gttg	ttct	ggct	ac ·	tgcta	ctcc	g	480
ccgg	ggtto	ctg 1	ttact	gtto	c go	cacco	cgaac	ato	gaag	gaag	ttg	ctctg	jtc ș	gacta	ctgg	įt	540
gaaa	atccc	gt 1	tctad	eggta	ıa aç	gctat	cccc	g cto	gagg	jtta	tcaa	aaggt	gg ·	tcgto	acct	g	600
attt	tctç	gee a	actct	caaaa	ıa aa	aaato	gcgad	gaa	actgo	gctg	ctaa	agctt	gt ·	tgcto	tggg	jt	660
atca	aacgo	ctg 1	ttgct	tact	a co	gtgg	gtete	g gad	gttt	ctg	ttat	cccg	jac '	ttcts	ggtga	ıc	720
gtt	gttgt	tg 1	tggc	cacto	ja co	getet	gate	g act	ggtt	aca	ctg	gtgac	tt (cgact	ctgt	t	780
atco	gatto	gca a	acact	tgcg	jt ta	actca	agaco	gta	agatt	tta	gcct	ggad	cc (gactt	tcac	t	840
atco	gaaac	ga 1	tcaco	ectgo	c go	cagga	atgca	gtt	tcc	gta	ccca	agcgt	.cg	tggcd	gtac	c	900
ggt	gege	gca a	aacc	gggta	it tt	acco	gtttc	gto	ggcgo	cgg	gcga	agcgt	cc .	atcc	gtat	g	960
ttc	gataç	gct (ctgtt	ctgt	g to	gagto	gttat	gad	gagg	gtt	gcg	gtgg	jta :	cgaad	tgac	t	1020
ccg	gctga	aaa o	ctact	gtac	g co	ctgcç	gtgca	a tao	catga	ata	cgc	gggt	ct	gccgg	gtgtg	ſt	1080
caaç	gacca	acc 1	tggaa	atttt	g gg	gaago	gtgto	ttt	acto	gcc	tgad	ccat	at	cgaco	gcaca	C	1140
ttto	etgto	ccc a	agact	caaac	a gt	ctg	gtgaa	a aac	cctgo	cgt	acct	ggtg	igc (gtato	aago	:C	1200
acto	gtgtg	gcg (cccgt	gege	a g	gege	egeca	a ccç	gagct	ggg	acca	aaatg	jtg (gaagt	geet	g	1260
atco	egtet	ga a	aacco	gacco	t go	cacgo	gtaco	g aco	gccad	ctgc	tgta	accgo	ct	gggtg	gcagt	g	1320
caga	aacga	aaa 1	tcacç	gctga	ic go	cacco	eggto	act	aaat	aca	ttat	gact	ag	catga	igege	a	1380
gaco	tgga	aag 1	tggtg	gactt	c c												1401
<211 <212 <213 <220	L> LE 2> T\ 3> OF 0> FE 3> OT	ENGTI (PE : RGAN: EATUI THER	ISM: RE:	57 Arti DRMAT			-		n of	Art:	ific:	ial S	Sequ	ence:	Syn	ıthe	tic
<400)> SE	EQUEI	ICE:	78													
Ala 1	Val	Asp	Phe	Ile 5	Pro	Val	Glu	Asn	Leu 10	Glu	Thr	Thr	Met	Arg 15	Ser		
Pro	Val	Phe	Thr 20	Asp	Asn	Ser	Ser	Pro 25	Pro	Val	Val	Pro	Gln 30	Ser	Phe		
Gln	Val	Ala 35	His	Leu	His	Ala	Pro 40	Thr	Gly	Ser	Gly	Lys 45	Ser	Thr	Lys		
Val	Pro 50	Ala	Ala	Tyr	Ala	Ala 55	Gln	Gly	Tyr	Lys	Val 60	Leu	Val	Leu	Asn		
Pro 65	Ser	Val	Ala	Ala	Thr 70	Leu	Gly	Phe	Gly	Ala 75	Tyr	Met	Ser	Lys	Ala 80		
His	Gly	Ile	Asp	Pro 85	Asn	Ile	Arg	Thr	Gly 90	Val	Arg	Thr	Ile	Thr 95	Thr		
Gly	Ser	Pro	Ile 100	Thr	Tyr	Ser	Thr	Tyr 105	Gly	Lys	Phe	Leu	Ala 110	Asp	Gly		
Gly	Cys	Ser 115	Gly	Gly	Ala	Tyr	Asp 120	Ile	Ile	Ile	Cys	Asp 125	Glu	Ser	His		
Ser	Thr 130	Asp	Ala	Thr	Ser	Ile 135	Leu	Gly	Ile	Gly	Thr	Val	Leu	Asp	Gln		

Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro 145 150 150 160

_																	
Pro	Gly	Ser	Val	Thr 165	Val	Pro	His	Pro	Asn 170	Ile	Glu	Glu	Val	Ala 175	Leu		
Ser	Thr	Thr	Gly 180	Glu	Ile	Pro	Phe	Tyr 185	Gly	Lys	Ala	Ile	Pro 190	Leu	Glu		
Val	Ile	Lys 195	Gly	Gly	Arg	His	Leu 200	Ile	Phe	СЛв	His	Ser 205	Lys	Lys	Lys		
Cys	Asp 210	Glu	Leu	Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val		
Ala 225	Tyr	Tyr	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240		
Val	Val	Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp		
Phe	Asp	Ser	Val 260	Ile	Asp	CÀa	Asn	Thr 265	Сла	Val	Thr	Gln	Thr 270	Val	Asp		
Phe	Ser	Leu 275	Asp	Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln		
Asp	Ala 290	Val	Ser	Arg	Thr	Gln 295	Arg	Arg	Gly	Arg	Thr 300	Gly	Arg	Gly	Lys		
Pro 305	Gly	Ile	Tyr	Arg	Phe 310	Val	Ala	Pro	Gly	Glu 315	Arg	Pro	Ser	Gly	Met 320		
Phe	Asp	Ser	Ser	Val 325	Leu	CAa	Glu	CÀa	Tyr 330	Asp	Ala	Gly	Cys	Ala 335	Trp		
Tyr	Glu	Leu	Thr 340	Pro	Ala	Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met		
Asn	Thr	Pro 355	Gly	Leu	Pro	Val	360 360	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu		
Gly	Val 370	Phe	Thr	Gly	Leu	Thr 375	His	Ile	Asp	Ala	His 380	Phe	Leu	Ser	Gln		
Thr 385	Lys	Gln	Ser	Gly	Glu 390	Asn	Leu	Pro	Tyr	Leu 395	Val	Ala	Tyr	Gln	Ala 400		
Thr	Val	СЛа	Ala	Arg 405	Ala	Gln	Ala	Pro	Pro 410	Pro	Ser	Trp	Asp	Gln 415	Met		
Trp	Lys	Сув	Leu 420	Ile	Arg	Leu	Lys	Pro 425	Thr	Leu	His	Gly	Pro 430	Thr	Pro		
Leu	Leu	Tyr 435	Arg	Leu	Gly	Ala	Val 440	Gln	Asn	Glu	Ile	Thr 445	Leu	Thr	His		
Pro	Val 450	Thr	Lys	Tyr	Ile	Met 455	Thr	Ser	Met	Ser	Ala 460	Asp	Leu	Glu	Val		
Val 465	Thr	Ser															
<211 <212 <213 <220)> FI 3> O	ENGTI (PE: RGAN: EATUI THER	H: 14 DNA ISM: RE: INFO	401 Art:			_		n of	Art:	ific	ial S	Seque	ence:	: Synth	netic	;
<400)> SI	EQUEI	ICE :	79													
gct	gttga	act t	tat	cccg	gt to	gaaa	atcto	gaç	gacta	acta	tgc	gttct	cc (ggttt	tcact		60
gaca	aacto	ctt o	ctcc	geeg	gt to	gttc	cgcaç	g tct	ttc	agg	ttg	ctcac	cct (gcato	gctccg	1	.20
acto	ggtto	ctg (gtaaa	atcta	ac ta	aaagt	tcca	a gct	gctt	acg	ctg	ctcaç	ggg t	taca	aaagtt	1	.80
ctg	gttct	ga a	acca	gtct	gt to	gctg	ctact	ctg	gggtt	tcg	gcg	cctac	cat o	gtcta	aaagct	2	40

201

-continued

cacggtateg accegaacat tegtactggt gtacgtacta teactactgg ttetecgate

cacggcac	cg u		jaact		gear	99	. 900	.cgcc	iccu	ccu	-cuc	-99		egae		00
acttactc	ta c	ttac	ggta	aa at	taat	ggct	gad	ggtg	gtt	gct	ctggt	gg .	tgctt	acga	t 3	60
atcatcat	ct g	cgad	gaaa	ag co	cacto	ctact	gad	gcta	ectt	ctat	cctç	999	tatco	gtac	c 4	20
gttctgga	cc a	ıggct	gaaa	ac to	gcag	gtgct	: cgt	ctg	gttg	ttct	ggct	cac ·	tgcta	ctcc	g 4	80
ccgggttc	tg t	tact	gtt	cc go	cacco	cgaac	ato	gaaç	gaag	ttg	ctctg	gtc	gacta	ctgg	t 5	40
gaaatccc	gt t	ctac	ggta	aa aq	gctat	cccc	gcto	gago	gtta	tcaa	aaggt	gg	tcgto	acct	g 6	00
attttctg	cc a	ctct	aaaa	aa aa	aaaa	gcgac	gaa	ectgo	gctg	ctaa	agctt	gt	tgcto	tggg	t 6	60
atcaacgc	tg t	tgct	tact	a co	cgtg	gtctg	gad	gttt	ctg	ttat	cccç	gac ·	ttctg	gtga	c 7	20
gttgttgt	tg t	ggc	cacto	ga co	getet	gato	g act	ggtt	aca	ctg	gtgad	ctt (cgact	ctgt	t 7	80
atcgattg	ca a	cact	tgcg	gt ta	actca	agaco	gta	agatt	tta	gcct	ggad	ccc (gactt	tcac	t 8	40
atcgaaac	ga t	caco	cctgo	ec go	cagga	atgca	gtt	teed	gta	ccca	agcgt	cg ·	tggc	gtac	c 9	00
ggtcgcgg	ca a	acco	gggta	at tt	cacco	gtttc	gtg	gege	eegg	gcga	agcgt	cc .	atcco	gtat	g 9	60
ttcgatag	ct c	tgtt	ctgt	g to	gagt	gttat	gad	gege	gtt	gcg	gtg	gta	cgaac	tgac	t 10	20
ccggctga	aa c	tact	gtad	eg co	ctgc	gtgca	tac	catga	ata	cgc	egggt	ct	geegg	gtgtg	t 10	80
caagacca	cc t	ggaa	attt	g gg	gaag	gtgto	ttt	acto	gcc	tgad	cccat	at ·	cgacç	gcaca	c 11	40
tttctgtc	cc a	ıgact	aaac	ca gt	ctg	gtgaa	aad	cctgo	cgt	acct	ggt	ggc (gtato	aagc	c 12	00
actgtgtg	cg c	ccgt	gcg	ca go	gege	egeca	ı dağ	gaget	999	acca	aaato	gtg	gaagt	gcct	g 12	60
atccgtct	ga a	acco	gacco	ct go	cacg	gtaco	g aco	gccac	etge	tgta	accgo	ect (gggtg	gcagt	g 13	20
cagaacga	aa t	cacç	getga	ac go	cacco	cggto	act	aaat	aca	ttat	gact	tg	catga	ıgcgc	a 13	80
gacctgga	ag t	ggtg	gactt	c c											14	01
<210> SE <211> LE <212> TY <213> OR <220> FE <223> OT po	NGTH PE: GANI ATUR HER	I: 46 PRT SM: E:	57 Art: DRMA:			_		n of	Art:	ific:	ial s	Sequ	ence:	Syn	thetic	
<400> SE	QUEN	ICE :	80													
Ala Val . 1	Asp	Phe	Ile 5	Pro	Val	Glu	Asn	Leu 10	Glu	Thr	Thr	Met	Arg 15	Ser		
Pro Val	Phe	Thr 20	Asp	Asn	Ser	Ser	Pro 25	Pro	Val	Val	Pro	Gln 30	Ser	Phe		
Gln Val	Ala 35	His	Leu	His	Ala	Pro 40	Thr	Gly	Ser	Gly	Lys 45	Ser	Thr	Lys		
Val Pro . 50	Ala	Ala	Tyr	Ala	Ala 55	Gln	Gly	Tyr	Lys	Val 60	Leu	Val	Leu	Asn		
Gln Ser 7	Val	Ala	Ala	Thr 70	Leu	Gly	Phe	Gly	Ala 75	Tyr	Met	Ser	Lys	Ala 80		
His Gly	Ile	Asp	Pro 85	Asn	Ile	Arg	Thr	Gly 90	Val	Arg	Thr	Ile	Thr 95	Thr		
Gly Ser	Pro	Ile 100	Thr	Tyr	Ser	Thr	Tyr 105	Gly	Lys	Phe	Leu	Ala 110	Asp	Gly		
Gly Cys		Gly	Gly	Ala	Tyr	Asp	Ile	Ile	Ile	Cys	Asp 125	Glu	Ser	His		
	115															

Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln

135

130

-continued

```
Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro
                   150
                                       155
Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu
Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu
Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys
Ser Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val
Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp
Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp
Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp
Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Ile Thr Leu Pro Gln
Asp Ala Val Ser Arg Thr Gln Arg Arg Gly Arg Thr Gly Arg Gly Lys
                      295
Pro Gly Ile Tyr Arg Phe Val Ala Pro Gly Glu Arg Pro Ser Gly Met
                 310
                                    315
Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala Gly Cys Ala Trp
              325
                                 330
Tyr Glu Leu Thr Pro Ala Glu Thr Thr Val Arg Leu Arg Ala Tyr Met
Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu Glu Phe Trp Glu
                           360
Gly Val Phe Thr Gly Leu Thr His Ile Asp Ala His Phe Leu Ser Gln
                    375
Thr Lys Gln Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr Gln Ala
                   390
Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met
Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro
                     425
Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Ile Thr Leu Thr His
Pro Val Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val
Val Thr Ser
465
<210> SEQ ID NO 81
<211> LENGTH: 21
<212> TYPE: DNA
<213 > ORGANISM: Artificial Sequence
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     oligonucleotide
<400> SEQUENCE: 81
                                                                     21
ggcggctgca gcggtggcgc g
```

<210> SEQ ID NO 82 <211> LENGTH: 7

```
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
<400> SEQUENCE: 82
Gly Gly Cys Ser Gly Gly Ala
<210> SEQ ID NO 83
<211> LENGTH: 21
<212> TYPE: DNA
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     oligonucleotide
<400> SEQUENCE: 83
gatgaatgtc atagcaccga t
<210> SEQ ID NO 84
<211> LENGTH: 7
<212> TYPE: PRT
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     peptide
<400> SEQUENCE: 84
Asp Glu Cys His Ser Thr Asp
<210> SEQ ID NO 85
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     oligonucleotide
<400> SEQUENCE: 85
agcaaaaaga aatgcgatga a
                                                                      21
<210> SEQ ID NO 86
<211> LENGTH: 7
<212> TYPE: PRT
<213 > ORGANISM: Artificial Sequence
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     peptide
<400> SEQUENCE: 86
Ser Lys Lys Cys Asp Glu
<210> SEQ ID NO 87
<211> LENGTH: 466
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     polypeptide
<400> SEQUENCE: 87
Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser
```

Pro	Val	Phe	Thr 20	Asp	Asn	Ser	Ser	Pro 25	Pro	Val	Val	Pro	Gln 30	Ser	Phe
Gln	Val	Ala 35	His	Leu	His	Ala	Pro 40	Thr	Gly	Ser	Gly	Lys 45	Ser	Thr	Lys
Val	Pro 50	Ala	Ala	Tyr	Ala	Ala 55	Gln	Gly	Tyr	Lys	Val 60	Leu	Val	Leu	Asn
Pro 65	Ser	Val	Ala	Ala	Thr 70	Leu	Gly	Phe	Gly	Ala 75	Tyr	Met	Ser	Lys	Ala 80
His	Gly	Ile	Asp	Pro 85	Asn	Ile	Arg	Thr	Gly 90	Val	Arg	Thr	Ile	Thr 95	Thr
Gly	Ser	Pro	Ile 100	Thr	Tyr	Ser	Thr	Tyr 105	Gly	Lys	Phe	Leu	Ala 110	Asp	Gly
Gly	Cys	Ser 115	Gly	Gly	Ala	Tyr	Asp 120	Ile	Ile	Ile	Cys	Asp 125	Glu	Cys	His
Ser	Thr 130	Asp	Ala	Thr	Ser	Ile 135	Leu	Gly	Ile	Gly	Thr 140	Val	Leu	Asp	Gln
Ala 145	Glu	Thr	Ala	Gly	Ala 150	Arg	Leu	Val	Val	Leu 155	Ala	Thr	Ala	Thr	Pro 160
Pro	Gly	Ser	Val	Thr 165	Val	Pro	His	Pro	Asn 170	Ile	Glu	Glu	Val	Ala 175	Leu
Ser	Thr	Thr	Gly 180	Glu	Ile	Pro	Phe	Tyr 185	Gly	Lys	Ala	Ile	Pro 190	Leu	Glu
Val	Ile	Lys 195	Gly	Gly	Arg	His	Leu 200	Ile	Phe	Сув	His	Ser 205	Lys	Lys	Lys
CÀa	Asp 210	Glu	Leu	Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val
Ala 225	Tyr	Tyr	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240
Val	Val	Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp
Phe	Asp	Ser	Val 260	Ile	Asp	CAa	Asn	Thr 265	Cys	Val	Thr	Gln	Thr 270	Val	Asp
Phe	Ser	Leu 275	Asp	Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln
Asp	Ala 290	Val	Ser	Arg	Thr	Gln 295	Arg	Arg	Gly	Arg	Thr 300	Gly	Arg	Gly	Lys
Pro 305	Gly	Ile	Tyr	Arg	Phe 310	Val	Ala	Pro	Gly	Glu 315	Arg	Pro	Ser	Gly	Met 320
Phe	Asp	Ser	Ser	Val 325	Leu	Cys	Glu	Cys	Tyr 330	Asp	Ala	Gly	Сув	Ala 335	Trp
Tyr	Glu	Leu	Thr 340	Pro	Ala	Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met
Asn	Thr	Pro 355	Gly	Leu	Pro	Val	360 CAa	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu
Gly	Val 370	Phe	Thr	Gly	Leu	Thr 375	His	Ile	Asp	Ala	His 380	Phe	Leu	Ser	Gln
Thr 385	Lys	Gln	Ser	Gly	Glu 390	Asn	Leu	Pro	Tyr	Leu 395	Val	Ala	Tyr	Gln	Ala 400
Thr	Val	Cys	Ala	Arg 405	Ala	Gln	Ala	Pro	Pro 410	Pro	Ser	Trp	Asp	Gln 415	Met
Trp	Lys	Cys	Leu 420	Ile	Arg	Leu	Lys	Pro 425	Thr	Leu	His	Gly	Pro 430	Thr	Pro
Leu	Leu	Tyr	Arg	Leu	Gly	Ala	Val	Gln	Asn	Glu	Ile	Thr	Leu	Thr	His

-continued

Pro Val Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val 455 Val Thr 465 <210> SEQ ID NO 88 <211> LENGTH: 3011 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223 > OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 88 Met Ser Thr Asn Pro Lys Pro Gln Lys Lys Asn Lys Arg Asn Thr Asn Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 40 Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 55 Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 100 105 Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 135 Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Gln Val Arg Asn Ser Thr Gly Leu Tyr His Val Thr Asn Asp Cys Pro Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Ala Ile Leu His Thr Pro Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ala Ser Arg Cys Trp Val Ala Met Thr Pro Thr Val Ala Thr Arg Asp Gly Lys Leu Pro Ala Thr 250 Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr Leu Cys Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Gly 280 Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Gly Cys 295 Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp

_															
Asp	Met	Met	Met	Asn 325	Trp	Ser	Pro	Thr	Thr 330	Ala	Leu	Val	Met	Ala 335	Gln
Leu	Leu	Arg	Ile 340	Pro	Gln	Ala	Ile	Leu 345	Asp	Met	Ile	Ala	Gly 350	Ala	His
Trp	Gly	Val 355	Leu	Ala	Gly	Ile	Ala 360	Tyr	Phe	Ser	Met	Val 365	Gly	Asn	Trp
Ala	Lys 370	Val	Leu	Val	Val	Leu 375	Leu	Leu	Phe	Ala	Gly 380	Val	Asp	Ala	Glu
Thr 385	His	Val	Thr	Gly	Gly 390	Ser	Ala	Gly	His	Thr 395	Val	Ser	Gly	Phe	Val 400
Ser	Leu	Leu	Ala	Pro 405	Gly	Ala	Lys	Gln	Asn 410	Val	Gln	Leu	Ile	Asn 415	Thr
Asn	Gly	Ser	Trp 420	His	Leu	Asn	Ser	Thr 425	Ala	Leu	Asn	Cys	Asn 430	Asp	Ser
Leu	Asn	Thr 435	Gly	Trp	Leu	Ala	Gly 440	Leu	Phe	Tyr	His	His 445	Lys	Phe	Asn
Ser	Ser 450	Gly	Cys	Pro	Glu	Arg 455	Leu	Ala	Ser	Cys	Arg 460	Pro	Leu	Thr	Asp
Phe 465	Asp	Gln	Gly	Trp	Gly 470	Pro	Ile	Ser	Tyr	Ala 475	Asn	Gly	Ser	Gly	Pro 480
Asp	Gln	Arg	Pro	Tyr 485	CAa	Trp	His	Tyr	Pro 490	Pro	Lys	Pro	Cys	Gly 495	Ile
Val	Pro	Ala	500 Lys	Ser	Val	CÀa	Gly	Pro 505	Val	Tyr	CÀa	Phe	Thr 510	Pro	Ser
Pro	Val	Val 515	Val	Gly	Thr	Thr	Asp 520	Arg	Ser	Gly	Ala	Pro 525	Thr	Tyr	Ser
Trp	Gly 530	Glu	Asn	Asp	Thr	Asp 535	Val	Phe	Val	Leu	Asn 540	Asn	Thr	Arg	Pro
Pro 545	Leu	Gly	Asn	Trp	Phe 550	Gly	Cys	Thr	Trp	Met 555	Asn	Ser	Thr	Gly	Phe 560
Thr	Lys	Val	Cys	Gly 565	Ala	Pro	Pro	Cys	Val 570	Ile	Gly	Gly	Ala	Gly 575	Asn
Asn	Thr	Leu	His 580	СЛа	Pro	Thr	Aap	Сув 585	Phe	Arg	Lys	His	Pro 590	Aap	Ala
Thr	Tyr	Ser 595	Arg	СЛа	Gly	Ser	Gly 600	Pro	Trp	Ile	Thr	Pro 605	Arg	CÀa	Leu
Val	Asp 610	Tyr	Pro	Tyr	Arg	Leu 615	Trp	His	Tyr	Pro	Cys 620	Thr	Ile	Asn	Tyr
Thr 625	Ile	Phe	Lys	Ile	Arg 630	Met	Tyr	Val	Gly	Gly 635	Val	Glu	His	Arg	Leu 640
Glu	Ala	Ala	CÀa	Asn 645	Trp	Thr	Arg	Gly	Glu 650	Arg	CÀa	Asp	Leu	Glu 655	Asp
Arg	Asp	Arg	Ser 660	Glu	Leu	Ser	Pro	Leu 665	Leu	Leu	Thr	Thr	Thr 670	Gln	Trp
Gln	Val	Leu 675	Pro	Сув	Ser	Phe	Thr 680	Thr	Leu	Pro	Ala	Leu 685	Ser	Thr	Gly
Leu	Ile 690	His	Leu	His	Gln	Asn 695	Ile	Val	Asp	Val	Gln 700	Tyr	Leu	Tyr	Gly
Val 705	Gly	Ser	Ser	Ile	Ala 710	Ser	Trp	Ala	Ile	Lys 715	Trp	Glu	Tyr	Val	Val 720
Leu	Leu	Phe	Leu	Leu 725	Leu	Ala	Asp	Ala	Arg 730	Val	CÀa	Ser	Cya	Leu 735	Trp
Met	Met	Leu	Leu	Ile	Ser	Gln	Ala	Glu	Ala	Ala	Leu	Glu	Asn	Leu	Val

												COII	CIII	ucu	
			740					745					750		
Ile	Leu	Asn 755	Ala	Ala	Ser	Leu	Ala 760	Gly	Thr	His	Gly	Leu 765	Val	Ser	Phe
Leu	Val 770	Phe	Phe	Сув	Phe	Ala 775	Trp	Tyr	Leu	Lys	Gly 780	Lys	Trp	Val	Pro
Gly 785	Ala	Val	Tyr	Thr	Phe 790	Tyr	Gly	Met	Trp	Pro 795	Leu	Leu	Leu	Leu	Leu 800
Leu	Ala	Leu	Pro	Gln 805	Arg	Ala	Tyr	Ala	Leu 810	Asp	Thr	Glu	Val	Ala 815	Ala
Ser	Cys	Gly	Gly 820	Val	Val	Leu	Val	Gly 825	Leu	Met	Ala	Leu	Thr 830	Leu	Ser
Pro	Tyr	Tyr 835	Lys	Arg	Tyr	Ile	Ser 840	Trp	Cys	Leu	Trp	Trp 845	Leu	Gln	Tyr
Phe	Leu 850	Thr	Arg	Val	Glu	Ala 855	Gln	Leu	His	Val	Trp 860	Ile	Pro	Pro	Leu
Asn 865	Val	Arg	Gly	Gly	Arg 870	Asp	Ala	Val	Ile	Leu 875	Leu	Met	Cys	Ala	Val 880
His	Pro	Thr	Leu	Val 885	Phe	Asp	Ile	Thr	890	Leu	Leu	Leu	Ala	Val 895	Phe
Gly	Pro	Leu	Trp 900	Ile	Leu	Gln	Ala	Ser 905	Leu	Leu	Lys	Val	Pro 910	Tyr	Phe
Val	Arg	Val 915	Gln	Gly	Leu	Leu	Arg 920	Phe	Cys	Ala	Leu	Ala 925	Arg	rys	Met
Ile	Gly 930	Gly	His	Tyr	Val	Gln 935	Met	Val	Ile	Ile	Lys 940	Leu	Gly	Ala	Leu
Thr 945	Gly	Thr	Tyr	Val	Tyr 950	Asn	His	Leu	Thr	Pro 955	Leu	Arg	Asp	Trp	Ala 960
His	Asn	Gly	Leu	Arg 965	Asp	Leu	Ala	Val	Ala 970	Val	Glu	Pro	Val	Val 975	Phe
Ser	Gln	Met	Glu 980	Thr	Lys	Leu	Ile	Thr 985	Trp	Gly	Ala	Asp	Thr 990	Ala	Ala
Cys	Gly	Asp 995	Ile	Ile	Asn	Gly	Leu 1000		Val	l Sei	r Ala	a Arg		rg G	ly Arg
Glu	Ile 1010		ı Lev	ı Gly	Pro	10:		sp G	Ly Me	et Va		er 1 020	Lys	Gly :	Гrр
Arg	Leu 1025		ı Ala	a Pro) Il∈	Th:		La Ty	/r Al	la G		ln ' 035	Thr .	Arg (31y
Leu	Leu 1040		/ Cys	; Ile	: Ile	Th:		er Le	eu Th	nr G		rg 2 050	Asp	Lys A	Asn
Gln	Val 1055		ı Gly	/ Glu	ı Val	106		Le Va	al Se	er Th		la 1 065	Ala	Gln :	Γhr
Phe	Leu 1070		a Thi	Cys	; Ile	Ası 10		Ly Vá	al Cy	ys Ti		nr ' 080	Val	Tyr I	His
Gly	Ala 1085	_	/ Thi	Arç	J Thr	109		La Se	er Pi	ro Ly		ly 1 095	Pro '	Val I	Ile
Gln	Met 1100		. Thi	: Asr	ı Val	L As _l		ln As	sp Le	eu Va		ly ' 110	Trp	Pro <i>l</i>	Ala
Pro	Gln 1115		/ Sei	r Arg	g Ser	Let 112		ır Pi	co Cy	ys Tl		7s (125	Gly	Ser S	Ser
Asp	Leu 1130		r Leu	ı Val	. Thr	Arç		is Al	La As	sp Va		le :	Pro '	Val <i>I</i>	Arg
Arg	Arg 1145	_	/ Asr	Ser	: Arg	g Gly		er Le	eu Le	eu Se		ro 1	Arg :	Pro I	Ile

Ser	Tyr 1160	Leu	Lys	Gly	Ser	Ser 1165	Gly	Gly	Pro	Leu	Leu 1170	Сув	Pro	Ala
Gly	His 1175	Ala	Val	Gly	Ile	Phe 1180	Arg	Ala	Ala	Val	Cys 1185	Thr	Arg	Gly
Val	Ala 1190	Lys	Ala	Val	Asp	Phe 1195	Ile	Pro	Val	Glu	Asn 1200	Leu	Glu	Thr
Thr	Met 1205	Arg	Ser	Pro	Val	Phe 1210	Thr	Asp	Asn	Ser	Ser 1215	Pro	Pro	Val
Val	Pro 1220	Gln	Ser	Phe	Gln	Val 1225	Ala	His	Leu	His	Ala 1230	Pro	Thr	Gly
Ser	Gly 1235	Lys	Ser	Thr	Lys	Val 1240	Pro	Ala	Ala	Tyr	Ala 1245	Ala	Gln	Gly
Tyr	Lys 1250	Val	Leu	Val	Leu	Asn 1255	Pro	Ser	Val	Ala	Ala 1260	Thr	Leu	Gly
Phe	Gly 1265	Ala	Tyr	Met	Ser	Lys 1270	Ala	His	Gly	Ile	Asp 1275	Pro	Asn	Ile
Arg	Thr 1280	Gly	Val	Arg	Thr	Ile 1285	Thr	Thr	Gly	Ser	Pro 1290	Ile	Thr	Tyr
Ser	Thr 1295	Tyr	Gly	Lys	Phe	Leu 1300	Ala	Asp	Gly	Gly	Cys 1305	Ser	Gly	Gly
Ala	Tyr 1310	Asp	Ile	Ile	Ile	Cys 1315	Asp	Glu	CÀa	His	Ser 1320	Thr	Asp	Ala
Thr	Ser 1325	Ile	Leu	Gly	Ile	Gly 1330	Thr	Val	Leu	Asp	Gln 1335	Ala	Glu	Thr
Ala	Gly 1340	Ala	Arg	Leu	Val	Val 1345	Leu	Ala	Thr	Ala	Thr 1350	Pro	Pro	Gly
Ser	Val 1355	Thr	Val	Pro	His	Pro 1360	Asn	Ile	Glu	Glu	Val 1365	Ala	Leu	Ser
Thr	Thr 1370	Gly	Glu	Ile	Pro	Phe 1375	Tyr	Gly	Lys	Ala	Ile 1380	Pro	Leu	Glu
Val	Ile 1385	Lys	Gly	Gly	Arg	His 1390	Leu	Ile	Phe	СЛа	His 1395	Ser	Lys	ГЛа
Lys	Cys 1400	Asp	Glu	Leu	Ala	Ala 1405	Lys	Leu	Val	Ala	Leu 1410	Gly	Ile	Asn
Ala	Val 1415	Ala	Tyr	Tyr	Arg	Gly 1420	Leu	Asp	Val	Ser	Val 1425	Ile	Pro	Thr
Ser	Gly 1430	Asp	Val	Val	Val	Val 1435	Ala	Thr	Asp	Ala	Leu 1440	Met	Thr	Gly
Tyr	Thr 1445	Gly	Asp	Phe	Asp	Ser 1450	Val	Ile	Asp	Cys	Asn 1455	Thr	CÀa	Val
Thr	Gln 1460	Thr	Val	Asp	Phe	Ser 1465	Leu	Asp	Pro	Thr	Phe 1470	Thr	Ile	Glu
Thr	Ile 1475	Thr	Leu	Pro	Gln	Asp 1480	Ala	Val	Ser	Arg	Thr 1485	Gln	Arg	Arg
Gly	Arg 1490	Thr	Gly	Arg	Gly	Lys 1495	Pro	Gly	Ile	Tyr	Arg 1500	Phe	Val	Ala
Pro	Gly 1505	Glu	Arg	Pro	Ser	Gly 1510	Met	Phe	Asp	Ser	Ser 1515	Val	Leu	СЛа
Glu	Cys 1520	Tyr	Asp	Ala	Gly	Cys 1525	Ala	Trp	Tyr	Glu	Leu 1530	Thr	Pro	Ala
Glu	Thr 1535	Thr	Val	Arg	Leu	Arg 1540	Ala	Tyr	Met	Asn	Thr 1545	Pro	Gly	Leu

Pro	Val 1550	CÀa	Gln	Asp	His	Leu 1555		Phe	Trp	Glu	Gly 1560		Phe	Thr
Gly	Leu 1565	Thr	His	Ile	Asp	Ala 1570		Phe	Leu	Ser	Gln 1575	Thr	Lys	Gln
Ser	Gly 1580	Glu	Asn	Leu	Pro	Tyr 1585	Leu	Val	Ala	Tyr	Gln 1590	Ala	Thr	Val
CÀa	Ala 1595	Arg	Ala	Gln	Ala	Pro 1600		Pro	Ser	Trp	Asp 1605	Gln	Met	Trp
ГÀа	Сув 1610	Leu	Ile	Arg	Leu	Lys 1615		Thr	Leu	His	Gly 1620	Pro	Thr	Pro
Leu	Leu 1625	Tyr	Arg	Leu	Gly	Ala 1630		Gln	Asn	Glu	Ile 1635	Thr	Leu	Thr
His	Pro 1640	Val	Thr	Lys	Tyr	Ile 1645	Met	Thr	Cys	Met	Ser 1650	Ala	Asp	Leu
Glu	Val 1655	Val	Thr	Ser	Thr	Trp 1660		Leu	Val	Gly	Gly 1665	Val	Leu	Ala
Ala	Leu 1670	Ala	Ala	Tyr	Cys	Leu 1675	Ser	Thr	Gly	Cys	Val 1680	Val	Ile	Val
Gly	Arg 1685	Val	Val	Leu	Ser	Gly 1690		Pro	Ala	Ile	Ile 1695	Pro	Asp	Arg
Glu	Val 1700	Leu	Tyr	Arg	Glu	Phe 1705	Asp	Glu	Met	Glu	Glu 1710	Cys	Ser	Gln
His	Leu 1715	Pro	Tyr	Ile	Glu	Gln 1720		Met	Met	Leu	Ala 1725	Glu	Gln	Phe
ГÀв	Gln 1730		Ala	Leu	Gly	Leu 1735		Gln	Thr	Ala	Ser 1740	Arg	Gln	Ala
Glu	Val 1745	Ile	Ala	Pro	Ala	Val 1750	Gln	Thr	Asn	Trp	Gln 1755	Lys	Leu	Glu
Thr	Phe 1760	Trp	Ala	Lys	His	Met 1765		Asn	Phe	Ile	Ser 1770	Gly	Ile	Gln
Tyr	Leu 1775	Ala	Gly	Leu	Ser	Thr 1780		Pro	Gly	Asn	Pro 1785	Ala	Ile	Ala
Ser	Leu 1790	Met	Ala	Phe	Thr	Ala 1795	Ala	Val	Thr	Ser	Pro 1800	Leu	Thr	Thr
Ser	Gln 1805	Thr	Leu	Leu	Phe	Asn 1810		Leu	Gly	Gly	Trp 1815	Val	Ala	Ala
	Leu 1820		Ala	Pro		Ala 1825		Thr			Val 1830		Ala	Gly
Leu	Ala 1835	Gly	Ala	Ala	Ile	Gly 1840	Ser	Val	Gly	Leu	Gly 1845	Lys	Val	Leu
Ile	Asp 1850	Ile	Leu	Ala	Gly	Tyr 1855	Gly	Ala	Gly	Val	Ala 1860	Gly	Ala	Leu
Val	Ala 1865	Phe	ГÀв	Ile	Met	Ser 1870	Gly	Glu	Val	Pro	Ser 1875	Thr	Glu	Asp
Leu	Val 1880	Asn	Leu	Leu	Pro	Ala 1885	Ile	Leu	Ser	Pro	Gly 1890	Ala	Leu	Val
Val	Gly 1895	Val	Val	СЛа	Ala	Ala 1900	Ile	Leu	Arg	Arg	His 1905	Val	Gly	Pro
Gly	Glu 1910	Gly	Ala	Val	Gln	Trp 1915	Met	Asn	Arg	Leu	Ile 1920	Ala	Phe	Ala
Ser	Arg 1925	Gly	Asn	His	Val	Ser 1930	Pro	Thr	His	Tyr	Val 1935	Pro	Glu	Ser
Asp	Ala	Ala	Ala	Arg	Val	Thr	Ala	Ile	Leu	Ser	Ser	Leu	Thr	Val

	1940					1945					1950			
Thr	Gln 1955	Leu	Leu	Arg	Arg	Leu 1960	His	Gln	Trp	Ile	Ser 1965		Glu	CÀa
Thr	Thr 1970	Pro	Cys	Ser	Gly	Ser 1975	Trp	Leu	Arg	Asp	Ile 1980		Asp	Trp
Ile	Cys 1985	Glu	Val	Leu	Ser	Asp 1990		Lys	Thr	Trp	Leu 1995		Ala	ГÀа
Leu	Met 2000	Pro	Gln	Leu	Pro	Gly 2005	Ile	Pro	Phe	Val	Ser 2010		Gln	Arg
Gly	Tyr 2015	ГЛа	Gly	Val	Trp	Arg 2020	Val	Asp	Gly	Ile	Met 2025		Thr	Arg
CÀa	His 2030	CÀa	Gly	Ala	Glu	Ile 2035	Thr	Gly	His	Val	Lys 2040		Gly	Thr
Met	Arg 2045	Ile	Val	Gly	Pro	Arg 2050	Thr	Сув	Arg	Asn	Met 2055		Ser	Gly
Thr	Phe 2060	Pro	Ile	Asn	Ala	Tyr 2065	Thr	Thr	Gly	Pro	Cys 2070		Pro	Leu
Pro	Ala 2075	Pro	Asn	Tyr	Thr	Phe 2080	Ala	Leu	Trp	Arg	Val 2085		Ala	Glu
Glu	Tyr 2090	Val	Glu	Ile	Arg	Gln 2095	Val	Gly	Asp	Phe	His 2100	-	Val	Thr
Gly	Met 2105	Thr	Thr	Asp	Asn	Leu 2110	Lys	CÀa	Pro	CÀa	Gln 2115		Pro	Ser
Pro	Glu 2120	Phe	Phe	Thr	Glu	Leu 2125	Asp	Gly	Val	Arg	Leu 2130		Arg	Phe
Ala	Pro 2135	Pro	CÀa	Lys	Pro	Leu 2140	Leu	Arg	Glu	Glu	Val 2145		Phe	Arg
Val	Gly 2150	Leu	His	Glu	Tyr	Pro 2155	Val	Gly	Ser	Gln	Leu 2160		CÀa	Glu
Pro	Glu 2165	Pro	Asp	Val	Ala	Val 2170		Thr	Ser	Met	Leu 2175		Asp	Pro
Ser	His 2180	Ile	Thr	Ala	Glu	Ala 2185	Ala	Gly	Arg	Arg	Leu 2190		Arg	Gly
Ser	Pro 2195	Pro	Ser	Val	Ala	Ser 2200	Ser	Ser	Ala	Ser	Gln 2205		Ser	Ala
Pro	Ser 2210	Leu	Lys	Ala	Thr	Сув 2215	Thr	Ala	Asn	His	Asp 2220	Ser	Pro	Asp
Ala	Glu 2225	Leu	Ile	Glu	Ala	Asn 2230	Leu	Leu	Trp	Arg	Gln 2235	Glu	Met	Gly
Gly	Asn 2240	Ile	Thr	Arg	Val	Glu 2245	Ser	Glu	Asn	ГÀа	Val 2250	Val	Ile	Leu
Asp	Ser 2255	Phe	Asp	Pro	Leu	Val 2260	Ala	Glu	Glu	Asp	Glu 2265	Arg	Glu	Ile
Ser	Val 2270	Pro	Ala	Glu	Ile	Leu 2275	Arg	Lys	Ser	Arg	Arg 2280	Phe	Ala	Gln
Ala	Leu 2285	Pro	Val	Trp	Ala	Arg 2290	Pro	Asp	Tyr	Asn	Pro 2295	Pro	Leu	Val
Glu	Thr 2300	Trp	ГЛа	Lys	Pro	Asp 2305	Tyr	Glu	Pro	Pro	Val 2310		His	Gly
Сув	Pro 2315	Leu	Pro	Pro	Pro	Lys 2320	Ser	Pro	Pro	Val	Pro 2325	Pro	Pro	Arg
Lys	Lys 2330	Arg	Thr	Val	Val	Leu 2335	Thr	Glu	Ser	Thr	Leu 2340	Ser	Thr	Ala

Leu	Ala 2345		Leu	Ala	Thr	Arg 2350		Phe	Gly	Ser	Ser 2355		Thr	Ser
Gly	Ile 2360		Gly	Asp	Asn	Thr 2365		Thr	Ser	Ser	Glu 2370	Pro	Ala	Pro
Ser	Gly 2375	Сув	Pro	Pro	Asp	Ser 2380		Ala	Glu	Ser	Tyr 2385		Ser	Met
Pro	Pro 2390	Leu	Glu	Gly	Glu	Pro 2395		Asp	Pro	Asp	Leu 2400		Asp	Gly
Ser	Trp 2405	Ser	Thr	Val	Ser	Ser 2410		Ala	Asn	Ala	Glu 2415		Val	Val
CAa	Cys 2420	Ser	Met	Ser	Tyr	Ser 2425		Thr	Gly	Ala	Leu 2430		Thr	Pro
CAa	Ala 2435		Glu	Glu	Gln	Lys 2440		Pro	Ile	Asn	Ala 2445		Ser	Asn
Ser	Leu 2450		Arg	His	His	Asn 2455		Val	Tyr	Ser	Thr 2460		Ser	Arg
Ser	Ala 2465	-	Gln	Arg	Gln	Lys 2470		Val	Thr	Phe	Asp 2475		Leu	Gln
Val	Leu 2480	Asp	Ser	His	Tyr	Gln 2485		Val	Leu	Lys	Glu 2490		Lys	Ala
Ala	Ala 2495	Ser	Lys	Val	Lys	Ala 2500		Leu	Leu	Ser	Val 2505	Glu	Glu	Ala
CÀa	Ser 2510	Leu	Thr	Pro	Pro	His 2515		Ala	ГЛа	Ser	Lys 2520	Phe	Gly	Tyr
Gly	Ala 2525	_	Asp	Val	Arg	Сув 2530	His	Ala	Arg	Lys	Ala 2535	Val	Thr	His
Ile	Asn 2540		Val	Trp	ГÀЗ	Asp 2545		Leu	Glu	Asp	Asn 2550	Val	Thr	Pro
Ile	Asp 2555	Thr	Thr	Ile	Met	Ala 2560		Asn	Glu	Val	Phe 2565	Сув	Val	Gln
Pro	Glu 2570	ГÀЗ	Gly	Gly	Arg	Lys 2575	Pro	Ala	Arg	Leu	Ile 2580	Val	Phe	Pro
Asp	Leu 2585	Gly	Val	Arg	Val	Сув 2590		Lys	Met	Ala	Leu 2595	_	Asp	Val
Val	Thr 2600	rys	Leu	Pro	Leu	Ala 2605	Val	Met	Gly	Ser	Ser 2610		Gly	Phe
Gln	Tyr 2615	Ser	Pro	Gly	Gln	Arg 2620	Val	Glu	Phe	Leu	Val 2625	Gln	Ala	Trp
ГÀа	Ser 2630	ràa	ГÀа	Thr	Pro	Met 2635	Gly	Phe	Ser	Tyr	Asp 2640	Thr	Arg	Cys
Phe	Asp 2645	Ser	Thr	Val	Thr	Glu 2650	Ser	Asp	Ile	Arg	Thr 2655	Glu	Glu	Ala
Ile	Tyr 2660	Gln	CAa	CÀa	Asp	Leu 2665	Asp	Pro	Gln	Ala	Arg 2670	Val	Ala	Ile
ГÀа	Ser 2675	Leu	Thr	Glu	Arg	Leu 2680	Tyr	Val	Gly	Gly	Pro 2685	Leu	Thr	Asn
Ser	Arg 2690	Gly	Glu	Asn	Cys	Gly 2695	Tyr	Arg	Arg	Cys	Arg 2700	Ala	Ser	Gly
Val	Leu 2705	Thr	Thr	Ser	СЛа	Gly 2710	Asn	Thr	Leu	Thr	Сув 2715		Ile	Lys
Ala	Arg 2720	Ala	Ala	Cys	Arg	Ala 2725	Ala	Gly	Leu	Gln	Asp 2730	Сув	Thr	Met

-continued

Lou Val. Cur. Cly. Arp. Arp. Lou. Val. Val. Ilo. Cur. Cly. Cor. Ala. Cly.
Leu Val Cys Gly Asp Asp Leu Val Val Ile Cys Glu Ser Ala Gly 2735 2740 2745
Val Gln Glu Asp Ala Ala Ser Leu Arg Ala Phe Thr Glu Ala Met 2750 2755 2760
Thr Arg Tyr Ser Ala Pro Pro Gly Asp Pro Pro Gln Pro Glu Tyr 2765 2770 2775
Asp Leu Glu Leu Ile Thr Ser Cys Ser Ser Asn Val Ser Val Ala 2780 2785 2790
His Asp Gly Ala Gly Lys Arg Val Tyr Tyr Leu Thr Arg Asp Pro 2795 2800 2805
Thr Thr Pro Leu Ala Arg Ala Ala Trp Glu Thr Ala Arg His Thr 2810 2815 2820
Pro Val Asn Ser Trp Leu Gly Asn Ile Ile Met Phe Ala Pro Thr 2825 2830 2835
Leu Trp Ala Arg Met Ile Leu Met Thr His Phe Phe Ser Val Leu 2840 2845 2850
Ile Ala Arg Asp Gln Leu Glu Gln Ala Leu Asp Cys Glu Ile Tyr 2855 2860 2865
Gly Ala Cys Tyr Ser Ile Glu Pro Leu Asp Leu Pro Pro Ile Ile 2870 2875 2880
Gln Arg Leu His Gly Leu Ser Ala Phe Ser Leu His Ser Tyr Ser 2885 2890 2895
Pro Gly Glu Ile Asn Arg Val Ala Ala Cys Leu Arg Lys Leu Gly 2900 2905 2910
Val Pro Pro Leu Arg Ala Trp Arg His Arg Ala Arg Ser Val Arg 2915 2920 2925
Ala Arg Leu Leu Ala Arg Gly Gly Arg Ala Ala Ile Cys Gly Lys 2930 2935 2940
Tyr Leu Phe Asn Trp Ala Val Arg Thr Lys Leu Lys Leu Thr Pro 2945 2950 2955
Ile Ala Ala Ala Gly Gln Leu Asp Leu Ser Gly Trp Phe Thr Ala 2960 2965 2970
Gly Tyr Ser Gly Gly Asp Ile Tyr His Ser Val Ser His Ala Arg 2975 2980 2985
Pro Arg Trp Ile Trp Phe Cys Leu Leu Leu Ala Ala Gly Val 2990 2995 3000
Gly Ile Tyr Leu Leu Pro Asn Arg 3005 3010
<210> SEQ ID NO 89
<211> LENGTH: 38 <212> TYPE: PRT
<pre><213> ORGANISM: Artificial Sequence <220> FEATURE:</pre>
<pre><223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide</pre>
<400> SEQUENCE: 89
Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg 1 5 10 15
Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr Ala 20 25 30
Thr Gly Asn Leu Pro Gly
35

<210> SEQ ID NO 90

```
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
      6xHis tag
<400> SEQUENCE: 90
His His His His His
<210> SEQ ID NO 91
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     peptide
<400> SEQUENCE: 91
Met Ser Gly Leu Asn Asp Ile Phe Glu Ala Gln Lys Ile Glu Trp His
                                   10
Glu
<210> SEQ ID NO 92
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     peptide
<400> SEQUENCE: 92
Gly Ser Gly Ser Asn Ser Met
1
   5
<210> SEQ ID NO 93
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     peptide
<400> SEQUENCE: 93
Gly Ser Gly Ser Gly
<210> SEQ ID NO 94
<211> LENGTH: 15
<212> TYPE: PRT
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     peptide
<400> SEQUENCE: 94
Gly Leu Asn Asp Ile Phe Glu Ala Gln Lys Ile Glu Trp His Glu
<210> SEQ ID NO 95
<211> LENGTH: 11
<212> TYPE: PRT
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     peptide
```

```
<400> SEQUENCE: 95
Gly Ser Gly Ser Gly His His His His His
               5
<210> SEQ ID NO 96
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
<400> SEQUENCE: 96
Gly Ser Gly Ser Gly His His His His His Gly Gly
<210> SEQ ID NO 97
<211> LENGTH: 54
<212> TYPE: PRT
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
    polypeptide
<400> SEQUENCE: 97
Thr Asn Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gln Ile
Val Gly Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val
                              25
Arg Ala Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg
                          40
Gln Pro Ile Pro Lys Ala
  50
<210> SEQ ID NO 98
<211> LENGTH: 49
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     polypeptide
<400> SEQUENCE: 98
Thr Asn Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gln Ile
Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Thr Arg Lys
Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro Ile Pro Lys
Ala
<210> SEQ ID NO 99
<211> LENGTH: 51
<212> TYPE: PRT
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
    polypeptide
<400> SEQUENCE: 99
Thr Asn Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gln Ile
             5
Val Gly Gly Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Thr
```

```
30
Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro Ile
       35
                           40
Pro Lys Ala
  50
<210> SEQ ID NO 100
<211> LENGTH: 52
<212> TYPE: PRT
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223 > OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     polypeptide
<400> SEQUENCE: 100
Thr Asn Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gln Ile
Val Gly Gly Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Ala
                   25
Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro
                          40
Ile Pro Lys Ala
   50
<210> SEQ ID NO 101
<211> LENGTH: 52
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     polypeptide
<400> SEQUENCE: 101
Thr Asn Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gln Ile
                           10
Val Gly Gly Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg
Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro
Ile Pro Lys Ala
   50
<210> SEQ ID NO 102
<211> LENGTH: 53
<212> TYPE: PRT
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
    polypeptide
<400> SEQUENCE: 102
Thr Asn Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gln Ile
                                  1.0
Val Gly Gly Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Ile
                              25
Ala Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln
                          40
                                               45
Pro Ile Pro Lys Ala
   50
```

-continued

```
<211> LENGTH: 52
<212> TYPE: PRT
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     polypeptide
<400> SEQUENCE: 103
Thr Asn Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gln Ile
Val Gly Gly Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val
Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro
Ile Pro Lys Ala
<210> SEQ ID NO 104
<211> LENGTH: 53
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     polypeptide
<400> SEQUENCE: 104
Thr Asn Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gln Ile
Val Gly Gly Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val
Ala Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln
Pro Ile Pro Lys Ala
   50
<210> SEQ ID NO 105
<211> LENGTH: 53
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     polypeptide
<400> SEQUENCE: 105
Thr Asn Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gln Ile
                                  10
Val Gly Gly Gly Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val
Arg Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln
Pro Ile Pro Lys Ala
   50
<210> SEQ ID NO 106
<211> LENGTH: 54
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     polypeptide
<400> SEQUENCE: 106
```

Thr Asn Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gln Ile

```
10
Val Gly Gly Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val
           20
                              25
Ile Ala Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg
                         40
Gln Pro Ile Pro Lys Ala
  50
<210> SEQ ID NO 107
<211> LENGTH: 42
<212> TYPE: PRT
<213 > ORGANISM: Artificial Sequence
<223 > OTHER INFORMATION: Description of Artificial Sequence: Synthetic
    polypeptide
<400> SEQUENCE: 107
Ile Ile Pro Asp Arg Glu Val Leu Tyr Arg Glu Phe Asp Glu Met Glu
                                  10
Glu Cys Ser Gln His Leu Pro Tyr Ile Glu Gln Gly Met Met Leu Ala
         20
                              25
Glu Gln Phe Lys Gln Lys Ala Leu Gly Leu
       35
<210> SEO ID NO 108
<211> LENGTH: 43
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     polypeptide
<400> SEQUENCE: 108
Ile Ile Pro Asp Arg Glu Val Leu Tyr Arg Glu Phe Asp Glu Met Glu
                     10
Glu Cys Ser Gln His Leu Pro Tyr Ile Glu Gln Gly Met Met Leu Ala
          20
                               25
Glu Gln Phe Lys Gln Lys Ala Leu Gly Leu Cys
<210> SEQ ID NO 109
<211> LENGTH: 466
<212> TYPE: PRT
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     polypeptide
<400> SEQUENCE: 109
Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser
Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe
                              25
Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Asn Ser Thr Lys
                40
Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn
                       55
Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala
                   70
His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr
                               90
```

Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 215 Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp 230 235 Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp 265 Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Ile Thr Leu Pro Gln 280 Asp Ala Val Ser Arg Thr Gln Arg Arg Gly Arg Thr Gly Arg Gly Lys 295 Pro Gly Ile Tyr Arg Phe Val Ala Pro Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr Thr Val Arg Leu Arg Ala Tyr Met Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu Glu Phe Trp Glu Gly Val Phe Thr Gly Leu Thr His Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Ile Thr Leu Thr His 440 Pro Val Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val Val Thr 465 <210> SEQ ID NO 110 <211> LENGTH: 466 <212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223			INF(rion	: Des	scrip	ption	n of	Art:	ific:	ial :	Seque	ence	: Synthetic
< 400)> SI	EQUEI	ICE :	110											
Ala 1	Val	Asp	Phe	Ile 5	Pro	Val	Glu	Asn	Leu 10	Glu	Thr	Thr	Met	Arg 15	Ser
Pro	Val	Phe	Thr 20	Asp	Asn	Ser	Ser	Pro 25	Pro	Val	Val	Pro	Gln 30	Ser	Phe
Gln	Val	Ala 35	His	Leu	His	Ala	Pro 40	Thr	Gly	Ser	Gly	Lys 45	Ala	Thr	ГÀа
Val	Pro 50	Ala	Ala	Tyr	Ala	Ala 55	Gln	Gly	Tyr	Lys	Val 60	Leu	Val	Leu	Asn
Pro 65	Ser	Val	Ala	Ala	Thr 70	Leu	Gly	Phe	Gly	Ala 75	Tyr	Met	Ser	ГÀа	Ala 80
His	Gly	Ile	Asp	Pro 85	Asn	Ile	Arg	Thr	Gly 90	Val	Arg	Thr	Ile	Thr 95	Thr
Gly	Ser	Pro	Ile 100	Thr	Tyr	Ser	Thr	Tyr 105	Gly	Lys	Phe	Leu	Ala 110	Asp	Gly
Gly	Cys	Ser 115	Gly	Gly	Ala	Tyr	Asp 120	Ile	Ile	Ile	Cys	Asp 125	Glu	Cys	His
Ser	Thr 130	Asp	Ala	Thr	Ser	Ile 135	Leu	Gly	Ile	Gly	Thr 140	Val	Leu	Aap	Gln
Ala 145	Glu	Thr	Ala	Gly	Ala 150	Arg	Leu	Val	Val	Leu 155	Ala	Thr	Ala	Thr	Pro 160
Pro	Gly	Ser	Val	Thr 165	Val	Pro	His	Pro	Asn 170	Ile	Glu	Glu	Val	Ala 175	Leu
Ser	Thr	Thr	Gly 180	Glu	Ile	Pro	Phe	Tyr 185	Gly	Lys	Ala	Ile	Pro 190	Leu	Glu
Val	Ile	Lys 195	Gly	Gly	Arg	His	Leu 200	Ile	Phe	Сла	His	Ser 205	ГÀз	ГЛа	Lys
CÀa	Asp 210	Glu	Leu	Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val
Ala 225	Tyr	Tyr	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240
Val	Val	Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp
Phe	Asp	Ser	Val 260	Ile	Asp	CÀa	Asn	Thr 265	Cys	Val	Thr	Gln	Thr 270	Val	Asp
Phe	Ser	Leu 275	Asp	Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln
Asp	Ala 290	Val	Ser	Arg	Thr	Gln 295	Arg	Arg	Gly	Arg	Thr 300	Gly	Arg	Gly	TÀa
Pro 305	Gly	Ile	Tyr	Arg	Phe 310	Val	Ala	Pro	Gly	Glu 315	Arg	Pro	Ser	Gly	Met 320
Phe	Asp	Ser	Ser	Val 325	Leu	Cys	Glu	Cys	Tyr 330	Asp	Ala	Gly	Сла	Ala 335	Trp
Tyr	Glu	Leu	Thr 340	Pro	Ala	Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met
Asn	Thr	Pro 355	Gly	Leu	Pro	Val	Cys	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu
Gly	Val 370	Phe	Thr	Gly	Leu	Thr 375	His	Ile	Asp	Ala	His 380	Phe	Leu	Ser	Gln
Thr 385	Lys	Gln	Ser	Gly	Glu 390	Asn	Leu	Pro	Tyr	Leu 395	Val	Ala	Tyr	Gln	Ala 400

Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met 410 Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Ile Thr Leu Thr His Pro Val Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val Val Thr <210> SEQ ID NO 111 <211> LENGTH: 466 <212> TYPE: PRT <213 > ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 111 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe 25 Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Glu Lys 40 Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly 105 Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln 135 Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 215 Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Ile Thr Leu Pro Gln

												0011			
		275					280					285			
Asp	Ala 290	Val	Ser	Arg	Thr	Gln 295	Arg	Arg	Gly	Arg	Thr 300	Gly	Arg	Gly	TÀa
Pro 305	Gly	Ile	Tyr	Arg	Phe 310	Val	Ala	Pro	Gly	Glu 315	Arg	Pro	Ser	Gly	Met 320
Phe	Asp	Ser	Ser	Val 325	Leu	Cys	Glu	Cys	Tyr 330	Asp	Ala	Gly	Cys	Ala 335	Trp
Tyr	Glu	Leu	Thr 340	Pro	Ala	Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met
Asn	Thr	Pro 355	Gly	Leu	Pro	Val	360 Cys	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu
Gly	Val 370	Phe	Thr	Gly	Leu	Thr 375	His	Ile	Asp	Ala	His 380	Phe	Leu	Ser	Gln
Thr 385	Lys	Gln	Ser	Gly	Glu 390	Asn	Leu	Pro	Tyr	Leu 395	Val	Ala	Tyr	Gln	Ala 400
Thr	Val	Cys	Ala	Arg 405	Ala	Gln	Ala	Pro	Pro 410	Pro	Ser	Trp	Asp	Gln 415	Met
Trp	Lys	Cys	Leu 420	Ile	Arg	Leu	Lys	Pro 425	Thr	Leu	His	Gly	Pro 430	Thr	Pro
Leu	Leu	Tyr 435	Arg	Leu	Gly	Ala	Val 440	Gln	Asn	Glu	Ile	Thr 445	Leu	Thr	His
Pro	Val 450	Thr	Lys	Tyr	Ile	Met 455	Thr	Cys	Met	Ser	Ala 460	Asp	Leu	Glu	Val
Val 465	Thr														
<210)> SI	O TI	OM C												
<211 <212 <213 <220	L> LE 2> TY 3> OF 0> FE 3> OT	ENGTH (PE: RGAN) EATUR	H: 46 PRT ISM: RE: INFO	Art: DRMA	ific: FION:		_		n of	Art:	ific:	ial :	Seque	ence	: Synthetic
<211 <212 <213 <220 <223	L> LE 2> TY 3> OF 0> FE 3> OT	ENGTH (PE: RGANI EATUR THER Olype	H: 46 PRT ISM: RE: INFO	Art: DRMA:			_		ı of	Art:	ific	ial :	Seque	ence	: Synthetic
<211 <212 <213 <220 <223	L> LH 2> TY 3> OF 0> FF 3> OT po	ENGTH (PE: RGANI EATUF THER DIYPE	H: 46 PRT ISM: RE: INFO	Art: DRMA: de		: De:	scrip	otion							·
<211 <212 <213 <220 <223 <400 Ala 1	L> LH 2> TY 3> OF 0> FH 3> OT po D> SH Val	ENGTH (PE: RGANI EATUR THER Dlype EQUEN Asp	H: 40 PRT ISM: RE: INFO Pptic	Art: DRMA: de 112 Ile 5	rion	: Des	scri <u>r</u> Glu	ption Asn	Leu 10	Glu	Thr	Thr	Met	Arg 15	Ser
<211 <212 <213 <220 <223 <400 Ala 1 Pro	L > LH 2 > TY 3 > OF 3 > OT PO PO Val	ENGTH YPE: RGANI EATUR THER Dlype EQUEN Asp	H: 46 PRT ISM: RE: INFO eptic NCE: Phe Thr 20	Art: DRMAT de 112 Ile 5 Asp	rion Pro	: De: Val Ser	Glu Ser	Asn Pro 25	Leu 10 Pro	Glu Val	Thr Val	Thr Pro	Met Gln 30	Arg 15 Ser	Ser Phe
<211 <212 <213 <220 <223 <400 Ala 1 Pro Gln	L> LH 2> TY 3> OH 3> OF 3> OT po Val Val	ENGTH (PE: RGANI EATUR THER Dlype EQUEN Asp Phe Ala 35	H: 46 PRT ISM: ISM: RE: INF(Phi Thr 20 His	Art: DRMAT de 112 Ile 5 Asp	Pro Asn	: De: Val Ser Ala	Glu Ser Pro	Asn Pro 25 Thr	Leu 10 Pro Gly	Glu Val Ser	Thr Val Gly	Thr Pro Lys 45	Met Gln 30 Ser	Arg 15 Ser Thr	Ser Phe Lys
<211 <212 <213 <222 <400 Ala 1 Pro Gln Val	1> LH 2> TY 3> OF 50> FF 3> OT po Val Val	ENGTH (PE: (PE: (PE: (PE: (PE: (PE: (PE: (PE:	H: 46 PRT ISM: RE: INF(eptic NCE: Phe Thr 20 His	Art: DRMA: 112 11e 5 Asp Leu Tyr	Pro Asn His	Val Ser Ala Ala	Glu Ser Pro 40	Asn Pro 25 Thr	Leu 10 Pro Gly Tyr	Glu Val Ser Lys	Thr Val Gly Val 60	Thr Pro Lys 45 Leu	Met Gln 30 Ser	Arg 15 Ser Thr	Ser Phe Lys Asn
<211 <212 <213 <222 <400 Ala 1 Pro Gln Val	1> LH 22> TY 33> OF FF 33> OF FF 33> OT pc 20> SI Val Val Val Pro 50	ENGTH (PE: CGANI) CHER Dlype SQUEN Asp Phe Ala 35 Ala	H: 46 PRT ISM: RE: INFC eptic VCE: Phe His Ala Ala	Art: DRMAT 112 11e 5 Asp Leu Tyr Ala	Pro Asn His Ala	Val Ser Ala Ala 55	Glu Ser Pro 40 Gln	Asn Pro 25 Thr Gly	Leu 10 Pro Gly Tyr	Glu Val Ser Lys Ala 75	Thr Val Gly Val 60 Ser	Thr Pro Lys 45 Leu Met	Met Gln 30 Ser Val	Arg 15 Ser Thr Leu	Ser Phe Lys Asn Ala
<211 <211 <212 <221 <220 <400 Ala 1 Pro Gln Val Pro 65 His	1> LH 2> TY 3> OF 3> OF 5> OF po Val Val Val Ser Gly	ENGTH (PE: RGANN) ERGANNI ELATUH ELAT	H: 46 PRT ISM: ISM: ISM: INF EE: INF EE Phe Thr 20 His Ala Ala Asp	Art: DRMA: de 112 Ile 5 Asp Leu Tyr Ala Pro 85	Pro Asn His Ala Thr 70	Val Ser Ala Ala 55 Leu Ile	Glu Ser Pro 40 Gln Gly	Asn Pro 25 Thr Gly Phe	Leu 10 Pro Gly Tyr Gly 90	Glu Val Ser Lys Ala 75	Thr Val Gly Val 60 Ser	Thr Pro Lys 45 Leu Met	Met Gln 30 Ser Val Ser	Arg 15 Ser Thr Leu Lys Thr 95	Ser Phe Lys Asn Ala 80 Thr
<211 <211 <212 <212 <223 <400 Ala 1 Pro Gln Val Pro 65 His	L> LH 2> TY 3> OF 90> FF 3> OT pc Val Val Val Fro 50 Ser Gly	ENGTH (PE:) (Pe:)	H: 46 PRT ISM: ISM: ISM: INFC Phe Thr 20 His Ala Ala Asp Ile 100	Art: DRMA: de 112 11e 5 Asp Leu Tyr Ala Pro 85	Pro Asn His Ala Thr 70 Asn	Val Ser Ala Ala 55 Leu Ile	Glu Ser Pro 40 Gln Gly Arg	Asn Pro 25 Thr Gly Phe Thr	Leu 10 Pro Gly Tyr Gly 90	Glu Val Ser Lys Ala 75 Val	Thr Val Gly Val 60 Ser Arg	Thr Pro Lys 45 Leu Met Thr	Met Gln 30 Ser Val Ser Ile Ala 110	Arg 15 Ser Thr Leu Lys Thr 95	Ser Phe Lys Asn Ala 80 Thr
<211 <212 <212 <213 <220 <400 Ala 1 Pro 65 His Gly Gly	L> LH 2> TY 3> OF 3> OF 40 Val Val Val Pro 50 Ser Gly Ser Cys	ENGTH (PE: CAN THE CAN	H: 46 PRT PRT PRT RE: INFC PPT INFC HIS Ala Ala Asp Ile 100 Gly	Art: DRMAT Ile 5 Asp Leu Tyr Ala Pro 85 Thr	Pro Asn His Ala Thr 70 Asn Tyr	Val Ser Ala Ala 55 Leu Ile Ser Tyr	Glu Ser Pro 40 Gln Gly Arg Thr	Asn Pro 25 Thr Gly Phe Thr Tyr 105	Leu 10 Pro Gly Tyr Gly 90 Gly	Glu Val Ser Lys Ala 75 Val Lys	Thr Val Gly Val 60 Ser Arg Phe	Thr Pro Lys 45 Leu Met Thr Leu Asp 125	Met Gln 30 Ser Val Ser Ile Ala 110 Glu	Arg 15 Ser Thr Leu Lys Thr 95 Asp	Ser Phe Lys Asn Ala 80 Thr Gly His

-continued

Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu 165 170 Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys 200 Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Ile Thr Leu Pro Gln Asp Ala Val Ser Arg Thr Gln Arg Arg Gly Arg Thr Gly Arg Gly Lys Pro Gly Ile Tyr Arg Phe Val Ala Pro Gly Glu Arg Pro Ser Gly Met 310 Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala Gly Cys Ala Trp 325 330 Tyr Glu Leu Thr Pro Ala Glu Thr Thr Val Arg Leu Arg Ala Tyr Met 340 345 Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu Glu Phe Trp Glu Gly Val Phe Thr Gly Leu Thr His Ile Asp Ala His Phe Leu Ser Gln 375 Thr Lys Gln Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr Gln Ala 395 390 Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Ile Thr Leu Thr His 440 Pro Val Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val Val Thr 465 <210> SEQ ID NO 113 <211> LENGTH: 466 <212> TYPE: PRT <213 > ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 113 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe 25 Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys 40

Val	Pro 50	Ala	Ala	Tyr	Ala	Ala 55	Gln	Gly	Tyr	Lys	Val 60	Leu	Val	Leu	Asn
Pro 65	Ser	Val	Ala	Ala	Thr 70	Leu	Gly	Phe	Gly	Ala 75	Tyr	Met	Ser	Lys	Ala 80
His	Gly	Ile	Asp	Pro 85	Asn	Ile	Arg	Thr	Gly 90	Val	Arg	Thr	Ile	Thr 95	Thr
Gly	Ser	Pro	Ile 100	Thr	Tyr	Ser	Thr	Tyr 105	Gly	Lys	Phe	Leu	Ala 110	Asp	Gly
Gly	Сув	Ser 115	Gly	Gly	Ala	Tyr	Asp 120	Ile	Ile	Ile	Сув	Asn 125	Glu	Сув	His
Ser	Thr 130	Asp	Ala	Thr	Ser	Ile 135	Leu	Gly	Ile	Gly	Thr 140	Val	Leu	Asp	Gln
Ala 145	Glu	Thr	Ala	Gly	Ala 150	Arg	Leu	Val	Val	Leu 155	Ala	Thr	Ala	Thr	Pro 160
Pro	Gly	Ser	Val	Thr 165	Val	Pro	His	Pro	Asn 170	Ile	Glu	Glu	Val	Ala 175	Leu
Ser	Thr	Thr	Gly 180	Glu	Ile	Pro	Phe	Tyr 185	Gly	Lys	Ala	Ile	Pro 190	Leu	Glu
Val	Ile	Lys 195	Gly	Gly	Arg	His	Leu 200	Ile	Phe	Càa	His	Ser 205	ГÀв	ГÀа	Lys
CÀa	Asp 210	Glu	Leu	Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val
Ala 225	Tyr	Tyr	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240
Val	Val	Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp
Phe	Asp	Ser	Val 260	Ile	Asp	Сув	Asn	Thr 265	Сув	Val	Thr	Gln	Thr 270	Val	Asp
Phe	Ser	Leu 275	Asp	Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln
Asp	Ala 290	Val	Ser	Arg	Thr	Gln 295	Arg	Arg	Gly	Arg	Thr 300	Gly	Arg	Gly	Lys
Pro 305	Gly	Ile	Tyr	Arg	Phe 310	Val	Ala	Pro	Gly	Glu 315	Arg	Pro	Ser	Gly	Met 320
Phe	Asp	Ser	Ser	Val 325	Leu	Cys	Glu	Cys	Tyr 330	Asp	Ala	Gly	Cys	Ala 335	Trp
Tyr	Glu	Leu	Thr 340		Ala	Glu	Thr	Thr 345		Arg	Leu	Arg	Ala 350		Met
Asn	Thr	Pro 355	Gly	Leu	Pro	Val	360	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu
Gly	Val 370	Phe	Thr	Gly	Leu	Thr 375	His	Ile	Asp	Ala	His 380	Phe	Leu	Ser	Gln
Thr 385	Lys	Gln	Ser	Gly	Glu 390	Asn	Leu	Pro	Tyr	Leu 395	Val	Ala	Tyr	Gln	Ala 400
Thr	Val	Cys	Ala	Arg 405	Ala	Gln	Ala	Pro	Pro 410	Pro	Ser	Trp	Asp	Gln 415	Met
Trp	Lys	Сув	Leu 420	Ile	Arg	Leu	Lys	Pro 425	Thr	Leu	His	Gly	Pro 430	Thr	Pro
Leu	Leu	Tyr 435	Arg	Leu	Gly	Ala	Val 440	Gln	Asn	Glu	Ile	Thr 445	Leu	Thr	His
Pro	Val 450	Thr	Lys	Tyr	Ile	Met 455	Thr	Сув	Met	Ser	Ala 460	Asp	Leu	Glu	Val

Val Thr 465 <210> SEQ ID NO 114 <211> LENGTH: 467 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 114 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala 65 70 75 80 His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Gln Gln Cys 120 His Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp 135 Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr 150 155 Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu 185 Glu Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys 200 Lys Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Ile Thr Leu Pro Gln Asp Ala Val Ser Arg Thr Gln Arg Arg Gly Arg Thr Gly Arg Gly Lys Pro Gly Ile Tyr Arg Phe Val Ala Pro Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala Gly Cys Ala 330 Trp Tyr Glu Leu Thr Pro Ala Glu Thr Thr Val Arg Leu Arg Ala Tyr 345

Met Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu Glu Phe Trp 360 Glu Gly Val Phe Thr Gly Leu Thr His Ile Asp Ala His Phe Leu Ser 375 Gln Thr Lys Gln Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Ile Thr Leu Thr His Pro Val Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val Val Thr 465 <210> SEO ID NO 115 <211> LENGTH: 466 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEOUENCE: 115 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe 25 Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys Ala Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu 170 Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu 185 Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp

225				230					235					240
Val Va	l Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp
Phe As	p Ser	Val 260	Ile	Asp	Cys	Asn	Thr 265	Cys	Val	Thr	Gln	Thr 270	Val	Asp
Phe Se	r Leu 275	_	Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln
Asp Al		Ser	Arg	Thr	Gln 295	Arg	Arg	Gly	Arg	Thr 300	Gly	Arg	Gly	Lys
Pro Gl 305	y Ile	Tyr	Arg	Phe 310	Val	Ala	Pro	Gly	Glu 315	Arg	Pro	Ser	Gly	Met 320
Phe As	p Ser	Ser	Val 325	Leu	Cys	Glu	Cys	Tyr 330	Asp	Ala	Gly	Cys	Ala 335	Trp
Tyr Gl	u Leu	Thr 340	Pro	Ala	Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met
Asn Th	r Pro 355		Leu	Pro	Val	Cys 360	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu
Gly Va		Thr	Gly	Leu	Thr 375	His	Ile	Asp	Ala	His 380	Phe	Leu	Ser	Gln
Thr Ly 385	s Gln	Ser	Gly	Glu 390	Asn	Leu	Pro	Tyr	Leu 395	Val	Ala	Tyr	Gln	Ala 400
Thr Va	l Cys	Ala	Arg 405	Ala	Gln	Ala	Pro	Pro 410	Pro	Ser	Trp	Asp	Gln 415	Met
Trp Ly	в Сув	Leu 420	Ile	Arg	Leu	Lys	Pro 425	Thr	Leu	His	Gly	Pro 430	Thr	Pro
Leu Le	u Tyr 435		Leu	Gly	Ala	Val 440	Gln	Asn	Glu	Ile	Thr 445	Leu	Thr	His
Pro Va		Lys	Tyr	Ile	Met 455	Thr	Сув	Met	Ser	Ala 460	Asp	Leu	Glu	Val
Val Th 465	ır													
<210><211><211><212><213><223>	LENGT TYPE : ORGAN FEATU	H: 4 PRT ISM: RE: INF	66 Art: ORMA'					n of	Art:	ific	ial :	Seque	ence	: Synthetic
<400>	SEQUE	NCE :	116											
Ala Va	l Asp	Phe	Ile 5	Pro	Val	Glu	Asn	Leu 10	Glu	Thr	Thr	Met	Arg 15	Ser
Pro Va	l Phe	Thr 20	Asp	Asn	Ser	Ser	Pro 25	Pro	Val	Val	Pro	Gln 30	Ser	Phe
Gln Va	1 Ala 35	His	Leu	His	Ala	Pro 40	Thr	Gly	Ser	Gly	Lуs 45	Ser	Thr	ГÀа
Val Pr		Ala	Tyr	Ala	Ala 55	Gln	Gly	Tyr	Lys	Val 60	Leu	Val	Leu	Asn
Pro Se	r Val	Ala	Ala	Thr 70	Leu	Gly	Phe	Gly	Ala 75	Tyr	Met	Ser	Lys	Ala 80
His Gl	y Ile	Asp	Pro 85	Asn	Ile	Arg	Thr	Gly 90	Val	Arg	Thr	Ile	Thr 95	Thr
Gly Se	r Pro	Ile 100	Thr	Tyr	Ser	Thr	Tyr 105	Gly	Lys	Phe	Leu	Ala 110	Asp	Gly

-continued

```
Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His
Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln
Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro
Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu
Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu
Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys
Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val
Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp
Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Gly Gly Asp
Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp
Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Ile Thr Leu Pro Gln
                         280
Asp Ala Val Ser Arg Thr Gln Arg Arg Gly Arg Thr Gly Arg Gly Lys
                      295
Pro Gly Ile Tyr Arg Phe Val Ala Pro Gly Glu Arg Pro Ser Gly Met
Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala Gly Cys Ala Trp
                                   330
Tyr Glu Leu Thr Pro Ala Glu Thr Thr Val Arg Leu Arg Ala Tyr Met
                             345
Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu Glu Phe Trp Glu
Gly Val Phe Thr Gly Leu Thr His Ile Asp Ala His Phe Leu Ser Gln
Thr Lys Gln Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr Gln Ala
                            395
Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met
Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro 420 425 430
Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Ile Thr Leu Thr His
Pro Val Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val
Val Thr
465
<210> SEQ ID NO 117
<211> LENGTH: 466
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
     polypeptide
```

<400> SEQUENCE: 117

Ala 1	Val	Asp	Phe	Ile 5	Pro	Val	Glu	Asn	Leu 10	Glu	Thr	Thr	Met	Arg 15	Ser
Pro	Val	Phe	Thr 20	Asp	Asn	Ser	Ser	Pro 25	Pro	Val	Val	Pro	Gln 30	Ser	Phe
Gln	Val	Ala 35	His	Leu	His	Ala	Pro 40	Thr	Gly	Ser	Gly	Lys 45	Ser	Thr	Lys
Val	Pro 50	Ala	Ala	Tyr	Ala	Ala 55	Gln	Gly	Tyr	Lys	Val 60	Leu	Val	Leu	Asn
Pro 65	Ser	Val	Ala	Ala	Thr 70	Leu	Gly	Phe	Gly	Ala 75	Tyr	Met	Ser	Lys	Ala 80
His	Gly	Ile	Asp	Pro 85	Asn	Ile	Arg	Thr	Gly 90	Val	Arg	Thr	Ile	Thr 95	Thr
Gly	Ser	Pro	Ile 100	Thr	Tyr	Ser	Thr	Tyr 105	Gly	Lys	Phe	Leu	Ala 110	Asp	Gly
Gly	Cya	Ser 115	Gly	Gly	Ala	Tyr	Asp 120	Ile	Ile	Ile	CÀa	Asp 125	Glu	Cys	His
Ser	Thr 130	Aap	Ala	Thr	Ser	Ile 135	Leu	Gly	Ile	Gly	Thr 140	Val	Leu	Aap	Gln
Ala 145	Glu	Thr	Ala	Gly	Ala 150	Arg	Leu	Val	Val	Leu 155	Ala	Thr	Ala	Thr	Pro 160
Pro	Gly	Ser	Val	Thr 165	Val	Pro	His	Pro	Asn 170	Ile	Glu	Glu	Val	Ala 175	Leu
Ser	Thr	Thr	Gly 180	Glu	Ile	Pro	Phe	Tyr 185	Gly	Lys	Ala	Ile	Pro 190	Leu	Glu
Val	Ile	Lys 195	Gly	Gly	Arg	His	Leu 200	Ile	Phe	Cys	His	Ser 205	Lys	Lys	Lys
CAa	Asp 210	Glu	Leu	Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val
Ala 225	Tyr	Tyr	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240
Val	Val	Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp
Phe	Asp	Ser	Val 260	Ile	Asp	Cys	Asn	Thr 265	Сув	Val	Thr	Gln	Thr 270	Val	Asp
Phe	Ser	Leu 275	Asp	Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln
Asp	Ala 290	Val	Ser	Arg	Thr	His 295		Arg	Gly	Arg	Thr 300	Gly	Arg	Gly	Lys
Pro 305	Gly	Ile	Tyr	Arg	Phe 310	Val	Ala	Pro	Gly	Glu 315	Arg	Pro	Ser	Gly	Met 320
Phe	Asp	Ser	Ser	Val 325	Leu	Cys	Glu	Cys	Tyr 330	Asp	Ala	Gly	Сув	Ala 335	Trp
Tyr	Glu	Leu	Thr 340	Pro	Ala	Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met
Asn	Thr	Pro 355	Gly	Leu	Pro	Val	360	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu
Gly	Val 370	Phe	Thr	Gly	Leu	Thr 375	His	Ile	Asp	Ala	His 380	Phe	Leu	Ser	Gln
Thr 385	Lys	Gln	Ser	Gly	Glu 390	Asn	Leu	Pro	Tyr	Leu 395	Val	Ala	Tyr	Gln	Ala 400
Thr	Val	Сув	Ala	Arg 405	Ala	Gln	Ala	Pro	Pro 410	Pro	Ser	Trp	Asp	Gln 415	Met

-continued

Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Ile Thr Leu Thr His Pro Val Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val 455 460 Val Thr 465 <210> SEQ ID NO 118 <211> LENGTH: 466 <212> TYPE: PRT <213 > ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 118 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe 25 Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr 90 Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly 100 105 Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln 135 Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 215 Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp 230 Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp 250 Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp 265 Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Ile Thr Leu Pro Gln 280 Asp Ala Val Ser Arg Thr Gln Arg Arg Gly Ala Thr Gly Arg Gly Lys 295

Pro Gly Ile Tyr Arg Phe Val Ala Pro Gly Glu Arg Pro Ser Gly Met 310 315 Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala Gly Cys Ala Trp 325 Tyr Glu Leu Thr Pro Ala Glu Thr Thr Val Arg Leu Arg Ala Tyr Met Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu Glu Phe Trp Glu Gly Val Phe Thr Gly Leu Thr His Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro 425 Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Ile Thr Leu Thr His 440 Pro Val Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val 455 450 Val Thr 465 <210> SEQ ID NO 119 <211> LENGTH: 466 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 119 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala 65 70 75 80 His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln 135 Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu

											-	con	tin [.]	ued	
			180					185					190		
Val	Ile	Lys 195	Gly	Gly	Arg	His	Leu 200	Ile	Phe	Сув	His	Ser 205	Lys	Lys	Lys
CÀa	Asp 210	Glu	Leu	Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val
Ala 225	Tyr	Tyr	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240
Val	Val	Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp
Phe	Asp	Ser	Val 260	Ile	Asp	Cys	Asn	Thr 265	Cys	Val	Thr	Gln	Thr 270	Val	Asp
Phe	Ser	Leu 275	Asp	Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln
Asp	Ala 290	Val	Ser	Arg	Thr	Gln 295	Arg	Arg	Gly	Arg	Thr 300	Gly	Lys	Gly	ГÀа
Pro 305	Gly	Ile	Tyr	Arg	Phe 310	Val	Ala	Pro	Gly	Glu 315	Arg	Pro	Ser	Gly	Met 320
Phe	Asp	Ser	Ser	Val 325	Leu	CÀa	Glu	Cys	Tyr 330	Asp	Ala	Gly	Cys	Ala 335	Trp
Tyr	Glu	Leu	Thr 340	Pro	Ala	Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met
Asn	Thr	Pro 355	Gly	Leu	Pro	Val	Cys 360	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu
Gly	Val 370	Phe	Thr	Gly	Leu	Thr 375	His	Ile	Asp	Ala	His 380	Phe	Leu	Ser	Gln
Thr 385	Lys	Gln	Ser	Gly	Glu 390	Asn	Leu	Pro	Tyr	Leu 395	Val	Ala	Tyr	Gln	Ala 400
Thr	Val	Сув	Ala	Arg 405	Ala	Gln	Ala	Pro	Pro 410	Pro	Ser	Trp	Asp	Gln 415	Met
Trp	Lys	Cys	Leu 420	Ile	Arg	Leu	Lys	Pro 425	Thr	Leu	His	Gly	Pro 430	Thr	Pro
Leu	Leu	Tyr 435	Arg	Leu	Gly	Ala	Val 440	Gln	Asn	Glu	Ile	Thr 445	Leu	Thr	His
Pro	Val 450	Thr	Lys	Tyr	Ile	Met 455	Thr	CÀa	Met	Ser	Ala 460	Asp	Leu	Glu	Val
Val 465	Thr														
<211 <212 <213 <220	0 > FI 3 > O	ENGTI YPE : RGAN EATUI	H: 40 PRT ISM: RE: INFO	66 Art: ORMA			-		n of	Art:	ific	ial :	Seque	ence	: Synthetic
< 400)> SI	EQUEI	NCE:	120											
Ala 1	Val	Asp	Phe	Ile 5	Pro	Val	Glu	Asn	Leu 10	Glu	Thr	Thr	Met	Arg 15	Ser
Pro	Val	Phe	Thr 20	Asp	Asn	Ser	Ser	Pro 25	Pro	Val	Val	Pro	Gln 30	Ser	Phe
Gln	Val	Ala 35	His	Leu	His	Ala	Pro 40	Thr	Gly	Ser	Gly	Lуs 45	Ser	Thr	Lys
Val	Pro 50	Ala	Ala	Tyr	Ala	Ala 55	Gln	Gly	Tyr	Lys	Val 60	Leu	Val	Leu	Asn

Pro 65	Ser	Val	Ala	Ala	Thr 70	Leu	Gly	Phe	Gly	Ala 75	Tyr	Met	Ser	Lys	Ala 80
His	Gly	Ile	Asp	Pro 85	Asn	Ile	Arg	Thr	Gly 90	Val	Arg	Thr	Ile	Thr 95	Thr
Gly	Ser	Pro	Ile 100	Thr	Tyr	Ser	Thr	Tyr 105	Gly	Lys	Phe	Leu	Ala 110	Asp	Gly
Gly	Cys	Ser 115	Gly	Gly	Ala	Tyr	Asp 120	Ile	Ile	Ile	Cys	Asp 125	Glu	Сув	His
Ser	Thr 130	Asp	Ala	Thr	Ser	Ile 135	Leu	Gly	Ile	Gly	Thr 140	Val	Leu	Asp	Gln
Ala 145	Glu	Thr	Ala	Gly	Ala 150	Arg	Leu	Val	Val	Leu 155	Ala	Thr	Ala	Thr	Pro 160
Pro	Gly	Ser	Val	Thr 165	Val	Pro	His	Pro	Asn 170	Ile	Glu	Glu	Val	Ala 175	Leu
Ser	Thr	Thr	Gly 180	Glu	Ile	Pro	Phe	Tyr 185	Gly	Lys	Ala	Ile	Pro 190	Leu	Glu
Val	Ile	Lys 195	Gly	Gly	Arg	His	Leu 200	Ile	Phe	Cys	His	Ser 205	Lys	Lys	Lys
Cys	Asp 210	Glu	Leu	Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val
Ala 225	Tyr	Tyr	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240
Val	Val	Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp
Phe	Asp	Ser	Val 260	Ile	Asp	CAa	Asn	Thr 265	Сув	Val	Thr	Gln	Thr 270	Val	Asp
Phe	Ser	Leu 275	Asp	Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln
Asp	Ala 290	Val	Ser	Arg	Thr	Gln 295	Arg	Arg	Gly	Arg	Thr 300	Gly	Arg	Gly	Lys
Pro 305	Gly	Ile	Tyr	Arg	Phe 310	Val	Ala	Pro	Gly	Glu 315	Arg	Pro	Ser	Gly	Met 320
Phe	Asp	Ser	Ser	Val 325	Leu	CAa	Glu	Сув	Tyr 330	Asp	Ala	Gly	Cys	Ala 335	Ala
Tyr	Glu	Leu	Thr 340	Pro	Ala	Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met
Asn	Thr	Pro 355		Leu	Pro		Сув 360		Asp	His		Glu 365		Trp	Glu
Gly	Val 370	Phe	Thr	Gly	Leu	Thr 375	His	Ile	Asp	Ala	His 380	Phe	Leu	Ser	Gln
Thr 385	Lys	Gln	Ser	Gly	Glu 390	Asn	Leu	Pro	Tyr	Leu 395	Val	Ala	Tyr	Gln	Ala 400
Thr	Val	Cys	Ala	Arg 405	Ala	Gln	Ala	Pro	Pro 410	Pro	Ser	Trp	Asp	Gln 415	Met
Trp	ГЛа	СЛа	Leu 420	Ile	Arg	Leu	Lys	Pro 425	Thr	Leu	His	Gly	Pro 430	Thr	Pro
Leu	Leu	Tyr 435	Arg	Leu	Gly	Ala	Val 440	Gln	Asn	Glu	Ile	Thr 445	Leu	Thr	His
Pro	Val 450	Thr	Lys	Tyr	Ile	Met 455	Thr	Cys	Met	Ser	Ala 460	Asp	Leu	Glu	Val
Val 465	Thr														

<211	> LE	EQ II ENGTH (PE:	I: 46												
		RGANI		Art:	lfic:	ial S	Seque	ence							
	3 > 07	EATUF CHER Olype	INFO		rion	: Des	crip	otion	n of	Arti	lfici	ial S	Seque	ence:	Synthetic
<400)> SI	EQUEN	ICE :	121											
Ala 1	Val	Asp	Phe	Ile 5	Pro	Val	Glu	Asn	Leu 10	Glu	Thr	Thr	Met	Arg 15	Ser
Pro	Val	Phe	Thr 20	Asp	Asn	Ser	Ser	Pro 25	Pro	Val	Val	Pro	Gln 30	Ser	Phe
Gln	Val	Ala 35	His	Leu	His	Ala	Pro 40	Thr	Gly	Ser	Gly	Lys 45	Ser	Thr	Lys
Val	Pro 50	Ala	Ala	Tyr	Ala	Ala 55	Gln	Gly	Tyr	Lys	Val 60	Leu	Val	Leu	Asn
Pro 65	Ser	Val	Ala	Ala	Thr 70	Leu	Gly	Phe	Gly	Ala 75	Tyr	Met	Ser	Lys	Ala 80
His	Gly	Ile	Asp	Pro 85	Asn	Ile	Arg	Thr	Gly 90	Val	Arg	Thr	Ile	Thr 95	Thr
Gly	Ser	Pro	Ile 100	Thr	Tyr	Ser	Thr	Tyr 105	Gly	Lys	Phe	Leu	Ala 110	Asp	Gly
Gly	Cys	Ser 115	Gly	Gly	Ala	Tyr	Asp 120	Ile	Ile	Ile	Cys	Asp 125	Glu	Cys	His
Ser	Thr 130	Asp	Ala	Thr	Ser	Ile 135	Leu	Gly	Ile	Gly	Thr 140	Val	Leu	Asp	Gln
Ala 145	Glu	Thr	Ala	Gly	Ala 150	Arg	Leu	Val	Val	Leu 155	Ala	Thr	Ala	Thr	Pro 160
Pro	Gly	Ser	Val	Thr 165	Val	Pro	His	Pro	Asn 170	Ile	Glu	Glu	Val	Ala 175	Leu
Ser	Thr	Thr	Gly 180	Glu	Ile	Pro	Phe	Tyr 185	Gly	Lys	Ala	Ile	Pro 190	Leu	Glu
Val	Ile	Lys 195	Gly	Gly	Arg	His	Leu 200	Ile	Phe	Cys	His	Ser 205	TÀa	Lys	Lys
Cys	Asp 210	Glu	Leu	Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val
Ala 225	Tyr	Tyr	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240
Val	Val	Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp
Phe	Asp	Ser	Val 260	Ile	Asp	CAa	Asn	Thr 265	Сув	Val	Thr	Gln	Thr 270	Val	Asp
Phe	Ser	Leu 275	Asp	Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln
Asp	Ala 290	Val	Ser	Arg	Thr	Gln 295	Arg	Arg	Gly	Arg	Thr 300	Gly	Arg	Gly	Lys
Pro 305	Gly	Ile	Tyr	Arg	Phe 310	Val	Ala	Pro	Gly	Glu 315	Arg	Pro	Ser	Gly	Met 320
Phe	Asp	Ser	Ser	Val 325	Leu	CÀa	Glu	Cys	Tyr 330	Asp	Ala	Gly	Ser	Ala 335	Trp
Tyr	Glu	Leu	Thr 340	Pro	Ala	Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met
Asn	Thr	Pro 355	Gly	Leu	Pro	Val	Cys 360	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu

-continued

Gly Val Phe Thr Gly Leu Thr His Ile Asp Ala His Phe Leu Ser Gln 375 Thr Lys Gln Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Ile Thr Leu Thr His Pro Val Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val 465 <210> SEQ ID NO 122 <211> LENGTH: 466 <212> TYPE: PRT <213 > ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 122 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys 40 Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn 55 Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu 170 Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys 200 Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp 230 235 Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp 250

Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp 265 Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Ile Thr Leu Pro Gln 280 Asp Ala Val Ser Arg Thr Gln Arg Arg Gly Arg Thr Gly Arg Gly Lys Pro Gly Ile Tyr Arg Phe Val Ala Pro Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr Thr Val Arg Leu Arg Ala Tyr Met Asn Thr Pro Gly Leu Pro Val Ser Gln Asp His Leu Glu Phe Trp Glu Gly Val Phe Thr Gly Leu Thr His Ile Asp Ala His Phe Leu Ser Gln 375 Thr Lys Gln Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr Gln Ala 390 395 Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro 425 Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Ile Thr Leu Thr His 440 Pro Val Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val 455 460 Val Thr 465 <210> SEQ ID NO 123 <211> LENGTH: 466 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 123 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala 75 His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr 90 Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Ser His Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln

130 135 140	
Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr P. 145 150 155 155	Pro .60
Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala L	ieu
Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu G 180 185 190	lu
Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Lys Lys 195 200 205	rγs
Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala V 210 215 220	al
Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly A 225 230 235	Asp 340
Val Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly A 245 250 250	yab
Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln Thr Val A 260 265 270	yab
Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Ile Thr Leu Pro G 275 280 285	ln
Asp Ala Val Ser Arg Thr Gln Arg Arg Gly Arg Thr Gly Arg Gly Ly 290 295 300	īÀa
Pro Gly Ile Tyr Arg Phe Val Ala Pro Gly Glu Arg Pro Ser Gly M 305 310 315 3.	let 320
Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala Gly Cys Ala T 325 330 335	rp
Tyr Glu Leu Thr Pro Ala Glu Thr Thr Val Arg Leu Arg Ala Tyr M 340 345 350	let
Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu Glu Phe Trp G 355 360 365	flu
Gly Val Phe Thr Gly Leu Thr His Ile Asp Ala His Phe Leu Ser G 370 375 380	iln
Thr Lys Gln Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr Gln A 385 390 395 4	Ala 100
Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln M 405 410 415	let
Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro 420 425 430	Pro
Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Ile Thr Leu Thr H 435 440 445	Iis
Pro Val Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu V 450 455 460	al al
Val Thr 465	
<210> SEQ ID NO 124 <211> LENGTH: 466 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: polypeptide <400> SEQUENCE: 124 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg S.	
1 5 10 15	

-continued
-concinued

_															
Pro	Val	Phe	Thr 20	Asp	Asn	Ser	Ser	Pro 25	Pro	Val	Val	Pro	Gln 30	Ser	Phe
Gln	Val	Ala 35	His	Leu	His	Ala	Pro 40	Thr	Gly	Ser	Gly	Lys 45	Ser	Thr	Lys
Val	Pro 50	Ala	Ala	Tyr	Ala	Ala 55	Gln	Gly	Tyr	Lys	Val 60	Leu	Val	Leu	Asn
Pro 65	Ser	Val	Ala	Ala	Thr 70	Leu	Gly	Phe	Gly	Ala 75	Tyr	Met	Ser	ГÀЗ	Ala 80
His	Gly	Ile	Asp	Pro 85	Asn	Ile	Arg	Thr	Gly 90	Val	Arg	Thr	Ile	Thr 95	Thr
Gly	Ser	Pro	Ile 100	Thr	Tyr	Ser	Thr	Tyr 105	Gly	Lys	Phe	Leu	Ala 110	Asp	Gly
Gly	Cys	Ser 115	Gly	Gly	Ala	Tyr	Asp 120	Ile	Ile	Ile	Cys	Asp 125	Glu	Cys	His
Ser	Thr 130	Asp	Ala	Thr	Ser	Ile 135	Leu	Gly	Ile	Gly	Thr 140	Val	Leu	Asp	Gln
Ala 145	Glu	Thr	Ala	Gly	Ala 150	Arg	Leu	Val	Val	Leu 155	Ala	Thr	Ala	Thr	Pro 160
Pro	Gly	Ser	Val	Thr 165	Val	Pro	His	Pro	Asn 170	Ile	Glu	Glu	Val	Ala 175	Leu
Ser	Thr	Thr	Gly 180	Glu	Ile	Pro	Phe	Tyr 185	Gly	Lys	Ala	Ile	Pro 190	Leu	Glu
Val	Ile	Lys 195	Gly	Gly	Arg	His	Leu 200	Ile	Phe	Ser	His	Ser 205	ГÀв	ГÀв	ГЛЗ
CAa	Asp 210	Glu	Leu	Ala	Ala	Lys 215	Leu	Val	Ala	Leu	Gly 220	Ile	Asn	Ala	Val
Ala 225	Tyr	Tyr	Arg	Gly	Leu 230	Asp	Val	Ser	Val	Ile 235	Pro	Thr	Ser	Gly	Asp 240
Val	Val	Val	Val	Ala 245	Thr	Asp	Ala	Leu	Met 250	Thr	Gly	Tyr	Thr	Gly 255	Asp
Phe	Asp	Ser	Val 260	Ile	Asp	CÀa	Asn	Thr 265	Cys	Val	Thr	Gln	Thr 270	Val	Asp
Phe	Ser	Leu 275	Asp	Pro	Thr	Phe	Thr 280	Ile	Glu	Thr	Ile	Thr 285	Leu	Pro	Gln
Asp	Ala 290	Val	Ser	Arg	Thr	Gln 295	Arg	Arg	Gly	Arg	Thr 300	Gly	Arg	Gly	Lys
Pro 305	Gly	Ile	Tyr		Phe 310		Ala	Pro	Gly	Glu 315		Pro	Ser		Met 320
Phe	Asp	Ser	Ser	Val 325	Leu	Cys	Glu	Сув	Tyr 330	Asp	Ala	Gly	Сув	Ala 335	Trp
Tyr	Glu	Leu	Thr 340	Pro	Ala	Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met
Asn	Thr	Pro 355	Gly	Leu	Pro	Val	360	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu
Gly	Val 370	Phe	Thr	Gly	Leu	Thr 375	His	Ile	Asp	Ala	His 380	Phe	Leu	Ser	Gln
Thr 385	Lys	Gln	Ser	Gly	Glu 390	Asn	Leu	Pro	Tyr	Leu 395	Val	Ala	Tyr	Gln	Ala 400
Thr	Val	Cys	Ala	Arg 405	Ala	Gln	Ala	Pro	Pro 410	Pro	Ser	Trp	Asp	Gln 415	Met
Trp	Lys	Сла	Leu 420	Ile	Arg	Leu	Lys	Pro 425	Thr	Leu	His	Gly	Pro 430	Thr	Pro
Leu	Leu	Tyr	Arg	Leu	Gly	Ala	Val	Gln	Asn	Glu	Ile	Thr	Leu	Thr	His

-continued

Pro Val Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu Val 455 Val Thr 465 <210> SEQ ID NO 125 <211> LENGTH: 466 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223 > OTHER INFORMATION: Description of Artificial Sequence: Synthetic polypeptide <400> SEQUENCE: 125 Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys 40 Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly 100 105 Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp Gln 135 Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Ser Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Asp Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp 250 Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Ile Thr Leu Pro Gln 280 Asp Ala Val Ser Arg Thr Gln Arg Arg Gly Arg Thr Gly Arg Gly Lys Pro Gly Ile Tyr Arg Phe Val Ala Pro Gly Glu Arg Pro Ser Gly Met

Phe	Asp	Ser	Ser	Val 325	Leu	Cys	Glu	Cys	Tyr 330	Asp	Ala	Gly	Сув	Ala 335	Trp
Tyr	Glu	Leu	Thr 340	Pro	Ala	Glu	Thr	Thr 345	Val	Arg	Leu	Arg	Ala 350	Tyr	Met
Asn	Thr	Pro 355	Gly	Leu	Pro	Val	360 CAa	Gln	Asp	His	Leu	Glu 365	Phe	Trp	Glu
Gly	Val 370	Phe	Thr	Gly	Leu	Thr 375	His	Ile	Asp	Ala	His 380	Phe	Leu	Ser	Gln
Thr 385	Lys	Gln	Ser	Gly	Glu 390	Asn	Leu	Pro	Tyr	Leu 395	Val	Ala	Tyr	Gln	Ala 400
Thr	Val	СЛа	Ala	Arg 405	Ala	Gln	Ala	Pro	Pro 410	Pro	Ser	Trp	Asp	Gln 415	Met
Trp	Lys	CÀa	Leu 420	Ile	Arg	Leu	ГЛа	Pro 425	Thr	Leu	His	Gly	Pro 430	Thr	Pro
Leu	Leu	Tyr 435	Arg	Leu	Gly	Ala	Val 440	Gln	Asn	Glu	Ile	Thr 445	Leu	Thr	His
Pro	Val 450	Thr	Lys	Tyr	Ile	Met 455	Thr	Cys	Met	Ser	Ala 460	Asp	Leu	Glu	Val
Val 465	Thr														

The invention claimed is:

- 1. An immunoassay for the combined detection of HCV $_{30}$ antigen and HCV antibody in a test sample, the method com
 - a) simultaneously providing the following reagents:

 - i. a solid phase capable of binding to biotin; ii. a biotinylated anti-HCV antibody for the capture of an HCV antigen present in said test sample;
 - iii. a first biotinylated HCV antigen for the capture of an anti-HCV antibody in said test sample, wherein the first biotinylated HCV antigen comprises the amino acid sequence as set forth in SEQ ID NO:101; and
 - iv. a first detectably labeled HCV antigen for binding to 40 the anti-HCV antibody captured by the first biotinylated HCV antigen of (iii);
 - b) incubating the reagents of step (a) under conditions to produce a reaction mixture, wherein
 - (i) the biotinylated anti-HCV antibody of (a)(ii) binds to 45 said solid phase through said biotin and specifically binds to the HCV antigen present in said test sample to produce a biotinylated anti-HCV antibody-HCV antigen complex captured on said solid phase;
 - (ii) the first biotinylated HCV antigen of (a)(iii) binds to said solid phase through said biotin and specifically binds to the anti-HCV antibody present in said test sample to produce a first biotinylated HCV antigenanti-HCV antibody complex captured on said solid phase; and
 - (iii) said first detectably labeled HCV antigen of (a)(iv) 55 specifically binds to the anti-HCV antibody in the first biotinylated HCV antigen-anti-HCV antibody complex captured on said solid phase;
 - c) isolating solid phase that comprises attached captured anti-HCV antibody and captured HCV antigen from unreacted test sample and reagents;
 - d. contacting the isolated solid phase with a detectably labeled conjugate antibody that binds to said HCV antigen captured in the biotinylated anti-HCV antibody-HCV antigen complex of (b)(i); and
 - e. detecting
 - (i) a first signal generated from the detectable label of the detectably labeled conjugate antibody, wherein pres-

- ence of the first signal indicates presence of the HCV antigen in the test sample; and
- (ii) a second signal generated from the detectable label of the first detectably labeled HCV antigen, wherein presence of the second signal indicates presence of the anti-HCV antibody in the test sample.
- 2. The immunoassay of claim 1, further comprising providing in step (a):
 - (v) a second biotinylated HCV antigen for the capture of a second anti-HCV antibody in said test sample, wherein said second biotinylated HCV antigen is distinct from the first biotinylated HCV antigen; and
 - (vi) a second detectably labeled HCV antigen for binding to the second anti-HCV antibody captured by the second biotinylated HCV antigen of (v);

wherein in step (b):

- (iv) the second biotinylated HCV antigen of (a)(v) binds to said solid phase through said biotin and specifically binds to the second anti-HCV antibody present in said test sample to produce a second biotinylated HCV antigen-second anti-HCV antibody complex captured on said solid phase; and
- (v) said second detectably labeled HCV antigen of (a) (vi) specifically binds to the second anti-HCV antibody in said second biotinylated HCV antigen-second anti-HCV antibody complex captured on said solid phase;

further comprising detecting in step (e):

- (iii) a third signal generated from the detectable label of the second detectably labeled HCV antigen, wherein presence of the third signal indicates presence of the second anti-HCV antibody in the test sample.
- 3. The immunoassay of claim 2, further comprising providing in step (a):
 - (vii) a third biotinylated HCV antigen for the capture of a third anti-HCV antibody in said test sample, wherein said third biotinylated HCV antigen is distinct from the first biotinylated HCV antigen or the second biotinylated HCV antigen; and
 - (viii) a third detectably labeled HCV antigen for binding to the third anti-HCV antibody captured by the third biotinylated HCV antigen of (vii);

278

wherein in step (b):

- (vi) the third biotinylated HCV antigen of (a) (vii) binds to said solid phase through said biotin and specifically binds to the third anti-HCV antibody present in said test sample to produce a third biotinylated HCV antigenthird anti-HCV antibody complex captured on said solid phase; and
- (vii) said third detectably labeled HCV antigen of (a)(viii) specifically binds to the third anti-HCV antibody in said third biotinylated HCV antigen-third anti-HCV antibody complex captured on said solid phase; and

further comprising detecting in step (e):

- (iv) a fourth signal generated from the detectable label of the third detectably labeled HCV antigen, wherein presence of the fourth signal indicates presence of the third anti-HCV antibody in the test sample.
- **4**. An immunoassay for the simultaneous detection of both HCV antigens and HCV antibodies in a test sample, wherein said combination assay comprises:
 - a. a first capture antigen comprising the amino acid sequence as set forth in SEQ ID NO:101;
 - b a first detection antigen comprising a peptide sequence of a first HCV protein and further comprising a first detectable label;
 - c. a second capture antigen comprising a peptide sequence of a second HCV protein;
 - d. a second detection antigen comprising a peptide sequence of a second HCV protein and further comprising a second detectable label;
 - e. a third capture antigen comprising a peptide sequence of a third HCV protein;
 - f. a third detection antigen comprising a peptide sequence of a third HCV protein and further comprising a third detectable label;
 - g. a first capture antibody; and
 - h. a conjugate antibody comprising a fourth detectable 35 label.
 - wherein said first capture antibody and said conjugate antibody specifically bind a fourth HCV protein from said test sample, and said combination assay is performed by:
 - (i) contacting said test sample with the first, second, and third capture antigens, the first, second, and third detection antigens, said first capture antibody and said conjugate antibody under conditions to allow:
 - a) formation of a first sandwich complex between said first capture antigen, the first detection antigen and a first anti-HCV antibody present in said test sample;
 - b) formation of a second sandwich complex between said second capture antigen, the second detection antigen and a second anti-HCV antibody present in said test sample:
 - c) formation of a third sandwich complex between said third capture antigen, the third detection antigen and a third anti-HCV antibody present in said test sample; and

280

d) formation of a fourth sandwich complex between said capture antibody, said conjugate antibody and the fourth HCV antigen present in said test sample; and

(ii) measuring first, second, third, and fourth signals generated from said first, second, third, and fourth detectable labels as a result of formation of said first, second, third, and fourth sandwich complexes, thereby simultaneously detecting the first, second, and third anti-HCV antibodies and the fourth HCV antigen present in said test sample.

5. The immunoassay of claim 4 wherein said second, third and fourth HCV proteins are independently selected from the group consisting of core antigen, E1, E2, NS2, NS3, NS4 and NS5 or distinct and independent portions of any one of core antigen, E1, E2, NS2, NS3, NS4 and NS5.

6. The immunoassay of claim **4** wherein each of the peptide sequences of said second and third HCV proteins are independently selected from different peptide sequences of the same protein selected from the group consisting of core antigen, E1, E2, NS2, NS3, NS4 and NS5.

7. The immunoassay of claim 4, wherein said first detection antigen is a core peptide that comprises a deletion of amino acids 34 and 48 and amino acids 115-121.

8. The immunoassay of claim **4**, wherein said fourth HCV protein is core antigen.

9. The immunoassay of claim 4 wherein the first capture antibody comprises two or more distinct antibodies.

10. The immunoassay of claim 4, wherein said first detection antigen is an acridinylated core peptide comprising a deletion of amino acids 34 and 48 and amino acids 115-121.

11. The immunoassay of claim 4, wherein said second capture antigen is a biotinylated NS3 recombinant antigen and said second detection antigen is an acridinylated NS3 recombinant antigen.

12. The immunoassay of claim 4 wherein said third capture antigen is biotinylated NS4 peptide and said third detection antigen is an acridinylated NS4 peptide.

13. A kit for the simultaneous detection of HCV antigens and antibodies in a sample comprising:

- a first pair of capture antigen and detection antigen for detecting a first anti-HCV antibody against a first HCV protein, wherein said detection antigen is detectably labeled, and wherein the capture antigen comprises the amino acid sequence as set forth in SEQ ID NO:101;
- a second pair of capture antigen and detection antigen for detecting a second anti-HCV antibody against a second HCV protein, wherein said detection antigen is detectably labeled;
- a third pair of capture antigen and detection antigen for detecting a third anti-HCV antibody against a third HCV protein, wherein said detection antigen is detectably labeled; and
- a first pair of capture antibody and conjugate antibody for detecting a fourth HCV protein, wherein said conjugate antibody is detectably labeled.

* * * * *